{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "ATS 2020"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from selenium import webdriver\n",
    "from bs4 import BeautifulSoup\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from tqdm import tqdm_notebook"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "import time"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "import selenium.webdriver.support.expected_conditions as EC"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "options = webdriver.ChromeOptions()\n",
    "options.add_argument('--headless')\n",
    "options.add_argument('--no-sandbox')\n",
    "options.add_argument('--disable-dev-shm-usage')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "driver = webdriver.Chrome(r'C:\\Users\\venug\\Downloads\\chromedriver.exe')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.get('https://www.abstractsonline.com/pp8/#!/8998/sessions/*/1')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "ResultsButton = driver.find_element_by_xpath('//*[@id=\"filter\"]/div/div/button[3]')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "ResultsButton.click()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "ids = BeautifulSoup(driver.page_source)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "t =ids.find_all('h1',class_ = 'name')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "//*[@id=\"paginator\"]/div/ul/li[7]/span"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "pg = driver.find_element_by_css_selector('#paginator > div > ul > li.next > span') #2 for page 1\n",
    "pg.click()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "- Get sessions in a dataframe/dictionary with session id as key along with objectives, descriptions and links of presentations, with a new row for each link\n",
    "- Iterate through these rows and obtain information on each of the presentations."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Extract all SessionLinks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "https://www.abstractsonline.com/pp8/#!/9045/sessions/*/1\n"
     ]
    }
   ],
   "source": [
    "SessInfo = {}\n",
    "IterationDict = {}\n",
    "i = 0\n",
    "driver.get('https://www.abstractsonline.com/pp8/#!/9045/sessions/*/1')\n",
    "timeout = 500\n",
    "locator = '//*[@id=\"filter\"]/div/div/button[3]'\n",
    "WebDriverWait(driver, timeout).until(EC.visibility_of_element_located((By.XPATH, locator)))\n",
    "time.sleep(1)\n",
    "ResultsButton = driver.find_element_by_xpath('//*[@id=\"filter\"]/div/div/button[3]')\n",
    "ResultsButton.click()\n",
    "prevurl = ''\n",
    "currenturl = driver.current_url\n",
    "time.sleep(1)\n",
    "while prevurl!=currenturl:\n",
    "    prevurl = currenturl\n",
    "    print(currenturl)\n",
    "    time.sleep(1)\n",
    "    Data = BeautifulSoup(driver.page_source)\n",
    "    Results = Data.find('ul',id = 'results')\n",
    "#     print(Results)\n",
    "    Sessions = Results.find_all('div',class_ = 'span9')\n",
    "    for j in Sessions:\n",
    "        \n",
    "#         SessInfo['Title'] = j.find('span',class_ = 'title color-primary').text\n",
    "#         SessInfo['url'] = 'https://www.abstractsonline.com/pp8/#!/8998/session/'+ j.find('h1',class_ = 'name')['data-id']\n",
    "#         print(SessInfo)\n",
    "        IterationDict[j.find('h1',class_ = 'name')['data-id']] = {}\n",
    "        IterationDict[j.find('h1',class_ = 'name')['data-id']]['Title'] = j.find('span',class_ = 'title color-primary').text\n",
    "        IterationDict[j.find('h1',class_ = 'name')['data-id']]['url'] = 'https://www.abstractsonline.com/pp8/#!/9045/session/'+ j.find('h1',class_ = 'name')['data-id']\n",
    "        i+=1\n",
    "    time.sleep(1)\n",
    "    pg = driver.find_element_by_css_selector('#params > div:nth-child(1) > div > ul > li.next > span') #2 for page 1\n",
    "    pg.click()\n",
    "    currenturl = driver.current_url\n",
    "#     print(currenturl)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "29"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(IterationDict.keys())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'838': {'Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/838'},\n",
       " '843': {'Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/843'},\n",
       " '841': {'Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/841'},\n",
       " '834': {'Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/834'},\n",
       " '853': {'Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/853'},\n",
       " '842': {'Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/842'},\n",
       " '844': {'Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/844'},\n",
       " '848': {'Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/848'},\n",
       " '854': {'Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/854'},\n",
       " '856': {'Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/856'},\n",
       " '35': {'Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/35'},\n",
       " '846': {'Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/846'},\n",
       " '839': {'Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/839'},\n",
       " '845': {'Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/845'},\n",
       " '847': {'Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/847'},\n",
       " '833': {'Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/833'},\n",
       " '855': {'Title': ' VCTPL06. Targeted Therapy',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/855'},\n",
       " '837': {'Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/837'},\n",
       " '840': {'Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/840'},\n",
       " '836': {'Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/836'},\n",
       " '852': {'Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/852'},\n",
       " '34': {'Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/34'},\n",
       " '857': {'Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/857'},\n",
       " '835': {'Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/835'},\n",
       " '860': {'Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/860'},\n",
       " '861': {'Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/861'},\n",
       " '865': {'Title': ' VOS.01. Opening Session',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/865'},\n",
       " '862': {'Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/862'},\n",
       " '36': {'Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'url': 'https://www.abstractsonline.com/pp8/#!/9045/session/36'}}"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "IterationDict\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Extract SessionDetails and urls for presentations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "driver = webdriver.Chrome(r'C:\\Users\\venug\\Downloads\\chromedriver.exe')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\venug\\anaconda3\\lib\\site-packages\\ipykernel_launcher.py:3: TqdmDeprecationWarning: This function will be removed in tqdm==5.0.0\n",
      "Please use `tqdm.notebook.tqdm` instead of `tqdm.tqdm_notebook`\n",
      "  This is separate from the ipykernel package so we can avoid doing imports until\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "06bfe22a90b44d15a87ec879a1149d9d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, max=29.0), HTML(value='')))"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "SessionDetails = {}\n",
    "\n",
    "for _id in tqdm_notebook(IterationDict.keys()):\n",
    "    iteration = 1\n",
    "#     driver = webdriver.Chrome(r'C:\\Users\\venug\\Downloads\\chromedriver.exe')\n",
    "    url = IterationDict[_id]['url']\n",
    "    driver.get(url)\n",
    "#     time.sleep(1)\n",
    "    timeout = 500\n",
    "    locator = '//*[@id=\"body\"]/div/div[2]/div[2]/table'\n",
    "    WebDriverWait(driver, timeout).until(EC.visibility_of_element_located((By.XPATH, locator)))\n",
    "    Data = BeautifulSoup(driver.page_source)\n",
    "    Table = Data.find('div',class_ = 'span7 presentation-table')\n",
    "    trs = Table.find('table',class_ = 'table').find_all('tr')\n",
    "    try:\n",
    "        Objectives = Data.find('div',class_ = 'span3 offset1').text\n",
    "    except:\n",
    "        Objectives = \"\"\n",
    "    try:\n",
    "        Description = Data.find('blockquote',class_ = 'description').text\n",
    "    except:\n",
    "        Description = \"\"\n",
    "    Location = Data.find('table',class_ = 'table table-bordered session-meta')\n",
    "    Date = Location.find_all('td')[0].text\n",
    "    Venue = Location.find_all('td')[1].text\n",
    "    for tr in trs:\n",
    "        t = _id + '-' + str(iteration)\n",
    "        SessionDetails[t] = {}\n",
    "        SessionDetails[t]['Session Title'] = IterationDict[_id]['Title']\n",
    "        SessionDetails[t]['Description'] = Description\n",
    "        SessionDetails[t]['Objectives'] = Objectives\n",
    "        SessionDetails[t]['PresentationUrl'] = 'https://www.abstractsonline.com/pp8/'+tr.find_all('td')[1].find('a')['href']\n",
    "        SessionDetails[t]['Date'] = Date\n",
    "        #SessionDetails[t]['Location'] = Location\n",
    "        iteration+=1\n",
    "#     driver.close()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'838-1': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10564',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-2': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10565',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-3': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11044',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-4': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10567',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-5': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11046',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-6': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10568',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-7': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11047',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-8': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10569',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-9': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11048',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-10': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10570',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-11': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11049',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-12': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10571',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-13': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11050',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-14': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10572',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-15': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11051',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '838-16': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11045',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM'},\n",
       " '843-1': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10681',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-2': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10682',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-3': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10683',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-4': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10684',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-5': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10685',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-6': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10686',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-7': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10687',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-8': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10689',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-9': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10690',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-10': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10691',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-11': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10692',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-12': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10693',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-13': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10694',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-14': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10695',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-15': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10696',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-16': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10697',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-17': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10698',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-18': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10699',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-19': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10700',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-20': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10702',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '843-21': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10803',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '841-1': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10679',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-2': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10680',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-3': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10836',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-4': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10593',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-5': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10837',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-6': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10597',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-7': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10838',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-8': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10594',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-9': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10839',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-10': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10595',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-11': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10840',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-12': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10793',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-13': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10841',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-14': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10596',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-15': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10842',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-16': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10599',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '841-17': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10843',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM'},\n",
       " '834-1': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10529',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-2': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10530',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-3': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10531',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-4': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10532',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-5': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10533',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-6': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10534',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-7': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10535',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-8': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10536',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-9': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10537',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '834-10': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10969',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM'},\n",
       " '853-1': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10749',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-2': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10861',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-3': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10750',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-4': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10862',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-5': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10751',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-6': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10863',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-7': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10958',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-8': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10864',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-9': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10752',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-10': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10865',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-11': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10753',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-12': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10866',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-13': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10756',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-14': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10867',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-15': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10754',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-16': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10868',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-17': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10757',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '853-18': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10869',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM'},\n",
       " '842-1': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10600',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-2': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10601',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-3': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10602',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-4': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10603',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-5': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10604',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-6': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10605',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-7': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10606',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-8': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10607',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-9': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10608',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-10': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10609',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-11': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10610',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-12': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10611',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-13': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10612',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-14': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10613',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-15': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10614',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-16': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10615',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-17': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10616',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-18': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10617',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-19': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10618',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-20': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10619',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-21': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10620',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-22': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10621',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-23': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10622',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-24': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10623',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-25': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10624',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-26': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10625',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-27': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10626',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-28': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10627',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-29': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10628',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-30': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10629',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-31': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10630',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-32': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10631',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-33': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10632',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-34': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10633',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-35': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10634',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-36': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10635',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-37': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10636',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-38': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10637',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-39': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10638',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-40': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10639',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-41': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10640',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-42': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10641',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-43': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10642',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-44': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10643',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-45': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10644',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-46': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10645',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-47': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10646',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-48': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10647',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-49': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10648',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-50': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10649',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-51': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10650',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-52': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10651',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-53': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10652',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-54': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10653',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-55': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10654',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-56': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10655',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-57': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10656',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-58': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10657',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-59': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10658',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-60': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10939',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '842-61': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10953',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-1': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10714',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-2': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10715',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-3': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10716',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-4': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10717',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-5': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10718',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-6': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10719',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '844-7': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10720',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '848-1': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10732',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-2': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10845',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-3': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10733',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-4': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10844',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-5': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10735',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-6': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10846',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-7': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10848',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-8': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10734',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-9': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10847',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-10': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10736',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-11': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10849',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-12': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10737',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-13': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10850',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-14': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10739',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '848-15': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10851',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM'},\n",
       " '854-1': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10758',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-2': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10871',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-3': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10759',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-4': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10872',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-5': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10760',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-6': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10873',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-7': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10765',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-8': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10874',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-9': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10761',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-10': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10875',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-11': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10762',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-12': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10876',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-13': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10960',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-14': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10877',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-15': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10798',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-16': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10878',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-17': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10763',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-18': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10879',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-19': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10766',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '854-20': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10880',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM'},\n",
       " '856-1': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10772',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-2': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10886',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-3': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10773',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-4': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10887',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-5': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10774',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-6': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10888',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-7': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10778',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-8': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10889',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-9': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10775',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-10': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10890',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-11': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10776',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-12': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10891',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-13': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10779',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-14': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10892',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-15': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10777',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-16': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10893',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-17': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10802',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '856-18': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10894',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM'},\n",
       " '35-1': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/97',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM'},\n",
       " '35-2': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/234',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM'},\n",
       " '35-3': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/2167',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM'},\n",
       " '35-4': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/6845',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM'},\n",
       " '35-5': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/2228',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM'},\n",
       " '35-6': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/2250',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM'},\n",
       " '846-1': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10703',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-2': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10704',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-3': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10705',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-4': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10706',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-5': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10707',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-6': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10709',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-7': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10710',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-8': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10711',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-9': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10712',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-10': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10713',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '846-11': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10812',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '839-1': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10975',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-2': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10977',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-3': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11053',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-4': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11054',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-5': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10574',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-6': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10987',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-7': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10575',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-8': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10990',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-9': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10576',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-10': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10993',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-11': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10577',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-12': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10997',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-13': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10578',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-14': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10999',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-15': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10579',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-16': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11003',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '839-17': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11007',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM'},\n",
       " '845-1': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10659',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-2': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10660',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-3': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10661',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-4': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10662',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-5': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10663',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-6': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10664',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-7': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10665',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-8': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10666',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-9': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10667',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-10': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10668',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-11': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10669',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-12': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10670',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-13': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10671',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-14': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10672',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-15': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10673',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-16': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10674',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-17': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10675',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-18': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10676',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-19': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10677',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '845-20': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10678',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-1': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10721',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-2': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10722',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-3': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10723',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-4': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10724',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-5': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10725',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-6': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10726',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-7': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10727',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-8': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10728',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-9': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10729',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-10': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10730',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '847-11': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10731',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM'},\n",
       " '833-1': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10520',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-2': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10521',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-3': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10996',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-4': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10522',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-5': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10998',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-6': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10523',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-7': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11005',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-8': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10524',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-9': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11004',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-10': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10525',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-11': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11008',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-12': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10526',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-13': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11009',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-14': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10528',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-15': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11010',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '833-16': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11028',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '855-1': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10767',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '855-2': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10881',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '855-3': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10768',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '855-4': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10882',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '855-5': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10962',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '855-6': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10883',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '855-7': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10885',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM'},\n",
       " '837-1': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10555',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-2': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10556',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-3': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10983',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-4': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10557',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-5': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10986',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-6': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10558',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-7': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10988',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-8': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10559',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-9': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10991',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-10': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10560',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-11': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10989',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-12': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10562',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-13': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10992',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-14': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10563',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-15': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10994',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '837-16': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10985',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM'},\n",
       " '840-1': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10580',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-2': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10581',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-3': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11034',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-4': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10583',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-5': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11036',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-6': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10586',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-7': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11037',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-8': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10587',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-9': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11039',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '840-10': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11033',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM'},\n",
       " '836-1': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10547',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-2': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10548',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-3': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10963',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-4': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10549',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-5': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10965',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-6': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10550',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-7': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10966',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-8': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10551',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-9': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10967',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-10': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10552',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-11': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10968',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-12': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10553',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-13': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10970',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '836-14': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10961',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM'},\n",
       " '852-1': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10796',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-2': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10852',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-3': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10741',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-4': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10853',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-5': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10742',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-6': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10854',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-7': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10746',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-8': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10855',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-9': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10743',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-10': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10856',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-11': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10747',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-12': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10857',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-13': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10744',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-14': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10858',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-15': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10745',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-16': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10859',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '852-17': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10860',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM'},\n",
       " '34-1': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/95',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '34-2': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8514',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '34-3': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11063',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '34-4': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/6808',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '34-5': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/6809',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '34-6': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8516',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '34-7': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11064',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM'},\n",
       " '857-1': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10781',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-2': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10895',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-3': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10782',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-4': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10896',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-5': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10783',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-6': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10897',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-7': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10789',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-8': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10898',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-9': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10784',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-10': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10899',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-11': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10785',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-12': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10900',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-13': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10786',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-14': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10901',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-15': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10902',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-16': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10787',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-17': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10903',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-18': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10788',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-19': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10904',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-20': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10791',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '857-21': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10910',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM'},\n",
       " '835-1': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10538',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-2': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10539',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-3': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11055',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-4': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10540',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-5': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11056',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-6': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10541',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-7': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11057',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-8': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10542',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-9': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11058',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-10': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10543',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-11': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11059',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-12': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10544',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-13': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11060',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-14': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10545',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-15': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11061',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-16': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10546',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-17': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11062',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '835-18': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11066',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM'},\n",
       " '860-1': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10825',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-2': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11016',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-3': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10829',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-4': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10835',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-5': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10830',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-6': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11012',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-7': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10831',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-8': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11013',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-9': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10832',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-10': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11014',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-11': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10833',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-12': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11018',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-13': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10834',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-14': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11019',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '860-15': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11017',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM'},\n",
       " '861-1': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10814',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-2': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10815',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-3': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10959',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-4': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10817',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-5': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10816',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-6': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10818',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-7': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10824',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-8': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10820',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-9': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11026',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-10': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10821',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-11': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11027',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-12': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10822',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-13': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11029',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-14': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10823',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-15': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11030',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '861-16': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11031',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM'},\n",
       " '865-1': {'Session Title': ' VOS.01. Opening Session',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Opening Session\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10954',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 9:30 AM'},\n",
       " '865-2': {'Session Title': ' VOS.01. Opening Session',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Opening Session\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10955',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 9:30 AM'},\n",
       " '865-3': {'Session Title': ' VOS.01. Opening Session',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Opening Session\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10956',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 9:30 AM'},\n",
       " '862-1': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10924',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-2': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10926',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-3': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10932',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-4': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10927',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-5': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10935',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-6': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10937',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-7': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10938',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '862-8': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10936',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM'},\n",
       " '36-1': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/99',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM'},\n",
       " '36-2': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8520',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM'},\n",
       " '36-3': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8521',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM'},\n",
       " '36-4': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8522',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM'}}"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "SessionDetails"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\venug\\anaconda3\\lib\\site-packages\\ipykernel_launcher.py:4: TqdmDeprecationWarning: This function will be removed in tqdm==5.0.0\n",
      "Please use `tqdm.notebook.tqdm` instead of `tqdm.tqdm_notebook`\n",
      "  after removing the cwd from sys.path.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "603ebc0a49e044f992eb7ff12c294a49",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, max=440.0), HTML(value='')))"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "PresentationDetails = {}\n",
    "\n",
    "\n",
    "for i in tqdm_notebook(SessionDetails.keys()):\n",
    "    PresentationDetails[i]= {}\n",
    "    PresentationDetails[i]['Session Title'] = SessionDetails[i]['Session Title'] \n",
    "    PresentationDetails[i]['Description'] = SessionDetails[i]['Description'] \n",
    "    PresentationDetails[i]['Objectives'] = SessionDetails[i]['Objectives']\n",
    "    PresentationDetails[i]['PresentationUrl'] = SessionDetails[i]['PresentationUrl'] \n",
    "    PresentationDetails[i]['Date'] = SessionDetails[i]['Date']\n",
    "#     PresentationDetails[i]['Location']  = SessionDetails[i]['Location'] \n",
    "    url = SessionDetails[i]['PresentationUrl']\n",
    "\n",
    "#     url = SessionDetails[i]['PresentationUrl']\n",
    "    driver.get(url)\n",
    "#         driver.refresh()\n",
    "    timeout = 500\n",
    "    locator = '//*[@id=\"body\"]/div/div[2]/div/dl/dd[2]'\n",
    "    WebDriverWait(driver, timeout).until(EC.visibility_of_element_located((By.XPATH, locator)))\n",
    "    time.sleep(2.5)\n",
    "    Data = BeautifulSoup(driver.page_source,'lxml')\n",
    "    PresentationDetails[i]['Presentation Title'] = Data.find('h1',class_ ='color-primary').text\n",
    "    PresentationDetails[i]['Presentation Time'] = Data.find('span',class_ = 'session-date').text\n",
    "    PresentationDetails[i]['Presentation Location'] = Data.find('span',class_ = 'session-location').text\n",
    "    ParticipantAbstract = Data.select('#body > div > div:nth-child(3) > div > dl')\n",
    "    headers = ParticipantAbstract[0].find_all('dt')\n",
    "    content = ParticipantAbstract[0].find_all('dd')\n",
    "    for j in range(len(headers)):\n",
    "        PresentationDetails[i][headers[j].text] = content[j].text\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'https://www.abstractsonline.com/pp8/#!/8998/presentation/10877'"
      ]
     },
     "execution_count": 300,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "url\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 301,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 301,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "driver.current_url == url"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'838-1': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10564',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Samra Turajlic. The Francis Crick Institute, London, United Kingdom',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-2': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10565',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Elana Judith Fertig. Johns Hopkins Sidney Kimmel Comp. Cancer Center, Baltimore, MD',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-3': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11044',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:50 PM - 3:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Samra Turajlic. The Francis Crick Institute, London, United Kingdom',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-4': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10567',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5702\\n                        \\n                         - A spatially resolved single cell atlas of the human breast\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:55 PM - 4:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Tapsi Kumar1, Quy Nguyen2, Kevin Nee2, Shanshan Bai1, Min Hu1, Emi Sei1, Anita Wood1, Jie Wiley1, Hui Chen1, Alejandro Contreras1, Mediget Teshome1, Ken Chen1, Bora Lim1, Devon Lawson2, Nicholas Navin1, Kai Kessenbrock2. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2University of California, Irvine, Irvine, CA ',\n",
       "  'Disclosures': '\\xa0T. Kumar: None.\\xa0Q. Nguyen: None.\\xa0K. Nee: None.\\xa0S. Bai: None.\\xa0M. Hu: None.\\xa0E. Sei: None.\\xa0A. Wood: None.\\xa0J. Wiley: None.\\xa0H. Chen: None.\\xa0A. Contreras: None.\\xa0M. Teshome: None.\\xa0K. Chen: None.\\xa0B. Lim: None.\\xa0D. Lawson: None.\\xa0N. Navin: None.\\xa0K. Kessenbrock: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-5': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11046',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:05 PM - 4:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-6': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10568',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5703\\n                        \\n                         - Oncologic therapy shapes the fitness landscape of clonal hematopoiesis\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:10 PM - 4:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Kelly L. Bolton1, Ryan N. Ptashkin1, Teng Gao1, Lior Braunstein1, Sean M. Devlin1, Minal Patel1, Antonin Berthon1, Aijazuddin Syed1, Mariko Yabe1, Catherine Coombs2, Nicole M. Caltabellotta1, Mike Walsh1, Ken Offit1, Zsofia Stadler1, Choonsik Lee1, Paul Pharoah3, Konrad H. Stopsack1, Barbara Spitzer1, Simon Mantha1, James Fagin1, Laura Boucai1, Christopher J. Gibson4, Benjamin Ebert4, Andrew L. Young5, Todd Druley5, Koichi Takahashi6, Nancy Gillis7, Markus Ball7, Eric Padron7, David Hyman1, Jose Baselga1, Larry Norton1, Stuart Gardos1, Virginia Klimek1, Howard Scher1, Dean Bajorin1, Eder Paraiso1, Ryma Benayed1, Maria Arcilla1, Marc Ladanyi1, David Solit1, Michael Berger1, Martin Tallman1, Montserrat Garcia-Closas8, Nilanjan Chatterjee1, Luis Diaz1, Ross Levine1, Lindsay Morton8, Ahmet Zehir1, Elli Papaemmanuil1. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2University of North Carolina at Chapel Hill, Chapel Hill, NC; 3University of Cambridge, Cambridge, United Kingdom; 4Dana-Farber Cancer Institute, Boston, MA; 5Washington University, St Louis, MO; 6The University of Texas MD Anderson Cancer Center, Houston, TX; 7Moffitt Cancer Center, Tampa, FL; 8National Cancer Institute, Bethesda, MD ',\n",
       "  'Disclosures': '\\xa0K.L. Bolton: None.\\xa0R.N. Ptashkin: None.\\xa0T. Gao: None.\\xa0L. Braunstein: None.\\xa0S.M. Devlin: None.\\xa0M. Patel: None.\\xa0A. Berthon: None.\\xa0A. Syed: None.\\xa0M. Yabe: None. C. Coombs:  ; Honoraria from AbbVie, Loxo, H3 Biomedicine, Medscape, Octapharma, and Pharmacyclics; has served as a consultant for AbbVie, Covance, Cowen & Co., and Dedham Group; has received institutional research; ..\\xa0N.M. Caltabellotta: None.\\xa0M. Walsh: None.\\xa0K. Offit: None.\\xa0Z. Stadler: None.\\xa0C. Lee: None.\\xa0P. Pharoah: None.\\xa0K.H. Stopsack: None.\\xa0B. Spitzer: None.\\xa0S. Mantha: None.\\xa0J. Fagin: None.\\xa0L. Boucai: None.\\xa0C.J. Gibson: None.\\xa0B. Ebert: None.\\xa0A.L. Young: None. T. Druley:  ; Chief Medical Officer, ArcherDX, Inc; salary and ownership; .\\xa0K. Takahashi:  ; Symbio Pharmaceuticals: Consultancy fee; ..\\xa0N. Gillis: None.\\xa0M. Ball: None. E. Padron:  ; Research Funding from Incyte, Kura Oncology, and Celgene; .\\xa0D. Hyman:  ; Consulted for Fount, Chugai, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, and Genentech/Roche. He has equity in Fount. He has received research grants from Loxo, Bayer, Puma, and AstraZeneca.; .\\xa0J. Baselga:  ; J.B. is an employee of AstraZeneca. He is on the Board of Directors of Foghorn and is a past board member of Varian Medical Systems, BristolMyers Squibb, Grail, Aura Biosciences and Infinity Pharmaceuticals. He has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, Juno, Eli Lilly, Seragon, Novartis, and Northern Biologics.; .. ; He has stock or other ownership interests in PMV Pharma, Grail, Juno, Varian, Foghorn, Aura, Infinity Pharmaceuticals, ApoGen, Northern Biologics as well as Tango and Venthera, for which is a cofounder. He has previously received Honoraria or Travel Expenses from Roche, Novartis, and Eli Lilly.; ..\\xa0L. Norton: None.\\xa0S. Gardos: None.\\xa0V. Klimek: None.\\xa0H. Scher: None.\\xa0D. Bajorin: None.\\xa0E. Paraiso: None.\\xa0R. Benayed: None.\\xa0M. Arcilla: None. M. Ladanyi:  ; Advisory boards: Astra-Zeneca, Bristol Myers Squibb, Takeda, Bayer, Merck. Research support: LOXO Oncology, Helsinn Therapeutics; .\\xa0D. Solit:  ; consultant/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina and Vivideon Therapeutics.; .\\xa0M. Berger:  ; Consulting and advisory board (Roche), Research support (Illumina); .\\xa0M. Tallman:  ; Research funding: AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight; Advisory Board: Daiichi-Sankyo, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma; Royalties from UpToDate; ..\\xa0M. Garcia-Closas: None.\\xa0N. Chatterjee: None. L. Diaz:  ; Luis A. Diaz (LAD) is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. He is a paid consultant to PGDx and Neophore. He is an uncompensated consultant for Merck but has received travel and research support for clinical trials from Merck.; .. ; LAD is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and LAD.; .. ; He holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore. His wife holds equity in Amgen. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies.; .\\xa0R. Levine:  ; R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis which include equity interest. He receives research support from and consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys and Novartis. He has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews; ..\\xa0L. Morton: None. A. Zehir:  ; Recieved honoraria from Illumina; ..\\xa0E. Papaemmanuil: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-7': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11047',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:20 PM - 4:25 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-8': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10569',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5704\\n                        \\n                         - Pan-cancer genomic characterization of patient-matched primary, extracranial, and brain metastases\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:25 PM - 4:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Olivia W. Lee1, Akash Mitra1, Won-Chul Lee1, Kazutaka Fukumura1, Hannah Beird1, Miles Andrews2, Grant Fischer1, John N. Weinstein1, Michael A. Davies1, Jason Huse1, P. Andrew Futreal1. 1The University of Texas MD Anderson Cancer Center, TX; 2Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Australia ',\n",
       "  'Disclosures': '\\xa0O.W. Lee: None.\\xa0A. Mitra: None.\\xa0W. Lee: None.\\xa0K. Fukumura: None.\\xa0H. Beird: None. M. Andrews:  ; Merck Sharp and Dohme.\\xa0G. Fischer: None.\\xa0J.N. Weinstein: None. M.A. Davies:  ; Bristol-Myers Squibb. ; Novartis. ; Array BioPharma. ; Roche and Genentech. ; GlaxoSmithKline. ; Sanofi-Aventis. ; AstraZeneca. ; Myriad Genetics. ; Oncothyreon.\\xa0J. Huse: None.\\xa0P. Futreal: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-9': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11048',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:20 PM - 4:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-10': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10570',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5705\\n                        \\n                         - Mechanisms and therapeutic implications of hypermutation in gliomas\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:40 PM - 4:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Mehdi Touat1, Yvonne Y. Li1, Adam N. Boynton1, Liam F. Spurr2, Bryan Iorgulescu1, Craig L. Bohrson3, Isidro Cortes-Ciriano4, Jack E. Geduldig1, Kristine Pelton1, Mary J. Lim-Fat1, Sangita Pal5, Shakti H. Ramkissoon6, Frank Dubois5, Charlotte Bellamy1, Naomi Currimjee1, Kenin Qian1, Seth Malinowski1, Aniket Shetty1, Kin-Hoe Chow1, Mat Verreault7, Erell Guillerm8, Samy Ammari9, Frdric Beuvon10, Karima Mokhtari7, Agusti Alentorn7, Caroline Dehais7, Caroline Houillier7, Florence Laigle-Donadey7, Dimitri Psimaras7, Alexandre Carpentier11, Philippe Cornu11, Laurent Capelle11, Bertrand Mathon11, Jill S. Barnholtz-Sloan12, Arnab Chakravarti13, Wenya L. Bi14, Garrett M. Frampton15, Marc Sanson16, Brian M. Alexander17, Andrew Cherniack1, Patrick Y. Wen1, David A. Reardon1, Aurelien Marabelle18, Peter J. Park3, Ahmed Idbaih19, Rameen Beroukhim1, Pratiti Bandopadhayay1, Franck Bielle20, Keith L. Ligon1. 1Dana-Farber Cancer Institute, Boston, MA; 2Broad Institute of MIT and Harvard, Cambridge, MA, MA; 3Harvard Medical School, Boston, MA; 4European Molecular European Bioinformatics Institute, Wellcome Genome Campus, HInxton, United Kingdom; 5Broad Institute of MIT and Harvard, Cambridge, MA; 6Foundation Medicine Inc, Cambridge, MA; 7Sorbonne Universit, Inserm, Paris, France; 8Hpitaux Universitaires La Piti Salptrire, Paris, France; 9Gustave Roussy, Villejuif, France; 10Universit Paris Descartes, Hpital Cochin, Paris, France; 11Sorbonne Universit, Hpitaux Universitaires La Piti Salptrire, Paris, France; 12Case Western Reserve University School of Medicine, Cleveland, OH; 13Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Cleveland, OH; 14Brigham & Women's Hospital, Harvard Medical School, Boston, MA; 15Foundation Medicine, Boston, MA; 16Sorbonne Universite, France; 17Dana Farber Cancer Institute, Boston, MA; 18Gustave Roussy, Paris, France; 19Sorbonne Universit, France; 20Sorbonne Universit, Paris, France \",\n",
       "  'Disclosures': '\\xa0\\xa0M. Touat:  ; Agios Pharmaceutical. ; Integragen. ; Taiho Oncology. ; travel, accommodations, expenses; Merck Sharp & Dome.\\xa0Y.Y. Li: None.\\xa0A.N. Boynton: None.\\xa0L.F. Spurr: None.\\xa0B. Iorgulescu: None.\\xa0C.L. Bohrson: None.\\xa0I. Cortes-Ciriano: None.\\xa0J.E. Geduldig: None.\\xa0K. Pelton: None.\\xa0M.J. Lim-Fat: None.\\xa0S. Pal: None.\\xa0S.H. Ramkissoon: None.\\xa0F. Dubois: None.\\xa0C. Bellamy: None.\\xa0N. Currimjee: None.\\xa0K. Qian: None.\\xa0S. Malinowski: None.\\xa0A. Shetty: None.\\xa0K. Chow: None.\\xa0M. Verreault: None.\\xa0E. Guillerm: None.\\xa0S. Ammari: None.\\xa0F. Beuvon: None.\\xa0K. Mokhtari: None.\\xa0A. Alentorn: None.\\xa0C. Dehais: None.\\xa0C. Houillier: None.\\xa0F. Laigle-Donadey: None.\\xa0D. Psimaras: None.\\xa0A. Carpentier: None.\\xa0P. Cornu: None.\\xa0L. Capelle: None.\\xa0B. Mathon: None.\\xa0J.S. Barnholtz-Sloan: None.\\xa0A. Chakravarti: None.\\xa0W.L. Bi: None. G.M. Frampton:  ; Foundation Medicine.\\xa0M. Sanson: None. B.M. Alexander:  ; Foundation Medicine.\\xa0A. Cherniack: None.\\xa0P.Y. Wen: None.\\xa0D.A. Reardon: None.\\xa0A. Marabelle: None.\\xa0P.J. Park: None.\\xa0A. Idbaih: None. R. Beroukhim:  ; Novartis. P. Bandopadhayay:  ; Novartis.\\xa0F. Bielle: None. K.L. Ligon:  ; Travera LLC. ; Eli Lilly. ; Rarecyte. ; Amgen. ; BMS. ; Integragen. ; Deciphera.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-11': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11049',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5705\\n                        \\n                         - Mechanisms and therapeutic implications of hypermutation in gliomas\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:40 PM - 4:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Mehdi Touat1, Yvonne Y. Li1, Adam N. Boynton1, Liam F. Spurr2, Bryan Iorgulescu1, Craig L. Bohrson3, Isidro Cortes-Ciriano4, Jack E. Geduldig1, Kristine Pelton1, Mary J. Lim-Fat1, Sangita Pal5, Shakti H. Ramkissoon6, Frank Dubois5, Charlotte Bellamy1, Naomi Currimjee1, Kenin Qian1, Seth Malinowski1, Aniket Shetty1, Kin-Hoe Chow1, Mat Verreault7, Erell Guillerm8, Samy Ammari9, Frdric Beuvon10, Karima Mokhtari7, Agusti Alentorn7, Caroline Dehais7, Caroline Houillier7, Florence Laigle-Donadey7, Dimitri Psimaras7, Alexandre Carpentier11, Philippe Cornu11, Laurent Capelle11, Bertrand Mathon11, Jill S. Barnholtz-Sloan12, Arnab Chakravarti13, Wenya L. Bi14, Garrett M. Frampton15, Marc Sanson16, Brian M. Alexander17, Andrew Cherniack1, Patrick Y. Wen1, David A. Reardon1, Aurelien Marabelle18, Peter J. Park3, Ahmed Idbaih19, Rameen Beroukhim1, Pratiti Bandopadhayay1, Franck Bielle20, Keith L. Ligon1. 1Dana-Farber Cancer Institute, Boston, MA; 2Broad Institute of MIT and Harvard, Cambridge, MA, MA; 3Harvard Medical School, Boston, MA; 4European Molecular European Bioinformatics Institute, Wellcome Genome Campus, HInxton, United Kingdom; 5Broad Institute of MIT and Harvard, Cambridge, MA; 6Foundation Medicine Inc, Cambridge, MA; 7Sorbonne Universit, Inserm, Paris, France; 8Hpitaux Universitaires La Piti Salptrire, Paris, France; 9Gustave Roussy, Villejuif, France; 10Universit Paris Descartes, Hpital Cochin, Paris, France; 11Sorbonne Universit, Hpitaux Universitaires La Piti Salptrire, Paris, France; 12Case Western Reserve University School of Medicine, Cleveland, OH; 13Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Cleveland, OH; 14Brigham & Women's Hospital, Harvard Medical School, Boston, MA; 15Foundation Medicine, Boston, MA; 16Sorbonne Universite, France; 17Dana Farber Cancer Institute, Boston, MA; 18Gustave Roussy, Paris, France; 19Sorbonne Universit, France; 20Sorbonne Universit, Paris, France \",\n",
       "  'Disclosures': '\\xa0\\xa0M. Touat:  ; Agios Pharmaceutical. ; Integragen. ; Taiho Oncology. ; travel, accommodations, expenses; Merck Sharp & Dome.\\xa0Y.Y. Li: None.\\xa0A.N. Boynton: None.\\xa0L.F. Spurr: None.\\xa0B. Iorgulescu: None.\\xa0C.L. Bohrson: None.\\xa0I. Cortes-Ciriano: None.\\xa0J.E. Geduldig: None.\\xa0K. Pelton: None.\\xa0M.J. Lim-Fat: None.\\xa0S. Pal: None.\\xa0S.H. Ramkissoon: None.\\xa0F. Dubois: None.\\xa0C. Bellamy: None.\\xa0N. Currimjee: None.\\xa0K. Qian: None.\\xa0S. Malinowski: None.\\xa0A. Shetty: None.\\xa0K. Chow: None.\\xa0M. Verreault: None.\\xa0E. Guillerm: None.\\xa0S. Ammari: None.\\xa0F. Beuvon: None.\\xa0K. Mokhtari: None.\\xa0A. Alentorn: None.\\xa0C. Dehais: None.\\xa0C. Houillier: None.\\xa0F. Laigle-Donadey: None.\\xa0D. Psimaras: None.\\xa0A. Carpentier: None.\\xa0P. Cornu: None.\\xa0L. Capelle: None.\\xa0B. Mathon: None.\\xa0J.S. Barnholtz-Sloan: None.\\xa0A. Chakravarti: None.\\xa0W.L. Bi: None. G.M. Frampton:  ; Foundation Medicine.\\xa0M. Sanson: None. B.M. Alexander:  ; Foundation Medicine.\\xa0A. Cherniack: None.\\xa0P.Y. Wen: None.\\xa0D.A. Reardon: None.\\xa0A. Marabelle: None.\\xa0P.J. Park: None.\\xa0A. Idbaih: None. R. Beroukhim:  ; Novartis. P. Bandopadhayay:  ; Novartis.\\xa0F. Bielle: None. K.L. Ligon:  ; Travera LLC. ; Eli Lilly. ; Rarecyte. ; Amgen. ; BMS. ; Integragen. ; Deciphera.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-12': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10571',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5706\\n                        \\n                         - Identifying regulators of cancer heterogeneity with phenotypic sorting and single cell sequencing\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:55 PM - 5:05 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': 'Kevin Chen, Stephanie Irene Fraley. University of California, San Diego, La Jolla, CA ',\n",
       "  'Disclosures': '\\xa0K. Chen: None. S.I. Fraley:  ; Melio Labs, Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-13': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11050',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 5:05 PM - 5:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-14': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10572',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5707\\n                        \\n                         - A standard operating procedure for the interpretation of oncogenicity/pathogenicity of somatic mutations\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 5:05 PM - 5:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Peter Horak1, Malachi Griffith2, Arpad Danos2, Beth A. Pitel3, Subha Madhavan4, Xuelu Liu5, Jennifer Lee6, Gordana Raca7, Shirley Li8, Alex H. Wagner2, Shashikant Kulkarni9, Obi L. Griffith2, Debyani Chakravarty10, Dmitriy Sonkin11. 1National Center for Tumor Diseases, Heidelberg, Germany; 2Washington University School of Medicine, St. Louis, MO; 3Mayo Clinic, Rochester, MN; 4Georgetown University Medical Center, Washington, DC; 5Dana-Farber Cancer Institute, Boston, MA; 6Frederick National Laboratory for Cancer Research, Rockville, MD; 7University of Southern California, Los Angeles, CA; 8Sunquest, Boston, MA; 9Baylor College of Medicine, Houston, TX; 10Memorial Sloan Kettering Cancer Center, New York, NY; 11National Cancer Institute, Rockville, MD ',\n",
       "  'Disclosures': '\\xa0P. Horak: None.\\xa0M. Griffith: None.\\xa0A. Danos: None.\\xa0B.A. Pitel: None. S. Madhavan:  ; Perthera Inc.\\xa0X. Liu: None.\\xa0J. Lee: None.\\xa0G. Raca: None. S. Li:  ; Sunquest Information Systems, Inc.\\xa0A.H. Wagner: None. S. Kulkarni:  ; Baylor Genetics.\\xa0O.L. Griffith: None.\\xa0D. Chakravarty: None.\\xa0D. Sonkin: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '838-15': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11051',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 5:15 PM - 5:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '838-16': {'Session Title': ' VMS.MCB09.01. Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11045',\n",
       "  'Date': ' April 28, 2020, 3:50 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 5:25 PM - 5:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Elana Judith Fertig. Johns Hopkins Sidney Kimmel Comp. Cancer Center, Baltimore, MD',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-1': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10681',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT181\\n                        \\n                         - Phase I/II clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) as treatment for adolescents and young adults (AYA) with cancers involving the CNS\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Lee Roy Morgan, Jr.1, Roy S. Weiner2, Tallat Mahmood3, Marcus Ware4, Andrew H. Rodgers1, Manish Bhandari5, Philip Friedlander6. 1Dekk-Tec inc, New Orleans, LA; 2Tulane University, New Orleans, LA; 3Detroit Clinical Research Center, Lansing, MI; 4Ochsner Medical Center, New Orleans, LA; 5The Christ Hospital, Cinicinnati, OH; 6Mount Sinai Medical School, New York, NY ',\n",
       "  'Disclosures': '\\xa0L.R. Morgan: None.\\xa0R.S. Weiner: None.\\xa0T. Mahmood: None.\\xa0M. Ware: None.\\xa0A.H. Rodgers: None.\\xa0M. Bhandari: None.\\xa0P. Friedlander: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-2': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10682',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT182\\n                        \\n                         - Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Daniella A. Bota1, Christopher M. Duma2, Santosh Kesari3, David E. Piccioni4, Renato V. LaRocca5, Robert T. O'Donnell6, Robert D. Aiken7, Jose A. Carrillo3, Candace Hsieh8, Chris J. E. Langford8, Krystal Carta8, Adrienne M. Wang8, James A. Langford8, Thomas H. Taylor1, Gabriel I. Nistor8, Robert O. Dillman8. 1University of California Irvine, Irvine, CA; 2Hoag Hospital, Newport Beach, CA; 3John Wayne Cancer Institute, Santa Monica, CA; 4University of California San Diego, La Jolla, CA; 5Norton Cancer Institute, Louisville, KY; 6University of California Davis, Sacramento, CA; 7Rutgers University, New Brunswick, NJ; 8AIVITA Biomedical Inc, Irvine, CA \",\n",
       "  'Disclosures': \"\\xa0D.A. Bota: None.\\xa0C.M. Duma: None.\\xa0S. Kesari: None.\\xa0D.E. Piccioni: None.\\xa0R.V. LaRocca: None.\\xa0R.T. O'Donnell: None.\\xa0R.D. Aiken: None.\\xa0J.A. Carrillo: None. C. Hsieh:  ; AIVITA Biomedical Inc. C.J.E. Langford:  ; AIVITA Biomedical Inc. K. Carta:  ; AIVITA Biomedical Inc. A.M. Wang:  ; AIVITA Biomedical Inc. J.A. Langford:  ; AIVITA Biomedical Inc.\\xa0T.H. Taylor: None. G.I. Nistor:  ; AIVITA Biomedical Inc. R.O. Dillman:  ; AIVITA Biomedical Inc.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-3': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10683',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT183\\n                        \\n                         - CD5+ B-cell count is a favorable prognostic factor associated with progression-free survival in glioblastoma patients receiving chemoradiation and pembrolizumab\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Cheryl J. Claunch, Claire Diaz, Riley A. Roth-Carter, Lauren Popp, Rochelle Fu, Amy E. Huddleston, Dana L. Moussalli, Julie Peterson, Kutluay Uluc, Laszlo Szidonya, Guang Fan, Ferdinando Pucci, Ramon F. Barajas, Leslie L. Muldoon, Edward A. Neuwelt, Prakash Ambady. Oregon Health & Science University, Portland, OR ',\n",
       "  'Disclosures': '\\xa0C.J. Claunch: None.\\xa0C. Diaz: None.\\xa0R.A. Roth-Carter: None.\\xa0L. Popp: None.\\xa0R. Fu: None.\\xa0A.E. Huddleston: None.\\xa0D.L. Moussalli: None.\\xa0J. Peterson: None.\\xa0K. Uluc: None.\\xa0L. Szidonya: None.\\xa0G. Fan: None.\\xa0F. Pucci: None.\\xa0R.F. Barajas: None.\\xa0L.L. Muldoon: None.\\xa0E.A. Neuwelt: None.\\xa0P. Ambady: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-4': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10684',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT184\\n                        \\n                         - Optimizing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nikola Mikic, Anders R. Korshj. Aarhus University Hospital, Dept. of Neurosurgery, Aarhus, Denmark ',\n",
       "  'Disclosures': '\\xa0N. Mikic: None. A.R. Korshj:  ; Novocure.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-5': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10685',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT185\\n                        \\n                         - A phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hyo S. Han1, Dawn Goodridge1, Avan Armaghani1, Ricardo Costa1, Aixa Soyano Muller1, Loretta Loftus1, Hatem Soliman1, Brooke Fridley1, Laila Khazai2, Aiana Cerezo1, Jesse Hevia1, Marilin Rosa1, Hung Khong1, Brian Czerniecki1. 1Moffitt Cancer Center, Tampa, FL; 2MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0H.S. Han:  ; Lilly. ; research funding to institution; Department of Defense. ; research funding to institution for this study; Horizon. ; research funding to institution; Abbvie. ; research funding to institution; BMS. ; research funding to institution; Pfizer. ; research funding to institution; Tesaro. ; research funding to institution; Seattle Genetics. ; research funding to institution; Prescient. ; research funding to institution; Novartis. ; research funding to institution; Arvinas. ; research funding to institution; Daiichi. ; Zymeworks.\\xa0D. Goodridge: None.\\xa0A. Armaghani: None. R. Costa:  ; pfizer. ; BMS. ; Daiichi-Sankyo. ; BMS.\\xa0A. Soyano Muller: None. L. Loftus:  ; Eli Lilly. ; Johnson and Johnson. ; Pfizer. ; Amgen. ; Gilead. ; Expert witness; Novartis. ; Athenax. ; Daiichi Sankyo. H. Soliman:  ; Eisai. ; Celgene. ; Novartis. ; Astrazeneca. ; Seattle Genetics.\\xa0B. Fridley: None.\\xa0L. Khazai: None.\\xa0A. Cerezo: None.\\xa0J. Hevia: None.\\xa0M. Rosa: None. H. Khong:  ; Exelixis. ; Aveo. ; Clearside Biomedical. ; Immunomedics. ; Mei Pharma. ; molecular templates. ; Savara Inc. ; TG therapeutics. ; Vicking therapeutics. ; Novartis. B. Czerniecki:  ; IP; Immunorestoration.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-6': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10686',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT186\\n                        \\n                         - HEPANOVA: Interim safety analysis from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Eleni Gkika, Thomas Brunner, Robert Thimme, Anca-Ligia Grosu. University of Freiburg, Freiburg, Germany ',\n",
       "  'Disclosures': '\\xa0E. Gkika: None.\\xa0T. Brunner: None.\\xa0R. Thimme: None.\\xa0A. Grosu: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-7': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10687',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT187\\n                        \\n                         - Pembrolizumab and nanoparticle albumin bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Patrizia Giannatempo1, Daniele Raggi1, Elena Far1, Laura Marandino1, Marco Bandini2, Maurizio Colecchia1, Filippo Pederzoli2, Giuseppina Calareso1, Russell Madison3, Francesco Monopoli1, Giusy Russo1, Roberto Ferrara1, Filippo De Braud1, Francesco Montorsi2, Andrea Necchi1. 1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 2San Raffaele Hospital and Scientific Institute, Milan, Italy; 3Foundation Medicine, Cambridge, MA ',\n",
       "  'Disclosures': '\\xa0P. Giannatempo: None.\\xa0D. Raggi: None.\\xa0E. Far: None.\\xa0L. Marandino: None.\\xa0M. Bandini: None.\\xa0M. Colecchia: None.\\xa0F. Pederzoli: None.\\xa0G. Calareso: None.\\xa0R. Madison: None.\\xa0F. Monopoli: None.\\xa0G. Russo: None.\\xa0R. Ferrara: None.\\xa0F. De Braud: None.\\xa0F. Montorsi: None.\\xa0A. Necchi: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-8': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10689',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT188\\n                        \\n                         - Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Shannon N. Westin1, Sanghoon Lee1, Li Zhao1, Ying Yuan1, Jimin Wu1, Richard Hajek1, Sara Sharafi1, Larissa A. Meyer1, Nicole D. Fleming1, Amir Jazaeri1, Robert L. Coleman1, Karen H. Lu1, Gordon B. Mills2, Jianhua Zhang1, Andrew Futreal1, Anil K. Sood1. 1UT MD Anderson Cancer Center, Houston, TX; 2Oregon Health Sciences University, Portland, OR ',\n",
       "  'Disclosures': '\\xa0\\xa0S.N. Westin:  ; AstraZeneca. ; Clovis Oncology. ; Tesaro/GSK. ; Merck. ; Pfizer. ; Novartis. ; ArQule. ; Bayer. ; Cotinga Pharmaceuticals. ; Circulogene Theranostics. ; Eisai.\\xa0S. Lee: None.\\xa0L. Zhao: None.\\xa0Y. Yuan: None.\\xa0J. Wu: None.\\xa0R. Hajek: None.\\xa0S. Sharafi: None. L.A. Meyer:  ; AstraZeneca. N.D. Fleming:  ; Tesaro. ; BMS. ; Pfizer. A. Jazaeri:  ; AstraZeneca. ; BMS. ; Pfizer. ; Iovance. ; Aravive. ; Eli Lilly. ; Immatics. ; DSMB member; Roche. ; GLG. ; Guidepoint. ; Simcere. ; PACT Pharma. R.L. Coleman:  ; AstraZeneca. ; AbbVie. ; Clovis Oncology. ; Tesaro/GSK. ; Cell Medica. ; COR2ED. ; Geistlich. ; Genmab. ; MoreHealth. ; Takeda. ; Aravive Biologics, Inc.. ; Cordgenics. ; Eisai Medical Research. ; Roche/Genentech, Inc.. ; ImmunoGen. ; Janssen. ; Merck. ; Novocure. ; OncoMed Pharmaceutical. ; Esperance.\\xa0K.H. Lu: None. G.B. Mills:  ; AstraZeneca. ; Chrysalis. ; ImmunoMET. ; Ionis. ; Lilly USA, LLC. ; Mills Institute for Personalized Care (MIPCC). ; Nuevolution. ; PDX Pharma. ; Signalchem Lifesciences. ; Symphogen. ; Tarveda. ; Catena Pharmaceuticals. ; Spindletop Ventures. ; Karus Therapeutics. ; Nanostring. ; Pfizer. ; Tesaro.\\xa0J. Zhang: None.\\xa0A. Futreal: None. A.K. Sood:  ; Merck. ; Kiyatec. ; Biopath. ; M-Trap.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-9': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10690',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT189\\n                        \\n                         - Patient-specific dendritic cell vaccines with tumor antigens from self-renewing autologous tumor cells in the treatment of primary advanced ovarian cancer: A multi-institutional phase II clinical trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Lisa N. Abaid1, Bradley R. Corr2, James R. Mason3, Richard L. Friedman4, Ramez N. Eskander5, Candace Hsieh6, Chris J. E. Langford6, Krystal Carta6, Adrienne M. Wang6, James A. Langford6, Gabriel I. Nistor6, Robert O. Dillman6. 1Hoag Hospital, Newport Beach, CA; 2University of Colorado, Denver, CO; 3Scripps Clinic and Research Foundation, La Jolla, CA; 4Providence Medical Center, Burbank, CA; 5University of California San Diego, La Jolla, CA; 6AIVITA Biomedica Inc, Irvine, CA ',\n",
       "  'Disclosures': '\\xa0L.N. Abaid: None.\\xa0B.R. Corr: None.\\xa0J.R. Mason: None.\\xa0R.L. Friedman: None.\\xa0R.N. Eskander: None. C. Hsieh:  ; AIVITA Biomedical Inc.\\xa0C.J.E. Langford:  ; AIVITA Biomedical Inc. K. Carta:  ; AIVITA Biomedical Inc. A.M. Wang:  ; AIVITA Biomedical Inc. J.A. Langford:  ; AIVITA Biomedical Inc. G.I. Nistor:  ; AIVITA Biomedical Inc. R.O. Dillman:  ; AIVITA Biomedical Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-10': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10691',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT190\\n                        \\n                         - A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Shun Lu1, Qiming Wang2, Guojun Zhang3, Xiaorong Dong4, Cheng-Ta Yang5, Yong Song6, Gee-Chen Chang7, You Lu8, Hongming Pan9, Chao-Hua Chiu10, Zhehai Wang11, Jifeng Feng12, Jianying Zhou13, Xingxiang Xu14, Renhua Guo15, Jianhua Chen16, Haihua Yang17, Yuan Chen18, Zhuang Yu19, Her-Shyong Shiah20, Chin-Chou Wang21, Nong Yang16, Jian Fang22, Ping Wang23, Kai Wang24, Yanping Hu25, Jianxing He26, Ziping Wang22, Jianhua Shi27, Shaoshui Chen28, Qiong Wu29, Changan Sun29, Chuan Li29, Hongying Wei29, Ying Cheng30, Wu-Chou Su31, Te-Chun Hsia32, Jiuwei Cui33, Yuping Sun34, James Chih-Hsin Yang35. 1Shanghai Chest Hospital, Shanghai, China; 2Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China; 3The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 4Wuhan Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; 5Chang Gung Memorial Hospital Linko, Taoyuan, Taiwan; 6Nanjing General Hospital of Nanjing Military Command, Nanjing, China; 7Taichung Veterans General Hospital, Taizhong, Taiwan; 8West China Hospital, Sichuan University, Chengdu, China; 9Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China; 10Taipei Veterans General Hospital, Taibei, Taiwan; 11Shandong Cancer Hospital, Jinan, China; 12Jiangsu Cancer Hospital, Nanjing, China; 13The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China; 14Subei People Hospital, Yangzhou, China; 15Jiangsu Province Hospital, Nanjing, China; 16Hunan Cancer Hospital, Changsha, China; 17Affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, China; 18Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; 19The Affiliated Hospital of Qingdao University, Qingdao, China; 20Taipei Medical University Hospital, Taibei, Taiwan; 21Chang Gung Memorial Hospital- Kaohsiung, Gaoxiong, Taiwan; 22Beijing Cancer Hospital, Beijing, China; 23Tianjin Oncology Hospital, Tianjin, China; 24The Second Hospital of Zhejiang University, Hangzhou, China; 25Hubei Cancer Hospital, Wuhan, China; 26The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 27Linyi Cancer Hospital, Linyi, China; 28The Affiliated Hospital of Binzhou Medical University, Binzhou, China; 29Hansoh Pharmaceutical Group Co. Ltd., Shanghai, China; 30Jilin Cancer Hospital, Changchun, China; 31National Cheng Kung University Hospital, Taibei, Taiwan; 32China Medical University Hospital, Taizhong, Taiwan; 33The First Hospital of Jilin University, Changchun, China; 34Jinnan Central Hospital, Jinan, China; 35National Taiwan University Hospital, Taibei, Taiwan ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Lu:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.. ; Advisor and consultant; AstraZeneca. ; Advisor and consultant; Hutchison MediPharma. ; Advisor and consultant; Roche. ; Advisor and consultant; BoehringerIngelheim. ; Advisor and consultant; Simcere. Q. Wang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0G. Zhang:  ; Advisor or consultant\\n; Hansoh Pharmaceutical Group Co. Ltd.\\xa0X. Dong:  ; Advisor or consultant\\n; Hansoh Pharmaceutical Group Co. Ltd.\\xa0C. Yang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Y. Song:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0G. Chang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Y. Lu:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0H. Pan:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0C. Chiu:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Z. Wang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. Feng:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. Zhou:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0X. Xu:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0R. Guo:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. Chen:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0H. Yang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Y. Chen:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Z. Yu:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0H. Shiah:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0C. Wang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0N. Yang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. Fang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0P. Wang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0K. Wang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Y. Hu:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. He:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Z. Wang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. Shi:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0S. Chen:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Q. Wu:  ; Hansoh Pharmaceutical Group Co. Ltd.\\xa0C. Sun:  ; Hansoh Pharmaceutical Group Co. Ltd.\\xa0C. Li:  ; Hansoh Pharmaceutical Group Co. Ltd.\\xa0H. Wei:  ; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Y. Cheng:  ; Advisor and consultant\\n; Hansoh Pharmaceutical Group Co. Ltd.\\xa0W. Su:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0T. Hsia:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J. Cui:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0Y. Sun:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd.\\xa0J.C. Yang:  ; Advisor and consultant; Hansoh Pharmaceutical Group Co. Ltd..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-11': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10692',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT191\\n                        \\n                         - Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jonathan W. Goldman1, Terrence L. Fisher2, Elizabeth Evans2, John E. Leonard2, Desa Rae Pastore2, Crystal Mallow2, Ernest Smith2, Andreas Schreder3, Kevin Chin4, Michael Shafique5, Thaddeus Beck6, Megan A. Baumgart7, Ramaswamy Govindan8, Nashat Gabrail9, Rachel E. Sanborn10, Alexander I. Spira11, Nagashree Seetharamu12, Yanyan Lou13, Aaron S. Mansfield14, Maurice Zauderer2. 1UCLA, Santa Monica, CA; 2Vaccinex, Inc., Rochester, NY; 3Merck KGaA, Darmstadt, Germany; 4EMD Serono, Billerica, MA; 5Moffitt Cancer Center, Tampa, FL; 6Highlands Oncology Group, Fayetteville, AR; 7University of Rochester, Rochester, NY; 8Washington University School of Medicine, St. Louis, MO; 9Gabrail Cancer Center, Canton, OH; 10Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; 11Virginia Cancer Center Specialists, Fairfax, VA; 12Feinstein Institutes for Medical Research, Northwell Health, Lake Success, NY; 13Mayo Clinic, Jacksonville, FL; 14Mayo Clinic, Rochester, MN ',\n",
       "  'Disclosures': '\\xa0\\xa0J.W. Goldman:  ; Vaccinex, Inc.. ; Pfizer. T.L. Fisher:  ; Vaccinex, Inc.\\xa0E. Evans:  ; Vaccinex, Inc.\\xa0J.E. Leonard:  ; Vaccinex, Inc.\\xa0D. Pastore:  ; Vaccinex, Inc.\\xa0C. Mallow:  ; Vaccinex, Inc.\\xa0E. Smith:  ; Vaccinex, Inc.\\xa0A. Schreder:  ; Merck KGaA. K. Chin:  ; EMD Serono. M. Shafique:  ; Merck KGaA. ; Vaccinex, Inc.. ; Nektar Therapeutics. ; PsiOxus Therapeutics. ; Amphivena. ; Genentech. ; Janssen Research & Development. T. Beck:  ; Abbvie. ; Alliance. ; Amgen. ; Ascentage Pharma Group. ; AstraZeneca. ; Bayer. ; Biodesix. ; Boston Biomedical. ; Bristol Myers Squibb. ; Calithera. ; Celgene. ; Eli Lilly. ; EMD-Serono. ; Evelo. ; Exact Sciences. ; Genentech-Roche. ; Hutchison. ; Immunomedics. ; Janssen. ; MT Group, Nektar, Novartis Pfizer, Polynoma, Seattle Genetics, Tesaro, TG Therapeutics, Vaccinex. M.A. Baumgart:  ; BMS. R. Govindan:  ; Genentech / Abbvie. ; GSK. ; Celgene. ; Astra Zeneca. ; Inivata. ; Merck Serono. ; Pfizer. ; BMS. ; EMD Serono. ; Lily. ; Ignyta. ; Nektar. ; Phillips Gilmore Oncology. ; Jounce Therapeutics.\\xa0N. Gabrail: None. R.E. Sanborn:  ; BMS, Medimmune, Merck. ; Astra Zeneca. ; Seattle Genetics, Genentech/Roche, Celldex.\\xa0A.I. Spira: None.\\xa0N. Seetharamu: None. Y. Lou:  ; Merck Sharp & Dohme, Bristol-Myers Squibb , Kyowa Hakko Kirin Pharma, Guardant Health, MacroGenics, Tolero Pharmaceuticals, Tesaro, Blueprint Medicines Corporation. ; Astra Zeneca.\\xa0A.S. Mansfield: None. M. Zauderer:  ; Vaccinex, Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-12': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10693',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT192\\n                        \\n                         - Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) alone or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jay M. Lee1, Pilar Garrido2, Edward S. Kim3, Cagatay Arslan4, Jean-Louis Pujol5, Yuanbo Song6, Cecile Blin7, Vanessa Rodrik-Outmezguine6, Bijoyesh Mookerjee6, Vanessa Passos6, Tony Mok8. 1University of California, Los Angeles, CA; 2Hospital Ramon Y Caja, Madrid, Spain; 3Levine Cancer Institute, Charlotte, NC; 4Izmir Medical Park Hospital, Izmir and Bahcesehir University Medicine Faculty, Istanbul, Istanbul, Turkey; 5Hospital Arnaud de Villeneuve, Montpellier, France; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ; 7Novartis Pharma AG, Basel, Switzerland; 8Chinese University of Hong Kong, Hong Kong, Hong Kong ',\n",
       "  'Disclosures': '\\xa0\\xa0J.M. Lee:  ; AstraZeneca, Bristol-Myers Squibb, Genentech, Novartis. ; Merck. P. Garrido:  ; Roche, AstraZeneca, Bristol (BMS), MSD, Pfizer, Boehringer Ingelheim, Novartis, Takeda. ; Guardant Health, Janssen, Abbvie, Lilly, Blueprint Medicines, Bayer. ; Gilead, Rovi, Sysmex. E.S. Kim:  ; Travel/Accommodation/Expenses; Roche, Boehringer Ingelheim, Pfizer, AstraZeneca, Merck, Takeda.\\xa0C. Arslan: None.\\xa0J. Pujol: None. Y. Song:  ; Novartis. C. Blin:  ; Novartis. V. Rodrik-Outmezguine:  ; Novartis. B. Mookerjee:  ; Novartis. ; GSK, Incyte, AstraZeneca. V. Passos:  ; Novartis. T. Mok:  ; Abbvie, ACEA Pharma, Amgen, Bayer, Blueprint Medicines Corporation, Celgene, CStone Pharma, Daiichi Sankyo, Eli Lilly, Fishawack Facilitate Ltd, Hengrui Therapeutics Inc, Ignyta, Inc.. ; Incyte Corporation, IQVIA, Janssen, Loxo-Oncology, Merck Serono, Novartis, OncoGenex Pharmaceuticals, Inc., OrigiMed, Pfizer. ; Roche/Genentech, Sanofi-Aventis R&D, SFJ Pharmaceutical Ltd., Takeda Pharmaceuticals HK Ltd., Vertex Pharmaceuticals, Yuhan Corporation. ; Alpha Biopharma Co., Ltd., Amoy Diagnostics Co., LTD., AstraZeneca (before 1/1/19), BI, InMed Medical Communication, Medscape/WebMD, MSD, MoreHealth, PeerVoice, PrIME Oncology,. ; AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cirina, G1 Therapeutics, Inc., geneDecode Co., Ltd., Hutchison Chi-Med, Merck Sharp & Dohme, Virtus Medical Group. ; Leadership role; ASCO, ATORG, CLCRF, CSCO, HKCF, HKCTS, IASLC (term ended on 30/4/19), St. Stephens College & Prep. School. ; AstraZeneca, BMS, Clovis Oncology, G1 Therapeutics, MSD, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda, XCovery. ; Stock option: \\nClearbridge Biomedics (now Biolidics Ltd.), Loxo-Oncology, OrigiMed Co. Ltd. And Virtus Medical Group; Hutchison Chi-Med and Sanomics Ltd.. ; AstraZeneca PLC and Hutchison Chi-Med.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-13': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10694',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT193\\n                        \\n                         - Efficacy and survival in newly diagnosed advanced extranodal natural killer/T-cell lymphoma: A randomized, controlled, multicenter and open-labeled study with DDGP regimen versus SMILE regimen\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Xinhua Wang1, Lei Zhang1, Xiangli Liu2, Xin Li1, Ling Li1, Xiaorui Fu1, Zhenchang Sun1, Jingjing Wu1, Xudong Zhang1, Jiaqin Yan1, Yu Chang1, Feifei Nan1, Zhiyuan Zhou1, Xiaolong Wu1, Li Tian1, Wencai Li3, Hongwei Xue4, Jinghua Wang5, LIqun Zou6, Liping Su7, Yi Lu8, Yanzhen Guo9, Ken H Young10, Yong Li11, Mingzhi Zhang1. 1Department of Oncology, the first affiliated hospital of zhengzhou university, zhengzhou, China; 2Medical Department of Kaifeng University, Kaifeng, China; 3Department of Pathology, the first affiliated hospital of zhengzhou university, zhengzhou, China; 4Department of Oncology, the affiliated hospital of Qingdao University, Qingdao, China; 5Department of Oncology, Nanjing General  hospital of Nanjing Military Command, Nanjing, China; 6Department of Oncology, West China Hospital, Sichuan University, Sichuan, China; 7Department of Hematology, Shanxi Cancer Hospital, Taiyuan, Shanxi, China; 8Department of Oncology, Xinxiang\\xa0central\\xa0hospital, Xinxiang, China; 9Department of Oncology, The First Affifiliated Hospital of H'nan University of Science and Technology, Luoyang, China; 10Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, TX; 11Department of medicine Dan L Duncan Comprehensive Cancer Center Baylor College of Medicine, Houston, TX \",\n",
       "  'Disclosures': '\\xa0X. Wang: None.\\xa0L. Zhang: None.\\xa0X. Liu: None.\\xa0X. Li: None.\\xa0L. Li: None.\\xa0X. Fu: None.\\xa0Z. Sun: None.\\xa0J. Wu: None.\\xa0X. Zhang: None.\\xa0J. Yan: None.\\xa0Y. Chang: None.\\xa0F. Nan: None.\\xa0Z. Zhou: None.\\xa0X. Wu: None.\\xa0L. Tian: None.\\xa0W. Li: None.\\xa0H. Xue: None.\\xa0J. Wang: None.\\xa0L. Zou: None.\\xa0L. Su: None.\\xa0Y. Lu: None.\\xa0Y. Guo: None.\\xa0K. Young: None.\\xa0Y. Li: None.\\xa0M. Zhang: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-14': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10695',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT194\\n                        \\n                         - Low-dose Interferon-alpha pre-conditioning and adoptive cell therapy in metastatic melanoma patients refractory to standard (immune) therapies - a phase 1/2 study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Monique K. van der Kooij1, Els M. E. Verdegaal2, Marten Visser3, Carolien E. van der Minne3, Linda de Bruin3, Pauline Meij4, Anton G. T. Terwisscha van Scheltinga4, Marij J. P. Welters3, Saskia J. A.M. Santegoets3, Noel F. C.C. de Miranda4, Inge C. F.M. Roozen4, Gerrit-Jan Liefers4, Ellen Kapiteijn5, Sjoerd H. van der Burg6. 1* Leiden University Medical Center/ Oncode Institute, Leiden, Netherlands; 2* Leiden University Medical Center/ Oncode Institute *: both authors contributed equally, Leiden, Netherlands; 3Leiden University Medical Center/ Oncode Institute, Leiden, Netherlands; 4Leiden University Medical Center, Leiden, Netherlands; 5** Leiden University Medical Center, Leiden, Netherlands; 6** Leiden University Medical Center/ Oncode Institute **: both authors contributed equally, Leiden, Netherlands ',\n",
       "  'Disclosures': '\\xa0M.K. van der Kooij: None.\\xa0E.M.E. Verdegaal: None.\\xa0M. Visser: None.\\xa0C.E. van der Minne: None.\\xa0L. de Bruin: None.\\xa0P. Meij: None.\\xa0A.G.T. Terwisscha van Scheltinga: None.\\xa0M.J.P. Welters: None.\\xa0S.J.A. Santegoets: None.\\xa0N.F.C. de Miranda: None.\\xa0I.C.F. Roozen: None.\\xa0G. Liefers: None. E. Kapiteijn:  ; Bristol-Myers Squibb. ; Amgen. ; Novartis. ; Roche. ; Merck. ; Pierre-Fabre.\\xa0S.H. van der Burg: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-15': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10696',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT195\\n                        \\n                         - A phase 2 clinical trial of palbociclib and ganitumab for relapsed/refractory Ewing sarcoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'David S. Shulman1, Katherine Thornton1, Edwin Choy2, Lillian M. Guenther1, Kerri Cavanaugh1, Megan Forsyth1, Kylene DeSmith1, Catherine Clinton1, Kimberly Stegmaier1, Brian D. Crompton1, Wendy B. London1, Steven G. DuBois1. 1Dana-Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital, Boston, MA ',\n",
       "  'Disclosures': '\\xa0D.S. Shulman: None.\\xa0K. Thornton: None.\\xa0E. Choy: None.\\xa0L.M. Guenther: None.\\xa0K. Cavanaugh: None.\\xa0M. Forsyth: None.\\xa0K. DeSmith: None.\\xa0C. Clinton: None.\\xa0K. Stegmaier: None.\\xa0B.D. Crompton: None.\\xa0W.B. London: None. S.G. DuBois:  ; Travel Expenses; Loxo Oncology. ; Travel Expenses; Roche Pharmaceuticals. ; Travel Expenses; Salarius Pharmaceuticals.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-16': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10697',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT196\\n                        \\n                         - Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM): Application of population pharmacokinetics (PopPK) and exposure-response (E-R) analyses\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Geraldine Ferron-Brady1, Chetan Rathi1, Jon Collins2, Herbert Struemper2, Joanna Opalinska1, Roxanne C Jewell2. 1GlaxoSmithKline, Collegeville, PA; 2GlaxoSmithKline, RTP, NC ',\n",
       "  'Disclosures': '\\xa0\\xa0G. Ferron-Brady:  ; GlaxoSmithKline. C. Rathi:  ; GlaxoSmithKline. J. Collins:  ; GlaxoSmithKline. H. Struemper:  ; GlaxoSmithKline. J. Opalinska:  ; GlaxoSmithKline. R. Jewell:  ; GlaxoSmithKline.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-17': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10698',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT197\\n                        \\n                         - The efficacy and safety of Geptanolimab (GB226) in patients with recurrent/metastatic/unresectable alveolar soft part sarcoma (ASPS): A multicenter, open-label, single-arm, phase 2 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Yuankai Shi1, Qiqing Cai2, Yu Jiang3, Gang Huang4, Minghong Bi5, Baocheng Wang6, Yuhong Zhou7, Guowen Wang8, Hongyan Ying9, Zhiwei Tao10, Chunmei Shi11, Fan Xie12, Chao Gao12. 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China; 2Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University/ Henan Cancer Hospital, Zhengzhou, China; 3Department of Oncology, West China Hospital, Sichuan University, Chengdu, China; 4Department of  Bone and Soft Tissue, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; 5Department of Oncology,The First Affiliated Hospital of Bengbu Medical College, Bengbu, China; 6Department of Oncology, General Hospital of Jinan Military Region, Jinan, China; 7Department of  Oncology, The Affiliated Zhongshan Hospitalof Fudan University, Shanghai, China; 8Department of Bone and Soft Tissue Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 9Department of Oncology, Peking Union Medical College Hospital, Beijing, China; 10Department of Bone and Soft Tissue Oncology, Jiangxi Cancer Hospital, Nanchang, China; 11Department of  Oncology, Fujian Medical University Union Hospital, Fuzhou, China; 12Department of Medical Science, Genor Biopharma Co., Ltd., Shanghai, China ',\n",
       "  'Disclosures': '\\xa0Y. Shi: None.\\xa0Q. Cai: None.\\xa0Y. Jiang: None.\\xa0G. Huang: None.\\xa0M. Bi: None.\\xa0B. Wang: None.\\xa0Y. Zhou: None.\\xa0G. Wang: None.\\xa0H. Ying: None.\\xa0Z. Tao: None.\\xa0C. Shi: None.\\xa0F. Xie: None.\\xa0C. Gao: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-18': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10699',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT198\\n                        \\n                         - Efficacy of metfOrmin in PrevenTIng glucocorticoid-induced diabetes in Melanoma, breAst or Lung Cancer patients with brain metastases: The phase II OPTIMAL study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Claudio Vernieri, Federico Nichetti, Francesca Ligorio, Emma Zattarin, Teresa Beninato, Riccardo Lobefaro, Giulia Bianchi, Giuseppe Capri, Marina Garassino, Giuseppe Lo Russo, Michele Del Vecchio, Paola Corsetto, Licia Rivoltini, Chiara Castelli, Filippo de Braud. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy ',\n",
       "  'Disclosures': '\\xa0C. Vernieri: None.\\xa0F. Nichetti: None.\\xa0F. Ligorio: None.\\xa0E. Zattarin: None.\\xa0T. Beninato: None.\\xa0R. Lobefaro: None. G. Bianchi:  ; Novartis. ; Eli Lilly.\\xa0G. Capri: None. M. Garassino:  ; AstraZeneca. ; MSD International GmbH. ; BMS. ; Boehringer Ingelheim Italia S.p.A. ; Celgene. ; Eli Lilly. ; Ignyta. ; Incyte. ; Inivata. ; Novartis. ; Pfizer. ; Roche. ; Takeda. ; Inivata. ; MedImmune. G. Lo Russo:  ; AstraZeneca. ; MSD International GmbH. ; Eli Lilly. ; BMS. M. Del Vecchio:  ; Novartis. ; Merck. ; BMS. ; Pierre Fabre. ; Sanofi.\\xa0P. Corsetto: None.\\xa0L. Rivoltini: None.\\xa0C. Castelli: None. F. de Braud:  ; Astra Zeneca. ; Novartis. ; Boehringer Ingelheim. ; Sanofi-Aventis. ; GSK. ; Roche. ; BMS. ; Johnson&Johnson. ; Pfizer. ; Recordati. ; Eisai. ; Merck. ; EMD Serono.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-19': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10700',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT199\\n                        \\n                         - Larotrectinib in TRK fusion cancer patients: Outcomes by prior therapy and performance status\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alexander Drilon1, Cornelis M. van Tilburg2, Anna F. Farago3, Shivaani Kummar4, Jordan Berlin5, Catherine M. Albert6, Ray McDermott7, Ulrik N. Lassen8, John A. Reeves9, Nicoletta Brega9, Barrett H. Childs9, Theodore W. Laetsch10, David S. Hong11. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Hopp Childrens Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; 3Massachusetts General Hospital, Boston, MA; 4Stanford University, Stanford, CA; 5Vanderbilt University, Nashville, TN; 6Seattle Childrens Hospital, Seattle, WA; 7Tallaght University Hospital, Dublin, Ireland; 8Righospitalet, Copenhagen, Denmark; 9Bayer HealthCare Pharmaceuticals, Whippany, NJ; 10UT Southwestern Medical Center, Dallas, TX; 11University of Texas MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Drilon:  ; Ignyta/Genentech/Roche. ; Loxo Oncology/Bayer/Lilly. ; Takeda/Ariad/Millenium. ; TP Therapeutics. ; AstraZeneca. ; Pfizer. ; Blueprint Medicines. ; Helsinn. ; Beigene. ; BergenBio. ; Hengrui Therapeutics. ; Exelixis. ; Tyra Biosciences. ; Verastem. ; MORE Health. ; GlaxoSmithKline, Teva, Taiho, PharmaMar. ; Foundation Medicine. ; Royalties; Wolters Kluwer. ; Food and beverage; Merck and Puma Biotechnology. ; CME honoraria; Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, and Research to Practice. C.M. van Tilburg:  ; Bayer. ; Novartis. A.F. Farago:  ; Bayer. ; Loxo Oncology. ; Genentech. ; Roche. ; Bristol-Myers Squibb. ; AstraZeneca. ; AbbVie. ; PharmaMar. ; Merck. ; Ignyta. ; Amgen. ; Lilly. ; Boehringer Ingelheim. ; Pfizer. ; H3 Biomedicine. ; Clinical Care Options. ; Medscape. ; Onclive. ; Research to Practice. ; PeerView. S. Kummar:  ; Travel support; Bayer. J. Berlin:  ; Bayer.\\xa0C.M. Albert: None. R. McDermott:  ; Travel expenses; Janssen-Cilag. ; Travel expenses; Pfizer. ; Bayer. ; Sanofi. ; Janssen. ; Astellas. ; BMS. ; MSD. ; Pfizer. ; Novartis. ; Clovis. ; Sanofi. ; Janssen. ; Bayer. ; Astellas. U.N. Lassen:  ; Bayer. J.A. Reeves:  ; Bayer. N. Brega:  ; Bayer. B.H. Childs:  ; Bayer. T.W. Laetsch:  ; Novartis. ; Bayer. ; Loxo. ; Lilly. ; Pfizer. ; Novartis. ; Bayer. ; Loxo. ; Abbvie. ; Amgen. ; Atara. ; Biotherapeutics. ; BMS. ; Lilly. ; Epizyme. ; GSK. ; Janssen. ; Jubilant Pharmaceuticals. ; Novella Clinical. ; Servier. D.S. Hong:  ; Novartis. ; Merck. ; Loxo Oncology. ; AstraZeneca. ; Personal fees; Roche. ; Personal fees; Pfizer. ; Bristol-Myers Squibb. ; Takeda. ; Personal fees; Boehringer Ingelheim. ; GSK.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-20': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10702',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT201\\n                        \\n                         - Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': 'Byoung Chul Cho1, Nathan Bahary2, Johanna Bendell3, Enriqueta Felip4, Melissa Johnson3, Yoon-Koo Kang5, Farah Louise Lim6, Teresa Macarulla4, Gulam Manji7, Do-Youn Oh8, Osama Rahma9, Simon Allen10, Edward Cha10, Denise Cotting11, Hans-Joachim Helms11, Jan Pintoffl11, Pakeeza Sayyed11, Xiaosong Zhang10, Kyu-pyo Kim5. 1Yonsei University Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of; 2University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA; 3Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; 4Vall dHebron Institute of Oncology (VHIO), Barcelona, Spain; 5Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of; 6Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; 7Columbia University Irving Medical Center, New York, NY; 8Seoul National University College of Medicine, Seoul, Korea, Republic of; 9Dana-Farber Cancer Institute, Boston, MA; 10Genentech, Inc, South San Francisco, CA; 11F. Hoffmann-La Roche, Ltd, Basel, Switzerland ',\n",
       "  'Disclosures': '\\xa0\\xa0B. Cho:  ; Novartis. ; Bayer. ; AstraZeneca. ; MOGAM Institute. ; Dong-A ST. ; Royalty; Champions Oncology. ; Janssen. ; Yuhan. ; Ono. ; Dizal Pharma. ; MSD. ; Boehringer-Ingelheim. ; Roche. ; BMS. ; Pfizer. ; Eli Lilly. ; Takeda. ; TheraCanVac Inc. ; Gencurix Inc. ; Bridgebio Therapeutics. N. Bahary:  ; BioLIneRx. ; AstraZeneca. ; Exelixis. ; BMS. ; Thermo Fisher. J. Bendell:  ; Travel & Expenses; Gilead, Roche/Genentech,. ; Travel & Expense Reimbursement; BMS, Lilly, Merck, Medimmune, Oncomed, ARMO,  Forma. ; Five Prime. ; Travel & Expense Reimbursement; Celgene, Taiho, Novartis, Boehringer Ingelheim, Ipsen,. ; EMD Serono,. ; Travel & Expense Reimbursement; Oncogenex,. ; Macrogenics, Innate,. ; GSK, Arch Oncology, Prelude Oncology, Array,  Sanofi, Merrimack,. ; Phoenix Bio, Cyteir, Molecular Partners, Torque, Tizona, Janssen, Tolero, TD2, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical. ; LEAP, TG Therapeutics, AstraZeneca,Daiichi Sankyo, Incyte, Apexigan, Amgen, Agios. ; Vyriad, Harpoon, ADC, Pfizer, Millenium, IMclone, Acerta Pharma, Rgenix, Bellicum. ; Mersana, Calithera, Blueprint, Evelo,  Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra,  Unum Therapeutics. ; Tarveda, Tyrogenex,  Marshall Edwards, Pieris, Mersana. ; Takeda, Eisai, Celldex, Cytomx. ; SynDevRex, Forty Seven, AbbVie, Onyx,. ; Koltan, Nektar, Boston Biomedical,. E. Felip:  ; Pfizer. ; Roche. ; AstraZeneca. ; Bristol-Myers Squibb. ; Novartis. ; Takeda. ; Lilly. ; Boehringer Ingelheim. ; Merck Sharp & Dohme. ; Medscape. ; Prime Oncology. ; Touchtime. ; Guardant Health. ; Abbvie. ; Blue Print Medicines. ; Merck KGaA. ; Samsung. ; Janssen. ; Fundacin Merck Salud. ; Grant for Oncology Innovation (GOI). ; Grfols. M. Johnson:  ; Abbvie. ; AstraZeneca. ; Boehringer Ingelheim. ; Incyte. ; Janssen. ; Lilly. ; Merck. ; Novartis. ; Genentech/Roche. ; Pfizer. ; Sanofi. ; Acerta. ; Adaptimmune. ; Amgen. ; Apexigen. ; Arcus Biosciences. ; Array Biopharma. ; Beigene. ; Birdie. ; Checkpoint Therapeutics. ; Corvus Pharmaceuticals. ; Cytomx. ; Dynavax. ; Emd Serono. ; Genm. ; Atreca. ; Glaxosmithkline. ; Gritstone Oncology. ; Guardant Health. ; Loxo Oncology. ; Mirati Therapeutics. ; Ribon Therapeutics. ; Food/Beverage/Travel; Daiichi Sankyo. ; Food/Beverage/Travel; Astellas. ; Achilles Therapeutics. ; Association of Community Cancer Centers. ; Calithera Biosciences. ; Otsuka Pharmaceuticals. ; Food/Beverage/Travel; Sysmex Inostics. ; Vapotherm. ; Exelixis. ; EMD Serono. ; Bristol Myers Squibb. ; Clovis. Y. Kang:  ; ALX Oncology. ; Zymeworks. ; Amgen. ; Novartis. ; Macrogenics. ; Daehwa. ; Surface Oncology. ; Ono. ; BMS. F. Lim:  ; Roche. ; Merck. ; BMS. ; GLG Consulting Firm. T. Macarulla:  ; Vall dHebrn University Hospital. ; Shire Pharmaceuticals. ; Roche. ; Batxer. ; Support for travel or accommodation; Sanofi. ; Celgene. ; QED Therapeutics. ; Baxalta. ; Incyte. ; Support for travel or accommodation; Servier. ; Lilly. ; Ipsen. ; Support for travel or accommodation; Merck. ; Support for travel or accommodation; H3 Biomedicine. G. Manji:  ; Roche/Genentech. ; Merck. ; BioLine. ; Regeneron. D. Oh:  ; Roche/Genentech. ; AstraZeneca. ; Novartis. ; Merck Serono. ; Bayer. ; Taiho. ; ASLAN. ; Halozyme. ; Zymeworks. ; Array. ; Eli Lilly. O. Rahma:  ; Merck. ; BMS. ; Celgene. ; Five Prime. ; GSK. ; GFK. ; Bayer. ; Roche/Genentech. ; Puretech. ; Imvax. ; Methods Of Using Pembrolizumab and Trebananib; Patent. S. Allen:  ; Genentech, Inc. ; Roche. E. Cha:  ; Genentech, Inc. ; Roche. D. Cotting:  ; Holding Roche non-voting equity securities; Roche. H. Helms:  ; F. Hoffmann-La Roche AG. ; genussscheine Roche. J. Pintoffl:  ; F. Hoffmann La Roche. P. Sayyed:  ; F. Hoffmann-La Roche. X. Zhang:  ; Genentech. ; Roche. K. Kim:  ; Asan Medical Center. ; Enzychem Lifescience.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '843-21': {'Session Title': ' VPO.CT02. Phase II Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10803',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT202\\n                        \\n                         - Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble lag-3 protein) and pembrolizumab\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Martin Forster1, Enriqueta Felip2, Bernhard Doger3, Margarita Majem4, Enric Carcereny5, Julio Peguero6, Pawan Bajaj7, Tim Clay8, Matthew Krebs9, Patricia Roxburgh10, Leora Horn11, Frederic Triebel12. 1University College London Hospitals NHS Foundation, London, United Kingdom; 2Vall dHebron University Hospital, Barcelona, Spain; 3START Madrid- Fundacin Jimnez Diaz, Madrid, Spain; 4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 5Catalan Institute of Oncology Badalona-Hospital Germans Trias i Pujol, barcelona, Spain; 6Oncology Consultants, Houston, TX; 7Griffith University, Gold Coast, Australia; 8St John of God Subiaco Hospital, Perth, Australia; 9The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom; 10University of Glasgow/ Beatson West of Scotland Cancer Centre, Edinburgh, United Kingdom; 11Vanderbilt University Medical Center, Nashville, TN; 12Immutep S.A.S, Paris, France ',\n",
       "  'Disclosures': '\\xa0\\xa0M. Forster:  ; AstraZeneca. ; BMS. ; Merck. ; MSD. ; Roche. E. Felip:  ; Abbvie. ; AstraZenenca. ; Boehringer Ingelheim. ; BMS. ; Elli Lilly. ; Merck KGaA. ; MSD. ; Novartis. ; Pfizer. ; Roche.\\xa0B. Doger: None.\\xa0M. Majem: None. E. Carcereny:  ; Roche. ; MSD. ; BMS. ; Boehringer Ingelheim. ; Takeda.\\xa0J. Peguero: None.\\xa0P. Bajaj: None.\\xa0T. Clay: None.\\xa0M. Krebs: None.\\xa0P. Roxburgh: None.\\xa0L. Horn: None. F. Triebel:  ; Immutep.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-1': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10679',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:30 AM - 9:31 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nilofer S. Azad. Johns Hopkins Sidney Kimmel Comp. Cancer Center, Baltimore, MD',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-2': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10680',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:30 AM - 9:31 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Manuel Hidalgo. Weill Cornell Medicine, New York, NY',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-3': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10836',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:30 AM - 9:35 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-4': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10593',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT011\\n                        \\n                         - Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:35 AM - 9:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Lajos Pusztai1, Hyo S. Han2, Christina Yau3, Denise Wolf4, Anne M. Wallace5, Rebecca Shatsky5, Teresa Helsten5, Judy C. Boughey6, Tufia Haddad6, Erica Stringer-Reasor7, Carla Falkson7, A. Jo Chien4, Rita Mukhtar4, Anthony Elias8, Borges Virginia8, Rita Nanda9, Douglas Yee10, Kevin Kalinsky11, Kathy S. Albain12, Aixa Soyano Muller2, Kathleen Kemmer13, Amy S. Clark14, Claudine Isaacs15, Alexandra Thomas16, Nola Hylton4, W. Fraser Symmans17, Jane Perlmutter18, Michelle Melisko4, Hope S. Rugo4, Richard Schwab19, Amy Wilson20, Amy Wilson20, Ruby Singhrao4, Smita Asare20, Laura J. van't Veer4, Angela M. DeMichele14, Ashish Sanil21, Donald A. Berry21, Laura J. Esserman4, Trial Consortium I-SPY 24. 1Yale University, New Haven, CT; 2Moffitt Cancer Center, Tampa, FL; 3Buck Institute for Age Research, Novato, CA; 4University of California, San Francisco, San Francisco, CA; 5University of California, San Diego, La Jolla, CA; 6Mayo Clinic Minnesota, Rochester, MN; 7University of Alabama at Birmingham, Birmingham, AL; 8University of Colorado Denver, Aurora, CO; 9University of Chicago, Chicago, IL; 10University of Minnesota, Minneapolis, MN; 11Columbia University, New York, NY; 12Loyola University Chicago Stritch School of Medicine, Maywood, IL; 13Oregon Health and Science University, Portland, OR; 14University of Pennsylvania, Philadelphia, PA; 15Georgetown University, Washington, DC; 16Wake Forest University, Salem, NC; 17MD Anderson Cancer Center, Houston, TX; 18Gemini Group, Ann Arbor, MI; 19University of California, San Diego, San Diego, CA; 20Quantum Leap Healthcare Collaborative, San Francisco, CA; 21Berry Consultants, Austin, TX \",\n",
       "  'Disclosures': \"\\xa0\\xa0L. Pusztai:  ; AstraZeneca. ; Merck. ; Novartis. ; Bristol-Myers Squibb. ; Genentech. ; Eisai. ; Pieris. ; Immunomedics. ; Seattle Genetics. ; Clovis. ; Syndax. ; H3Bio. ; Daiichi Sankyo. H.S. Han:  ; Department of Defense. ; Lilly. ; AbbVie. ; BMS. ; Novartis. ; Tesaro. ; Seattle Genetics. ; Horizon. ; Pfizer. ; Prescient. ; Arvinas. ; Zymeworks.\\xa0C. Yau: None.\\xa0D. Wolf: None.\\xa0A.M. Wallace: None.\\xa0R. Shatsky: None. T. Helsten:  ; Synthon. ; Lilly. ; AbbVie. ; Bayer. ; Pfizer. ; Novartis.\\xa0J.C. Boughey: None.\\xa0T. Haddad: None.\\xa0E. Stringer-Reasor: None. C. Falkson:  ; El-Lily. ; Genentech/Roche. ; Pfizer. ; Seattle Genetics.\\xa0A. Chien: None.\\xa0R. Mukhtar: None.\\xa0A. Elias: None.\\xa0B. Virginia: None. R. Nanda:  ; Aduro. ; AstraZeneca. ; Athenex. ; Celgene. ; Daiichi Sankyo, Inc. ; Genentech. ; MacroGenics. ; Merck. ; Novartis. ; Pfizer. ; Puma. ; Syndax. ; Corcept Therapeutics. ; Immunomedics. ; Odonate Therapeutics. ; Pfizer. ; Seattle Genetics.\\xa0D. Yee: None. K. Kalinsky:  ; Biotheranostics. ; Eli-Lilly. ; Pfizer. ; Novartis. ; Eisai. ; AstraZeneca. ; Incyte. ; Genentech. ; Spouse - full-time/part-time employee and stock shareholder (self managed); Pfizer. ; Calithera Biosciences. ; Acetylon. ; Seattle Genetics. ; Amgen. ; ZenoPharmaceuticals. ; Institutional support; CytomX Therapeutics. ; Spouse - full-time/part-time employee and stock shareholder (self managed); Array Biopharma.\\xa0K.S. Albain: None.\\xa0A. Soyano Muller: None.\\xa0K. Kemmer: None. A.S. Clark:  ; Novartis. C. Isaacs:  ; AstraZeneca. ; Pfizer. ; Genentech. ; Novartis.\\xa0A. Thomas: None.\\xa0N. Hylton: None.\\xa0W. Symmans: None.\\xa0J. Perlmutter: None.\\xa0M. Melisko: None.\\xa0H.S. Rugo: None.\\xa0R. Schwab: None.\\xa0A. Wilson: None.\\xa0A. Wilson: None.\\xa0R. Singhrao: None.\\xa0S. Asare: None. L.J. van't Veer:  ; Agendia NV.\\xa0A.M. DeMichele: None.\\xa0A. Sanil: None.\\xa0D.A. Berry: None. L.J. Esserman:  ; Blue Cross/Blue Shield.\\xa0T. I-spy 2: None.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-5': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10837',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:45 AM - 9:50 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-6': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10597',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:50 AM - 10:05 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Pamela N. Munster. UCSF, San Francisco, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-7': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10838',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:05 AM - 10:10 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-8': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10594',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT012\\n                        \\n                         - Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:10 AM - 10:20 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Grant A. McArthur1, Daniil Stroyakovskiy2, Helen Gogas3, Caroline Robert4, Karl Lewis5, Svetlana Protsenko6, Rodrigo Pereira7, Thomas Eigentler8, Piotr Rutkowski9, Lev Demidov10, Georgy Moiseevich Manikhas11, Yibing Yan12, K. C. Huang12, Anne Uyei12, Virgina McNally13, Ralf Gutzmer14, Paolo Ascierto15. 1Peter MacCallum Cancer Centre, Melbourne, Australia; 2Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation; 3Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece; 4Gustave Roussy and Universit Paris-Saclay, Villejuif-Paris, France; 5University of Colorado Comprehensive Cancer Center, Aurora, CO; 6N. N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russian Federation; 7Hospital das Clinicas, Porto Alegre, Brazil; 8University Hospital Tbingen, Tbingen, Germany; 9Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; 10N. N. Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russian Federation; 11St. Petersburg Oncology Hospital, St. Petersburg, Russian Federation; 12Genentech, Inc., South San Francisco, CA; 13Roche Products Ltd., Welwyn Garden City, United Kingdom; 14Klinik fr Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover (MHH), Hannover, Germany; 15Istituto Nazionale Tumori IRCCS Fondazione \"G. Pascale\", Naples, Italy ',\n",
       "  'Disclosures': '\\xa0\\xa0G.A. McArthur:  ; Reimbursements of cost for clinical trials to my employer, the Peter MacCallum Cancer Centre; Array Biopharma. ; Reimbursements of cost for clinical trials to my employer, the Peter MacCallum Cancer Centre; Roche Genentech.\\xa0D. Stroyakovskiy: None. H. Gogas:  ; Travel expenses, personal fees; BMS. ; Travel expenses, personal fees; Roche. ; Travel expenses, personal fees; MSD. ; Personal fees; Novartis. ; Personal fees; Amgen. ; Travel expenses; Pierre Fabre. C. Robert:  ; BMS. ; Pierre Fabre. ; Novartis. ; Amgen. ; Merck. ; Roche. ; MSD. ; Sanofi. ; Personal fees; Biothera. ; Personal fees; Ultimovacs. K. Lewis:  ; Roche/Genentech.\\xa0S. Protsenko: None. R. Pereira:  ; Personal fees; Roche. ; BMS. ; MSD. ; AstraZeneca. ; Sanofi. ; BeiGene. ; Regeneron. ; Myovant. ; Pfizer. ; Travel grants to medical conferences; Roche Laboratories. T. Eigentler:  ; Fees for patients treated in the framework of the trial; Roche. ; Personal fees; Roche. ; Personal fees; MSD. ; Personal fees; BMS. ; Personal fees; Novartis. ; Personal fees; Leo Pharma. ; Personal fees; Sanofi. P. Rutkowski:  ; Novartis. ; BMS. ; Roche. ; MSD. ; Pierre Fabre. ; Blueprint Medicines. L. Demidov:  ; Roche. ; Novartis. ; BMS. ; MSD. ; Amgen. G. Manikhas:  ; Roche. Y. Yan:  ; Roche. K.C. Huang:  ; Roche/Genentech. A. Uyei:  ; Roche. V. McNally:  ; Roche Products Ltd.\\xa0R. Gutzmer:  ; Honoraria for study participation to institution; Roche. ; Meeting support; BMS. ; Meeting support; Merck Serono. ; Amgen. ; Pierre Fabre. ; Sanofi Regeneron. ; MSD. ; Novartis. ; Almirall Hermal. ; Pfizer. ; Sun Pharma. ; 4SC. ; J&J. P. Ascierto:  ; BMS. ; Roche/Genentech. ; Travel support; MSD. ; Array. ; Novartis. ; Merck Serono. ; Pierre Fabre. ; Incyte. ; Genmab. ; NewLink Genetics. ; Medimmune. ; AstraZeneca. ; Syndax. ; Sun Pharma. ; Sanofi. ; Idera. ; Ultimovacs. ; Sandoz. ; Immunocore. ; 4SC, Alkermes, and Italfarmaco.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-9': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10839',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:20 AM - 10:25 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-10': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10595',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT013\\n                        \\n                         - SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:25 AM - 10:35 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alain Algazi1, Megan Othus2, Adil Daud1, Roger Lo3, Janice Mehnert4, Thach-Giao Truong5, Robert Conry6, Kari Kendra7, Gary Doolittle8, Joseph I. Clark9, Michael Messino10, Dennis F. Moore, Jr.11, Christopher Lao12, Bryan A. Faller13, Rangaswamy Govindarajan14, Amy Harker-Murray15, Luke Dreisbach16, James Moon2, Kenneth Grossman17, Antoni Ribas3. 1UCSF, San Francisco, CA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3UCLA, Los Angeles, CA; 4Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 5Kaiser Permanente NCAL/NCORP, Vallejo, CA; 6University of Alabama, Birmingham, AL; 7Ohio State University, Columbus, OH; 8University of Kansas Hospital -- Westwood Cancer Center, Westwood, KS; 9Loyola University, Chicago, IL; 10Messino Cancer Centers, Asheville, NC; 11Cancer Center of Kansas/Wichita NCORP, Wichita, KS; 12University of Michigan, Ann Arbor, MI; 13Missouri Baptist Medical Center, St. Louis, MO; 14University of Arkansas, Little Rock, AR; 15Medical College of Wisconsin, Milwaukee, WI; 16Eisenhower Medical Center, Rancho Mirage, CA; 17University of Utah, Salt Lake City, UT ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Algazi:  ; OncoSec. ; Valitor. ; Regeneron. ; Sensei. ; Acerta. ; Amgen. ; AstraZeneca. ; BMS. ; Dynavax. ; Genentech. ; Idera. ; Incyte. ; ISA. ; LOXO / Lilly. ; Merck. ; Novartis. ; Tessa. ; Array. M. Othus:  ; Merck. ; DSMC member; Celgene. ; DSMC member; Gycomimetics. ; Daiichi Sanko. A. Daud:  ; BMS. ; Checkmate. ; Incyte. ; Merck. ; Novartis. ; GSK. R. Lo:  ; Array. ; BMS. ; Merck. ; OncoSec. ; Novartis. ; Amgen. J. Mehnert:  ; Array. ; Merck. ; Sanofi. ; Polynoma. ; Amgen. ; AstraZeneca. ; Incyte. ; MacroGenetics. ; BMS. ; EMD Serano. ; Pfizer. ; Boehringer Ingelheim. ; Regeneron. ; Sanofi.\\xa0T. Truong: None.\\xa0R. Conry: None. K. Kendra:  ; Merck. ; BMS. ; Immunocore. ; Medpace. ; Novartis. G. Doolittle:  ; Novartis. ; BMS. ; Merck. J.I. Clark:  ; Immediate family member employed by BMS; BMS. ; Merck. ; Aveo. ; Argos Therapeutics. ; Genentech/Roche. ; Nektar.\\xa0M. Messino: None.\\xa0D.F. Moore: None. C. Lao:  ; BMS. ; Genentech. ; Merck. ; Dynavax. ; Novartis. ; Immunocor.\\xa0B.A. Faller: None.\\xa0R. Govindarajan: None.\\xa0A. Harker-Murray: None.\\xa0L. Dreisbach: None.\\xa0J. Moon: None. K. Grossman:  ; BMS. ; Genentech. ; Castle Biosciences. ; Novartis. ; Array. ; Pfizer. A. Ribas:  ; Amgen. ; Chugai. ; Merck. ; Novartis. ; Sanofi. ; Arcus. ; Bioncontech. ; Compugen. ; CytomX. ; ImaginAb. ; Isoplexis. ; Merus. ; Rgenix. ; Lutris. ; PACT Pharma. ; Tango Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-11': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10840',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:35 AM - 10:40 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-12': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10793',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Invited Speaker\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:40 AM - 10:55 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Charles L. Sawyers. Memorial Sloan Kettering Cancer Center, New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-13': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10841',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 10:55 AM - 11:00 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-14': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10596',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT014\\n                        \\n                         - IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:00 AM - 11:10 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Christopher J. Sweeney1, Silke Gillessen2, Dana Rathkopf3, Nobuaki Matsubara4, Charles Drake5, Karim Fizazi6, Josep M. Piulats7, Piotr J. Wysocki8, Gary L. Buchschacher Jr9, Jennifer Doss10, Sanjeev Mariathasan10, Edward E. Kadel, III10, Kobe Yuen10, Asim Datye11, Grozdana Rasuo11, Darren Tayama10, Patrick Williams10, Thomas Powles12. 1Dana-Farber Cancer Institute, Boston, MA; 2Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4National Cancer Center Hospital East, Chiba, Japan; 5Columbia University Irving Medical Center, New York, NY; 6Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 7Institut Catal dOncologia-IDIBELL, Barcelona, Spain; 8Department of Oncology, Jagiellonian University Medical College, Krakow, Poland; 9Southern California Permanente Medical Group, Los Angeles Medical Center, Los Angeles, CA; 10Genentech, Inc., South San Francisco, CA; 11F. Hoffmann-La Roche Ltd, Basel, Switzerland; 12Barts Cancer Institute, Queen Mary University of London, London, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0C.J. Sweeney:  ; Astellas Pharma. ; AstraZeneca. ; Bayer. ; Genentech/Roche. ; Janssen Biotech. ; Pfizer. ; Sanofi. ; Sotio. ; Patents, Royalties, Other Intellectual Property; Leuchemix. ; Patents, Royalties, Other Intellectual Property; Exelixis. S. Gillessen:  ; Active Biotech. ; Advanced Accelerator Applications. ; Amgen. ; Astellas Pharma. ; Bayer. ; BMS. ; CellSearch. ; Clovis Oncology. ; CureVac. ; Dendreon. ; ESSA Pharmaceuticals. ; Ferring. ; Innocrin. ; Janssen. ; MaxiVAX. ; Millennium. ; Nektar. ; Novartis. ; Pfizer. ; Orion. D. Rathkopf:  ; Genentech/Roche. ; Janssen Oncology. ; TRACON Pharma. ; AstraZeneca. ; Celgene. ; Ferring. ; Medivation. ; Millennium. ; Novartis. ; Taiho Pharmaceutical. ; Takeda. N. Matsubara:  ; Janssen. ; MSD. ; Taiho Pharmaceutical. ; Bayer. ; Roche. ; Sanofi. ; AstraZeneca. C. Drake:  ; Compugen. ; Potenza Therapeutics. ; ImmunExcite. ; NexImmune. ; Tizona Therapeutics. ; Agenus. ; Astellus Medivation. ; AstraZeneca/Medimmune. ; patent-licensing agreements; Bristol-Myers Squibb. ; patent-licensing agreements; Compugen. ; Dendreon. ; Janssen Oncology. ; Lilly. ; Merck. ; Pfizer. ; Pierre Fabre. ; Aduro Biotech. ; Roche/Genentech. K. Fizazi:  ; Astellas Pharma. ; Travel expenses\\n; Janssen Oncology. ; Merck. ; Sanofi. ; Travel expenses; Amgen. ; AstraZeneca. ; Bayer. ; Clovis Oncology. ; CureVac. ; ESSA. ; Orion Pharma. ; Roche/Genentech. J.M. Piulats:  ; Travel, accommodations, expenses; Astellas Oncology. ; Bristol-Myers Squibb. ; Clovis Oncology. ; Travel, accommodations, expenses; Janssen. ; Merck. ; Novartis. ; Roche. P.J. Wysocki:  ; Sanofi. G.L. Buchschacher Jr:  ; Travel accommodations; food and beverage; AstraZeneca. ; Travel accommodations; food and beverage; Roche. ; Genentech. ; MSD. J. Doss:  ; Genentech. S. Mariathasan:  ; Genentech. E.E. Kadel:  ; Genentech. ; F. Hoffman-La Roche. K. Yuen:  ; Genentech, Inc.\\xa0A. Datye:  ; Hoffmann-La Roche. G. Rasuo:  ; F. Hoffmann-La Roche. D. Tayama:  ; Genentech. P. Williams:  ; Genentech. T. Powles:  ; travel support; AstraZeneca. ; Genentech/Roche. ; travel support; BMS. ; travel support; Ipsen. ; travel support; Exelixis. ; travel support; Roche. ; travel support; Merck. ; travel support; Pfizer. ; travel support; Novartis. ; travel support; Incyte. ; travel support; Seattle Genetics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-15': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10842',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:10 AM - 11:15 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '841-16': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10599',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:15 AM - 11:30 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Padmanee Sharma. UT MD Anderson Cancer Center, Houston, TX',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '841-17': {'Session Title': ' VCTPL01. Opening Clinical Plenary',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10843',\n",
       "  'Date': ' April 27, 2020, 9:30 AM - 11:40 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:30 AM - 11:40 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '834-1': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10529',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' January 1, 0001, 12:00 AM - 12:00 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Aurelien Marabelle. Institute Gustave Roussy, Villejuif, France',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '834-2': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10530',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' January 1, 0001, 12:00 AM - 12:00 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sergio A. Quezada. University College London Cancer Institute, London, United Kingdom',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '834-3': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10531',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5666\\n                        \\n                         - A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:25 PM - 3:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Barzin Y. Nabet1, Mohammad S. Esfahani1, Emily G. Hamilton1, Jacob J. Chabon1, Everett J. Moding1, Hira Rizvi2, Chloe B. Steen1, Aadel A. Chaudhuri3, Chih Long Liu1, Angela B. Hui1, Henning Stehr1, Linda Goljenola1, Michael C. Jin1, Young-Jun Jeon1, Diane Tseng1, Taha Merghoub2, Joel W. Neal1, Heather A. Wakelee1, Sukhmani K. Padda1, Kavitha J. Ramchandran1, Millie Das1, Rene F. Bonilla1, Christopher Yoo1, Emily L. Chen1, Ryan B. Ko1, Aaron M. Newman1, Matthew D. Hellmann1, Ash A. Alizadeh1, Maximilian Diehn1. 1Stanford University, Stanford, CA; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Washington University in St. Louis, Saint Louis, MO ',\n",
       "  'Disclosures': '\\xa0B.Y. Nabet: None.\\xa0M.S. Esfahani: None.\\xa0E.G. Hamilton: None. J.J. Chabon:  ; Lexent Bio Inc.\\xa0E.J. Moding: None.\\xa0H. Rizvi: None.\\xa0C.B. Steen: None. A.A. Chaudhuri:  ; Roche Sequencing Solutions. ; Varian Medical Systems. ; Foundation Medicine. ; Roche Sequencing Solutions. ; Oscar Health.\\xa0C. Liu: None.\\xa0A.B. Hui: None.\\xa0H. Stehr: None.\\xa0L. Goljenola: None.\\xa0M.C. Jin: None.\\xa0Y. Jeon: None.\\xa0D. Tseng: None. T. Merghoub:  ; Cofounder; Imvaq. J.W. Neal:  ; Roche. ; Merck. ; Novartis. ; Boehringer Ingelheim. ; Adaptimmune. ; Exelixis. ; Nektar Therapeutics. ; Takeda Pharmaceuticals. ; GSK. ; AstraZeneca. ; Roche. ; Exelixis. ; Jounce Therapeutics. ; Takeda Pharmaceuticals. ; Eli Lilly and Company. H.A. Wakelee:  ; Novartis. ; AstraZeneca. ; Xcovery. ; Janssen. ; Mirati. S.K. Padda:  ; EpicentRx. ; Forty Seven Inc. ; Bayer. ; Boehringer Ingelheim. ; AstraZeneca. ; AbbVie. ; Pfizer. ; G1 Therapeutics.\\xa0K.J. Ramchandran: None. M. Das:  ; Abbvie. ; United Therapeutics. ; Varian. ; Celgene. ; AstraZeneca. ; Bristol-Myers Squibb.\\xa0R.F. Bonilla: None.\\xa0C. Yoo: None.\\xa0E.L. Chen: None.\\xa0R.B. Ko: None. A.M. Newman:  ; Roche. ; Merck. ; CiberMed. M.D. Hellmann:  ; Bristol-Myers Squibb. ; Merck. ; Genentech. ; AstraZeneca. ; MedImmune. ; Nektar. ; Syndax. ; Janssen. ; Mirati Therapeutics. ; Shattuck Labs. ; Blueprint Medicines. A.A. Alizadeh:  ; Ownership Interest; CiberMed. ; Ownership Interest; FortySeven. ; Genentech. ; Roche. ; Chugai. ; Gilead. ; Celgene. M. Diehn:  ; Ownership interest; CiberMed. ; Roche. ; AstraZeneca. ; BioNTech. ; Reflexion.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-4': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10532',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5667\\n                        \\n                         - Biomarkers associated with tertiary lymphoid structures are elevated in lung and bladder cancer patients who respond to durvalumab treatment\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:40 PM - 3:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sriram Sridhar, Christopher M. Morehouse, Yashaswi Shreshta, Marlon Rebelatto, Ikbel Achour, Ioannis Kagiampakis, Ezogelin Oflazoglu, Katie Streicher. AstraZeneca, Gaithersburg, MD ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Sridhar:  ; AstraZeneca. C.M. Morehouse:  ; AstraZeneca. Y. Shreshta:  ; AstraZeneca. M. Rebelatto:  ; AstraZeneca. I. Achour:  ; AstraZeneca. I. Kagiampakis:  ; neca. E. Oflazoglu:  ; AstraZeneca. K. Streicher:  ; AstraZeneca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-5': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10533',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5668\\n                        \\n                         - Genomic correlates of PD-L1 expression are associated with response to immunotherapy in non-small cell lung cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:55 PM - 4:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Liam F. Spurr1, Giuseppe Lamberti1, Yvonne Y. Li1, Biagio Ricciuti1, Gonzalo Recondo1, Renato Umeton1, Lynette M. Sholl2, Matthew L. Meyerson1, Andrew D. Cherniack3, Mark M. Awad1. 1Dana-Farber Cancer Institute, Boston, MA; 2Brigham and Womens Hospital, Boston, MA; 3Broad Institute, Cambridge, MA ',\n",
       "  'Disclosures': '\\xa0L.F. Spurr: None.\\xa0G. Lamberti: None.\\xa0Y.Y. Li: None.\\xa0B. Ricciuti: None. G. Recondo:  ; Amgen. ; Roche. ; Pfizer.\\xa0R. Umeton: None. L.M. Sholl:  ; AZD. ; EMD Serono. ; LOXO Oncology. ; Roche. ; Genentech. M.L. Meyerson:  ; OrigiMed. ; Bayer. ; Patent holder; EGFR mutations in lung cancer. A.D. Cherniack:  ; LabCorp. ; Merck. ; Bayer. M.M. Awad:  ; Bristol-Myers Squibb. ; Abbvie. ; Achilles. ; AstraZeneca. ; Hegrui. ; Maverick. ; Neon. ; Lilly. ; Genentech. ; Merck. ; Nektar. ; Syndax. ; Gritstone.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-6': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10534',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5669\\n                        \\n                         - Differential prognosis of immune biomarkers in metastatic vs. early triple negative breast cancer (TNBC) settings\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:10 PM - 4:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Kelly J. Dupree1, Ching-Wei Chang1, Meghna Das Thakur1, Timothy R. Wilson1, David Shames1, David Cameron2, Luciana Molinero1. 1Genentech, South San Francisco, CA; 2University of Edinburgh, Edinburgh, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0K.J. Dupree:  ; Genentech. C. Chang:  ; Genentech. M. Das Thakur:  ; Genentech. T.R. Wilson:  ; Genentech. D. Shames:  ; Genentech. D. Cameron:  ; Roche/Genentech. ; travel, accommodations, expenses; Novartis. ; AstraZeneca. ; Daiichi Sankyo. ; Eisai. ; Eli Lilly. ; Merck Sharp and Dohme. ; Oncolytics. ; Pfizer. ; Prima BioMed. ; Puma Biotechnology. ; Research Triangle. ; Samsung Bioepis Co. Ltd.. ; Seattle Genetics. ; Synthon. ; Zymeworks. L. Molinero:  ; Genentech.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-7': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10535',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5670\\n                        \\n                         - Machine learning methods to identify salient genomic predictors of clinical responses to immune checkpoint inhibitor therapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:25 PM - 4:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Emma G. Bigelow, Alexander Baras, Mark Yarchoan, Elizabeth M. Jaffee. Johns Hopkins University, Baltimore, MD ',\n",
       "  'Disclosures': '\\xa0E.G. Bigelow: None.\\xa0A. Baras: None. M. Yarchoan:  ; Bristol-Myers Squibb. ; Exelixis. ; Genentech/Roche. ; Incyte. ; Merck & Co. ; Eisai Inc.\\xa0E.M. Jaffee:  ; Inventor on licensed patents; Aduro Biotech. ; Lustgarten Foundation. ; Genocea. ; Adaptive Biotech. ; DragonFly. ; CSTONE. ; Achilles. ; Parker Institute. ; National Cancer Advisory Board. ; Amgen. ; Bristol Myer Squibb. ; Hertix. ; Corvus.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-8': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10536',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5671\\n                        \\n                         - Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:40 PM - 4:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Diana M. MERINO1, Laura M. Yee2, Lisa M. McShane2, P. Mickey Williams3, Tomas Vilimas3, Rajesh Patidar3, J. Carl Barrett4, Shu-Jen Chen5, Jen-Hao Cheng5, Jeffrey M. Conroy6, Dinesh Cyanam7, Kenneth R. Eyring8, David A. Fabrizio9, Vincent Funari10, Elizabeth P. Garcia11, Sean T. Glenn6, Christopher D. Gocke12, Vikas Gupta13, Lisa M. Haley12, Matthew D. Hellmann14, Laurel Keefer15, Lauryn R. Keeler16, Brett Kennedy8, Alexander J. Lazar17, Laura E. MacConaill11, Kristen L. Meier18, Arnaud Papin19, Naiyer A. Rizvi20, Ethan Sokol9, Phillip Stafford21, John F. Thompson15, Warren Tom22, Victor J. Weigman23, Mingchao Xie4, Chen Zhao18, Mark D. Stewart1, Jeff Allen1. 1Friends of Cancer Research, Washington, DC; 2National Cancer Institute, Bethesda, MD; 3Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Frederick, MD; 4AstraZeneca Pharmaceuticals LP, Waltham, MA; 5ACTGenomics co. Ltd., Taipei, Taiwan; 6Omniseq, Inc., Buffalo, NY; 7Thermo Fisher Scientific, Ann Arbor, MI; 8Intermountain Precision Genomics, Salt Lake City, UT; 9Foundation Medicine, Inc., Cambridge, MA; 10NeoGenomics Laboratories, Inc., Aliso Viejo, CA; 11Brigham and Womens Hospital, Boston, MA; 12Johns Hopkins University School of Medicine, Baltimore, MD; 13QIAGEN Inc., Aarhus, Denmark; 14Memorial Sloan Kettering Cancer Center, New York, NY; 15Personal Genome Diagnostics, Baltimore, MD; 16NeoGenomics Laboratories, Inc., Carlsbad, CA; 17MD Anderson Cancer Center, Houston, TX; 18Illumina, San Diego, CA; 19QIAGEN Inc., Waltham, MA; 20Columbia University Irving Medical Center, Washington, DC; 21Caris Life Sciences, Phoenix, AZ; 22Thermo Fisher Scientific, South San Francisco, CA; 23Q Squared Solutions, Morrisville, NC ',\n",
       "  'Disclosures': '\\xa0D.M. Merino: None.\\xa0L.M. Yee: None.\\xa0L.M. McShane: None.\\xa0P. Williams: None.\\xa0T. Vilimas: None.\\xa0R. Patidar: None. J. Barrett:  ; AstraZeneca Pharmaceuticals LP. S. Chen:  ; ACTGenomics co. Ltd.\\xa0J. Cheng:  ; ACTGenomics co. Ltd.\\xa0J.M. Conroy:  ; OmniSeq, Inc.\\xa0D. Cyanam:  ; Thermo Fisher Scientific. K.R. Eyring:  ; Intermountain Healthcare. D.A. Fabrizio:  ; Foundation Medicine, Inc.\\xa0V. Funari:  ; NeoGenomics Laboratories, Inc..\\xa0E.P. Garcia: None. S.T. Glenn:  ; OmniSeq, Inc..\\xa0C.D. Gocke: None. V. Gupta:  ; QIAGEN Inc..\\xa0L.M. Haley: None. M.D. Hellmann:  ; Merck. ; Bristol Myers Squibb. ; AstraZeneca. ; Genentech. ; Blueprint. ; Nektar. ; Syndax. ; Mirati. ; Immunai. ; Shattuck Labs. L. Keefer:  ; Personal Genome Diagnostics. L.R. Keeler:  ; NeoGenomics Laboratories, Inc.\\xa0B. Kennedy:  ; Intermountain Healthcare.\\xa0A.J. Lazar: None.\\xa0L.E. MacConaill: None. K.L. Meier:  ; Illumina. A. Papin:  ; QIAGEN Inc.\\xa0N.A. Rizvi:  ; Abbvie. ; Apricity. ; AstraZeneca. ; Bristol Myers Squibb. ; Bellicum. ; Boehringer. ; Brooklyn ImmunoTherapeutics. ; Calither. ; Dracen. ; Editas. ; EMD Serono. ; G1 Therapeutics. ; Genentech. ; Gilead. ; GSK. ; Illumina. ; Janssen. ; Eli Lilly. ; Merck. ; NeoGenomics. E. Sokol:  ; Foundation Medicine, Inc.\\xa0P. Stafford:  ; Caris Life Sciences. J.F. Thompson:  ; Personal Genome Diagnostics. W. Tom:  ; Thermo Fisher Scientific. V.J. Weigman:  ; Q Squared Solutions. M. Xie:  ; AstraZeneca Pharmaceuticals LP. C. Zhao:  ; Illumina.\\xa0M.D. Stewart: None.\\xa0J. Allen: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-9': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10537',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5672\\n                        \\n                         - Pharmacodynamics and potential predictive biomarkers of ABBV-428, a first-in-class mesothelin (MSLN)-CD40 bispecific, in patients with advanced solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:55 PM - 5:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hua Fang1, Shiming Ye1, Anita Reddy1, Tolga Turan1, Andrew Woolley1, Debra T. Chao1, Cyril Ramathal1, William R. Henner1, Kinjal Hew1, Michael McDevitt1, Joel Hayflick1, Frances Fan2, Kathryn Allaire2, Lawrence Fong2. 1AbbVie, Inc., Redwood City, CA; 2University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA ',\n",
       "  'Disclosures': '\\xa0\\xa0H. Fang:  ; AbbVie. S. Ye:  ; Abbvie. A. Reddy:  ; Abbvie. T. Turan:  ; Abbvie. A. Woolley:  ; Abbvie. D.T. Chao:  ; Abbvie. C. Ramathal:  ; Abbvie. W.R. Henner:  ; Abbvie. K. Hew:  ; Abbvie. M. McDevitt:  ; Abbvie. J. Hayflick:  ; Abbvie.\\xa0F. Fan: None.\\xa0K. Allaire: None. L. Fong:  ; Atreca. ; BioAlta. ; Bolt. ; IDEAYA. ; Nutcracker. ; Senti. ; TeneoBio. ; Abbvie. ; Bavarian Nordic. ; Bristol-Myers Squibb. ; Dendreon. ; Janssen Oncology. ; Merck. ; OncoSec. ; Roche/Genentech.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '834-10': {'Session Title': ' VMS.CL11.01. Predictive Biomarkers for Immunotherapeutics',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nClinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10969',\n",
       "  'Date': ' April 28, 2020, 3:20 PM - 5:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Late interferon-gamma blockade improves antitumor efficacy of anti-CTLA-4 and anti-PD-1 combination treatment\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 5:10 PM - 5:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Stephen Mok, Renee Chin, James P. Allison. UT MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0S. Mok: None.\\xa0R. Chin: None. J.P. Allison:  ; Jounce and Neon Therapeutics. ; Amgen. ; Kite Pharmaceuticals. ; BMS. ; Merck.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-1': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10749',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:30 PM - 1:31 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alexander M Marie Eggermont. Princess Maxima Center for Pediatric Oncology, Paris, France',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-2': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10861',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:30 PM - 1:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-3': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10750',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT041\\n                        \\n                         - The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:35 PM - 1:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Yuankai Shi1, Jianqiu Wu2, Zhen Wang3, Liling Zhang4, Zhao Wang5, Mingzhi Zhang6, Hong Cen7, Zhigang Peng8, Yufu Li9, Lei Fan10, Ye Guo11, Liping Ma12, Jie Cui13, Yuhuan Gao14, Haiyan Yang15, Hongyu Zhang16, Lin Wang17, Weihua Zhang18, Huilai Zhang19, Liping Xie20, Ming Jiang21, Hui Zhou22, Yuerong Shuang23, Hang Su24, Xiaoyan Ke25, Chuan Jin26, Xin Du27, Xin Du28, Li Liu29, Yaming Xi30, Zheng Ge31, Ru Feng32, Yang Zhang33, Shengyu Zhou34, Fan Xie35, Chao Gao35. 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted drugs, Beijing, China; 2Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China; 3Department of Oncology, Linyi Cancer Hospital, Linyi, China; 4Department of lymphoma, Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; 5Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China; 6Department of Oncology,The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 7Department of Hematologylymphoma and pediatric oncology, Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College, Nanning, China; 8Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China; 9Department of Hematology, Henan Cancer Hospital, Zhengzhou, China; 10Department of Hematology, Jiangsu Province Hospital, Nanjing, China; 11Department of Oncology, Shanghai Oriental Hospital, Shanghai, China; 12Department of Hematology, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou, China; 13Department of Hematology, Gansu Provincial Cancer Hospital, Lanzhou, China; 14Department of Hematology, The fourth hospital of Hebei Medical University, Shijiazhuang, China; 15Department of lymphoma, Zhejiang Cancer Hospital, Hangzhou, China; 16Department of Oncology, The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, China; 17Department of Oncology, Hainan General Hospital, Haikou, China; 18Department of Hematology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China; 19Department of lymphoma, Tianjin Medical University Cancer Institute  &  Hospital, Tianjin, China; 20Department of Hematology, West China Hospital Sichuan University, Chengdu, China; 21Department of Oncology, West China Hospital Sichuan University, Chengdu, China; 22Department of lymphoma, Hunan Cancer Hospital, Changsha, China; 23Department of Oncology, Jiangxi Cancer Hospital, Nanchang, China; 24Department of lymphoma, The Fifth Medical Center of The General Hospital of The People's Liberation Army of China, Beijing, China; 25Department of Hematology, Peking University Third Hospital, Beijing, China; 26Department of Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, China; 27Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China; 28Department of Hematology, Shenzhen Second People's Hospita, Shenzhen, China; 29Department of Hematology, Tangdu Hospital of the Fourth Military Medical University, Xian, China; 30Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, China; 31Department of Hematology, Zhongda Hospital Southeast University, Nanjing, China; 32Department of Hematology, Nanfang Hospital, Guangzhou, China; 33Department of Oncology, The Second Hospital Of Dalian Medical University, Dalian, China; 34Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targe, Beijing, China; 35Department of Medical Science, Genor Biopharma Co., Ltd., Shanghai, China \",\n",
       "  'Disclosures': '\\xa0Y. Shi: None.\\xa0J. Wu: None.\\xa0Z. Wang: None.\\xa0L. Zhang: None.\\xa0Z. Wang: None.\\xa0M. Zhang: None.\\xa0H. Cen: None.\\xa0Z. Peng: None.\\xa0Y. Li: None.\\xa0L. Fan: None.\\xa0Y. Guo: None.\\xa0L. Ma: None.\\xa0J. Cui: None.\\xa0Y. Gao: None.\\xa0H. Yang: None.\\xa0H. Zhang: None.\\xa0L. Wang: None.\\xa0W. Zhang: None.\\xa0H. Zhang: None.\\xa0L. Xie: None.\\xa0M. Jiang: None.\\xa0H. Zhou: None.\\xa0Y. Shuang: None.\\xa0H. Su: None.\\xa0X. Ke: None.\\xa0C. Jin: None.\\xa0X. Du: None.\\xa0X. Du: None.\\xa0L. Liu: None.\\xa0Y. Xi: None.\\xa0Z. Ge: None.\\xa0R. Feng: None.\\xa0Y. Zhang: None.\\xa0S. Zhou: None.\\xa0F. Xie: None.\\xa0C. Gao: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-4': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10862',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:45 PM - 1:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-5': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10751',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT042\\n                        \\n                         - Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:50 PM - 2:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Mallika Lala, Omobolaji Akala, Elliot Chartash, Mizuho Kalabis, Shu-Chih Su, Dinesh de Alwis, Vikram Sinha, Lokesh Jain. Merck & Co., Kenilworth, NJ ',\n",
       "  'Disclosures': '\\xa0\\xa0M. Lala:  ; Merck & Co., Inc.\\xa0O. Akala:  ; Merck & Co., Inc.\\xa0E. Chartash:  ; Merck & Co., Inc.\\xa0M. Kalabis:  ; Merck & Co., Inc.\\xa0S. Su:  ; Merck & Co., Inc.\\xa0D. de Alwis:  ; Merck & Co., Inc.\\xa0V. Sinha:  ; Merck & Co., Inc.\\xa0L. Jain:  ; Merck & Co., and Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-6': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10863',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:00 PM - 2:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-7': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10958',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:05 PM - 2:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Siwen Hu-Lieskovan. Huntsman Cancer Institute, Salt Lake City, UT',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-8': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10864',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:20 PM - 2:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-9': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10752',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT043\\n                        \\n                         - A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:25 PM - 2:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Mark Yarchoan1, Leslie Cope1, Robert A. Anders1, Anne Noonan2, Laura W. Goff3, Lipika Goyal4, Jill Lacy5, Daneng Li6, Anuj Patel7, Aiwu R. He8, Ghassan Abou-Alfa9, Kristen Spencer10, Edward Kim11, Stephanie Xavier1, Amanda Ruggieri12, S. Lindsey Davis13, Autumn McRee14, Paul Kunk15, Qingfeng Zhu1, Andrea Wang-Gillam16, Andrew Poklepovic17, Helen Chen18, Elad Sharon18, Gregory B. Lesinski19, Nilo Azad1. 1Johns Hopkins, Baltimore, MD; 2The Ohio State University, Columbus, OH; 3Vanderbilt-Ingram Cancer Center, Nashville, TN; 4Massachusetts General Hospital Cancer Center, Boston, MA; 5Yale Cancer Center, New Haven, CT; 6City of Hope, Duarte, CA; 7Dana-Farber Cancer Institute, Boston, MA; 8Georgetown University, Washington, DC; 9Memorial Sloan Kettering Cancer Center, New York City, NY; 10Rutgers Cancer Institute, New Brunswick, NJ; 11UC Davis, Sacramento, CA; 12Winship Cancer Institute of Emory University, Atlanta, GA; 13University of Colorado Hospital, Aurora, CO; 14Johns Hopkins, Chapel Hill, NC; 15University of Virginia, Charlottesville, VA; 16Siteman Cancer Center, Baltimore, MD; 17VCU Massey Cancer Center, Richmond, VA; 18NCI Cancer Therapy Evaluation Program (CTEP), Bethesda, MD; 19Winship Cancer Institute of Emory University, Altanta, GA ',\n",
       "  'Disclosures': '\\xa0\\xa0M. Yarchoan:  ; Eisai. ; Exelixis. ; Bristol-Myers Squibb. ; Exelixis. ; Merck & Co.. ; Incyte Corporation.\\xa0L. Cope: None.\\xa0R.A. Anders: None.\\xa0A. Noonan: None.\\xa0L.W. Goff: None.\\xa0L. Goyal: None.\\xa0J. Lacy: None.\\xa0D. Li: None.\\xa0A. Patel: None.\\xa0A.R. He: None.\\xa0G. Abou-Alfa: None.\\xa0K. Spencer: None.\\xa0E. Kim: None.\\xa0S. Xavier: None.\\xa0A. Ruggieri: None.\\xa0S. Davis: None.\\xa0A. McRee: None.\\xa0P. Kunk: None.\\xa0Q. Zhu: None.\\xa0A. Wang-Gillam: None.\\xa0A. Poklepovic: None.\\xa0H. Chen: None.\\xa0E. Sharon: None.\\xa0G.B. Lesinski: None. N. Azad:  ; Incyte. ; Astex. ; Syndex. ; Intensity Therapeutics. ; Merck. ; BMS. ; Array. ; Celgene. ; GSK. ; Agios. ; Bayer. ; EMD Serono. ; QED.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-10': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10865',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:35 PM - 2:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-11': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10753',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT044\\n                        \\n                         - Genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC)\\n',\n",
       "  'Presentation Time': ' April 28, 2020, 2:40 PM - 2:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Andrew X. Zhu1, Yinghui Guan2, Alexander R. Abbas2, Hartmut Koeppen2, Shan Lu2, Chih-Hung Hsu3, Kyung-Hun Lee4, Michael S. Lee5, Aiwu Ruth He6, Amit Mahipal7, Beiying Ding2, Jessica Spahn2, Wendy Verret2, Baek-Yeol Ryoo8, Yulei Wang2. 1Massachusetts General Hospital Cancer Center and Jiahui International Cancer Center, Boston, MA; 2Genentech, Inc., South San Francisco, CA; 3National Taiwan University Hospital, Taipei, Taiwan; 4Seoul National University, Seoul, Korea, Democratic People's Republic of; 5UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; 6Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; 7Mayo Clinic, Rochester, MN; 8Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Democratic People's Republic of \",\n",
       "  'Disclosures': '\\xa0\\xa0A.X. Zhu:  ; Eisai. ; BMS. ; Merck. ; Novartis. ; AstraZeneca. ; Bayer. ; Lilly. ; Exelixis. ; Roche/Genentech. Y. Guan:  ; Genentech, Inc.\\xa0A.R. Abbas:  ; Genentech, Inc.\\xa0H. Koeppen:  ; Genentech, Inc.\\xa0S. Lu:  ; Genentech, Inc.\\xa0C. Hsu:  ; F. Hoffmann La-Roche/Genentech. ; Eli Lilly. ; Merck/Serono. ; BMS. ; Ono Pharmaceutical. K. Lee:  ; F. Hoffmann La-Roche, Ltd.. ; AstraZeneca. ; Bayer. ; Eisai. ; Ono Pharmaceutical. ; Samsung Bioepis. M.S. Lee:  ; F Hoffmann La-Roche, Ltd. ; EMD Serono. ; Amgen. ; BMS. ; Pfizer. ; Exelixis. ; AstraZeneca. A.R. He:  ; F. Hoffmann La-Roche, Ltd.. ; Merck. ; AstraZeneca. ; Bayer. ; BMS. ; Eisai. ; Exelixis. A. Mahipal:  ; Eisai. ; Taiho Pharmaceuticals. B. Ding:  ; Genentech, Inc.\\xa0J. Spahn:  ; Genentech, Inc.\\xa0W. Verret:  ; Genentech, Inc..\\xa0B. Ryoo: None. Y. Wang:  ; Genentech, Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-12': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10866',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:50 PM - 2:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-13': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10756',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:55 PM - 3:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Zev A. Wainberg. UCLA Medical Center-Santa Monica, Santa Monica, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-14': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10867',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:10 PM - 3:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-15': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10754',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT045\\n                        \\n                         - Synergistic anti-tumor efficacy of the dual PI3K-/PI3K- inhibitor duvelisib with PD-1 blockade in solid tumor and lymphoma models\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:15 PM - 3:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Silvia Coma1, Christopher R. Funk2, Shuhua Wang2, Edmund K. Waller2, David T. Weaver1, Jonathan A. Pachter1. 1Verastem Oncology, Needham, MA; 2Emory University, Atlanta, GA ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Coma:  ; Verastem Oncology.\\xa0C.R. Funk: None.\\xa0S. Wang: None. E.K. Waller:  ; Verastem Oncology. D.T. Weaver:  ; Verastem Oncology. J.A. Pachter:  ; Verastem Oncology.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-16': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10868',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:25 PM - 3:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '853-17': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10757',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:30 PM - 3:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Margaret Callahan. Mem. Sloan Kettering Cancer Ctr., New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '853-18': {'Session Title': ' VCTPL04. Immunotherapy Clinical Trials 2',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10869',\n",
       "  'Date': ' April 28, 2020, 1:30 PM - 3:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:45 PM - 3:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '842-1': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10600',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT101\\n                        \\n                         - Phase I clinical trial: results from the use of 4-demethyl-4 cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) plus radiation as treatment for cancers involving the CNS\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Steven J. DiBiase1, Roy S. Weiner2, Tallat Mahmood3, Kendra Harris4, Ronald Kawauchi5, Kiran Devisetty6, James Herman7, Manish Bhandari8, Marcus Ware9, Paul Friedlander10, Lee R. Morgan11, Ali Baghian4. 1Weill Cornell Medicine, New York, NY; 2Tulane University Health Sciences Center, New Orleans, LA; 3Memorial Healthcare, Owasso, MI; 4Tulane Cancer Center, New Orleans, LA; 5Detroit Clinical Research Center, Lansing, MI; 6Karmanos Cancer Center Institute at McLaren Flint, Flint, MI; 7Sparrow Hospital, Lansing, MI; 8The Christ Hospital, Cincinnati, OH; 9Ochsner Medical Center, New Orleans, LA; 10Tisch Cancer Institute, New York, NY; 11DEKK-TEC, Inc., New Orleans, LA ',\n",
       "  'Disclosures': '\\xa0S.J. DiBiase: None.\\xa0R.S. Weiner: None.\\xa0T. Mahmood: None.\\xa0K. Harris: None.\\xa0R. Kawauchi: None.\\xa0K. Devisetty: None.\\xa0J. Herman: None.\\xa0M. Bhandari: None.\\xa0M. Ware: None.\\xa0P. Friedlander: None.\\xa0L.R. Morgan: None.\\xa0A. Baghian: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-2': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10601',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT102\\n                        \\n                         - Sequential bortezomib and temozolomide combination treatment in recurrent glioblastoma patients is safe, well tolerated and promotes immunological response in patients with positive clinical outcomes NCT03643549 phase IB study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Mohummad Aminur Rahman1, Jorunn Brekke2, Victoria Arnesen1, Marianne H. Hannisdal2, Andrea Gras Navarro11, Andreas Waha3, Lars Herfindal4, Cecilie B. Rygh5, Eirik Bratland6, Petter Brandal7, Judit Haasz5, Leif Oltedal5, Hrvoje Miletic8, Arvid Lundervold1, Stein A. Lie9, Dorota Goplen2, Martha Chekenya1. 1Department of Biomedicine, University of Bergen, Bergen, Norway; 2Department of Oncology, Haukeland University Hospital, Bergen, Norway; 3Department of Neuropathology, University of Bonn, Bonn, Germany; 4Department of Clinical Sciences, University of Bergen, Bergen, Norway; 5Department of Radiology, Haukeland University Hospital, Bergen, Norway; 6Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway; 7Department of Oncology, Oslo University Hospital, Oslo, Norway; 8Department of Pathology, Haukeland University Hospital, Bergen, Norway; 9Department of Clinical Dentistry, University of Bergen, Bergen, Norway ',\n",
       "  'Disclosures': '\\xa0M. Rahman: None.\\xa0J. Brekke: None.\\xa0V. Arnesen: None.\\xa0M.H. Hannisdal: None.\\xa0A. Navarro1: None.\\xa0A. Waha: None.\\xa0L. Herfindal: None.\\xa0C.B. Rygh: None.\\xa0E. Bratland: None.\\xa0P. Brandal: None.\\xa0J. Haasz: None.\\xa0L. Oltedal: None.\\xa0H. Miletic: None.\\xa0A. Lundervold: None.\\xa0S.A. Lie: None.\\xa0D. Goplen: None.\\xa0M. Chekenya: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-3': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10602',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT103\\n                        \\n                         - Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nikola Mikic1, Anders R. Korshj1, Slavka Lukacova2, Jens C. H. Srensen1, Frederik L. Hansen1, Axel Thielscher3, Sren O. S. Cortnum1, Trine L. Guldberg2, Yasmin Ramshad-Lassen2, Christian Rahbek4, Kre Eg Severinsen5, Gorm von Oettingen1. 1Aarhus University Hospital, Dept. of Neurosurgery, Aarhus, Denmark; 2Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark; 3Department of Health Technology, Technical University of Denmark, Lyngby, Denmark; 4Aarhus University Hospital, Dept. of Radiology, Aarhus, Denmark; 5Aarhus University Hospital, Dept. of Neurology, Aarhus, Denmark ',\n",
       "  'Disclosures': '\\xa0N. Mikic: None. A.R. Korshj:  ; Novocure.\\xa0S. Lukacova: None.\\xa0J.C.H. Srensen: None.\\xa0F.L. Hansen: None.\\xa0A. Thielscher: None.\\xa0S.O.S. Cortnum: None.\\xa0T.L. Guldberg: None.\\xa0Y. Ramshad-Lassen: None.\\xa0C. Rahbek: None.\\xa0K.E. Severinsen: None.\\xa0G. von Oettingen: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-4': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10603',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT104\\n                        \\n                         - Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Chia-Chi Lin1, Marta Gil-Martin2, Todd M. Bauer3, Aung Naing4, Darren Wan-Teck Lim5, John Sarantopoulos6, Ravit Geva7, Yuichi Ando8, Liqiong Fan9, Somesh Choudhury10, Pei-Jung Tu11, Cornelia Quadt12, Armando Santoro13. 1National Taiwan University Hospital, Taipei, Taiwan; 2Institut Catal d'Oncologia-IDIBELL, Hospital Duran i Reynals, Barcelona, Spain; 3Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN; 4The University of Texas MD Anderson Cancer Center, Houston, TX; 5National Cancer Centre Singapore, Singapore, Singapore; 6Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX; 7Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel; 8Nagoya University Hospital, Nagoya, Japan; 9Novartis Institute for BioMedical Research, Cambridge, MA; 10Novartis Institute for BioMedical Research, East Hanover, NJ; 11Translational Clinical Oncology, China and Novartis Institutes for BioMedical Research, Shanghai, China; 12Novartis Pharma AG, Basel, Switzerland; 13Humanitas Cancer Center  Humanitas Clinical and Research Hospital, Milan, Italy \",\n",
       "  'Disclosures': '\\xa0\\xa0C. Lin:  ; Boehringer-Ingelheim. ; Daiichi Sankyo. ; Novartis. ; Roche. ; BeiGene.\\xa0M. Gil-Martin: None. T.M. Bauer:  ; Exelixis. ; Recipient: Institution; Ignyta. ; Blueprint Medicines. ; Recipient: Institution; Moderna Therapeutics. ; Guardant Health. ; Loxo. ; Pfizer. ; Recipient: Institution; Pfizer. ; Bayer. ; Recipient: Institution; Medpacto, Inc., Ignyta, Top Alliance BioScience, Janssen, MedImmune, Leap Therapeutics, Merck, Novartis, Sanofi, Astellas Pharma, Five Prime Therapeutics, Foundation Medicine, Merrimack. ; Recipient: Institution; Calithera Biosciences, Principa Biopharma, Roche, Amgen, Incyte, Abbvie, Boehringer Ingelheim, Clovis Oncology, Onyx, GlaxoSmithKline, Deciphera, Millennium, Immunocore, Bristol-Myers Squibb. ; Recipient: Institution; Moderna Therapeutics, Jacobio, Loxo, Daiichi Sankyo, Mirati Therapeutics, AstraZeneca, Stemline Therapeutics, Kolltan Pharmaceuticals, Karyopharm Therapeutics, Immunogen, Aileron Therapeutics, MabVax. ; Recipient: Institution; Lilly, Pfizer, Genentech/Roche, Peleton, Takeda, Phosplatin Therapeutics, ARMO BioSciences. ; Travel, Accommodations, Expenses; Astellas Pharma, Clovis Oncology, Celgene, Genentech, Novartis, Lilly, Pharmacyclics, AstraZeneca, EMD Serono, Merck, Sysmex, Pfizer. A. Naing:  ; NCI; EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor; Amplimmune; ARMO BioSciences; Eli Lilly; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Merck; BMS; Pfizer, CytomX Therapeutics. ; Neon Therapeutics; Calithera Biosciences; TopAlliance Biosciences; Kymab; PsiOxus; Immune Deficiency Foundation (Spouse). ; CytomX Therapeutics; Novartis. ; Travel and accommodation expense; ARMO BioSciences. D. Wan-Teck Lim:  ; Bristol-Myers Squibb. ; Roche Genentech. ; Merck. ; Pfizer.\\xa0J. Sarantopoulos: None. R. Geva:  ; Boehringer Ingelheim, Merck Sharp & Dohme, Bayer, BOL Pharma. ; Pfizer, Merck Sharp & Dohme, Janssen, Bristol-Myers Squibb, Medison, Novartis. ; Options; BOL Pharma. Y. Ando:  ; Yakult Honsha Co., Ltd.. ; Eisai Co., Ltd.. ; Mochida Pharmaceutical Co., Ltd.. ; Nippon Kayaku Co., Ltd.. ; Chugai Pharmaceutical Co.,Ltd.. ; Taiho Pharmaceutical Co., Ltd.. ; Kyowa Hakko Kirin Co., Ltd. ; Daiichi Sankyo Co., Ltd.. ; Ono Pharmaceutical Co., Ltd.. ; Otsuka Holdings Co., Ltd.. ; Sawai Pharmaceutical Co., Ltd.. ; Sertrion Healthcare Japan Co., Ltd.. ; Eli Lilly Japan K.K.. ; Novartis Pharma K.K. ; Bayer Holding Ltd.. ; Bristol-Myers Squibb. ; Roche Diagnostics K.K. ; Geo Holdings Corportation. L. Fan:  ; Novartis Institutes for Biomedical Research, Cambridge, MA. S. Choudhury:  ; NOVARTIS PHARMACEUTICALS, EAST HANOVER, NJ, US. P. Tu:  ; China and Novartis Institutes for Biomedical Research, Shanghai, China. C. Quadt:  ; Novartis Pharma. A. Santoro:  ; Bristol-Myers Squibb. ; Servier. ; Gilead. ; Pfizer. ; Eisai. ; Bayer. ; Merck Sharp & Dome. ; Arqule. ; Sanofi. ; Takeda. ; Roche. ; AbbVie. ; Amgen. ; Celgene. ; AstraZeneca. ; Lilly. ; Sandoz. ; Novartis.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-5': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10604',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT105\\n                        \\n                         - First in human phase I trial of adenoviral vectors expressing Flt3L and HSV1-TK to treat newly diagnosed high-grade glioma by reprogramming the brain immune system\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'PEDRO LOWENSTEIN, Daniel Orringer, Yoshie Umemura, Oren Sagher, Jason Heth, Shawn Hervey-Jumper, Aaron Mammoser, Denise Leung, Ted Lawrence, Mishell Kim, Daniel Wahl, Paul McKeever, Sandra Camelo-Piragua, Andrew Lieberman, Sriram Venneti, Kait Verbal, Karen Sagher, Patrick Dunn, Daniel Zamler, Andrea Comba, David Altshuler, Lili Zhao, Karin Muraszko, Larry Junck, Maria G. Castro. University of Michigan, Ann Arbor, MI ',\n",
       "  'Disclosures': '\\xa0P. Lowenstein: None.\\xa0D. Orringer: None.\\xa0Y. Umemura: None.\\xa0O. Sagher: None.\\xa0J. Heth: None.\\xa0S. Hervey-Jumper: None.\\xa0A. Mammoser: None.\\xa0D. Leung: None.\\xa0T. Lawrence: None.\\xa0M. Kim: None.\\xa0D. Wahl: None.\\xa0P. McKeever: None.\\xa0S. Camelo-Piragua: None.\\xa0A. Lieberman: None.\\xa0S. Venneti: None.\\xa0K. Verbal: None.\\xa0K. Sagher: None.\\xa0P. Dunn: None.\\xa0D. Zamler: None.\\xa0A. Comba: None.\\xa0D. Altshuler: None.\\xa0L. Zhao: None.\\xa0K. Muraszko: None.\\xa0L. Junck: None.\\xa0M.G. Castro: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-6': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10605',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT106\\n                        \\n                         - PriCoTTF trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sied Kebir1, Lazaros Lazaridis1, Teresa Schmidt1, Christoph Oster1, Daniela Pierscianek2, Nika Guberina3, Christoph Kleinschnitz4, Martin Proescholdt5, Peter Hau6, Anca-Ligia Grosu7, Ulrich Sure2, Bjrn Scheffler8, Martin Stuschke3, Martin Glas1. 1Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, Essen, Germany; 2Department of Neurosurgery, University Hospital Essen, Essen, Germany; 3Department of Radiotherapy, University Hospital Essen, Essen, Germany; 4Department of Neurology, University Hospital Essen, Essen, Germany; 5Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany; 6Department of Neurology and Wilhelm Sander-Neuro-Oncology Unit, University of Regensburg, Regensburg, Germany; 7Department for Radiation Oncology, University Medical Center Freiburg, Freiburg, Germany; 8DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Kebir:  ; Novocure. L. Lazaridis:  ; Novocure.\\xa0T. Schmidt: None.\\xa0C. Oster: None.\\xa0D. Pierscianek: None.\\xa0N. Guberina: None.\\xa0C. Kleinschnitz: None.\\xa0M. Proescholdt: None.\\xa0P. Hau: None.\\xa0A. Grosu: None.\\xa0U. Sure: None.\\xa0B. Scheffler: None.\\xa0M. Stuschke: None. M. Glas:  ; Novartis. ; UCB. ; TEVA. ; Bayer. ; Novocure. ; Medac. ; Merck. ; Kyowa Kirin. ; Roche. ; AbbVie. ; Daiichi Sankyo.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-7': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10606',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT107\\n                        \\n                         - Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jose Silva1, Kevin Kalinsky2, Cody Chiuzan3, Tizita Zeleke1, Pan Qingfei4, Jiyang Yu5. 1MSSM, NYC, NY; 2Columbia University, NYC, NY; 3Columbia Un., NYC, NY; 4Saint Judes Children Hospital, Memphis, TN; 5Saint Jude Children Hospital, Menphis, TN ',\n",
       "  'Disclosures': '\\xa0J. Silva: None.\\xa0K. Kalinsky: None.\\xa0C. Chiuzan: None.\\xa0T. Zeleke: None.\\xa0P. Qingfei: None.\\xa0J. Yu: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-8': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10607',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT108\\n                        \\n                         - A phase 1b study of abemaciclib in combination with pembrolizumab for patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC) (NCT02779751): Preliminary results\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hope S. Rugo1, J. Thad Beck2, Guy Jerusalem3, Hans Wildiers4, Peter Kabos5, Michael Chisamore6, Rhian McNaughton7, Yanyun Chen8, Anwar Hossain8, Sara M. Tolaney9. 1Department of Medical Oncology, University of California, San Francisco, CA; 2Highland Oncology Group, Fayetteville, AR; 3CHU and Liege University, Domaine du Sart Tilman, Liege, Belgium; 4University Hospitals Leuven, Leuven, Belgium; 5Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO; 6Merck & Co., Inc., Kenilworth, NJ; 7Eli Lilly and Company, Erl Wood, United Kingdom; 8Eli Lilly and Company, Indianapolis, IN; 9Dana-Farber Cancer Institute, Boston, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0H.S. Rugo:  ; Travel accommodations and expenses; Pfizer. ; Travel accommodations and expenses; Puma Biotechnology. ; Travel accommodations and expenses; Mylan. ; Travel accommodations and expenses; Amgen. ; Travel accommodations and expenses; AstraZeneca. ; Travel accommodations and expenses; Macrogenics. ; Travel accommodations and expenses; Daiichi Sankyo. ; Travel accommodations and expenses; Merck. ; Travel accommodations and expenses; Novartis. ; Travel accommodations and expenses; OBI Pharma. ; Eisai. ; Eli Lilly and Company. ; Genentech. ; Immunomedics. ; Odonate Therapeutics. ; Seattle Genetics. J. Beck:  ; AbbVie. ; Novartis. ; Amgen. ; Pfizer. ; AstraZeneca. ; Bayer. ; Seattle Genetics. ; Boston Biomedical. ; Bristol Myers Squibb. ; Tesaro. ; Celgene. ; Eli Lilly. ; EMD-Serono. ; Evelo. ; Exact Sciences. ; Genentech-Roche. ; Hutchinson. ; Immunomedics. ; Janssen. ; MT Group. G. Jerusalem:  ; Personal fees and nonfinancial support; Novartis. ; Personal fees and nonfinancial support; Roche. ; Personal fees and nonfinancial support; Pfizer. ; Personal fees and nonfinancial support; Eli Lilly and Company. ; Personal fees and nonfinancial support; Amgen. ; Personal fees and nonfinancial support; Bristol Myers Squibb. ; Personal fees and nonfinancial support; AstraZeneca. ; Personal fees; AbbVie. ; Personal fees; Daiichi Sankyo. ; Nonfinancial support; MedImmune. ; Nonfinancial support; MerckKGaA. H. Wildiers:  ; Travel support including, travel, accommodations, and expenses; Roche. ; Travel support including, travel, accommodations, and expenses; TRM Oncology. ; Travel support including, travel, accommodations, and expenses; Pfizer. ; Travel support including, travel, accommodations, and expenses; Puma Biotechnology. ; AstraZeneca. ; Amgen. ; Eli Lilly and Company. ; Novartis. ; AbbVie. ; Vifor Pharma. ; Celldex Therapeutics. ; Janssen-Cilag. ; Orion Corporation. P. Kabos:  ; Eli Lilly and Company. ; Pfizer. ; AstraZeneca. ; Sanofi. ; Genentech. ; Radius Health. M. Chisamore:  ; Merck & Co., Inc.\\xa0R. McNaughton:  ; Eli Lilly and Company. Y. Chen:  ; Eli Lilly and Company. A. Hossain:  ; Eli Lilly and Company. S.M. Tolaney:  ; AstraZeneca. ; Eli Lilly and Company. ; Merck. ; Nektar. ; Pfizer. ; Genentech/Roche. ; Immunomedics. ; Bristol Myers Squibb. ; Novartis. ; Eisai. ; Nanostring. ; Puma. ; Sanofi. ; Celldex. ; Odonate. ; Seattle Genetics. ; G1 Therapeutics. ; AbbVie. ; Anthenex. ; Exelixis.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-9': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10608',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT109\\n                        \\n                         - A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Kevin Kalinsky1, Dejan Juric2, Philippe L. Bedard3, Mafalda Oliveira4, Andres Cervantes5, Erika Hamilton6, Ian E. Krop7, Nick Turner8, Peter Schmid9, Andrea Varga10, Antoine Italiano11, Zachary Veitch12, Cristina Saura13, Valentina Gambardella14, Sravanthi Cheeti15, Naoki Kotani15, Guiyuan Lei16, Katherine E. Hutchinson15, Stephanie Royer-Joo15, Anjali Vaze15, Jennifer L. Schutzman15, Komal Jhaveri17. 1Columbia University Irving Medical Center, New York, NY; 2Massachusetts General Hospital, Boston, MA; 3University of Toronto, Toronto, ON, Canada; 4Vall dHebron University Hospital, Barcelona, Spain; 5University of Valencia, Valencia, Spain; 6Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; 7Dana-Farber Cancer Institute, Boston, MA; 8The Institute of Cancer Research, London, United Kingdom; 9Cancer Research UK Barts Centre, London, United Kingdom; 10Gustave Roussy Cancer Campus, Villejuif, France; 11Institut Bergoni, Bordeaux, France; 12St. Michael's Hospital, Toronto, ON, Canada; 13Vall dHebron University Hospital, Barcelona, Spain; 14INCLIVA Biomedical Research Institute of Hospital Clinico de Valencia, Valencia, Spain; 15Genentech, Inc., South San Francisco, CA; 16Roche Products Limited, Welwyn Garden City, United Kingdom; 17Memorial Sloan Kettering Cancer Center, New York, NY \",\n",
       "  'Disclosures': '\\xa0\\xa0K. Kalinsky:  ; Biotheranostics. ; Eli Lilly. ; Spouse Employee and Stock Shareholder (self managed); Pfizer. ; Novartis. ; Eisai. ; AstraZeneca. ; Incyte. ; Genentech. ; Calithera Biosciences. ; Acetylon. ; Seattle Genetics. ; Amgen. ; Zeno Pharmaceuticals. ; CytomX Therapeutics. ; Spouse Employee and Stock Shareholder (self managed); Array BioPharma. ; Spouse Employee and Stock Shareholder (self managed); Pfizer. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd; F. Hoffmann-La Roche Ltd. D. Juric:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd; F. Hoffmann-La Roche Ltd. ; Food and beverage; Genentech, Inc.\\xa0P.L. Bedard:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd; F. Hoffmann-La Roche Ltd. M. Oliveira:  ; AstraZeneca. ; Philips Healthcare. ; Genentech. ; Travel grants and support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. ; Travel grants; Novartis. ; Immunomedics. ; Seattle Genetics. ; GSK. ; Boehringer-Ingelheim. ; PUMA Biotechnology. ; Zenith Epigenetics. ; Travel grants; Pierre-Fabre. ; Travel grants; GP Pharma. ; Travel grants; Grnenthal. ; Travel grants; Eisai. A. Cervantes:  ; Genentech. ; Merck Serono. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. ; BeiGene. ; Bayer. ; Servier. ; Eli Lilly. ; Novartis. ; Takeda. ; Astellas. ; FibroGen. ; Amcure. ; Sierra Oncology. ; AstraZeneca. ; MedImmune. ; BMS. ; MSD. ; Pierre Fabre. E. Hamilton:  ; AstraZeneca. ; Hutchinson MediPharma, OncoMed, MedImmune, StemCentrx, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Millenium, TapImmune, Cascadian, BerGenBio, Medivation, Tesaro, Eisai. ; Pfizer, Genentech, Novartis, Mersana Therapeutics, Eli Lilly, Boehringer Ingelheim, Daiichi Sankyo, Black Diamond, Silverback Therapeutics.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. ; H3 Biomedicine, Radius Health, Acerta, Takeda, MacroGenics, AbbVie, Immunomedics, Fujifilm, Effector, Merus, NuCana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono.. ; ArQule, Syros, Clovis, Cytomx, InventisBio, Deciphera, Unum Therapeutics, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Orinove, Molecular Templates.. ; Puma Biotechnology. I.E. Krop:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. ; Genentech. ; Bristol Meyers Squibb. ; Daiichi Sankyo. ; Macrogenics. ; Context Therapeutics. ; Taiho Oncology. ; Celltrion. N. Turner:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. P. Schmid:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. A. Varga:  ; Astrazeneca. ; BMS. ; Boehringer Ingelheim. ; Janssen Cilag. ; Merck. ; Novartis. ; Pfizer. ; Sanofi. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. A. Italiano:  ; Bayer. ; BMS. ; MSD. ; Pharmamar. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. ; Daiichi Sankyo. ; Ipsen. ; Merck. ; SpringWorks. Z. Veitch:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. C. Saura:  ; Vall dHebron University Hospital. ; AstraZeneca. ; BMS. ; Celgene. ; Daiichi Sankyo. ; Eisai. ; Genomic Health. ; MSD. ; Novartis. ; Pfizer. ; Philips HealthWorks. ; Pierre Fabre. ; Puma Biotechnology. ; Synthon. ; Sanofi. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. V. Gambardella:  ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. S. Cheeti:  ; Genentech, Inc.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. N. Kotani:  ; Genentech, Inc.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. G. Lei:  ; Roche Products Limited. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. K.E. Hutchinson:  ; Stocks (as part of employee compensation); Genentech, Inc.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. S. Royer-Joo:  ; Genentech, Inc.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. A. Vaze:  ; Genentech, Inc.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. J.L. Schutzman:  ; Stocks (as part of employee compensation); Genentech, Inc.. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd. K. Jhaveri:  ; Memorial Sloan Kettering Cancer Center. ; Novartis. ; Clovis Oncology. ; Genentech. ; AstraZeneca. ; ADC Therapeutics. ; Novita Pharmaceuticals. ; Debio Pharmaceuticals. ; Pfizer. ; Zymeworks. ; Spectrum Pharmaceuticals. ; BMS. ; Jounce Therapeutics. ; Taiho Oncology. ; Synthon. ; Intellisphere. ; AbbVie. ; Support for third-party editing assistance for this abstract, furnished by Daniel Clyde, PhD, of Health Interactions.; F. Hoffmann-La Roche Ltd.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-10': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10609',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT110\\n                        \\n                         - Prospective experimental treatment of colorectal cancer patients using tumor organoids\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Salo Nol Ooft1, Fleur Weeber1, Luuk Schipper1, Krijn Dijkstra1, Chelsea McLean1, Sovann Kaing1, Joris van de Haar1, Warner Prevoo1, Erik Werkhoven1, Petur Snaebjornsson1, Louisa Hoes1, Mirjam Chalabi1, Daphne van der velden1, Monique van Leerdam1, Henk Boot1, Cecile Grootscholte1, Alwin Huitema1, Haiko Bloemendal2, Edwin Cuppen3, Emile Voest1. 1NKI - AVL, Amsterdam, Netherlands; 2Radboud UMC, Amsterdam, Netherlands; 3UMC Utrecht, Amsterdam, Netherlands ',\n",
       "  'Disclosures': '\\xa0S.N. Ooft: None.\\xa0F. Weeber: None.\\xa0L. Schipper: None.\\xa0K. Dijkstra: None.\\xa0C. McLean: None.\\xa0S. Kaing: None.\\xa0J. van de Haar: None.\\xa0W. Prevoo: None.\\xa0E. Werkhoven: None.\\xa0P. Snaebjornsson: None.\\xa0L. Hoes: None.\\xa0M. Chalabi: None.\\xa0D. van der velden: None.\\xa0M. van Leerdam: None.\\xa0H. Boot: None.\\xa0C. Grootscholte: None.\\xa0A. Huitema: None.\\xa0H. Bloemendal: None.\\xa0E. Cuppen: None.\\xa0E. Voest: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-11': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10610',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT111\\n                        \\n                         - Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Laura Reyes Uribe1, Wenhui Wu2, Ozkan Gelincik3, Prashant V. Bommi1, Alejandro Francisco-Cruz4, Luisa M. Solis4, Patrick M. Lynch5, Ramona Lim6, Elena Stoffel7, Priyanka Kanth8, N. Jewel Samadder9, Maureen E. Mork10, Melissa W. Taggart11, Ginger L. Milne12, Lawrence J. Marnett12, Lana Vornik1, Diane D. Liu13, Maria Revuelta14, Kyle Chang1, Y. Nancy You15, Levy Kopelovich3, Ignacio I. Wistuba16, J. Jack Lee13, Shizuko Sei17, Robert H. Shoemaker17, Eva Szabo17, Ellen Richmond17, Asad Umar17, Marjorie Perloff17, Powell H. Brown1, Steven M. Lipkin3, Eduardo Vilar1. 1Department of Clinical Cancer Prevention. UT MD Anderson Cancer Center, Houston, TX; 2Department of Clinical Cancer Prevention,UT MD Anderson Cancer Center, Houston, TX; 3Weill Cornell Medical College, New York, NY; 4Department of Translational Molecular Pathology. UT MD Anderson Cancer Center, Houston, TX; 5Department of Gastroenterology, Hepatology and Nutrition. UT MD Anderson Cancer Center, Houston, TX; 6Department of Gastroenterology. Dana-Farber Cancer Institute, Boston, MA; 7Division of Gastroenterology, Department of Internal Medicine. University of Michigan, Ann Arbor, MI; 8Division of Gastroenterology, Cancer Control and Population Sciences. Huntsman Cancer Institute, Salt Lake City, UT; 9Department of Gastroenterology and Hepatology. Mayo Clinic, Phoenix, AZ; 10Department of Clinical Cancer Genetics Program. UT MD Anderson Cancer Center, Houston, TX; 11Department of Pathology. UT MD Anderson Cancer Center, Houston, TX; 12Departments of Biochemistry, Medicine, and Pharmacology.Vanderbilt University School of Medicine, Nashville, TN; 13Department of Biostatistics. UT MD Anderson Cancer Center, Houston, TX; 14Weill Cornell Medicine, New York City, NY; 15Department of Surgical Oncology. UT MD Anderson Cancer Center, Houston, TX; 16Department of Translational Molecular Pathology,UT MD Anderson Cancer Center, Houston, TX; 17Division of Cancer Prevention, National Cancer Institute, Bethesda, MD ',\n",
       "  'Disclosures': '\\xa0L. Reyes Uribe: None.\\xa0W. Wu: None.\\xa0O. Gelincik: None.\\xa0P.V. Bommi: None.\\xa0A. Francisco-Cruz: None.\\xa0L.M. Solis: None.\\xa0P.M. Lynch: None.\\xa0R. Lim: None.\\xa0E. Stoffel: None.\\xa0P. Kanth: None. N. Samadder:  ; Dr. Samadder has a consulting role with Janssen Research and Development, and Cancer Prevention Pharmaceuticals.; Janssen.\\xa0M.E. Mork: None.\\xa0M.W. Taggart: None.\\xa0G.L. Milne: None.\\xa0L.J. Marnett: None.\\xa0L. Vornik: None.\\xa0D.D. Liu: None.\\xa0M. Revuelta: None.\\xa0K. Chang: None.\\xa0Y. You: None.\\xa0L. Kopelovich: None. I.I. Wistuba:  ; Dr. Wistuba has an advisory role with Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health and MSD; Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health and MSD. ; Dr. Wistuba has received speaker fees from Medscape, MSD, Genentech/Roche, Pfizer; Medscape, MSD, Genentech/Roche, Pfizer. ; Dr. Wistuba has received research support from Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya; Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis,.\\xa0J. Lee: None.\\xa0S. Sei: None.\\xa0R.H. Shoemaker: None.\\xa0E. Szabo: None.\\xa0E. Richmond: None.\\xa0A. Umar: None.\\xa0M. Perloff: None.\\xa0P.H. Brown: None.\\xa0S.M. Lipkin: None. E. Vilar:  ; Dr Vilar has a consulting and advisory role with Janssen Research and Development and Co-Principal Investigators in an NIH/NCI U01 award with Co-Investigators employed by Nouscom, s.r.l.; Janssen.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-12': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10611',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT112\\n                        \\n                         - A multi-mineral approach to alter biomarkers of growth and differentiation in the human colon: Results from an interventional trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Muhammad N. Aslam, Shannon McClintock, Karsten Knuver, Mohamed Ali H. Jawad-Makki, Haris Ahmad, Danielle (Kim) Turgeon, James Varani. University of Michigan Medical School, Ann Arbor, MI ',\n",
       "  'Disclosures': '\\xa0M.N. Aslam: None.\\xa0S. McClintock: None.\\xa0K. Knuver: None.\\xa0M.H. Jawad-Makki: None.\\xa0H. Ahmad: None.\\xa0D. Turgeon: None.\\xa0J. Varani: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-13': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10612',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT113\\n                        \\n                         - A novel laser emission microscopy for early detection of colon cancer: Analysis of at-risk human colon from an interventional trial (research in progress)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Muhammad N. Aslam1, Yun-Lu Sun2, Ingrid Bergin1, Mohamed Ali H. Jawad-Makki1, Karsten Knuver1, Danielle (Kim) Turgeon1, James Varani1, Xudong Fan2. 1University of Michigan Medical School, Ann Arbor, MI; 2Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI ',\n",
       "  'Disclosures': '\\xa0M.N. Aslam: None.\\xa0Y. Sun: None.\\xa0I. Bergin: None.\\xa0M.H. Jawad-Makki: None.\\xa0K. Knuver: None.\\xa0D. Turgeon: None.\\xa0J. Varani: None.\\xa0X. Fan: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-14': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10613',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT114\\n                        \\n                         - Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Emily J. Koubek1, Brian A. Costello1, Jun Yin1, Renee M. McGovern1, Sarah A. Buhrow1, Renee A. Schoon1, Carrie A. Strand1, Yixing Jiang2, Mitesh J. Borad3, Naoko Takebe4, Scott H. Kaufmann1, Alex A. Adjei1, Joel M. Reid1. 1Mayo Clinic, Rochester, MN; 2University of Maryland, Baltimore, MD; 3Mayo Clinic, Scottsdale, AZ; 4National Cancer Institute, Rockville, MD ',\n",
       "  'Disclosures': '\\xa0E.J. Koubek: None.\\xa0B.A. Costello: None.\\xa0J. Yin: None.\\xa0R.M. McGovern: None.\\xa0S.A. Buhrow: None.\\xa0R.A. Schoon: None.\\xa0C.A. Strand: None.\\xa0Y. Jiang: None.\\xa0M.J. Borad: None.\\xa0N. Takebe: None.\\xa0S.H. Kaufmann: None.\\xa0A.A. Adjei: None.\\xa0J.M. Reid: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-15': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10614',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT115\\n                        \\n                         - Efficacy of surufatinib in Western patients with pancreatic neuroendocrine tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'John Kauh. Hutchison MediPharma International Inc, Florham Park, NJ ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Kauh:  ; Hutchison MediPharma International Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-16': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10615',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT116\\n                        \\n                         - A phase I study of ribociclib plus everolimus in patients with metastatic pancreatic adenocarcinoma refractory to chemotherapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Benjamin Adam Weinberg1, Hongkun Wang1, Agnieszka K. Witkiewicz2, John L. Marshall1, Aiwu R. He1, Erik S. Knudsen2, Michael J. Pishvaian3. 1Georgetown University, Washington, DC; 2Roswell Park Comprehensive Cancer Center, Buffalo, NY; 3MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0H. Wang: None.\\xa0A.K. Witkiewicz: None.\\xa0J.L. Marshall: None.\\xa0A.R. He: None.\\xa0E.S. Knudsen: None.\\xa0M.J. Pishvaian: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-17': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10616',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT117\\n                        \\n                         - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Niels Halama1, Anja Williams1, Ulrike Prfer1, Anna Frmming2, Diana Beyer2, Dirk Eulberg2, Jarl Ulf Jungnelius2, Aram Mangasarian2. 1National Center for Tumor Diseases, Heidelberg, Germany; 2NOXXON Pharma AG, Berlin, Germany ',\n",
       "  'Disclosures': '\\xa0\\xa0N. Halama:  ; Merck KGaA Darmstadt. ; Contract Research to home Institution; Bristol-Myers Squibb. ; Contract Research to home Institution; Ono Pharma. ; Contract Research to home Institution; NOXXON Pharma AG.\\xa0A. Williams: None.\\xa0U. Prfer: None. A. Frmming:  ; Stock options; NOXXON Pharma AG. D. Beyer:  ; Stock options; NOXXON Pharma AG. D. Eulberg:  ; Stock options; NOXXON Pharma AG. J. Jungnelius:  ; Stock options; NOXXON Pharma AG. ; Monocl. ; Oncopeptides. ; Isofol. ; Stock options; Biovica. ; Ryvu Therapeutics. A. Mangasarian:  ; Stock options; NOXXON Pharma AG.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-18': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10617',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT118\\n                        \\n                         - Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Andrea Wang-Gillam1, Robert McWilliams2, A. Craig Lockhart3, Benjamin R Tan1, Rama Suresh1, Kian-Huat Lim1, Katrina S. Pedersen1, Nikolaos Trikalinos1, Olivia Aranha1, Haeseong Park1, Lee Ratner1, Nicholas Boice1, David G. Denardo1. 1Washington University in St. Louis, St. Louis, MO; 2Mayo Clinic, Rochester, MN; 3University of Miami, Miami, FL ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Wang-Gillam:  ; Merck. ; Eisai. ; AstraZeneca.\\xa0R. McWilliams: None.\\xa0A. Lockhart: None.\\xa0B. Tan: None.\\xa0R. Suresh: None. K. Lim:  ; Aclaris. K.S. Pedersen:  ; Array.\\xa0N. Trikalinos: None.\\xa0O. Aranha: None.\\xa0H. Park: None.\\xa0L. Ratner: None.\\xa0N. Boice: None. D.G. Denardo:  ; Gossamer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-19': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10618',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT119\\n                        \\n                         - Organoid sensitivity in pancreatic cancer correlates with clinical response to treatment and reveals utility for reducing toxicity: Preliminary results from the HOPE trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Joseph Elan Grossman1, Ling Huang1, Lakshmi Muthuswamy1, Sofia Perea1, Dipikaa Akshinthala1, Raul Gonzalez1, Leo Tsai1, Jonah Cohen1, Mandeep Sawhney1, Douglas Pleskow1, Tyler M. Berzin1, Bruno Bockorny1, Andrea Bullock1, Benjamin Schlechter2, Mary Linton B. Peters1, Catherine Conahan3, Supraja Narasimhan4, Christine Lim1, Roger Davis1, Robert Besaw5, Martin Smith1, Tara Kent1, Mark Callery1, Senthil K. Muthuswamy1, Manuel Hidalgo6. 1BIDMC, Harvard Medical School, Boston, MA; 2Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; 3Boston College, Boston, MA; 4Karyopharm Therapeutics, Newton, MA; 5BIDMC, Boston, MA; 6Weill Medical College of Cornell University, New York, NY ',\n",
       "  'Disclosures': '\\xa0J.E. Grossman: None.\\xa0L. Huang: None.\\xa0L. Muthuswamy: None.\\xa0S. Perea: None.\\xa0D. Akshinthala: None.\\xa0R. Gonzalez: None.\\xa0L. Tsai: None.\\xa0J. Cohen: None.\\xa0M. Sawhney: None.\\xa0D. Pleskow: None.\\xa0T.M. Berzin: None.\\xa0B. Bockorny: None.\\xa0A. Bullock: None.\\xa0B. Schlechter: None.\\xa0M.B. Peters: None.\\xa0C. Conahan: None.\\xa0S. Narasimhan: None.\\xa0C. Lim: None.\\xa0R. Davis: None.\\xa0R. Besaw: None.\\xa0M. Smith: None.\\xa0T. Kent: None.\\xa0M. Callery: None.\\xa0S.K. Muthuswamy: None.\\xa0M. Hidalgo: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-20': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10619',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT120\\n                        \\n                         - AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in a phase Ib trial in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jiafu Ji. Peking University Cancer Hospital, Beijing, China ',\n",
       "  'Disclosures': '\\xa0J. Ji: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-21': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10620',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT121\\n                        \\n                         - A phase Ib study of recombinant vaccinia virus in combination with immune checkpoint inhibition (ICI) in advanced renal cell carcinoma (RCC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sun Young Rha1, Jamie Merchan2, Sung Yong Oh3, Chan Kim4, Woo Kyun Bae5, Hyun Woo Lee6, Myles Dillon7, Raquel Deering7, Glenn Kroog7, Kyoung Soo Ha8. 1Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of; 2University of Miami Health System, Miami, FL; 3Dong-A University Hospital, Busan, Korea, Republic of; 4Cha University Bundang Medical Center, Seongnam, Korea, Republic of; 5Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of; 6Ajou University Hospital, Suwon, Korea, Republic of; 7Regeneron Pharmaceuticals, Inc., New York, NY; 8Sillajen Biotherapeutics, Inc., San Francisco, CA ',\n",
       "  'Disclosures': '\\xa0S. Rha: None.\\xa0J. Merchan: None.\\xa0S. Oh: None.\\xa0C. Kim: None.\\xa0W. Bae: None.\\xa0H. Lee: None. M. Dillon:  ; Regeneron Pharmaceuticals, Inc.\\xa0R. Deering:  ; Regeneron Pharmaceuticals, Inc.\\xa0G. Kroog:  ; Regeneron Pharmaceuticals, Inc.\\xa0K. Ha:  ; Sillajen Biotherapeutics, Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-22': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10621',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT122\\n                        \\n                         - Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Scott T. Tagawa, Joseph Osborne, Charlene Thomas, Escarleth Fernandez, Muhammad J. Niaz, Shankar Vallabhajosula, Panagiotis Vlachostergios, Ana M. Molina, Cora Sternberg, Sharon Singh, Amie Patel, Angela Tan, John Babich, David M. Nanus, Karla Ballman, Neil H. Bander. Weill Cornell Medical College, New York, NY ',\n",
       "  'Disclosures': '\\xa0\\xa0S.T. Tagawa:  ; Novartis. ; POINT Biopharma. ; Bayer. ; Amgen.\\xa0J. Osborne: None.\\xa0C. Thomas: None.\\xa0E. Fernandez: None.\\xa0M.J. Niaz: None. S. Vallabhajosula:  ; NCM USA.\\xa0P. Vlachostergios: None.\\xa0A.M. Molina: None.\\xa0C. Sternberg: None.\\xa0S. Singh: None.\\xa0A. Patel: None.\\xa0A. Tan: None.\\xa0J. Babich: None.\\xa0D.M. Nanus: None.\\xa0K. Ballman: None. N.H. Bander:  ; BZL Biologics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-23': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10622',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT123\\n                        \\n                         - Phase I study of a B cell-based and monocyte-based immunotherapeutic vaccine, BVAC-C, in human papillomavirus type 16- or 18-positive recurrent cervical cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Chel Hun Choi1, Hyun Jin Choi2, Jeong-Won Lee1, Eun-Suk Kang1, Duck Cho1, Byung Kwan Park1, Yong-Man Kim3, Dae-Yeon Kim3, Hyungseok Seo4, Myunghwan Park5, Wuhyun Kim5, Ki-Young Choi5, Taegwon Oh5, CHANG-YUIL KANG4, Byoung-Gie Kim1. 1Samsung Medical Center, Seoul, Korea, Republic of; 2Chung-Ang University hospital, Seoul, Korea, Republic of; 3Asan Medical Center, Seoul, Korea, Republic of; 4Seoul National University, Seoul, Korea, Republic of; 5Cellid, Inc., Seoul, Korea, Republic of ',\n",
       "  'Disclosures': '\\xa0C. Choi: None.\\xa0H. Choi: None.\\xa0J. Lee: None.\\xa0E. Kang: None.\\xa0D. Cho: None.\\xa0B. Park: None.\\xa0Y. Kim: None.\\xa0D. Kim: None.\\xa0H. Seo: None. M. Park:  ; Cellid, Inc.\\xa0W. Kim:  ; Cellid, Inc.\\xa0K. Choi:  ; Cellid, Inc.\\xa0T. Oh:  ; Cellid, Inc.\\xa0C. Kang:  ; CEO; Cellid, Inc..\\xa0B. Kim: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-24': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10623',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT124\\n                        \\n                         - First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Erika Hamilton1, Gini F. Fleming2, Premal H. Thaker3, Vivek Subbiah4, Chris Chen5, Abraham Fong5, Daniel Brickman5, Kathleen Moore6. 1Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; 2The University of Chicago Medicine, Chicago, IL; 3Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO; 4The University of Texas MD Anderson Cancer Center, Houston, TX; 5AbbVie, Inc., Redwood City, CA; 6Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, OK ',\n",
       "  'Disclosures': '\\xa0\\xa0E. Hamilton:  ; Pfizer. ; Genentech/Roche. ; Eli Lilly. ; Puma Biotechnology. ; Daiichi Sankyo. ; AbbVie, Inc. ; Mersana Therapeutics. ; Boehringer Ingelheim. ; AstraZeneca. ; Novartis. ; Silverback Therapeutics. ; Black Diamond. ; Nanostring. ; Seattle Genetics, Hutchinson MediPharma, OncoMed, MedImmune, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Millenium, TapImmune, BerGenBio, Medivation, Tesaro, Eisai, H3 Biomedicine. ; Radius Health, Acerta, Takeda, Macrogenics, Immunomedics, FujiFilm, Effector, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, ArQule, Syros, Clovis, Cytomx, InventisBio. ; Deciphera, Unum Therapeutics, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Orinove, Molecular Templates, Compugen, G1 Therapeutics. ; Karyopharm Therapeutics and Torque Therapeutics. G.F. Fleming:  ; Corcept Therapeutics. ; AbbVie, Inc. ; Genentech/Roche. ; Tesaro. ; Syndax. ; Forty Seven. ; Iovance. ; Syros. ; Astex. ; Merck. ; Sanofi. ; Sermonix. ; Eisai. ; Vaniam Group. ; Author fees; Wolters Kluwer. P.H. Thaker:  ; Immunogen. ; Eisai. ; Merck. ; VBL Therapeutics. ; Celsion. ; Aravive. ; Stryker. ; Novocure. ; AbbVie, Inc. ; Astra Zeneca. ; Tesaro. ; Glaxo Smith Kline. V. Subbiah:  ; travel; Novartis. ; Bayer. ; GlaxoSmithKline. ; Nanocarrier. ; Vegenics. ; Celgene. ; Northwest Biotherapeutics. ; Berghealth. ; travel; Incyte. ; Fujifilm. ; travel; Pharmamar. ; D3. ; Loxo Oncology. ; Pfizer, Multivir, Altum, Dragonfly therapeutics, Takeda, Roche/ Genentech, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center. ; Amgen, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines. ; AbbVie, Inc. ; Alfa-sigma. ; MedImmune. ; travel; ASCO, ESMO, Helsinn, US-FDA. ; Eli Lilly, R-Pharma US, Helsinn. C. Chen:  ; AbbVie, Inc.\\xa0A. Fong:  ; AbbVie, Inc.\\xa0D. Brickman:  ; AbbVie, Inc.\\xa0K. Moore:  ; AbbVie, Inc. ; Astra Zeneca. ; Clovis. ; Immunogen. ; Merck. ; Tesaro. ; OncMed. ; Samumed. ; VBL Therapeutics. ; Cue Pharmaceuticals. ; Vigeo. ; Aravive.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-25': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10624',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT125\\n                        \\n                         - STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FR) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"R. Wendel Naumann1, Denise Uyar2, John W. Moroney3, Fadi S. Braiteh4, Russell J. Schilder5, John P. Diaz6, Erika Hamilton7, Sami Diab8, Lainie P. Martin9, David M. O'Malley10, Richard T. Penson11, Clifford DiLea12, Michael Palumbo13, Venita DeAlmeida13, Shannon Matheny13, Arturo Molina13. 1Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; 2Medical College of Wisconsin, Milwaukee, WI; 3University of Chicago, Chicago, IL; 4Comprehensive Cancer Centers of Nevada, Las Vegas, NV; 5Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; 6Miami Cancer Institute at Baptist Health, Miami, FL; 7Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN; 8Rocky Mountain Cancer Center, Aurora, CO; 9University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA; 10Ohio State University, Wexner Medical Center, Columbus, OH; 11Massachusetts General Hospital, Boston, MA; 12Aclairo Pharmaceutical Development Group, Vienna, VA; 13Sutro Biopharma, Inc., South San Francisco, CA \",\n",
       "  'Disclosures': \"\\xa0\\xa0R. Naumann:  ; Levine Cancer Institute, Carolinas Medical Center. ; Astra-Zeneca. ; Clovis. ; Genentech. ; GSK-Tesaro. ; Bristol Myers Squib. ; Merck. ; Mersana. ; OncoMed. ; Sutro Biopharma. ; Intuitive. ; Esai. D. Uyar:  ; Medical College of Wisconsin. ; Merck. J.W. Moroney:  ; University of Chicago. ; Clovis. F.S. Braiteh:  ; Comprehensive Cancer Centers of Nevada. ; Amgen. ; Astra Zeneca/Medimmune. ; Boehringer Ingelheim. ; Bristol Myers Squibb. ; Celgene. ; Clovis. ; Eisai. ; Eli Lilly. ; Exelixis. ; Gilead. ; Gilead. ; Incyte. ; Ipsen. ; Lexicon. ; Loxo Oncology. ; Merck. ; Pfizer. ; PUMA. ; Roche/Genentech. R.J. Schilder:  ; Sidney Kimmel Cancer Center, Thomas Jefferson University. ; Immunogen. ; Incyte. ; Flatiron. ; Chair, IDSM; Celsion. ; Clovis. J.P. Diaz:  ; Miami Cancer Institute at Baptist Health. E. Hamilton:  ; Sarah Cannon Research Institute, Tennessee Oncology PLLC. ; Pfizer. ; Genentech/Roche. ; Lilly. ; Puma Biotechnology. ; Daiichi Sankyo. ; Mersana Therapeutics. ; Boehringer Ingelheim. ; AstraZeneca. ; Novartis. ; Silverback Therapeutics. ; Black Diamond. ; NanoString. ; Seattle Genetics. ; Hutchinson MediPharma. ; OncoMed. ; StemCentrx. ; Curis. ; Verastem. ; Zymeworks. S. Diab:  ; Rocky Mountain Cancer Center. L.P. Martin:  ; University of Pennsylvania Abramson Cancer Center. ; Astra Zeneca. ; Agenus. D.M. O'Malley:  ; Ohio State University, Wexner Medical Center. ; AstraZeneca. ; Clovis. ; Tesaro. ; Immunogen. ; Ambry. ; Janssen/J&J. ; Abbvie. ; Regeneron. ; Amgen. ; Novocure. ; Genentech/Roche. ; GOG Foundation. ; Agenus. ; Iovance. ; Genelux. ; Eisai. R.T. Penson:  ; Massachusetts General Hospital. ; Array BioPharma. ; AstraZeneca. ; Eisai. ; Genetech. ; Regeneron. ; Sanofi-Aventis US LLC. ; Tesaro, Inc.. ; Vascular Biogenics LTD. ; AbbVie. ; Clovis Oncology. ; Janssen Oncology (J&J). ; Merck & Co.. ; NewLink Genetics. ; Pieris Pharma Inc.. ; Roche, Inc.. ; Syndax Pharmaceuticals. ; BMJ. ; Blackwell Publishing Medicine. ; UpToDate. C. DiLea:  ; Aclairo Pharmaceutical Development Group. M. Palumbo:  ; Sutro Biopharma, Inc.\\xa0V. DeAlmeida:  ; Sutro Biopharma, Inc.\\xa0S. Matheny:  ; Sutro Biopharma, Inc.\\xa0A. Molina:  ; Sutro Biopharma, Inc..\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-26': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10625',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT126\\n                        \\n                         - A synthetic DNA plasmid encoding HPV6 E6 and E7 proteins in patients with HPV6-associated aerodigestive lesions\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Charu Aggarwal1, Roger B. Cohen1, Matthew P. Morrow2, Kimberly A. Kraynyak2, Jocelyn Cheung2, Kelsie Dickerson2, Veronique Schulten2, Dawson Knoblock2, Elisabeth Gillespie2, Joshua M. Bauml1, Malissa Diehl2, Jean Boyer2, Michael Dallas2, David B. Weiner3, Jeffrey M. Skolnik2. 1University of Pennsylvania, Philadelphia, PA; 2Inovio Pharmaceuticals, Plymouth Meeting, PA; 3Wistar Institute, Philadelphia, PA ',\n",
       "  'Disclosures': '\\xa0C. Aggarwal: None.\\xa0R.B. Cohen: None. M.P. Morrow:  ; Inovio Pharmaceuticals. K.A. Kraynyak:  ; Inovio Pharmaceuticals. J. Cheung:  ; Inovio Pharmaceuticals. K. Dickerson:  ; Inovio Pharmaceuticals. V. Schulten:  ; Inovio Pharmaceuticals. D. Knoblock:  ; Inovio Pharmaceuticals. E. Gillespie:  ; Inovio Pharmaceuticals.\\xa0J.M. Bauml: None. M. Diehl:  ; Inovio Pharmaceuticals. J. Boyer:  ; Inovio Pharmaceuticals. M. Dallas:  ; Inovio Pharmaceuticals. D.B. Weiner:  ; Inovio Pharmaceuticals. J.M. Skolnik:  ; Inovio Pharmaceuticals.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-27': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10626',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT127\\n                        \\n                         - A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jinji Yang1, Qing Zhou1, Huajun Chen1, Lin Wu2, Jun Zhao3, Renhua Guo4, Yun Fan5, Hepeng Shi6, Weizhe Xue6, Peilong Zhang6, Han-Zhang Han7, Xuan Lin7, Shuyin Chen7, Lu Zhang7, Hao Liu7, Xinru Mao7, Bin Gan1, Yilong Wu1. 1Guangdong Provincial Peoples Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; 2Hunan cancer hospital, Changsha, China; 3Beijing University School of Oncology, Beijing Cancer Hospital, Beijing, China; 4The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China; 5Zhejiang Cancer Hospital, Hangzhou, China; 6Beijing Pearl Biotechnology Limited Liability Company, Beijing, China; 7Burning Rock Biotech, Guangzhou, China ',\n",
       "  'Disclosures': '\\xa0J. Yang: None.\\xa0Q. Zhou: None.\\xa0H. Chen: None.\\xa0L. Wu: None.\\xa0J. Zhao: None.\\xa0R. Guo: None.\\xa0Y. Fan: None.\\xa0H. Shi: None.\\xa0W. Xue: None.\\xa0P. Zhang: None.\\xa0H. Han: None.\\xa0X. Lin: None.\\xa0S. Chen: None.\\xa0L. Zhang: None.\\xa0H. Liu: None.\\xa0X. Mao: None.\\xa0B. Gan: None.\\xa0Y. Wu: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-28': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10627',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT128\\n                        \\n                         - IMU-201-101 - an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Pravin Kaumaya,1, Tanios Bekaii-Saab2, Tri Phan3, Mark T. Marino4, Nick Ede4, Anthony Good4. 1Ohio State University, Columbus, OH; 2Mayo Clinic, Phoenix/Scottsdale, AZ; 3St Vincent's Clinical School, UNSW, Sydney, Australia; 4Imugene Ltd, Sydney, Australia \",\n",
       "  'Disclosures': '\\xa0\\xa0P. Kaumaya,:  ; Imugene Ltd. T. Bekaii-Saab:  ; Clinical Researcher; Imugene Ltd. T. Phan:  ; Imugene Ltd. M.T. Marino:  ; Imugene Ltd. N. Ede:  ; Imugene Ltd. A. Good:  ; Imugene Ltd.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-29': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10628',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT129\\n                        \\n                         - HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with pembrolizumab (MK3475) in patients with refractory solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Dionysis Papadatos-Pastos1, Abhijit Pal2, Melek Akay1, Malaka Ameratunga3, Sanjena Mithra1, Joo-Ern Ang3, Sofia Levva1, Reece Caldwell4, Ruth Riisnaes4, Mateus Crespo4, Wei Yuan4, George Seed4, Bora Gurel4, Ines Figueiredo4, Rita Pereira4, Susana Miranda4, Anna Ferreira4, Suzanne Carreira4, Claudia Bertan4, Chloe Baker4, Ricardo Morilla3, Robert Brown5, Nahal Masrour5, Toby Prout4, Anna Zachariou4, Alison Turner4, Mona Parmar4, Mark Van de Velde4, Ben Jenkins4, Christina Yap4, Nina Tunariu3, Udai Banerji3, Juanita Lopez3, Anna Minchom3, Johann De Bono3. 1University College London Hospitals, London, United Kingdom; 2The Royal Marsden, London, United Kingdom; 3The Royal Marsden and Institute of Cancer Research, London, United Kingdom; 4The Institute of Cancer Research, London, United Kingdom; 5Imperial College London, London, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0D. Papadatos-Pastos:  ; TAKEDA. ; ROCHE. ; Astra-Zeneca. ; Pfizer. ; Boehringer-Ingelheim.\\xa0A. Pal: None.\\xa0M. Akay: None.\\xa0M. Ameratunga: None.\\xa0S. Mithra: None.\\xa0J. Ang: None.\\xa0S. Levva: None.\\xa0R. Caldwell: None.\\xa0R. Riisnaes: None.\\xa0M. Crespo: None.\\xa0W. Yuan: None.\\xa0G. Seed: None.\\xa0B. Gurel: None.\\xa0I. Figueiredo: None.\\xa0R. Pereira: None.\\xa0S. Miranda: None.\\xa0A. Ferreira: None.\\xa0S. Carreira: None.\\xa0C. Bertan: None.\\xa0C. Baker: None.\\xa0R. Morilla: None.\\xa0R. Brown: None.\\xa0N. Masrour: None.\\xa0T. Prout: None.\\xa0A. Zachariou: None.\\xa0A. Turner: None.\\xa0M. Parmar: None.\\xa0M. Van de Velde: None.\\xa0B. Jenkins: None. C. Yap:  ; Celgene. ; Faron Pharmaceuticals.\\xa0N. Tunariu: None. U. Banerji:  ; Astellas. ; Novartis. ; Karus Therapeutics. ; Phoenix ACT. ; eEli Lilly. ; Astex. ; Vernalis. ; Janssen. ; Boehringer-Ingelheim. J. Lopez:  ; Roche-Genentech. ; GenMab. ; Basilea. A. Minchom:  ; Janssen. ; Novartis. ; Faron Pharmaceuticals. ; Bayer. J. De Bono:  ; Astra Zeneca. ; Astellas. ; Bayer. ; Boehringer-Ingelheim. ; Cellcentric. ; Daiichi. ; Genentech/Roche. ; Merck Serono. ; Merck Sharp & Dohme. ; Menarini/Silicon Biosystems. ; Orion. ; Pfizer. ; Qiagen. ; Sanofi. ; Aventis. ; Sierra Oncology. ; Taiho. ; Vertex.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-30': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10629',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT130\\n                        \\n                         - Evidence for synergistic immune responses in the first-in-human (FIH) combination of B cell-activating immunotherapy (IO) with anti-PD1 immune checkpoint inhibitor nivolumab (N) as 2nd-line therapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Tania Crombet1, Jason Muhitch2, Circe Mesa3, Rachel Evans2, Danay S. Hernandez1, Patricia L. Luaces1, Zaima Mazorra1, Orestes Morales1, Carlos Cedeno2, Aileen Cinquino2, Daniel T. Fisher2, Kelvin Lee2, Mary Reid2, Grace Dy2. 1Center for Molecular Immunology, Havana, Cuba; 2Roswell Park Comprehensive Cancer Center, Buffalo, NY; 3Innovative Immunotherapy Alliance, Havana, Cuba ',\n",
       "  'Disclosures': '\\xa0\\xa0T. Crombet:  ; Center for Molecular Immunology.\\xa0J. Muhitch: None. C. Mesa:  ; Innovative Immunotherapy Alliance.\\xa0R. Evans: None. D.S. Hernandez:  ; Center for Molecular Immunology. P.L. Luaces:  ; Center for Molecular Immunology. Z. Mazorra:  ; Center for Molecular Immunology. O. Morales:  ; Center for Molecular Immunology.\\xa0C. Cedeno: None.\\xa0A. Cinquino: None.\\xa0D.T. Fisher: None.\\xa0K. Lee: None.\\xa0M. Reid: None.\\xa0G. Dy: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-31': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10630',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT131\\n                        \\n                         - The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ulrich Jaeger1, Nina Worel1, Joseph P. McGuirk2, Peter A. Riedell3, Isabelle Fleury4, Peter Borchmann5, Simon Newsome6, Ahmed M. Abdelhady6, Alessandra Forcina6, Lida Bubuteishvili Pacaud6, Edmund K. Waller7. 1Medical University of Vienna, Vienna, Austria; 2University of Kansas Medical Center, Kansas City, KS; 3University of Chicago, Chicago, IL; 4Maisonneuve-Rosemont Hospital and University of Montreal, Montreal, QC, Canada; 5University Hospital of Cologne, Cologne, Germany; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ; 7Emory University, Atlanta, GA ',\n",
       "  'Disclosures': '\\xa0\\xa0U. Jaeger:  ; Novartis Pharmaceuticals Corporation. ; Roche. ; Sandoz. ; Abbvie. ; Celgene. ; Gilead. ; Takeda-Millenium. ; Amgen. ; Eisai. ; Janssen. ; MSD. ; BMS. ; Sanofi. N. Worel:  ; Sanofi-Genzyme. ; Malinckrodt Therakos. ; Jazz. ; Celgene. ; Novartis Pharmaceuticals Corporation. J.P. McGuirk:  ; Novartis Pharmaceuticals Corporation. ; Fresenius Biotech. ; Astellas. ; Bellicum Pharmaceuticals. ; Kite Pharmaceuticals. ; Gamida Cell. ; Pluristem Ltd. ; Manuscript preparation; ArticulateScience LLC. ; Juno Therapeutics. P.A. Riedell:  ; Bayer. ; Kite/Gilead. ; Novartis. ; Verastem. ; Celgene. I. Fleury:  ; Gilead. ; Novartis Pharmaceuticals Corporation. ; Roche. ; Seattle Genetics. ; Janssen. ; Abbvie.\\xa0P. Borchmann: None. S. Newsome:  ; Novartis Pharmaceuticals Corporation. A.M. Abdelhady:  ; Novartis Pharmaceuticals Corporation. A. Forcina:  ; Novartis Pharmaceuticals Corporation. L. Bubuteishvili Pacaud:  ; Novartis Pharmaceuticals Corporation. E.K. Waller:  ; Novartis Pharmaceuticals Corporation. ; Travel expenses; Pharmacyclics. ; Stock and Patents & Royalties; Cerus Corporation. ; Stock; Chimerix. ; Patents & Royalties: Patents, royalties or other intellectual property; Cambium Oncology. ; Amgen. ; Kalytera.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-32': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10631',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT132\\n                        \\n                         - Orelabrutinib, a potent and selective Brutons tyrosine kinase inhibitor with superior safety profile and excellent PK/PD properties\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Bin Zhang1, Renbin Zhao1, Ruixia Liang1, Yingxiang Gao1, Richard Liu1, Xiangyang Chen1, Zhengguang Lu1, Zuopeng Wang1, Liqin Yu1, Sepehr Shakib2, Jisong Cui1. 1Beijing InnoCare Pharma Tech Co., Ltd., Beijing, China; 2Department of Clinical Pharmacology, Royal Adelaide Hospital, ADELAIDE, Australia ',\n",
       "  'Disclosures': '\\xa0\\xa0B. Zhang:  ; Beijing InnoCare Pharma Tech Co., Ltd.\\xa0R. Zhao:  ; 1.\\tBeijing InnoCare Pharma Tech. Co., Ltd.\\xa0R. Liang:  ; Beijing InnoCare Pharma Tech. Co., Ltd.\\xa0Y. Gao:  ; Beijing InnoCare Pharma Tech Co., Ltd.\\xa0R. Liu:  ; Beijing InnoCare Pharma Tech. Co., Ltd.\\xa0X. Chen:  ; Beijing InnoCare Pharma Tech Co., Ltd.\\xa0Z. Lu:  ; Beijing InnoCare Pharma Tech Co., Ltd.\\xa0Z. Wang:  ; Beijing InnoCare Pharma Tech. Co., Ltd.\\xa0L. Yu:  ; Beijing InnoCare Pharma Tech. Co., Ltd..\\xa0S. Shakib: None. J. Cui:  ; Beijing InnoCare Pharma Tech. Co., Ltd..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-33': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10632',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT133\\n                        \\n                         - Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Dhara N. Amin1, Rajat Bannerji2, Raghuveer \\t Singh Mali1, Jason Oeh1, Eva Lin1, Anuradha Zindal1, MaryAnn Go1, Shang-Fan Yu1, Maxwell Krem3, Chris Arthur4, Uwe Hahn5, Anna M. Johnston6, Vinit G. Karur7, Nadia Khan8, Paula Marlton9, Tycel Phillips10, Giuseppe Gritti11, John F. Seymour12, Monica Tani13, Sam Yuen Yuen14, Scott Martin1, Matthew T. Chang1, Christopher M. Rose1, Victoria C. Pham1, Elizabeth A. Lasater1, Andrew G. Polson1, YiMeng Chang1, Jamie Hirata1, Lisa Musick1, Deepak Sampath1, Christopher R. Flowers15, Ingrid E. Wertz1. 1Genentech, Inc., San Francisco, CA; 2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 3Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY; 4Royal North Shore Hospital, Sydney, Australia; 5The Queen Elizabeth Hospital, Adelaide, Australia; 6Royal Hobart Hospital, Hobart, Australia; 7Baylor Scott & White Healthcare, Temple, TX; 8Fox Chase Cancer Center, Philadelphia, PA; 9Princess Alexandra Hospital, and University of Queensland, Brisbane, Australia; 10University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; 11Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy; 12Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; 13Ospedale S. Maria delle Croci, Ravenna, Italy; 14Calvary Mater Newcastle, Waratah, Australia; 15MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0D.N. Amin:  ; Roche.\\xa0R. Bannerji: None. R. Singh Mali:  ; Roche. J. Oeh:  ; Roche. E. Lin:  ; Roche.\\xa0A. Zindal: None. M. Go:  ; Roche. S. Yu:  ; Roche.\\xa0M. Krem: None.\\xa0C. Arthur: None.\\xa0U. Hahn: None.\\xa0A.M. Johnston: None.\\xa0V.G. Karur: None.\\xa0N. Khan: None.\\xa0P. Marlton: None.\\xa0T. Phillips: None.\\xa0G. Gritti: None.\\xa0J.F. Seymour: None.\\xa0M. Tani: None.\\xa0S. Yuen: None. S. Martin:  ; Roche. M.T. Chang:  ; Roche. C.M. Rose:  ; Roche. V.C. Pham:  ; Roche. E.A. Lasater:  ; Roche. A.G. Polson:  ; Roche. Y. Chang:  ; Roche. J. Hirata:  ; Roche. L. Musick:  ; Roche. D. Sampath:  ; Roche.\\xa0C.R. Flowers: None. I.E. Wertz:  ; Roche.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-34': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10633',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT134\\n                        \\n                         - Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hani M. Babiker1, Vivek Subbiah2, Asim Ali3, Alain Algazi4, Jacob Schachter5, Michal Lotem6, Corinne Maurice-Dror7, Daniel Hendler8, Shah Rahimian9, Hans Minderman10, Cara Haymaker2, Chantale Bernatchez2, Ravi Murthy2, Rolf Hultsch11, Nadia Caplan6, Gregory Woodhead1, Charles Hennemeyer1, Sri Chunduru9, Peter Anderson12, Adi Diab2, Erkut Borazanci11, Igor Puzanov10. 1University of Arizona Cancer Center, Tucson, AZ; 2University of Texas MD Anderson Cancer Center, Houston, TX; 3Saint Lukes University Health Network, Easton, PA; 4University of California, San Francisco, CA; 5Sheba Medical Center, Tel HaShomer, Israel; 6Hadassah Hebrew University Medical Center, Jerusalem, Israel; 7Rambam Health, Haifa, Israel; 8Rabin Medical Center, Petach Tikva, Israel; 9Idera Pharmaceuticals, Exton, PA; 10Roswell Park Comprehensive Cancer Center, Buffalo, NY; 11HonorHealth, Scottsdale, AZ; 12Cleveland Clinic, Cleveland, OH ',\n",
       "  'Disclosures': '\\xa0\\xa0H.M. Babiker:  ; Bayer. ; BMS. ; Endocyte. ; Guardant360. ; SIRTeX. ; Tracon. V. Subbiah:  ; Idera Pharmaceuticals. ; Blueprint Medicines. ; Loxo Oncology. ; Novartis Oncology. ; Bayer.\\xa0A. Ali: None.\\xa0A. Algazi: None.\\xa0J. Schachter: None.\\xa0M. Lotem: None.\\xa0C. Maurice-Dror: None.\\xa0D. Hendler: None. S. Rahimian:  ; Idera Pharmaceuticals.\\xa0H. Minderman: None. C. Haymaker:  ; Idera Pharmaceuticals. C. Bernatchez:  ; Idera Pharmaceuticals.\\xa0R. Murthy: None.\\xa0R. Hultsch: None.\\xa0N. Caplan: None.\\xa0G. Woodhead: None.\\xa0C. Hennemeyer: None. S. Chunduru:  ; Idera Pharmaceuticals.\\xa0P. Anderson: None. A. Diab:  ; Idera Pharmaceuticals. ; Nektar Therapeutics. ; BMS. ; Novartis. ; Array BioPharma. E. Borazanci:  ; Ambry Genetics. ; BMS. ; Corcept. ; Daiichi Sankyo. ; Eli Lilly. ; Fujifilm. ; Idera Pharmaceuticals. ; Ipsen. ; Minneamrita Therapeutics. ; Mabvax. ; Pharmacyclics. ; Samumed.\\xa0I. Puzanov: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-35': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10634',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT135\\n                        \\n                         - A phase 1b study of palbociclib + nab-paclitaxel in patients (pts) with metastatic adenocarcinoma of the pancreas (PDAC)\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Manuel Hidalgo1, Rocio Garcia Carbonero2, Kian-Huat Lim3, Wells Messersmith4, Ignacio Garrido-Laguna5, Erkut Borazanci6, Andrew Lowy7, Laura Medina Rodriguez8, Daniel Laheru9, Xin Huang10, Meggan Tammaro11, Jean-Franois Martini10, Arthur Kudla11, Kenneth Kern10, Teresa Macarulla12. 1Weill Cornell Medicine, New York, NY; 2Servicio de Oncologia, Hospital Universitario 12 de Octubre, Madrid, Spain; 3Washington University School of Medicine, Division of Oncology, St. Louis, MO; 4University of Colorado Anschutz Medical Campus, Aurora, CO; 5Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; 6HonorHealth/TGen, Scottsdale, AZ; 7UC San Diego Moores Cancer Center, San Diego, CA; 8Hospital Virgen De La Victoria, Mlaga, Mlaga, Spain; 9The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; 10Pfizer Inc, San Diego, CA; 11Pfizer Inc, New York, NY; 12Hospital Universitari Vall D'Hebron, Barcelona, Spain \",\n",
       "  'Disclosures': '\\xa0\\xa0M. Hidalgo:  ; Founder; Champions Oncology, Inc. ; Founder; Nelum Oncology. ; Agenus. ; BioOncotech. ; Pharmacyte. ; Bioline. ; Erytech. ; BioExcell. ; inxMed. ; Takeda. ; Oncomatrix. ; Royalty recipient for PALB2 patent; Myriad. R. Garcia Carbonero:  ; AAA. ; Amgen. ; Bayer. ; BMS. ; Ipsen. ; Lilly. ; Merck. ; MSD. ; Novartis. ; PharmaMar. ; Pfizer. ; Roche. ; Sanofi.\\xa0K. Lim: None. W. Messersmith:  ; Pfizer.\\xa0I. Garrido-Laguna: None. E. Borazanci:  ; Corcept Therapeutics. ; InVitae. ; Ipsen. ; BioNTech AG. ; Idera. ; Samumed. ; Pharmacyclics. ; Minneamrita Therapeutics. ; Eli Lilly. ; Bristol-Myers Squibb. ; Daiichi Sankyo. ; Merck. ; MabVax. ; Helix.\\xa0A. Lowy: None.\\xa0L. Medina Rodriguez: None.\\xa0D. Laheru: None. X. Huang:  ; Pfizer Inc. M. Tammaro:  ; *at the time of the study; Pfizer Inc. J. Martini:  ; Pfizer Inc. A. Kudla:  ; Pfizer Inc. K. Kern:  ; Pfizer Inc.\\xa0T. Macarulla: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-36': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10635',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT136\\n                        \\n                         - Phase I study with rapamycin combined with irinotecan, the SFCE RAPIRI I trial, a new way to target tumor hypoxia in pediatric refractory cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sarah Jannier1, Veronique Kemmel2, Consuelo Sebastia2, Agathe Chammas2, Amelia-Naomi Sabo2, Erwan Pencreach2, Franoise Farace3, Benoit Lhermitte2, Birgit Geoerger3, Isabelle Aerts4, Didier Frappaz5, Pierre Leblond5, Nicolas Andre6, Yves Perel7, Nadge Corradini5, Anne Isabelle Bertozzi8, Florence Vincent2, Natacha Entz-Werle2. 1University hospital of Strasbourg, Strasbourg, France; 2University Hospital of Strasbourg, Strasbourg, France; 3Institut Gustave Roussy, Villejuif, France; 4Institut Curie, Paris, France; 5Centre Lon Berard, Lyon, France; 6AP-HM, Marseille, France; 7CHU Bordeaux, Bordeaux, France; 8CHU Toulouse, Toulouse, France ',\n",
       "  'Disclosures': '\\xa0S. Jannier: None.\\xa0V. Kemmel: None.\\xa0C. Sebastia: None.\\xa0A. Chammas: None.\\xa0A. Sabo: None.\\xa0E. Pencreach: None.\\xa0F. Farace: None.\\xa0B. Lhermitte: None.\\xa0B. Geoerger: None.\\xa0I. Aerts: None.\\xa0D. Frappaz: None.\\xa0P. Leblond: None.\\xa0N. Andre: None.\\xa0Y. Perel: None.\\xa0N. Corradini: None.\\xa0A. Bertozzi: None.\\xa0F. Vincent: None.\\xa0N. Entz-Werle: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-37': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10636',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT137\\n                        \\n                         - A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"James I. Geller1, Dennis Brown2, Jeffrey Bacha3, Neil Sankar3, Sarath Kanekal3, Mark Leggas4, Lars Wagner5. 1Division of Oncology at Cincinnati Children's Hospital Medical Center; University of Cincinnati Department of Pediatrics, Cincinnati, OH; 2Valent Technologies LLC, Menlo Park, CA; 3Edison Oncology Holding Corp., Menlo Park, CA; 4University of Kentucky, Lexington, KY; 5Duke Univ. Medical Center, Durham, NC \",\n",
       "  'Disclosures': '\\xa0J.I. Geller: None. D. Brown:  ; Valent Technologies LLC. ; Edison Oncology Holding Corp.\\xa0J. Bacha:  ; Edison Oncology Holding Corp.. ; Valent Technologies LLC. N. Sankar:  ; Edison Oncology Holding Corp.. ; Valent Technologies LLC. S. Kanekal:  ; Edison Oncology Holding Corp.. ; Valent Technologies LLC.\\xa0M. Leggas: None.\\xa0L. Wagner: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-38': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10637',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT138\\n                        \\n                         - Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Byoung Chul Cho1, Konstantin Penkov2, Igor Bondarenko3, Joanna Pikiel4, Hee Kyung Ahn5, Alison Forgie6, Ira Jacobs7, Vinicius Bonato8, Xinmeng Jasmine Mu8, Keith Ching8, Jeffrey Chou6, Melissa L. Johnson9. 1Yonsei Cancer Center, Seoul, Korea, Republic of; 2NHI Railway Hospital St. Petersburg, St. Petersburg, Russian Federation; 3Dnipropetrovsk Medical Academy, Dnipro, Ukraine; 4Szpitale Pomorskie Sp. z o.o, Gdynia, Poland; 5Gachon University Gil Medical Center, Incheon, Korea, Republic of; 6Pfizer, San Francisco, CA; 7Pfizer, New York, NY; 8Pfizer, San Diego, CA; 9Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN ',\n",
       "  'Disclosures': '\\xa0\\xa0B. Cho:  ; Novartis. ; Bayer. ; AstraZeneca. ; MOGAM Institute. ; Dong-A ST. ; Roaylties; Champions Oncology. ; Janssen. ; Yuhan. ; Ono. ; Dizal Pharma. ; MSD. ; Boehringer-Ingelheim. ; Roche. ; BMS. ; Pfizer. ; Eli Lilly. ; Takeda. ; TheraCanVac Inc. ; Gencurix Inc. ; Bridgebio Therapeutics. K. Penkov:  ; AbbVie. ; Astra Zeneca. ; MSD. ; Pfizer. ; Prestige Biopharma. ; Regeneron. ; Tanvex. I. Bondarenko:  ; Lilly. ; EMD Serono. ; Janssen. ; Pfizer. ; AstraZeneca. ; Genentech/Roche. ; Regeneron. ; Abbvie. ; Boehringer Ingelheim. ; Sanofi. ; INC. ; Merck. ; DaiichiSankyo. ; G1 Therapeutics. ; Cytomx. ; BeiGene. ; Incyte. ; Amgen.\\xa0J. Pikiel: None. H. Ahn:  ; AstraZeneca. ; Boehringer Ingelheim. ; Eisai. ; Ono. ; Roche. A. Forgie:  ; Pfizer. I. Jacobs:  ; Pfizer. V. Bonato:  ; Pfizer. X. Mu:  ; Pfizer. K. Ching:  ; Pfizer. J. Chou:  ; Pfizer. M.L. Johnson:  ; Institutional research funding from BerGenBio, Lilly, EMD Serono, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Genentech/Roche, Stemcentrix, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Apexigen, Abbvie, Tarveda, Adaptimmune, Syndax, Neovia, Boehringer Ingelheim, Sanofi, Hengrui Therapeutics; Multiple. ; institutional research funding from INC, Merck, DaiichiSankyo, Lycera, G1 Therapeutics, Dynavax, Loxo, Cytomx; Multiple. ; spouse role as contract lobbyist for Astellas and Otsuka Pharmaceuticals; Multiple. ; consulting honoraria (to institution) from Genentech/Roche, Celgene, Boehringer Ingelheim, Sanofi, Mirati, Loxo, Calithera, AstraZeneca, and Merck; Multiple.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-39': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10638',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT139\\n                        \\n                         - Ceritinib (Cer) in combination with gemcitabine (Gem)-based chemotherapy in patients (pts) with advanced solid tumors, a phase I study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Christos Fountzilas1, Alex Adjei2, Mateusz Opyrchal3, Rachel Evans1, Kristopher Attwood1, Andrew Goey1, John Wilton1, Wen Wee Ma2, Renuka Iyer1. 1Roswell Park Cancer Institute, Buffalo, NY; 2Mayo Clinic, Rochester, MN; 3Washington University St Louis, St Louis, MO ',\n",
       "  'Disclosures': '\\xa0C. Fountzilas: None.\\xa0A. Adjei: None.\\xa0M. Opyrchal: None.\\xa0R. Evans: None.\\xa0K. Attwood: None.\\xa0A. Goey: None.\\xa0J. Wilton: None.\\xa0W. Ma: None.\\xa0R. Iyer: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-40': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10639',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT140\\n                        \\n                         - Proof-of-concept evidence of immune modulation by blockade of the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway in the phase I dose escalation study of Ipatasertib (Ipa) in combination with atezolizumab (A) in patients (pts) with advanced solid tumors (Ice-CAP)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Juanita S. Lopez1, Andrea Biondo1, Crescens Tiu1, Mariana Scaranti1, Malaka Ameratunga1, Anna Zachariou2, Alison Turner2, Nina Tunariu1, Toby Prout2, Mona Parmar2, Hannah Badham1, Karen Swales2, Wei Yuan2, Ricardo Morilla1, Mateus Crespo2, Rob Daly1, Ines Figueiredo2, Bora Gurel2, Rita Pereira2, Ruth Riisnaes2, Igor Vivanco1, Anna Minchom1, Ben Jenkins2, Christina Yap2, Udai Banerji1, Johann De Bono1. 1The Royal Marsden NHS Foundation Trust Hospital and the Institute of Cancer Research, London, United Kingdom; 2The Institute of Cancer Research, London, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0J.S. Lopez:  ; Roche-Genentech. ; Genmab. ; Basilea.\\xa0A. Biondo: None.\\xa0C. Tiu: None.\\xa0M. Scaranti: None.\\xa0M. Ameratunga: None.\\xa0A. Zachariou: None.\\xa0A. Turner: None.\\xa0N. Tunariu: None.\\xa0T. Prout: None.\\xa0M. Parmar: None.\\xa0H. Badham: None.\\xa0K. Swales: None. W. Yuan:  ; Jilin Huarui Gene Technology Ltd..\\xa0R. Morilla: None.\\xa0M. Crespo: None.\\xa0R. Daly: None.\\xa0I. Figueiredo: None.\\xa0B. Gurel: None.\\xa0R. Pereira: None.\\xa0R. Riisnaes: None. I. Vivanco:  ; Basilea. ; Genmab. A. Minchom:  ; Janssen. ; Novartis. ; Faron Pharmaceuticals. ; Bayer.\\xa0B. Jenkins: None. C. Yap:  ; Celgene. ; Faron Pharmaceuticals. U. Banerji:  ; Astellas. ; Novartis. ; Karus Therapeutics. ; Phoenix ACT. ; Eli Lilley. ; Astex. ; Vernalis. ; Jannsen. ; Boehringer-Ingelheim. J. De Bono:  ; AstraZeneca. ; AStellas. ; Bayer. ; Boehringer Ingelheim. ; Cellcentric. ; Daiichi. ; Genentech/Roche. ; Merck Serono. ; Merck Sharp & Dohme. ; Menarini/Silicon Biosystems. ; Orion. ; Pfizer. ; Qiagen. ; Sanofi Aventis. ; Sierra Oncology. ; Taiho. ; Vertex.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-41': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10640',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT141\\n                        \\n                         - Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"James Spicer1, Bristi Basu2, Ana Montes3, Udai Banerji4, Rebecca Kristeleit5, Gareth J. Veal6, Christopher Corrigan1, Stephen Till1, George Nintos3, Timothy Brier3, Ionut G. Funingana7, Joo Ern Ang4, Kam Zaki8, Annie Griffin9, Claire Barton10, Paul Jones11, Sarah Mellor11, Susan Brook11, Katie Stoddart11, Christopher Selkirk11, Simon Carroll11, Heike Lentfer11, Natalie Woodman1, Amy Pope1, Giulia Pellizzari1, Mano Nakamura1, Kristina M. Ilieva1, Atousa Khiabany1, Chara Stavraka1, Hannah Gould1, Jitesh Chauhan1, Heather Bax1, Sarah Pinder3, Debra Josephs3, Sophia Karagiannis1. 1King's College London, London, United Kingdom; 2University of Cambridge, Cambridge, United Kingdom; 3Guys and St Thomas NHS Foundation Trust, London, United Kingdom; 4The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; 5University College London, London, United Kingdom; 6Newcastle University, Newcastle upon Tyne, United Kingdom; 7Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; 8University College London Hospitals NHS Foundation Trust, London, United Kingdom; 9University of Southampton, Southampton, United Kingdom; 10Barton Oncology Ltd, London, United Kingdom; 11Cancer Research UK, London, United Kingdom \",\n",
       "  'Disclosures': '\\xa0\\xa0J. Spicer:  ; IGEM Therapeutics.\\xa0B. Basu: None.\\xa0A. Montes: None. U. Banerji:  ; Karus Therapeutics. ; Novartis. ; Astellas. ; Janssen. ; Boehringer-Ingelheim. ; Onyx Pharmaceuticals. ; BTG International. ; Verastem. ; Chugai/Roche. ; AstraZeneca. ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research.\\xa0R. Kristeleit: None.\\xa0G.J. Veal: None.\\xa0C. Corrigan: None.\\xa0S. Till: None.\\xa0G. Nintos: None.\\xa0T. Brier: None.\\xa0I.G. Funingana: None. J. Ang:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors; Institute of Cancer Research.\\xa0K. Zaki: None.\\xa0A. Griffin: None.\\xa0C. Barton: None.\\xa0P. Jones: None.\\xa0S. Mellor: None.\\xa0S. Brook: None.\\xa0K. Stoddart: None.\\xa0C. Selkirk: None.\\xa0S. Carroll: None.\\xa0H. Lentfer: None.\\xa0N. Woodman: None.\\xa0A. Pope: None.\\xa0G. Pellizzari: None.\\xa0M. Nakamura: None.\\xa0K.M. Ilieva: None.\\xa0A. Khiabany: None.\\xa0C. Stavraka: None.\\xa0H. Gould: None.\\xa0J. Chauhan: None.\\xa0H. Bax: None.\\xa0S. Pinder: None.\\xa0D. Josephs: None. S. Karagiannis:  ; IGEM Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-42': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10641',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT142\\n                        \\n                         - A phase I trial of surufatinib plus toripalimab in patients with advanced solid tumor\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ming Lu1, Yanshuo Cao1, Jifang Gong1, Yu Sun2, Jie Li1, Lin Shen1. 1Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China; 2Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China ',\n",
       "  'Disclosures': '\\xa0M. Lu: None.\\xa0Y. Cao: None.\\xa0J. Gong: None.\\xa0Y. Sun: None.\\xa0J. Li: None.\\xa0L. Shen: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-43': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10642',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT143\\n                        \\n                         - Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Rajiv Shinde1, Angelika Terbuch1, Martin Little2, Reece Caldwell1, Roopa Kurup2, Ruth Riisnaes3, Mateus Crespo3, Ruth Ruddle3, Bora Gurel3, Adam Stewart3, Jenny King3, Mona Parmar3, Alison Turner3, Florence Raynaud3, Muneeb Mahmud3, Christina Yap3, Jonathan A. Pachter4, Gordon B. Mills5, Anna Minchom1, Juanita Lopez1, Susana N. Banerjee1, Johann S. de Bono6, Matthew Krebs7, Udai Banerji6. 1The Royal Marsden and The Institute of Cancer Research, London, United Kingdom; 2The Christie NHS Foundation Trust, Manchester, United Kingdom; 3The Institute of Cancer Research, London, United Kingdom; 4Verastem Oncology, Needham, MA; 5Knight Cancer Institute, Oregon Health & Science University, Portland, OR; 6The Institute of Cancer Research and The Royal Marsden, London, United Kingdom; 7The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom ',\n",
       "  'Disclosures': '\\xa0R. Shinde: None.\\xa0A. Terbuch: None.\\xa0M. Little: None.\\xa0R. Caldwell: None.\\xa0R. Kurup: None. R. Riisnaes:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. M. Crespo:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. R. Ruddle:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. B. Gurel:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. A. Stewart:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. J. King:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. M. Parmar:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. A. Turner:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. F. Raynaud:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. M. Mahmud:  ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. C. Yap:  ; Celgene. ; Faron Pharmaceuticals. ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research. J.A. Pachter:  ; Verastem Oncology. G.B. Mills:  ; AstraZeneca. ; Chrysallis Biotechnology. ; ImmunoMET. ; Ionis. ; Lilly. ; PDX Pharmaceuticals. ; Signalchem Lifesciences. ; Symphogen. ; Tarveda. ; Catena Pharmaceuticals. ; Spindle Top Ventures. ; Licensed technology (HRD assay); Myriad Genetics. ; Patent (DSP); Nanostring. A. Minchom:  ; Novartis Oncology. ; Faron Pharmaceuticals. ; Bayer Pharmaceuticals. J. Lopez:  ; Roche. ; Travel; Basilea. ; Genmab. S.N. Banerjee:  ; AstraZeneca. ; Tesaro. ; Clovis. ; Amgen. ; Genmab. J.S. de Bono:  ; AstraZeneca. ; Astellas. ; Bayer. ; Boehringer Ingelheim. ; Cellcentric. ; Daiichi. ; Genentech/Roche. ; Genmab. ; GSK. ; Janssen. ; Merck Serono. ; Merck Sharp & Dohme. ; Menarini/Silicon Biosystems. ; Orion. ; Pfizer. ; Qiagen. ; Sanofi Aventis. ; Sierra Oncology. ; Taiho. ; Vertex Pharmaceuticals. M. Krebs:  ; Roche. ; Travel expenses; BerGenBio. ; Janssen. ; Achilles. U. Banerji:  ; Boehringer-Ingelheim. ; Janssen. ; Astellas. ; Karus Therapeutics. ; Novartis. ; Phoenix Solutions. ; Onyx Pharmaceuticals. ; BTG International. ; Verastem. ; Chugai/Roche. ; AstraZeneca. ; Employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1 and HSF1 inhibitors.; The Institute of Cancer Research.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-44': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10643',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT144\\n                        \\n                         - PD-1-CD28-enhanced receptor and anti-CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Xinfeng Chen1, Xuan Zhao1, Liping Wang1, Weiyue Gu2, Yi Zhang1. 1The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 2Beijing Chineo Co., Ltd., Beijing, China ',\n",
       "  'Disclosures': '\\xa0X. Chen: None.\\xa0X. Zhao: None.\\xa0L. Wang: None.\\xa0W. Gu: None.\\xa0Y. Zhang: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-45': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10644',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT145\\n                        \\n                         - A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jeffrey Yachnin1, Gustav J. Ullenhag2, Ana Carneiro3, Dorte L. Nielsen4, Kristoffer Staal Rohrberg5, Anne Mnsson Kvarnhammar6, Erika Bgeman6, Camilla S. Wennersten6, Charlotte Astrid Russell6. 1Karolinska Institutet, Stockholm, Sweden; 2Uppsala University Hospital, Uppsala, Sweden; 3Skane University Hospital and Lund University, Lund, Sweden; 4Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark; 5Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark; 6Alligator Bioscience AB, Lund, Sweden ',\n",
       "  'Disclosures': '\\xa0J. Yachnin: None. G.J. Ullenhag:  ; Speaker/teaching activities; BMS. ; Speaker/teaching activities; Sanofi. ; Speaker/teaching activities; Roche. ; Speaker/teaching activities; Lilly. ; Speaker/teaching activities; MSD. ; Speaker/teaching activities; Pierre Fabre. ; Novartis. ; Pfizer. ; LIDDS.\\xa0A. Carneiro: None.\\xa0D.L. Nielsen: None. K. Staal Rohrberg:  ; Congress and travel costs.; Roche. ; Loxo Oncology. ; Congress and travel costs.; Bayer. ; Orion Pharma. ; Pfizer. ; PUMA. ; Cantargia. ; Genmab. ; Congress and travel costs.; Novartis. ; Incyte. ; Symphogen. ; Astra-Zeneca. ; Alligator. ; Merck. ; Congress and travel costs.; Sanofi. ; BMS. ; Eli Lilly. A. Mnsson Kvarnhammar:  ; Alligator Bioscience AB. E. Bgeman:  ; Alligator Bioscience AB. C.S. Wennersten:  ; Alligator Bioscience AB. C.A. Russell:  ; Alligator Bioscience AB. ; Genmab.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-46': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10645',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT146\\n                        \\n                         - RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Emerson Lim1, Erika P. Hamilton2, Rebecca Redman3, Michael A. Postow4, Russell J. Schilder5, Monica M. Mita6, Alain C. Mita6, Bartosz Chmielowski7, James Strauss8, Angela Jain9, Shubham Pant10, Olivier Rixe11, Tomislav Dragovich12, R. Donald Harvey13, Igor Puzanov14, Kevin B. Kim15, Eric K. Rowinsky16, Michael Szarek16, Foster Gonsalves16, Isabel Kurth16, Celia Andreu16, Robert W. Busby16, David Darst16, Masoud Tavazoie16, Syed Raza16, Narayan Lebaka1616, Robert Wasserman16, Gerald Falchook17. 1Columbia University Medical Center, New York, NY; 2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; 3University of Louisville,, Louisville,, KY; 4Weill-Cornell Medical Center and Memorial Sloan Kettering Cancer Center., New York, NY; 5Thomas Jefferson University, Philadelphia, PA; 6Cedars-Sinai Medical Center, Los Angeles, CA; 7Jonsson Comprehensive Cancer Center, Los Angeles, CA; 8Mary Crowley Cancer Research, Dallas, TX; 9Fox Chase Cancer Center, Philadelphia, PA; 10MD Anderson Cancer Center, Houston, TX; 11University of New Mexico, Santa Fe, NM; 12Banner Health/MD Anderson Cancer Center, Gilbert, AZ; 13Winship Cancer Institute of Emory University, Altanta, GA; 14Roswell Park Cancer Center, Buffalo, NY; 15California Pacific Medical Center Research Institute,, San Francisco, AR; 16Rgenix, Inc., New York, NY; 17Sarah Cannon Research Institute at HealthONE, Denver, CO ',\n",
       "  'Disclosures': '\\xa0\\xa0E. Lim:  ; Rgenix. E.P. Hamilton:  ; Rgenix. ; Pfizer, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana Therapeutics, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond and NanoString. ; Seattle Genetics, Puma, AstraZeneca, Hutchinson MediPharma, OncoMed, MedImmune, StemCentrx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millenium,. ; TapImmune, Lilly, BerGenBio, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, Eisai, H3 Biomedicine, Radius Health, Acerta, Takeda, Macrogenics, Abbvie, Immunomedics, FujiFilm, Effector, Merus,. ; Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros, Clovis, Cytomx, InventisBio, Deciphera, Unum Therapeutics, Sermonix Pharmaceuticals, Sutro,. ; Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback Therapeutics, Compugen, G1Therapeutics, Karyopharm Therapeutics and Torque Thera. R. Redman:  ; Rgenix. M.A. Postow:  ; Rgenix. ; BMS. ; Merck. ; Array BioPharma. ; Novartis. ; NewLink Genetics. ; Infinity. ; AstraZeneca. R.J. Schilder:  ; Rgenix. ; Clovis. ; Immuogen. ; Incyte. ; Flatiron. ; Celsion. M.M. Mita:  ; Rgenix. A.C. Mita:  ; Rgenix. ; Genentech. B. Chmielowski:  ; Rgenix. J. Strauss:  ; Rgenix. ; Dialectic Therapeutics. ; Abbvie. ; Abbott Laboratories. ; Bristol-Myers Squibb. ; Intuitive Surgical. ; Johnson & Johnson. ; Merck. ; Tempus. A. Jain:  ; Rgenix. S. Pant:  ; Rgenix. O. Rixe:  ; Rgenix. ; Kyowa/Kirin. ; Oxford Biotherapeutics. ; Nanobiotix. ; IMV Inc. ; Newlink. ; Seattle Genetics. ; Bexion. T. Dragovich:  ; Rgenix. R. Harvey:  ; Rgenix. I. Puzanov:  ; Rgenix. ; Amgen. ; Celldex. K.B. Kim:  ; Rgenix. E.K. Rowinsky:  ; Rgenix. M. Szarek:  ; Rgenix. F. Gonsalves:  ; Rgenix. I. Kurth:  ; Rgenix. C. Andreu:  ; Rgenix. R.W. Busby:  ; Rgenix. D. Darst:  ; Rgenix. ; Apellis Pharmaceuticals. ; OrbiMed Capital. ; PSP Investments. M. Tavazoie:  ; Rgenix. S. Raza:  ; Rgenix. N. Lebaka16:  ; Rgenix. R. Wasserman:  ; Rgenix. ; Northern Biologics. ; Sectoral Asset Management. G. Falchook:  ; Rgenix. ; Royalties; Wolters Kluwer. ; Fujifilm. ; Travel support; Sarah Cannon Research Institute. ; Total Health Conferencing. ; 3-V Biosciences, Abbisko, Abbvie, ADC Therapeutics, Aileron, American Society of Clinical Oncology, Amgen, ARMO, AstraZeneca, BeiGene, Bioatla, Biothera, Celldex, Celgene, Ciclomed, Curegenix, Curis,. ; Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Exelixis, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce, Kolltan, Loxo, MedImmune,. ; Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Novartis, OncoMed, Oncothyreon, Precision Oncology, Prelude, Regeneron, Ribon, Strategia, Syndax, Taiho, Takeda, Tarveda,. ; Tesaro, Tocagen, Turning Point Therapeutics, U.T. MD Anderson Cancer Center, Vegenics, Xencor.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-47': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10646',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT147\\n                        \\n                         - Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alison Schram1, Erkut Borazanci2, Irene Brana3, Maria Vieito Villar3, Elena Garralda3, Anna Spreafico4, Marc Oliva4, Nehal Lakhani5, Robert Wasserman6, Kimberly Hoffmann6, Robin Hallett6, Judit Anido6, Dorotea Maetzel6, Patricia Giblin6, Enda Moran6, Adrianne Kelly6, Joan Seoane7, Daniel D. Von Hoff2, Lillian Siu4, Josep Tabernero7. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2HonorHealth, Scottsdale, AZ; 3Vall dHebron Institute of Oncology (VHIO), Barcelona, Spain; 4Princess Margaret Cancer Center, Toronto, ON, Canada; 5START - Midwest, Grand Rapids, MI; 6Northern Biologics, Toronto, ON, Canada; 7Vall dHebron Institute of Oncology, Barcelona, Spain ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Schram:  ; Northern Biologics. E. Borazanci:  ; Ipsen. ; Fujifilm. ; Concept. ; Northern BIologics. ; Minneamrita. ; Eli Lilly. ; Bioline. ; BMS. ; Merck. ; Ambry. ; Mabvax. I. Brana:  ; Northern Biologics. ; Orion Pharmac. ; BMS. ; Travel/Accommodation/Expenses; Astra Zeneca. ; Travel/Accommodation/Expenses; Merck Serono. ; Celgene. ; Gliknik. ; GSK. ; Jannsen. ; Kura. ; MSD. ; Novartis. ; Pfizer. ; Roche. M. Vieito Villar:  ; Northern Biologics. E. Garralda:  ; Novartis, Roche, Thermo Fisher, Agios Pharmaceuticals, Amgen, Bayer  Beigene USA, Blueprint Medicines, BMS, Cellestia Biotech, Debiopharm, F.Hoffmann La Roche Ltd, Forma Therapeutics. ; Genentech Inc, Genmab B.V, GSK, Glycotope Gmbh, Incyte Biosciences, Incyte Corporation, ICO, Kura Oncology In, Lilly, S., Loxo Oncology Inc, Macrogenics Inc, Menarini Ricerche Spa. ; Merck, Sharp & Dohme de Espaa, S.A, Nanobiotix, S.A, Novartis Farmacutica, S.A, Pfizer, SLU, Pharma Mar, S.A.U, Pierre Fabre Medicament, Principia Biopharma  Inc, Psioxus Therapeutics Ltd. ; Sanofi, Sierra Oncology, Inc, Sotio A.S, Symphogen AS. ; Roche Genentech , F.Hoffmann La Roche,  Ellipses Pharma, Neomed Therapeutics Inc, Boehringer Ingelheim,  Janssen Global Services, SeaGen, TFS, Alkermes, Thermo Fisher, Bristol Mayers Squibb. ; Travel grants; Bristol Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope. ; Merck Sharp & Dohme, Roche, Thermo Fisher. A. Spreafico:  ; Northern Biologics. ; Merck. ; Bristol-Myers Squibb. ; Novartis. ; Oncorus. ; Janssen Oncology/Johnson & Johnson. ; Symphogen. ; AstraZeneca/Medimmune. ; Bayer. ; Surface Oncology. ; Roche. ; Regeneron. ; Alkermes. ; Array Biopharma. M. Oliva:  ; Northern Biologics. ; Bristol-Myers Squibb. N. Lakhani:  ; ALX Oncology. ; Forty Seven Inc. ; INhibRx. ; Amgen. ; Incyte. ; MacroGenics. ; Arqule. ; Loxo. ; Livzon. ; Ascentage. ; Merck. ; Northern Biologics. ; Apexian. ; Asana Biosciences. ; Pfizer. ; Formation Biologics/Forbius. ; Beigene. ; Regeneron. ; Constellation Pharma. ; TaiRx, CytomX, Coordination Pharma, Symphogen, Cerulean, Jounce Therapeutics. R. Wasserman:  ; Northern Biologics. ; Rgenix. K. Hoffmann:  ; Northern Biologics. R. Hallett:  ; Northern Biologics. J. Anido:  ; Northern Biologics/Mosaic Biomedicals. D. Maetzel:  ; Northern Biologics. P. Giblin:  ; Northern Biologics. ; Revitope. E. Moran:  ; Northern Biologics. A. Kelly:  ; Northern Biologics.\\xa0J. Seoane:  ; Northern Biologics/Mosaic Biomedicals. ; Roche-Glycart. D.D. Von Hoff:  ; McKesson. ; Medtronic, CerRx, SynDevRx, UnitedHealthcare, Anthem Inc, Stromatis Pharma, Systems Oncology. ; DNAtrix, Esperance Pharmaceuticals, Five Prime Therapeutics, Imaging Endpoints, Immodulon Therapeutics, Medical Prognosis Institute, Senhwa Biosciences, Tolero Pharmaceuticals, Trovagene. ; Arvinas, Alpha Cancer Technologies, Bellicum Pharmaceuticals, CanBas, Horizon Discovery, Lixte Biotechnology, Oncolyze, RenovoRx, TD2, AADi, Aptose Biosciences, BiolineRx, CV6 Therapeutics. ; EMD Serono, CytomX Therapeutics, Evelo Therapeutics, Fujifilm, Intezyne Technologies, Kalos Therapeutics, Kura, Phosplatin Therapeutics, SOTIO, Strategia Therapeutics, Sun Biopharma, Synergene. ; Hills Pharma, Actinium Pharmaceuticals, Cancer Prevention Pharmaceuticals, Geistlich Pharma, HUYA Bioscience International, Immunophotonics, Novocure, CORRONA, Genzada Pharmaceuticals. ; L.E.A.F. Pharmaceuticals, Oncology Venture, Reflexion Medical, TP Therapeutics, Verily, Athenex, Fate Therapeutics, FibroGen, Jounce Therapeutics, Samus Therapeutics, Aeglea Biotherapeutics. ; 2X Oncology, Innokeys, Novita Pharmaceuticals, NuCana BioMed, Ipsen, Biospecifics Technologies, Riptide Bioscience, Vicus Therapeutics, Codiak Biosciences, Decoy Biosystems, Agenus, Globe Life Scienc. ; Kelun - Klus Pharma, RadImmune, Samumed, SOBI, Adicet Bio, BioXCel therapeutics, Bryologyx, Celgene, Helix BioPharma, Sirnaomics, AiMed Bio, Boston Scientific, Corcept Therapeutics, Erimos Pharma. ; Gimbal, Amunix, Pfizer, Apeiron, GiraFpharma, Axis Therapeutics, DrugCendR, ImmuneOncia, Orphagen Pharmaceuticals. ; Lilly, Genentech, Celgene, Incyte, Merrimack, Plexxikon, Minneamrita Therapeutics, Abbvie, Aduro Biotech, Cleave Biosciences, CytRx Corporation, Daiichi Sankyo, Deciphera, Endocyte, Exelixis. ; Five Prime Therapeutics, Gilead Sciences, Merck, Pfizer, Pharmacyclics, Phoenix Biotech, Samumed, Strategia, Halozyme. L. Siu:  ; Merck. ; Leadership role; Treadwell therapeutics. ; Agios. ; Pfizer. ; Celgene. ; AstraZeneca/Medimmune. ; Morphosys, Roche, GeneSeeq, Loxo, Oncorus, Seattle Genetics, GSK, Voronoi , Arvinas , Tessa, Navire. ; Symphogen. ; Novartis, Bristol-Myers Squibb, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, Astellas, Bayer, Abbvie, Amgen, Intensity Therapeutics, Mirati, Shattucks, Avid. J. Tabernero:  ; Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly. ; MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen,. ; Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS, Roche Diagnostics..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-48': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10647',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT148\\n                        \\n                         - Clinical results of the multiparameter phase 1 trial EVESOR meant to optimize the doses and dosing schedules of the combination EVErolimus and SORafenib in solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Benoit You1, Michel Tod2, Lea Payen3, Jonathan Lopez4, Jerome Guitton5, Pascal Rousset6, Juliette Fontaine7, Julien Peron1, Denis Maillet1, Sophie Tartas1, Nathalie Bonnin1, Veronique Trillet-Lenoir1, Olivier Colomban2, Diane Augu-Denechere1, Gilles Freyer1, Alicja Puszkiel8. 1Institut de Cancerologie des Hospices Civils de Lyon, Pierre-Bnite, France; 2Univ Lyon; Universit Claude Bernard Lyon 1; Facult de mdecine Lyon-Sud; EMR UCBL/HCL 3738; Lyon; France, Lyon, France; 3Hospices Civils de Lyon, Laboratoire de Biochimie et Biologie Moleculaire du CHLS, Lyon 69003, France, Lyon, France; 4Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire de Biochimie et Biologie molculaire, 69495 Pierre-Bnite CEDEX, France; Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellise LIGUE Contre le Cancer, 69008 Lyon,, Lyon, France; 5Biochemistry and Toxicology Laboratory, Lyon Sud Hospital, 69310 Pierre-Bnite, France; Toxicology Department, ISPB Faculty of Pharmacy, University of Lyon, Claude Bernard Lyon 1 University,69008 Lyon, France, Lyon, France; 6Service de radiologie, Institut de Cancrologie des Hospices Civils de Lyon (IC-HCL); Centre Hospitalier Lyon-Sud; Lyon; France, Pierre-Bnite, France; 7Department of Pathology, Centre Hospitalier Lyon Sud, Lyon, France, Lyon, France; 81.\\tUniv Lyon; Universit Claude Bernard Lyon 1; Facult de mdecine Lyon-Sud; EMR UCBL/HCL 3738; Lyon; France, Lyon, France ',\n",
       "  'Disclosures': '\\xa0\\xa0B. You:  ; Travel for congress; Astra Zeneca. ; Travel for congress; TESARO. ; Travel for congress; CLOVIS. ; Travel for congress; MSD. ; Travel for congress; Roche. ; BAYER. ; NOVARTIS. ; AMGEN. ; ECS Progastrin.\\xa0M. Tod: None.\\xa0L. Payen: None.\\xa0J. Lopez: None.\\xa0J. Guitton: None.\\xa0P. Rousset: None.\\xa0J. Fontaine: None. J. Peron:  ; Travel for congress; MSD. ; AStra Zenenca; BMS. ; AStra Zeneca. ; Roche. D. Maillet:  ; Travel for congress; MSD. ; Travel for congress; BMS. ; Travel for congress; Roche.\\xa0S. Tartas: None. N. Bonnin:  ; Novartis. ; Roche.\\xa0V. Trillet-Lenoir: None.\\xa0O. Colomban: None.\\xa0D. Augu-Denechere: None. G. Freyer:  ; Astra Zeneca. ; Roche. ; TESARO. ; CLOVIS. ; MSD.\\xa0A. Puszkiel: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-49': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10648',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT149\\n                        \\n                         - SNDX-6352-0502 - A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 monotherapy in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nilo Azad1, Drew Rasco2, Sunil Sharma3, Matthew Taylor4, Christine Quaranto5, David L. Tamang5, Robert Nordness5, Michael L. Meyers5, Serap Sankoh5, Peter Ordentlich5, Anthony W. Tolcher6. 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; 2START Center for Cancer Care, San Antonio, TX; 3Honor Health, Scottsdale, AZ; 4Oregon Health and Science University, Portland, OR; 5Syndax Pharmaceuticals, Inc., Waltham, MA; 6NEXT Oncology, San Antonio, TX ',\n",
       "  'Disclosures': '\\xa0N. Azad: None.\\xa0D. Rasco: None.\\xa0S. Sharma: None.\\xa0M. Taylor: None. C. Quaranto:  ; Syndax Pharmaceuticals, Inc.\\xa0D.L. Tamang:  ; Syndax Pharmaceuticals, Inc.\\xa0R. Nordness:  ; Syndax Pharmaceuticals Inc. M.L. Meyers:  ; Syndax Pharmaceuticals, Inc.\\xa0S. Sankoh:  ; Syndax Pharmaceuticals, Inc.\\xa0P. Ordentlich:  ; Syndax Pharmaceuticals, Inc..\\xa0A.W. Tolcher: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-50': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10649',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT150\\n                        \\n                         - A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sophie Postel-Vinay*1, Vincent K. Lam*2, Willeke Ros3, Todd M. Bauer4, Aaron R. Hansen5, Daniel C. Cho6, F. Stephen Hodi7, Jan H.M. Schellens3, Jennifer K. Litton2, Sandrine Aspeslagh1, Karen A. Autio8, Frans L. Opdam3, Meredith McKean4, Neeta Somaiah2, Stephane Champiat1, Mehmet Altan2, Anna Spreafico5, Osama Rahma7, Elaine M. Paul9, Christoph M. Ahlers10, Helen Zhou10, Herbert Struemper9, Shelby A. Gorman10, Maura Watmuff10, Kaitlin M. Yablonski10, Niranjan Yanamandra10, Michael J. Chisamore11, Emmett V. Schmidt11, Axel Hoos10, Aurlien Marabelle1, Jeffrey S. Weber6, John V. Heymach2. 1Gustave Roussy, Villejuif, France; 2The University of Texas MD Anderson Cancer Center, Houston, TX; 3Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; 4Sarah Cannon Research Institute/TN Oncology, Nashville, TN; 5Princess Margaret Cancer Centre, Toronto, ON, Canada; 6Perlmutter Cancer Center at NYU Langone Medical Center, New York, NY; 7Dana-Farber Cancer Institute, Boston, MA; 8Memorial Sloan Kettering Cancer Center, New York, NY; 9GlaxoSmithKline, Research Triangle Park, NC; 10GlaxoSmithKline, Collegeville, PA; 11Merck & Co., Inc, Kenilworth, NJ ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Postel-Vinay*:  ; Gustave Roussy. ; Merck KGaA. ; Roche. ; Boehringer Ingelheim. V.K. Lam*:  ; GSK. ; BMS. ; Takeda. ; Adaptimmune. ; Achilles Therapeutics.\\xa0W. Ros: None. T.M. Bauer:  ; Moderna Therapeutics. ; Pfizer. ; Guardant Health. ; Loxo Pharmaceuticals. ; Exelexis. ; Ignyta. ; Bayer. ; Institutional: Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, MedImmune/AZ, Abbvie, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Eli Lilly, GSK, Novartis, Genentech/Roche. ; Deciphera, Merrimack Pharmaceuticals, Immunogen, Millennium Pharmaceuticals, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma,. ; Peleton, Immunocore, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience. ; Janssen Pharmaceuticals, Clovis Oncology, Takeda, Karyopharm Therapeutics, Onyx Pharmaceuticals, Phosplati Therapeutics, Foundation Medicine. A.R. Hansen:  ; Genentech/Roche, Merck, GSK, Bristol-Myers Squibb, Novartis, Boston Biomedical, Boehringer-Ingelheim, AstraZeneca, Medimmune. D.C. Cho:  ; Nektar, Pfizer, Puretech, Torque, HUYA.\\xa0F. Hodi:  ; Novartis. ; BMS. ; Genentech. ; Merck. ; Sanofi. ; EMD Serono. ; Verastem. ; Pfizer. ; Bayer. ; Aduro. ; Amgen. ; Apricity, Bicara, Boston Pharma, Pionyr, 7 Hills, Torque, Takeda, Compass. J.H. Schellens:  ; share and patent holder on oral taxanes; Modra Pharmaceuticals. J.K. Litton:  ; The University of Texas, MD Anderson Cancer Center. ; GSK. ; Novartis. ; Medivation/Pfizer. ; Genentech. ; EMD-Serono. ; Astra-Zeneca. ; Medimmune. ; Zenith. ; Ayala. ; Up To Date review panels for NCCN, ASCO, NIH PDQ. ; Medlearning. ; Physicians Education Resource. ; Prime Oncology. ; Medscape. ; Clinical Care Options. ; Medpage. S. Aspeslagh:  ; UZbrussel. ; BSMO. ; ESMO. ; personal fees for oral presentations; MSD, BMS, Astra Zeneca, Amgen, Roche, Sanofi, Pfizer and Novartis. K.A. Autio:  ; Institution: GSK, Pfizer, Astra-Zeneca, CytomX, Amgen, Tizona. F.L. Opdam:  ; Netherlands Cancer Institute. M. McKean:  ; Institution: Epizyme, Exelexis, Genentech, GSK, Infinity, Jacobio, Moderna, Regeneron, Tizona, Prelude, Ascentage Pharma, Ideaya Biosciences, Ikena Oncology. ; Array Biopharma. ; publication support to institution; Novartis.\\xa0N. Somaiah: None. S. Champiat:  ; Amgen, AstraZeneca, BMS, Janssen, MSD, Novartis and Roche. ; As part of Gustave Roussy Drug Development Department (DITEP):\\nPrincipal/sub-Investigator of Clinical Trials; Abbvie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno. M. Altan:  ; GSK. ; Genentech. ; Nektar Therapeutics. ; Merck. ; Novartis. ; Jounce Therapeutics. ; BMS. ; Eli Lilly. A. Spreafico:  ; University Health Network and Assistant Professor University of Toronto. ; MERCK. ; BMS. ; Novartis. ; Oncorus. ; Janssen. ; Institution: Novartis, Bristol-Myers Squibb, Symphogen AZ/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen/J&J, Roche, Regeneron, Alkermes, Array Biopharma, GSK. O. Rahma:  ; GSK. ; Merck. ; Celgene. ; Five Prime. ; GFK. ; Bayer. ; Roche/Genentech. ; Puretech. ; Imvax. E.M. Paul:  ; GSK. C.M. Ahlers:  ; GSK. H. Zhou:  ; GSK. H. Struemper:  ; GSK. S.A. Gorman:  ; GSK. M. Watmuff:  ; GSK. K.M. Yablonski:  ; GSK. N. Yanamandra:  ; GSK. M.J. Chisamore:  ; Merck & Co. Inc. E.V. Schmidt:  ; Merck & Co. Inc. A. Hoos:  ; GSK. A. Marabelle:  ; Pfizer. ; Roche/Genentech. ; Astra Zeneca/Medimmune. ; BMS. J.S. Weber:  ; Nextcure. ; Biond. ; Celldex. ; Protean. ; CytoMx. ; Altor. ; BMS. ; GSK. ; Merck. ; Novartis. ; Amgen. ; Genentech. ; Astra Zeneca. ; Incyte. ; Named on a CTLA-4 biomarker patent by Moffitt,and a PD-1 biomarker by Biodesix; Moffitt, Biodesix. J.V. Heymach:  ; GSK. ; Astra Zeneca. ; Patent; Spectrum Pharmaceuticals. ; Checkmate Pharmaceuticals. ; Brightpath Biotherapeutics. ; Eli Lilly & Co. ; Kairos Venture Investments. ; Triptych Health Partners. ; NIH/NCI, American Cancer Society. ; Cancer Prevention & Research Institute of Texas. ; AACR Johnson & Johnson Lung Cancer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-51': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10650',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT151\\n                        \\n                         - Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Apostolia M. Tsimberidou1, Philip Beer2, Jennifer Bendall2, James Dow2, Justine King2, Hilary McElwaine-Johnn2, Ignacio I. Wistuba1. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2Karus Therapeutics Ltd, Oxfordshire, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0A.M. Tsimberidou:  ; Principal Investigator on company sponsored trial; Karus Therapeutics Ltd. P. Beer:  ; Karus Therapeutics Ltd. J. Bendall:  ; Karus Therapeutics Ltd. J. Dow:  ; Karus Therapeutics Ltd. J. King:  ; Karus Therapeutics Ltd. H. McElwaine-Johnn:  ; Karus Therapeutics Ltd. I.I. Wistuba:  ; Co-Investigator/collaborator on company sponsored trial; Karus Therapeutics Ltd.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-52': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10651',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT152\\n                        \\n                         - First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Laurence Buisseret1, Sylvie Rottey2, Johann de Bono3, Manon Mossakowski4, Brant Delafontaine2, Thubeena Manickavasagar3, Nuria Kotecki5, Chiara Martinoli6, Manfred Schneider6, Olivier De Henau6, Patricia Chevron6, Joanne Lager7, Jean-Pascal Machiels8. 1Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; 2Department of Medical Oncology, Drug Research Unit Ghent,  Universitair Ziekenhuis Ghent, Ghent, Belgium; 3Division of Clinical Studies, The Institute of Cancer Research, Royal Marsden National Hospital Trust, Sutton, United Kingdom; 4Department of medical oncology, Cliniques universitaires Saint-Luc, Universite catholique de Louvain, Brussels, Belgium; 5Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Bruusels, Belgium; 6iTeos Therapeutics SA, Gosselies, Belgium; 7iTeos Therapeutics Inc, Cambridge, MA; 8Department of medical oncology and head and neck surgery, Cancer center, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Universite catholique de Louvain, Brussels, Belgium ',\n",
       "  'Disclosures': '\\xa0\\xa0L. Buisseret:  ; AstraZeneca. ; Bristol-Myers Squibb. ; Roche.\\xa0S. Rottey: None. J. de Bono:  ; Astra Zeneca. ; Bayer. ; Boehringer Ingelheim. ; Genentech/Roche. ; Merck Sharp & Dohme. ; Pfizer. ; Sanofi Aventis. ; Astellas. ; GSK. ; Janssen. ; Cellcentric. ; Daiichi. ; Genmab,. ; Merck Serono. ; Menarini/Silicon Biosystems. ; Orion. ; Sierra Oncology. ; Taiho. ; Vertex Pharmaceuticals.\\xa0M. Mossakowski: None.\\xa0B. Delafontaine: None.\\xa0T. Manickavasagar: None.\\xa0N. Kotecki: None. C. Martinoli:  ; iTeos Therapeutics SA. M. Schneider:  ; iTeos Therapeutics SA. O. De Henau:  ; iTeos Therapeutics SA. ; Bristol-Myers Squibb. P. Chevron:  ; iTeos Therapeutics SA. J. Lager:  ; iTeos Therapeutics Inc. J. Machiels:  ; Astra Zeneca. ; ALX Oncology. ; Bayer. ; Boehringer Ingelheim. ; Bristol-Myers squibb. ; Cue Biopharma. ; Incyte. ; Janssen. ; Merck Serono. ; Merck Sharp & Dohme. ; Novartis. ; Pfizer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-53': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10652',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT153\\n                        \\n                         - SDX-7320 elicits improvements in tumor-related and metabolic biomarkers: Results of a phase 1 dose-escalation study in patients with advanced refractory or late-stage solid tumors\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Monica M. Mita1, Johanna Bendell2, Alain C. Mita1, Michael Gordon3, Jasgit Sachdev3, Bradley J. Carver4, James Shanahan4, Benjamin Mayes4, Kris Awerkamp5, David Browning4, Neal Salomon6, Kimberly Sullivan7, Alfred Anderson-Villaluz8, Joe Johnson9, John S. Petersen10, David J. Turnquist11, Peter Cornelius4. 1Cedars-Sinai, Los Angeles, CA; 2Sarah Cannon Research Institute, Nashville, TN; 3Honor Health, Scottsdale, AZ; 4Syndevrx Inc., Cambridge, MA; 5TD2, Scottsdale, AZ; 6Syndevrx, Inc, Cambridge, MA; 7Development Insights, Beverly, MA; 8Radius Health, Waltham, MA; 9Quanterix, Billerica, MA; 10Syndevrx, Inc, Cambridge, CA; 11Sojournix, Inc, Arlington, MA ',\n",
       "  'Disclosures': '\\xa0M.M. Mita: None.\\xa0J. Bendell: None.\\xa0A.C. Mita: None.\\xa0M. Gordon: None.\\xa0J. Sachdev: None. B.J. Carver:  ; Syndevrx Inc.\\xa0J. Shanahan:  ; Syndevrx Inc.\\xa0B. Mayes:  ; Syndevrx Inc..\\xa0K. Awerkamp: None.\\xa0D. Browning: None.\\xa0N. Salomon: None.\\xa0K. Sullivan: None.\\xa0A. Anderson-Villaluz: None.\\xa0J. Johnson: None. J.S. Petersen:  ; Syndevrx Inc..\\xa0D.J. Turnquist: None. P. Cornelius:  ; Syndevrx Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-54': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10653',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT154\\n                        \\n                         - An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jeffrey A. Bacha1, Dennis Brown1, Sarath Kanekal1, Ian Nisbet2, Neil Sankar1, Wang Shen3, Helen Wheeler4, Kathy Skoff2, Zhen Zhong Wang5. 1Edison Oncology Holding Corp., Menlo Park, CA; 2Senz Oncology, Melbourne, Australia; 3Valent Technologies LLC, Menlo Park, CA; 4Northern Sydney Cancer Center, Sydney, Australia; 5jiangsu kanion pharmaceutical co ltd, Lianyungang, China ',\n",
       "  'Disclosures': '\\xa0\\xa0J.A. Bacha:  ; Edison Oncology. ; Valent Technologies LLC. D. Brown:  ; Edison Oncology Holding Corp. ; Valent Technologies LLC. S. Kanekal:  ; Edison Oncology Holding Corp.. ; Valent Technologies LLC. I. Nisbet:  ; Senz Oncology. N. Sankar:  ; Edison Oncology Holding Corp.. ; Valent Technologies LLC. W. Shen:  ; Valent Technologies LLC. ; Edison Oncology Holding Corp..\\xa0H. Wheeler: None. K. Skoff:  ; Senz Oncology. Z. Wang:  ; Kanion Pharmaceutical.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-55': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10654',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT155\\n                        \\n                         - General pharmacodynamics algorithm-based clinical protocol design with two to three dose-data points for single-drug, and ten data points for two-drug-combination synergy quantification, using computer simulation for digitalized data analysis and conclusions\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ting-Chao Chou. PD Science LLC, Paramus, NJ ',\n",
       "  'Disclosures': '\\xa0T. Chou: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-56': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10655',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT156\\n                        \\n                         - Characterization of PEN-866, a Heat Shock Protein 90 (HSP90) binding conjugate of SN-38, in patient plasma and tumors from the first in human study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Anish Thomas1, Kristina Kriksciukaite2, Gerald Falchook3, Johanna Bendel4, Susanna Ulahannan5, Christophe Redon1, Laura Mei2, Kerry Whalen2, Jeffrey Bloss2, Mark T. Bilodeau2. 1National Cancer Institute, Bethesda, MD; 2Tarveda Therapeutics, Watertown, MA; 3Sarah Cannon Research Institute at HelathONE, Denver, CO; 4Sarah Cannon research Insitute/Tennessee Oncology, Nashville, TN; 5Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK ',\n",
       "  'Disclosures': '\\xa0A. Thomas: None. K. Kriksciukaite:  ; Tarveda Therapeutics. G. Falchook:  ; royalties; Wolters Kluwer. ; Fujifilm. ; EMD Serono. ; travel; Bristol-Myers Squibb. ; speakers bureau; Travel Health Conferencing. ; 3-V Biosciences. ; Abbvie. ; ADC Therapeutics. ; Aileron. ; Amgen. ; ARMO. ; AstraZeneca. ; BeiGene. ; Bioatla. ; Biothera. ; Celldex. ; Celgene. ; Ciclomed. ; Curagenix. ; Curis. J. Bendel:  ; Gilead. ; Genentech/Roche. ; Bristol-Myers Squibb. ; Five Prime. ; Lilly. ; Merck. ; MedImmune. ; Celgene. ; EMD Serono. ; Taiho. ; Macrogenics. ; GlaxoSmithKline. ; Novartis. ; OncoMed. ; LEAP. ; TG Therapeutics. ; AstraZeneca. ; Boehringer-Ingelheim. ; Daiichi Sankyo. ; Bayer. S. Ulahannan:  ; Array. ; Incyte. ; Bayer. ; Exelixis. ; Abbvie. ; ArQule. ; AstraZeneca. ; Boehringer Ingelheim. ; Bristol-Myers Squibb. ; Celgene. ; Ciclomed. ; Evelo Biosciences. ; G1 Therapeutics. ; Incyte. ; Klus Pharma. ; Macrogenics. ; Merck & Co., Inc.. ; Mersana therapeutics. ; OncoMed Pharmaceuticals. ; Pfizer.\\xa0C. Redon: None. L. Mei:  ; Tarveda Therapeutics. K. Whalen:  ; Tarveda Therapeutics. J. Bloss:  ; Tarveda Therapeutics. M.T. Bilodeau:  ; Tarveda Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-57': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10656',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT157\\n                        \\n                         - Phase IB study of nivolumab and veliparib in patients with advanced solid tumors and lymphoma with and without alterations in selected DNA repair genes\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Elena Vagia, Pedro Viveiros, Cyra-Yoonsun Kang, Aparna Kalyan, Valerie Nelson, Devalingam Mahalingam, Young Kwang Chae. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL ',\n",
       "  'Disclosures': '\\xa0E. Vagia: None.\\xa0P. Viveiros: None.\\xa0C. Kang: None.\\xa0A. Kalyan: None.\\xa0V. Nelson: None.\\xa0D. Mahalingam: None. Y.K. Chae:  ; AstraZeneca. ; Genentech. ; Takeda Pharmaceuticals. ; Guardant Health. ; Foundation Medicine. ; Abbvie. ; BMS. ; Lexent Bio. ; Freenome. ; Biodesix.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-58': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10657',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT158\\n                        \\n                         - Addressing the clinical trial participation of underrepresented minorities at the USC Norris Comprehensive Cancer Center (NCCC) through the National Outreach Network Community Health Educator (NON-CHE) Program\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Lourdes Baezconde, Juan Carmen, Carolina Aristizabal. University of Southern California, Los Angeles, CA ',\n",
       "  'Disclosures': '\\xa0L. Baezconde: None.\\xa0J. Carmen: None.\\xa0C. Aristizabal: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-59': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10658',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT159\\n                        \\n                         - First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of neuroendocrine tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Izabela Tworowska1, Ebrahim S. Delpassand1, Julien Torgue2, Farah Shanoon3, Jason Hurt4, Rodolfo Nunez3. 1RadioMedix Inc., Houston, TX; 2Orano Med LLC, Plano, TX; 3Excel Diagnostics Clinic, Houston, TX; 4Orano Med LLC, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0I. Tworowska:  ; RadioMedix. E.S. Delpassand:  ; RadioMedix. J. Torgue:  ; Orano Med  LLC. F. Shanoon:  ; Excel Diagnostics Clinic. J. Hurt:  ; Orano Med LLC. R. Nunez:  ; Excel Diagnostics Clinic.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-60': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10939',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT160\\n                        \\n                         - The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Enrica Marchi1, Helen Ma1, Francesca Montanari1, Ahmed Sawas1, Jennifer K. Lue1, Changchun Deng1, Kareema T. Whitfield1, Sandra Klein1, Matthew V. Matthew1, Freedy J. Loffredo1, Luigi Scotto1, Hyejung Lee1, Hye A. Kim1, Alice T. Jacobs1, Aishling M. Rada1, Karen A. Khan1, Salvia Salvia2, John Lister3, Nora N. Benanni4, Mark A. Francescone1, Pier Luigi Zinzani5, Wonseog Kim6, Owen A. O\\'Connor1. 1Columbia University Medical Center, New York, NY; 2Beth Israel Deaconess Medical Center, Boston, MA; 3Allegheny Medical Center, Pittsburg, PA; 4Mayo Clinic, Rochester, MN; 5Institute of Hematology \"L. & A. Seragnoli\", Bologna, Italy; 6Samsung Medical Center, Seoul, Korea, Republic of ',\n",
       "  'Disclosures': \"\\xa0\\xa0E. Marchi:  ; Research Funding; Celgene. ; Research Funding; Merck. ; Scientific Advisory; Mundipharma. ; Scientific Advisory; Spectrum Pharmaceutical. ; Scientific Advisory; Verastem.\\xa0H. Ma: None. F. Montanari:  ; Research Funding; Seattle Genetics. A. Sawas:  ; Research Funding; Affimed. ; Consultation/Speaking Fees; Daiichi Sankyo. ; Consultation/Speaking Fees; Gilead.\\xa0J.K. Lue: None.\\xa0C. Deng: None.\\xa0K.T. Whitfield: None.\\xa0S. Klein: None.\\xa0M.V. Matthew: None.\\xa0F.J. Loffredo: None.\\xa0L. Scotto: None.\\xa0H. Lee: None.\\xa0H.A. Kim: None.\\xa0A.T. Jacobs: None.\\xa0A.M. Rada: None.\\xa0K.A. Khan: None.\\xa0S. Salvia: None.\\xa0J. Lister: None. N.N. Benanni:  ; Research Funding; Bristol-Myers Squibb. ; Kite Pharma/Gilead. ; Seattle Genetics. ; Adicet Bio. ; Purdue Pharma.\\xa0M.A. Francescone: None. P. Zinzani:  ; Verastem. ; Celltrion. ; Gilead. ; Janssen-Cilag. ; BMS. ; Servier. ; Sandoz. ; MSD. ; Immune Design. ; Celgene. ; Portola. ; Roche. ; Eusapharma. ; Kyowa Kirin. ; Sanofi. W. Kim:  ; Takeda. ; Roche. ; Jassen. ; Mundipharma. ; Kyowa Kirin. ; Pfizer. ; Norvatis. ; Celltrion. ; Donga pharma. ; Celltrion. O.A. O'Connor:  ; Research Support; Spectrum Pharmaceutical. ; Scientific Advisory; Millenium Pharmaceutical. ; Research Support; Seattle Genetics. ; Research Support; Celgene. ; Research Support; Merck. ; Research Support & Scientific Advisory; TG Therapeutics. ; Research Support; Agensys, Inc. ; Research Support & Scientific Advisory (unpaid); Trillium. ; Research Support & Scientific Advisory; Mundipharma. ; Research Support; Mundipharma.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '842-61': {'Session Title': ' VPO.CT01. Phase I Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10953',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT00\\n                        \\n                         - Test title for the 2020 Annual Meeting\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Michael Beveridge. Account Institution 1, Philadelphia, PA ',\n",
       "  'Disclosures': '\\xa0\\xa0M. Beveridge:  ; Merck. ; Genentech. ; AstraZeneca. ; Novocure. ; Johnson & Johnson. ; Roche. ; Novartis. ; PMV Pharma. ; Juno. ; BioPharm.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-1': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10714',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT211\\n                        \\n                         - EF-19 - A post-approval registry study of TTFields for the treatment of recurrent glioblastoma (GBM)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Jay-Jiguang Zhu1, Robert T. O'Donnell2, Zvi Ram3. 1University of Texas Health Science Center, Houston, TX; 2University of California at Davies, Sacramento, CA; 3Tel Aviv Medical Center, Tel Aviv, Israel \",\n",
       "  'Disclosures': \"\\xa0\\xa0J. Zhu:  ; NCI/NRG Oncology, Boston Biomedical of Sumitomo Dainippon Pharma Global Oncology, DEKK-TEC, Inc., Diffusion Pharmaceuticals LLC., Five Prime Therapeutics, Inc., Immuno-Cellular Therapeutics LTD., Nov. ; Tocagen, Inc.\\xa0R. O'Donnell: None. Z. Ram:  ; Novocure.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-2': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10715',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT212\\n                        \\n                         - A phase III randomized study of paclitaxel (T) and trastuzumab (H) versus T, H and lapatinib (L) in first line treatment of HER2+ metastatic breast cancer (MBC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"John Crown1, William Jacot2, Denis M. Collins3, Linda Coate4, Anna Saetersdal5, M John Kennedy6, Catherine Kelly7, Blanca Cantos Sanchez De Ibarguen8, Raquel Andrs Conejero9, Luis Costa10, Margarida Brito11, Maccon Keane12, Pedro Sanchez Rovira13, Miguel Martin14, Miriam O'Connor15, Manuel Ramos Vazquez16, Elena Alvarez17, Seamus O'Reilly18, Johanna Mattson19, Laura Jolis Lopez20, Alvaro Rodriguez Lescure21, Esperanza Blanco22, Coralia Bueno Muino23, Brian Moulton24, Norma O'Donovan3, Andres Hernando25, Marc Nolan25, Imelda Parker25, Giuseppe Gullo26, Bryan Hennessy27. 1Saint Vincent's University Hospital/Cancer Trials Ireland, Dublin, Ireland; 2CRLC Val d'Aurelle Hospital, Montpellier, France; 3Dublin City University, Dublin, Ireland; 4University Hospital Limerick, Limerick, Ireland; 5Oslo University Hospital, Oslo, Norway; 6St James's Hospital, Dublin, Ireland; 7Mater Hospital, Dublin, Ireland; 8Hospital Puerta de Hierro (Madrid) and GEICAM Spanish Breast Cancer Group, Madrid, Spain; 9Hospital Clinico Universitario Lozano Blesa (Zaragoza) and GEICAM Spanish Breast Cancer Group, Zaragoza, Spain; 10Hospital Santa Maria, Lisbon, Portugal; 11IPO Lisbon, Lisbon, Portugal; 12University Hospital Galway, Galway, Ireland; 13Complejo Hospitalario de Jaen and GEICAM Spanish Breast Cancer Group, Jaen, Spain; 14Hospital General Universitario Gregorio Maranon (Madrid) and GEICAM Spanish Breast Cancer Group, Madrid, Spain; 15University Hospital Waterford, Waterford, Ireland; 16Centro Oncologico de Galicia (A Coruna) and GEICAM Spanish Breast Cancer Group, A Coruna, Spain; 17Complejo Hospitalario Xeral Calde (Lugo) and GEICAM Spanish Breast Cancer Group, Lugo, Spain; 18Cork University Hospital, Cork, Ireland; 19Helsinki University Hospital, Helsinki, Finland; 20Hospital de Granollers (Barcelona) and GEICAM Spanish Breast Cancer Group, Barcelona, Spain; 21Hospital General de Elche (Valencia) and GEICAM Spanish Breast Cancer Group, Valencia, Spain; 22Hospital Infanta Cristina (Badajoz) and GEICAM Spanish Breast Cancer Group, Badajoz, Spain; 23Hospital Infanta Cristina (Parla, Madrid) and GEICAM Spanish Breast Cancer Group, Madrid, Spain; 24Clinical Oncology Development Europe, Dublin, Ireland; 25Cancer Trials Ireland, Dublin, Ireland; 26Saint Vincent's University Hospital, Dublin, Ireland; 27Beaumont Hospital, Dublin, Ireland \",\n",
       "  'Disclosures': \"\\xa0\\xa0J. Crown:  ; Conference travel; Novartis. ; Puma Biotechnology, Inc. ; Oncomark. ; Conference travel; Pfizer. ; MSD Ireland. ; G1 Therapeuticss. ; Conference travel; Abbvie. W. Jacot:  ; Travel expenses and accommodation; Astra Zeneca. ; Travel expenses and accommodation; Eisai. ; Travel expenses and accommodation; Lilly France. ; MSD. ; Travel expenses and accommodation; Novartis. ; Travel expenses and accommodation; Pfizer. ; Travel expenses and accommodation; Roche. ; Travel expenses and accommodation; Chugai Pharma. ; Travel expenses and accommodation; GSK. ; Travel expenses and accommodation; Pierre Fabre. ; Travel expenses and accommodation; Sanofi Aventis. D.M. Collins:  ; Roche/Genentech. ; Puma Biotechnology, Inc.\\xa0L. Coate: None.\\xa0A. Saetersdal: None.\\xa0M. Kennedy: None.\\xa0C. Kelly: None. B. Cantos Sanchez De Ibarguen:  ; Roche. ; Novartis. ; Eisai. ; Kern.\\xa0R. Andrs Conejero: None.\\xa0L. Costa: None.\\xa0M. Brito: None.\\xa0M. Keane: None.\\xa0P. Sanchez Rovira: None. M. Martin:  ; Roche/Genentech. ; Puma. ; Novartis. ; AstraZeneca. ; Amgen. ; Taiho Oncology. ; PharmaMar. ; Eli Lilly. ; Daiichi Sankyo. ; Pfizer.\\xa0M. O'Connor: None. M. Ramos Vazquez:  ; Novartis. ; Roche. ; Pfizer.\\xa0E. Alvarez: None. S. O'Reilly:  ; Travel expenses to meeting; Roche. J. Mattson:  ; Pfizer. ; Takeda.\\xa0L. Jolis Lopez: None. A. Rodriguez Lescure:  ; AstraZeneca. ; Roche. ; Pfizer. ; Novartis. ; Mylan. ; KERN Pharma. ; Lilly.\\xa0E. Blanco: None.\\xa0C. Bueno Muino: None. B. Moulton:  ; Novartis.\\xa0N. O'Donovan: None.\\xa0A. Hernando: None.\\xa0M. Nolan: None.\\xa0I. Parker: None. G. Gullo:  ; Regeneron Pharmaceuticals, Inc..\\xa0B. Hennessy: None.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-3': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10716',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT213\\n                        \\n                         - Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"David Planchard1, Mustafa zgrolu2, Davey Daniel3, Augusto Villegas4, David Vicente5, Shuji Murakami6, Rina Hui7, Corinne Faivre-Finn8, Luis Paz-Ares9, Yi-Long Wu10, Euan Macpherson11, Michael Newton12, Phillip Dennis12, Scott J. Antonia13. 1Gustave Roussy, Department of Medical Oncology, Thoracic Unit, Villejuif, France; 2Istanbul University  Cerrahpaa, Cerrahpaa School of Medicine, Cerrahpaa, Turkey; 3Tennessee Oncology, Chattanooga, TN, and Sarah Cannon Research Institute, Nashville, TN; 4Cancer Specialists of North Florida, Jacksonville, FL; 5Department of Clinical Oncology, H.U.V. Macarena, Seville, Spain; 6Kanagawa Cancer Center, Yokohoma, Japan; 7Westmead Hospital and the University of Sydney, Sydney, Australia; 8The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom; 9Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, Spain; 10Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Science, Guangzhou, China; 11AstraZeneca, Macclesfield, United Kingdom; 12AstraZeneca, Gaithersburg, MD; 13H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL \",\n",
       "  'Disclosures': '\\xa0\\xa0D. Planchard:  ; AstraZeneca. ; Boehringer Ingelheim. ; Bristol-Myers Squibb. ; Celgene. ; Novartis. ; Pfizer. ; MSD. ; Roche. ; prIME Oncology. ; Peer CME.\\xa0M. zgrolu: None. D. Daniel:  ; Institutional Research Support; AstraZeneca. ; Institutional Research Support; Genentech. ; Institutional Research Support; Guardant Health. ; Institutional Research Support; Janssen. ; Institutional Research Support; Bristol-Myers Squibb. ; Institutional Research Support; G1 Therapeutics. ; Institutional Research Support; Merck. ; Institutional Research Support; Novartis. ; Institutional Research Support; Abb Vie. ; Institutional Research Support; ARMO BioSciences. ; Institutional Research Support; Immunomedics. ; Institutional Research Support; Eli Lilly. ; Institutional Research Support; Merus NV. ; Institutional Research Support; Daiichi Sankyo. A. Villegas:  ; AstraZeneca.\\xa0D. Vicente: None. S. Murakami:  ; Takeda Pharmaceutical. ; AstraZeneca. ; Chugai Pharmaceutical. ; Boehringer Ingelheim. ; Taiho Pharmaceutical. ; Ono Pharmaceutical. R. Hui:  ; AstraZeneca. ; Bristol-Myers Squibb. ; MSD. ; Novartis. ; Roche. C. Faivre-Finn:  ; Payment to institution; AstraZeneca. L. Paz-Ares:  ; Leadership; Genomica. ; Immediate Family Member, Leadership; European Medicines Agency. ; Travel, Immediate Family Member; Roche/Genentech. ; Travel; AstraZeneca. ; Travel; Bristol-Myers Squibb. ; Travel; MSD. ; Travel; Lilly. ; Travel, Immediate Family Member; Pfizer. ; Boehringer Ingelheim. ; Immediate Family Member; Merck Serono. ; PharmaMar. ; Immediate Family Member; Novartis. ; Celgene. ; Immediate Family Member; Amgen. ; Incyte. ; Immediate Family Member; Ipsen. ; Immediate Family Member; SERVIER. ; Immediate Family Member; Sanofi. Y. Wu:  ; Eli Lilly. ; Institutional Research Support; Roche. ; Pfizer. ; Sanofi. ; Merck. ; Institutional Research Support; Boehringer Ingelheim. E. Macpherson:  ; AstraZeneca. M. Newton:  ; AstraZeneca. P. Dennis:  ; AstraZeneca. S.J. Antonia:  ; Travel; Bristol-Myers Squibb. ; Travel; AstraZeneca. ; Travel; Merck. ; Travel; Boehringer Ingelheim. ; Travel; Novartis. ; Memgen. ; Travel; FLX Bio. ; Cellular Biomedicine Group.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-4': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10717',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT214\\n                        \\n                         - CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Bruce E. Johnson1, Tae Min Kim2, T. Jeroen N. Hiltermann3, Fabrice Barlesi4, Christian Grohe5, Yasushi Goto6, Orvar Gunnarsson7, Tobias Overbeck8, Noemi Reguart9, Martin Wermke10, Gilberto Castro Castro, Jr.11, Enriqueta Felip12, Alastair Greystoke13, Benjamin J. Solomon14, Stephanie Deudon15, Anne-Laure Louveau16, Vanessa Passos17, Daniel SW Tan18. 1Dana-Farber Cancer Institute, Boston, MA; 2Seoul National University Hospital, Seoul, Korea, Republic of; 3University Medical Center Groningen, Groningen, Netherlands; 4Aix-Marseille University, Marseille, France; 5Evangelische Lungenklinik Berlin, Berlin, Germany; 6National Cancer Centre Hospital, Tokyo, Japan; 7Landspitali University Hospital, Reykjavik, Iceland; 8University Hospital Gttingen - University Medical Centre Gttingen, Groningen, Germany; 9Hospital Clinic i Provincial de Barcelona, Barcelona, Spain; 10Uniklinikum Dresden, Dresden, Germany; 11Instituto do Cncer do Estado de So Paulo, So Paulo, Brazil; 12Vall dHebron Institute of Oncology, Barcelona, Spain; 13Newcastle upon Tyne Hospitals, High Heaton, United Kingdom; 14Peter MacCallum Cancer Centre, Melbourne, Australia; 15Novartis Pharma AG, Basel, Switzerland; 16Novartis Pharma SAS, Rueil-Malmaison, Paris, France; 17Novartis Pharmaceuticals Corporation, East Hanover, NJ; 18National Cancer Centre, Singapore, Singapore ',\n",
       "  'Disclosures': '\\xa0\\xa0B.E. Johnson:  ; Novartis Steering Committee. ; Array Biopharma Steering Committee. ; Cannon Medical Imaging. T.M. Kim:  ; Research grant / Funding (self)\\tAstraZeneca-KHIDI outside this work; AstraZeneca. ; Novartis. ; Takeda. ; Sanofi. ; Bayer. T. Hiltermann:  ; BMS, AZD, CANCER-ID, Roche. ; BMS, AZD, Merck, Boehringer, Pfizer, Eli Lilly, Roche, Platform immunotherapy. F. Barlesi:  ; Honoraria (Self); Astra-Zeneca, Bayer, Bristol-Myers Squibb, BoehringerIngelheim, Eli Lilly Oncology, F. HoffmannLa Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda. ; Honoraria (Institution); Abbvie, ACEA, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, BoehringerIngelheim, Eisai, Eli Lilly Oncology, F. HoffmannLa Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis. ; Honoraria (Institution); Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis and Takeda.\\xa0C. Grohe: None. Y. Goto:  ; Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Glaxo Smith Kline, MSD, Guardant Health, Dai-ichi Sankyo, Kyorin, Chugai,   Illumina. ; AstraZeneca, Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, MSD, Shionogi Pharma, Novartis. ; Abbvie, Eli Lilly, Taiho Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, Dai-ichi Sankyo, Pfizer, Novartis, Kyorin, Chugai, Guardant Health. O. Gunnarsson:  ; Novartis. T. Overbeck:  ; consulting fees from AstraZeneca, BMS, Boehringer-Ingelheim, Eli Lilly, Medac, MSD, Novartis, Roche/Genentech. ; travel support from AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Roche/Genentech; sponsored research agreements from AstraZeneca, Eli Lilly, Roche/Genentech, Sanofi-Aventis. N. Reguart:  ; MSD, BMS, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, Abbvie, Ipsen, Novartis, Astrazeneca, Lilly, Takeda. ; MSD, BMS, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, Abbvie, Ipsen, Novartis, Astrazeneca, Lilly, Takeda. ; Research grant / Funding (institution): FIS_Instituto de Salud Carlos III\\n; Pfizer, Nanostring, Novartis. ; Travel / Accommodations / Expenses; MSD, BMS, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, Abbvie, Ipsen, Novartis, Astrazeneca, Lilly, Takeda. M. Wermke:  ; Novartis, Boehringer, Macrogenesis, AstraZeneca, Celgene, Bristol-Meyers-Squibb, MSD. ; Bristol-Myers Squibb, Boehringer. ; Travel / Accommodations / Expenses: AstraZeneca, Bristol Myers Squibb; Novartis. G. Castro:  ; Lilly, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Novartis, Pfizer, Roche. ; Lilly, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Pfizer, Roche, Yuhan. ; AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Novartis, Pfizer, Roche. ; Lilly, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Novartis, Pfizer, Pierre Fabre, Roche, GSK, Beigene. ; Travel/Accommodation/Expenses; Lilly, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Serono, MSD, Novartis, Pfizer, Pierre Fabre, Roche. E. Felip:  ; Pfizer, Roche, Boehringer Ingelheim, Astra Zeneca, Bristol-Myers Squibb, Guardant Health, Novartis, Takeda, ABBVIE, Blue Print Medicines, Lilly, Merck KGaA, Mrck Sharp & Dohme, Janssen, Samsung.. ; Pfizer, Roche, Astra Zeneca, Bristol-Myers Squibb, Novartis, Takeda, Lilly, Mrck Sharp & Dohme, Medscape, Prime Oncology, Touchtime.. ; Fundacin Merck Salud, Grant for Oncology Innovation (GOI).. ; Officer/Board of Directors; Grfols (Independent Memeber). A. Greystoke:  ; AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Takeda and Roche. ; Travel/Accommodation/Expenses; Boehringer-Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Takeda and Roche. B.J. Solomon:  ; Honoraria (Institution): Pfizer, Bristol Myers Squibb; Novartis, AstraZeneca, Roche-Genentech, Bristol MyersSquibb, Merck, Loxo Oncology, Gritstone Oncology. ; Novartis, AstraZeneca, Roche-Genentech, Bristol Myers Squibb, Merck, Loxo Oncology, Gritstone Oncology, Pfizer. S. Deudon:  ; Novartis. A. Louveau:  ; Novartis. V. Passos:  ; Novartis. D.S. Tan:  ; Travel/Accommodation/Expenses; Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda. ; Novartis, Bayer, Boehringer Ingelheim, Celgene, Astra Zeneca, Eli-lily, Loxo. ; Novartis, Astra Zeneca, GlaxoSmithKline, Bayer, Pfizer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-5': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10718',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT215\\n                        \\n                         - RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreated EGFR mutation-positive metastatic NSCLC: Next generation sequencing (NGS) results\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Edward Garon1, Martin Reck2, Kazuto Nishio3, John Victor Heymach4, Makoto Nishio5, Silvia Novello6, Luis Paz-Ares7, Sanjay Popat8, Santiago Ponce Aix9, Sameera Wijayawardana10, Rebecca R. Hozak10, Carla Visseren-Grul10, Kazuhiko Nakagawa11. 1David Geffen School of Medicine at University of California Los Angeles/TRIO-US Network, Los Angeles, CA; 2LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL),, Grosshansdorf, Germany; 3Department of Medical Oncology, Kindai University, Osaka, Japan; 4The University of Texas MD Anderson Cancer Center Departments of Thoracic/Head & Neck Medical Oncology and Cancer Biology, Houston, TX; 5The Cancer Institute Hospital of JFCR,, Tokyo, Japan; 6University of Torino, Torino, Italy; 7Hospital Universitario 12 de Octubre, Madrid, Spain; 8Royal Marsden NHS Trust, London, United Kingdom; 9Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; 10Eli Lilly and Company, Indianapolis, IN; 11Kindai University Faculty of Medicine, Osaka, Japan ',\n",
       "  'Disclosures': '\\xa0\\xa0E. Garon:  ; Eli Lilly and Company. ; Astra Zeneca. ; BMS. ; Merck. ; Novartis. ; Genentech. ; Neon. ; Iovance. ; Dynavax. ; Mirati. ; Dracen. ; EMD Serono. M. Reck:  ; Abbvie. ; Amgen. ; Astra Zeneca. ; BMS. ; Boehringer-Ingelheim. ; Celegene. ; Eli Lilly and Company. ; Merck. ; MSD. ; Novartis. ; Pfizer. ; Roche.\\xa0K. Nishio: None. J.V. Heymach:  ; Astra Zeneca. ; Boehringer Ingelheim. ; EMD Serono. ; Genentech. ; Eli Lilly and Company. ; Merck. ; Roche. ; Spectrum. ; Guardant. ; Janssen. ; Novartis. ; Foundation Medicine. M. Nishio:  ; Ono Pharmaceutical. ; BMS. ; Pfizer. ; Chugai Pharmaceutical. ; Eli Lilly and Company. ; Taiho Pharmaceutical. ; Astra Zeneca. ; Boehringer Ingelheim. ; MSD. ; Novartis. ; Daiichi Sankyo Healthcare. ; Merck Serono. S. Novello:  ; Takeda. ; MSD. ; Roche. ; BMS. ; Eli Lilly and Company. ; Astra Zeneca. ; BI. ; Abbvie. ; Pfizer. L. Paz-Ares:  ; GEnomica. ; Eli Lilly and Company. ; MSD. ; Roche. ; PharmaMar. ; Merck. ; Astra Zeneca. ; Novartis. ; Boehringer Ingelheim. ; Celgene. ; Servier. ; Sysmex. ; Amgen. ; Incyte. ; Pfizer. ; Ipsen. ; Adacap. ; BMS. ; Bayer. ; Co-founder; Altum Sequencing. S. Popat:  ; editorial writing support; Millenium Pharmaceuticals. ; National Health Service. ; travel, accomodations and related expenses; Boehringer Ingelheim. S. Ponce Aix:  ; Roche. ; BMS. ; Travel, accomodations and related expenses; MSD. ; Pfizer. ; Astra Zeneca. ; BI. ; Janssen. S. Wijayawardana:  ; Eli Lilly and Company. R.R. Hozak:  ; Eli Lilly and Company. C. Visseren-Grul:  ; Eli Lilly and Company. K. Nakagawa:  ; MSD K.K.. ; Eli Lilly Japan K.K.. ; BMS. ; Taiho Pharmaceutical. ; Ono Pharmaceutical. ; Chugai Pharmaceutical. ; Astra Zeneca. ; Astellas Pharma. ; Novartis Pharma K.K.. ; Boehringer Ingelheim Japan. ; Pfizer Japan. ; Takeda Pharmaceutical. ; SymBio Pharmaceuticals. ; Daiichi Sankyo. ; Kyorin Pharmaceutical. ; CareNet, Inc. ; Nichi-Iko Pharmaceutical Co, Ltd. ; Hisamitsu Pharmaceutical Co. ; Yodosha Co, Ltd. ; Clinical Trial Co.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-6': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10719',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT216\\n                        \\n                         - IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Mark A. Socinski1, Tony S. K. Mok2, Makoto Nishio3, Robert M. Jotte4, Federico Cappuzzo5, Francisco Orlandi6, Daniil Stroyakovskiy7, Naoyuki Nogami8, Delvys Rodriguez-Abreu9, Denis Moro-Sibilot10, Christian A. Thomas11, Fabrice Barlesi12, Gene Finley13, Shengchun Kong14, Xiaoyan Liu14, Anthony Lee14, Shelley Coleman14, Geetha Shankar14, Martin Reck15. 1AdventHealth Cancer Institute, Orlando, FL; 2The State Key Laboratory in Oncology in South China, Hong Kong, China; 3The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 4Rocky Mountain Cancer Centers, Denver, CO; 5Azienda Unit Sanitaria Locale della Romagna, Ravenna, Italy; 6Instituto Nacional del Trax, Prosalud Oncologa, Santiago, Chile; 7Moscow City Oncology Hospital No. 62, Moscow, Russian Federation; 8National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; 9Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; 10Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France; 11New England Cancer Specialists, Scarborough, ME; 12Aix-Marseille Universit, CNRS, INSERM, CRCM, Assistance Publique Hpitaux de Marseille, Marseille, France; 13Allegheny Health Network Cancer Institute, Pittsburgh, PA; 14Genentech, Inc., South San Francisco, CA; 15LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany ',\n",
       "  'Disclosures': '\\xa0\\xa0M.A. Socinski:  ; Genentech. ; AstraZeneca. ; Merck. ; Guardant Health. ; Bristol-Myers Squibb. ; Bayer. ; Spectrum Pharmaceuticals. ; Novartis. ; Support of parent study and funding\\nof editorial support; F. Hoffmann-La Roche. T.S.K. Mok:  ; AstraZeneca. ; Support of parent study and funding\\nof editorial support; Roche/Genentech. ; Eli Lilly. ; Bristol-Myers Squibb ; Boehringer Ingelheim ; Novartis ; Merck Sharp & Dohme ; Pfizer. ; Takeda. ; Janssen. ; Stock option as\\nindependent non-executive director; Hutchinson ChiMed. ; OrigiMed ; Hegrui Therapeutics ; Sanofi-Aventis R&D ; Yuhan Corporation. ; Merck Serono ; Vertex. ; Clovis Oncology. ; Sanomics ; Loxo-Oncology. ; SFJ Pharmaceuticals. ; ACEA Biosciences. ; geneDecode. ; Oncogenex ; Celgene. ; Amoy Diagnostics LCo. td.. ; Ignyta Inc. ; Taiho. ; Eisai ; Xcovery. ; Fishawack Facilitate Ltd. M. Nishio:  ; BMS. ; Chugai Pharmaceutical. ; Eli Lilly. ; MSD. ; Novartis. ; Ono Pharmaceutical. ; Pfizer. ; Taiho Pharmaceutical. ; Boehringer Ingelheim. ; Merck Serono. ; Sankyo Healthcare. R.M. Jotte:  ; Support of parent study and funding\\nof editorial support; F. Hoffmann-La Roche. F. Cappuzzo:  ; Support of parent study and funding\\nof editorial support; F. Hoffmann-La Roche. ; Pfizer. ; MSD. ; AstraZeneca. ; Takeda. ; BMS.\\xa0F. Orlandi: None.\\xa0D. Stroyakovskiy: None.\\xa0N. Nogami: None.\\xa0D. Rodriguez-Abreu: None.\\xa0D. Moro-Sibilot: None.\\xa0C.A. Thomas: None.\\xa0F. Barlesi: None.\\xa0G. Finley: None.\\xa0S. Kong: None.\\xa0X. Liu: None.\\xa0A. Lee: None.\\xa0S. Coleman: None. G. Shankar:  ; Support of parent study and funding\\neditorial support; Roche. ; Genentech. M. Reck:  ; Abbvie. ; Amgen. ; AstraZeneca. ; BMS. ; Boehringer Ingelheim. ; Celgene. ; Lilly. ; Merck. ; MSD. ; Novartis. ; Pfizer. ; Roche.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '844-7': {'Session Title': ' VPO.CT03. Phase III Clinical Trials',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10720',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT217\\n                        \\n                         - POLO: Homologous recombination repair gene mutations (HRRm) in metastatic pancreatic cancer (mPaC) tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Zhongwu Lai1, Talia Golan2, Hedy L. Kindler3, Brian Dougherty1, Athena Matakidou4, Liqin Dong4, Gershon Locker5, Elizabeth A. Harrington6. 1AstraZeneca, Waltham, MA; 2The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel; 3University of Chicago, Chicago, IL; 4Centre for Genomics Research, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge, United Kingdom; 5Oncology Global Medicines Development, AstraZeneca, Gaithersburg, MD; 6Translational Medicine, Early Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0Z. Lai:  ; AstraZeneca. T. Golan:  ; Personal fees; AstraZeneca. ; AstraZeneca. ; MSD Merck. ; Personal fees; AbbVie. ; Personal fees; Teva. H.L. Kindler:  ; AstraZeneca. ; Personal fees; AstraZeneca. ; Personal fees; Aldeyra Therapeutics. ; Personal fees; Astellas. ; Personal fees and non-financial support; Boehringer-Ingelheim. ; Bristol-Myers Squibb. ; Erytech. ; Personal fees; Five Prime Therapeutics. ; Personal fees; Ipsen Pharmaceuticals. ; Personal fees; Kyowa. ; Personal fees and non-financial support; Paredox Therapeutics. ; Aduro. ; Bayer. ; Deciphera. ; Glaxo Smith Kline. ; Lilly. ; Polaris. ; Verastem. ; Grants, personal fees and non-financial support; Merck. ; Personal fees; MedImmune. B. Dougherty:  ; AstraZeneca. A. Matakidou:  ; AstraZeneca. L. Dong:  ; AstraZeneca. G. Locker:  ; AstraZeneca. E.A. Harrington:  ; AstraZeneca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-1': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10732',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:20 PM - 1:21 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alberto Bardelli. Univ. of Turin School of Medicine, Turin, Italy',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-2': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10845',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:20 PM - 1:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-3': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10733',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT021\\n                        \\n                         - Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:25 PM - 1:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'David D. Thiel1, Xiaoji Chen2, Kathryn N. Kurtzman2, Jessica Yecies2, Tony Wu2, Quan Zhang2, Hai Liu2, Nan Zhang2, Eric T. Fung2, Michael V. Seiden3, Minetta C. Liu4, Geoffrey R. Oxnard5, Earl Hubbell2, Alexander M. Aravanis2, Anne-Renee Hartman2, Eric A. Klein6. 1Mayo Clinic Florida, Jacksonville, FL; 2GRAIL, Menlo Park, CA; 3US Oncology Research, The Woodlands, TX; 4Mayo Clinic Rochester, Rochester, MN; 5Dana Farber Cancer Institute, Boston, MA; 6Cleveland Clinic, Cleveland, OH ',\n",
       "  'Disclosures': '\\xa0D.D. Thiel: None. X. Chen:  ; GRAIL. K.N. Kurtzman:  ; GRAIL. ; Illumina, Inc.\\xa0J. Yecies:  ; GRAIL. T. Wu:  ; GRAIL. Q. Zhang:  ; GRAIL. H. Liu:  ; GRAIL. N. Zhang:  ; GRAIL. E.T. Fung:  ; GRAIL. M.V. Seiden:  ; McKesson Corporation. M.C. Liu:  ; The Mayo Clinic was compensated for MCLs advisory board activities for GRAIL, Inc.; GRAIL. G.R. Oxnard:  ; Inivata Ltd. ; Guardant Health, Inc.. ; Sysmex Corporation. ; Bio-Rad Laboratories. ; DropWorks, Inc.. ; AstraZeneca plc. ; GRAIL. E. Hubbell:  ; GRAIL. A.M. Aravanis:  ; GRAIL. ; Foresite Labs. A. Hartman:  ; ARH is a former employee of GRAIL, Inc; GRAIL. E.A. Klein:  ; GRAIL, Inc. ; Cellanyx, LLC.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-4': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10844',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:35 PM - 1:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-5': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10735',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT022\\n                        \\n                         - A first-of-its-kind prospective study of a multi-cancer blood test to screen and manage 10,000 women with no history of cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:40 PM - 1:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nickolas Papadopoulos. Johns Hopkins Sidney Kimmel Comp. Cancer Center, Baltimore, MD ',\n",
       "  'Disclosures': '\\xa0\\xa0N. Papadopoulos:  ; Thrive Earlier Detection Inc. ; Scientific Advisor; PGDx Inc. ; Scientific Advisor; Neophore. ; Sysmex, Qiagen, Invitae, PGDx, Thrive, Horizon Discovery, Thermo FIsher, as well as other companies, have licensed previously described technologies from Johns Hopkins University. NP is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors. The terms are regulated by JHU.; Other.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-6': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10846',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:50 PM - 1:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-7': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10848',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:10 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-8': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10734',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT023\\n                        \\n                         - Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:15 PM - 2:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Chris Abbosh1, Alexander Frankell2, Aaron Garnett3, Thomas Harrison3, Morgan Weichert3, Abel Licon3, Selvaraju Veeriah1, Bob Daber4, Mike Moreau4, Adrian Chesh4, Kevin Litchfield2, Emilia Lim2, Daniel Cooke2, Clare Puttick2, Maise Al Bakir2, Fabio Gomes5, Akshay Patel6, Lizi Manzano1, Ariana Huebner1, Nicolas Carey7, Joan Riley7, Paula Roberts3, Todd Druley3, Jacqui A. Shaw7, Nicholas McGranahan1, Mariam Jamal-Hanjani1, Nicolai Birkbak8, Josh Stahl3, Charles Swanton2, Lung TRACERx consortium. 1UCL Cancer Institute, London, United Kingdom; 2Francis Crick Institute, London, United Kingdom; 3Archer Diagnostics, Boulder, CO; 4Genosity, Iselin, NJ; 5The Christie NHS Foundation Trust, Manchester, United Kingdom; 6University of Birmingham, Birmingham, United Kingdom; 7University of Leicester, Leicester, United Kingdom; 8Department of Molecular Medicine, Aarhaus, Denmark ',\n",
       "  'Disclosures': '\\xa0\\xa0C. Abbosh:  ; Travel and accommodation expenses; Archer Diagnostics. ; Astrazeneca. ; Novartis. ; Bristol Myers Squibbs. ; Achilles Therapeutics.\\xa0A. Frankell: None. A. Garnett:  ; Archer Diagnostics. T. Harrison:  ; Archer Diagnostics. M. Weichert:  ; Archer Diagnostics. A. Licon:  ; Archer Diagnostics.\\xa0S. Veeriah: None. B. Daber:  ; Genosity. ; Archer Diagnostics. M. Moreau:  ; Genosity. A. Chesh:  ; Genosity. K. Litchfield:  ; Roche. ; Bristol Myers Squibb.\\xa0E. Lim: None.\\xa0D. Cooke: None.\\xa0C. Puttick: None. M. Al Bakir:  ; Achilles therapeutics.\\xa0F. Gomes: None.\\xa0A. Patel: None.\\xa0L. Manzano: None.\\xa0A. Huebner: None.\\xa0N. Carey: None.\\xa0J. Riley: None. P. Roberts:  ; Archer Diagnostics. T. Druley:  ; Archer Diagnostics.\\xa0J.A. Shaw: None.\\xa0N. McGranahan: None. M. Jamal-Hanjani:  ; Achilles Therapeutics.\\xa0N. Birkbak: None. J. Stahl:  ; Archer Diagnostics. C. Swanton:  ; Boehringer Ingelheim. ; Novartis. ; Eli Lilly. ; Roche Ventana. ; GlaxoSmithKline. ; Pfizer. ; Genentech. ; Celgene. ; GRAIL. ; APOGEN Biotechnologies. ; EPIC Bioscience. ; Bristol Myers Squibbs. ; Achilles Therapeutics. ; Astrazeneca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-9': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10847',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:25 PM - 2:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-10': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10736',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT024\\n                        \\n                         - Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:30 PM - 2:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Karthick Vishwanathan1, James Dunyak1, Philip Overend2, Ryan Hartmaier1, Aleksandra Markovets1, Juliann Chmielecki1, Ganesh Mugundu1, Carl Barrett3, Helen Tomkinson2, Martin Johnson2. 1AstraZeneca, Boston, MA; 2AstraZeneca, Cambridge, United Kingdom; 3AstraZeneca, Waltham, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0K. Vishwanathan:  ; AstraZeneca. J. Dunyak:  ; AstraZeneca. P. Overend:  ; AstraZeneca. R. Hartmaier:  ; AstraZeneca. A. Markovets:  ; AstraZeneca. J. Chmielecki:  ; AstraZeneca. G. Mugundu:  ; AstraZeneca. C. Barrett:  ; AstraZeneca. H. Tomkinson:  ; AstraZeneca. M. Johnson:  ; AstraZeneca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-11': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10849',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:40 PM - 2:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-12': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10737',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT025\\n                        \\n                         - Impact of the EML4-ALK fusion variant on the efficacy of lorlatinib in patients (pts) with ALK-positive advanced non-small cell lung cancer (NSCLC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:45 PM - 2:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Todd M. Bauer1, Jean-Franois Martini2, Benjamin Besse3, Chia-Chi Lin4, Ross A. Soo5, Gregory J. Riely6, Sai-Hong Ignatius Ou7, Francesca Toffalorio8, Antonello Abbattista8, Holger Thurm2, D. Ross Camidge9, Steven Kao10, Rita Chiari11, Shirish Gadgeel12, Enriqueta Felip13, Alice T. Shaw14, Benjamin J. Solomon15. 1Sarah Cannon Cancer Research Institute/Tennessee Oncology, PLLC, Nashville, TN; 2Pfizer Oncology, La Jolla, CA; 3Gustave Roussy, Villejuif, France; 4National Taiwan University Hospital, Taipei, Taiwan; 5National University Cancer Institute, Singapore, Singapore; 6Memorial Sloan Kettering Cancer Center, New York, NY; 7Chao Family Comprehensive Cancer Center, University of California at Irvine Medical Center, Orange, CA; 8Pfizer Oncology, Milan, Italy; 9University of Colorado Cancer Center, Aurora, CO; 10Chris O'Brien Lifehouse, New South Wales, Australia; 11Oncology Unit Ospedali Riuniti Padova Sud AULSS6 Euganea, Padova, Italy; 12Karmanos Cancer Center, Detroit, MI; 13Vall dHebron Institute of Oncology, Barcelona, Spain; 14Massachusetts General Hospital, Boston, MA; 15Peter MacCallum Cancer Centre, Victoria, Australia \",\n",
       "  'Disclosures': '\\xa0\\xa0T.M. Bauer:  ; Tennessee Oncology, Sarah Cannon Research Institute. ; Daiichi Sankyo. ; Medpacto, Inc.. ; Incyte. ; Mirati Therapeutics. ; MedImmune. ; Abbvie. ; AstraZeneca. ; Leap Therapeutics. ; MabVax. ; Stemline Therapeutics. ; Merck. ; Eli Lilly. ; GlaxoSmithKline. ; Novartis. ; Pfizer. ; Genentech/Roche. ; Deciphera. ; Merrimack Pharmaceuticals. ; Emailed additional disclosures to cme@aacr.org; Emailed additional disclosures to cme@aacr.org. J. Martini:  ; Pfizer. B. Besse:  ; Abbvie. ; Amgen. ; AstraZeneca. ; BeiGene. ; Blueprint Medicines. ; BMS. ; Boehringer Ingelheim. ; Celgene. ; Cristal Therapeutics. ; Daiichi-Sankyo. ; Eli Lilly. ; GSK. ; Ignyta. ; IPSEN. ; Inivata. ; Janssen. ; Merck KGaA. ; MSD. ; Nektar. ; Emailed additional disclosures to cme@aacr.org; Emailed additional disclosures to cme@aacr.org. C. Lin:  ; Travel, accommodations, expenses; Novartis. ; Boehringer Ingelheim. ; Blueprint Medicines. ; Roche. ; Travel, accommodations, expenses; Daiichi Sankyo. ; Travel, accommodations, expenses; Eli Lilly. ; Travel, accommodations, expenses; BeiGene. R.A. Soo:  ; AstraZeneca. ; Boehringer Ingelheim. ; Amgen. ; BMS. ; Celgene. ; Ignyta. ; Lilly. ; Merck. ; Novartis. ; Pfizer. ; Roche. ; Taiho. ; Takeda. ; Yuhan. G.J. Riely:  ; Novartis. ; Roche. ; Millenium Pharmaceuticals. ; GlaxoSmithKline. ; Pfizer. ; Infinity Pharmaceuticals. ; Takeda. ; Mirati Therapeutics. ; Merck. ; Travel, accommodations, expenses; Merck Sharp & Dohme. ; Patents, royalties, other intellectual property; Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases. S.I. Ou:  ; Pfizer. ; Roche. ; AstraZeneca. ; MedImmune. ; Ariad Pharmaceuticals. ; Ignyta. ; Astellas Pharma. ; Chugai Pharma. ; Revolution Medicines. ; Genentech. ; Takeda. ; Foundation Medicine. ; Turning Point Therapeutics. ; Merck. F. Toffalorio:  ; Pfizer. A. Abbattista:  ; Pfizer. H. Thurm:  ; Pfizer. D. Camidge:  ; Takeda. ; Roche. ; G1 Therapeutics. ; Mersana. ; AstraZeneca. ; Genoptix. ; Ignyta. ; Daiichi Sankyo. ; Hansoh. ; Lycera. ; Biothera. ; Revolution Medicines. S. Kao:  ; Pfizer. ; Travel, accommodations, expenses; AstraZeneca. ; Travel, accommodations, expenses; Roche. ; Travel, accommodations, expenses; Bristol-Myers Squibb. ; MSD Oncology. ; Travel, accommodations, expenses; Boehringer Ingelheim. R. Chiari:  ; Takeda Hellas. S. Gadgeel:  ; Travel, accommodations, expenses; Merck. ; AstraZeneca. ; Pfizer. ; Genentech. ; Blueprint Medicines. ; ARIAD Pharmaceuticals. ; Takeda. ; Travel, accommodations, expenses; Genentech/Roche. ; Boehringer-Ingelheim. ; Novocure. ; Xcovery. ; Pharmamar. E. Felip:  ; Fundacin Merck Salud. ; Grant for Oncology Innovation (GOI). ; Pfizer. ; Roche. ; Boehringer Ingelheim. ; AstraZeneca. ; Bristol-Myers Squibb. ; Guardant Health. ; Novartis. ; Takeda. ; Abbvie. ; Blue Print Medicines. ; Lilly. ; Merck KGaA. ; Merck Sharp & Dohme. ; Janssen. ; Samsung. ; Medscape. ; prIME Oncology. ; Emailed additional disclosures to cme@aacr.org; Emailed additional disclosures to cme@aacr.org. A.T. Shaw:  ; Pfizer. ; Novartis. ; Genentech. ; TP Therapeutics. ; Ignyta. ; ARIAD Pharmaceuticals. ; Daiichi Sankyo. ; Roche. ; Blueprint Medicines. ; EMD Serono. ; Taiho Pharmaceutical. ; KSQ Therapeutics. ; Natera. ; Loxo Pharmaceuticals. ; Takeda. ; Bayer. ; Chugai Pharma. ; Foundation medicine. ; Guardant Health. B.J. Solomon:  ; Pfizer. ; AstraZeneca. ; Bristol-Myers Squibb. ; Merck Sharp & Dohme. ; Novartis. ; Roche/Genentech. ; Loxo Oncology. ; Gritstone Oncology.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-13': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10850',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:55 PM - 3:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '848-14': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10739',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:00 PM - 3:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Corey J. Langer. University of Pennsylvania, Philadelphia, PA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '848-15': {'Session Title': ' VCTPL02. Early Detection and ctDNA',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10851',\n",
       "  'Date': ' April 28, 2020, 1:20 PM - 3:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:15 PM - 3:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-1': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10758',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:45 AM - 10:46 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Katayoun Rezvani. UT MD Anderson Cancer Center, Houston, TX',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-2': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10871',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:45 AM - 10:50 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-3': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10759',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT051\\n                        \\n                         - Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:50 AM - 11:00 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Haneen Shalabi1, Bonnie Yates1, Shilpa Shahani1, Haiying Qin1, Steven L. HIghfill1, Sandhya Panch1, Minh Tran1, David Stroncek1, Leah Hoffman1, Lauren Little1, Katherine Graap1, Maryalice Stetler-Stevenson1, Constance Yuan1, Hao-Wei Wang1, Terry J. Fry2, Nirali N. Shah1. 1National Institutes of Health, Bethesda, MD; 2University of Colorado Anschutz Medical Campus and Center for Cancer and Blood Disorders, Aurora, CO ',\n",
       "  'Disclosures': '\\xa0H. Shalabi: None.\\xa0B. Yates: None.\\xa0S. Shahani: None.\\xa0H. Qin: None.\\xa0S.L. HIghfill: None.\\xa0S. Panch: None.\\xa0M. Tran: None.\\xa0D. Stroncek: None.\\xa0L. Hoffman: None.\\xa0L. Little: None.\\xa0K. Graap: None.\\xa0M. Stetler-Stevenson: None.\\xa0C. Yuan: None.\\xa0H. Wang: None.\\xa0T.J. Fry: None.\\xa0N.N. Shah: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-4': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10872',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:00 AM - 11:05 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-5': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10760',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT052\\n                        \\n                         - Clinical safety and efficacy study of TruUCAR GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:05 AM - 11:15 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Xinxin Wang1, Shiqi Li2, Lei Gao3, Zhongtao Yuan2, Kun Wu4, Lin Liu2, Le Luo2, Yao Liu3, Cheng Zhang3, Jia Liu1, Chunhui Yang1, Yu Li2, Zhimin Li1, Jiaping He1, Duanpeng Wang1, Xun Ye1, Xu Tan3, Ruihao Huang3, Jianning Ge1, Yu Han1, Dingsong Zhang2, Youcheng Wang2, Lihua Fang2, Yingnian Chen2, Wei Cao1, Sanbin Wang2, Xi Zhang3. 1Gracell Biotechnologies Co.,\\xa0Ltd., Shanghai, China; 2920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, China; 3The Second Affiliated Hospital of Army Medical University, Chongqing, China; 4The First Affiliated Hospital of Kunming Medical University, Kunming, China \",\n",
       "  'Disclosures': '\\xa0\\xa0X. Wang:  ; Gracell Biotechnologies Co.,\\xa0Ltd..\\xa0S. Li: None.\\xa0L. Gao: None.\\xa0Z. Yuan: None.\\xa0K. Wu: None.\\xa0L. Liu: None.\\xa0L. Luo: None.\\xa0Y. Liu: None.\\xa0C. Zhang: None. J. Liu:  ; Gracell Biotechnologies Co.,\\xa0Ltd.\\xa0C. Yang:  ; Gracell Biotechnologies Co.,\\xa0Ltd..\\xa0Y. Li: None. Z. Li:  ; Gracell Biotechnologies Co.,\\xa0Ltd.\\xa0J. He:  ; Gracell Biotechnologies Co.,\\xa0Ltd.\\xa0D. Wang:  ; Gracell Biotechnologies Co.,\\xa0Ltd.\\xa0X. Ye:  ; Gracell Biotechnologies Co.,\\xa0Ltd..\\xa0X. Tan: None.\\xa0R. Huang: None. J. Ge:  ; Gracell Biotechnologies Co.,\\xa0Ltd.\\xa0Y. Han:  ; Gracell Biotechnologies Co.,\\xa0Ltd..\\xa0D. Zhang: None.\\xa0Y. Wang: None.\\xa0L. Fang: None.\\xa0Y. Chen: None. W. Cao:  ; Gracell Biotechnologies Co.,\\xa0Ltd..\\xa0S. Wang: None.\\xa0X. Zhang: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-6': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10873',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:15 AM - 11:20 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-7': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10765',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:20 AM - 11:35 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Yvonne Y. Chen. UCLA, Los Angeles, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-8': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10874',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:35 AM - 11:40 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-9': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10761',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT053\\n                        \\n                         - Use of CRISPR knock-out screen to identify genes that regulate tumor cell sensitivity to NK cell-based immunotherapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:40 AM - 11:50 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Davide Bernareggi1, Qi Xie1, Briana Prager1, Li Xiqing1, Silvio Gutkind2, Dan S. Kaufman1. 1UCSD, La Jolla, CA; 2UCSD, Moores Cancer Center, La Jolla, CA ',\n",
       "  'Disclosures': '\\xa0D. Bernareggi: None.\\xa0Q. Xie: None.\\xa0B. Prager: None.\\xa0L. Xiqing: None.\\xa0S. Gutkind: None.\\xa0D.S. Kaufman: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-10': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10875',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:50 AM - 11:55 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-11': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10762',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT054\\n                        \\n                         - The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:55 AM - 12:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Henrieta Fraser1, Rebecca Pike1, Sarah Thirkell1, Asiya Arshad1, Sam Jide-Banwo1, Hollie Bartley1, Evi Rologi1, Michal Pruchniak1, Shreenal Patel1, Jennine Mootien1, Jane Robertson1, Andrew Craig1, Max Salm1, Katy Newton1, Luke Goodsell1, Fong Chan1, Gareth Wilson1, Stephen Frenk1, Iraj Ali1, Karl Peggs2, Mark W. Lowdell2, Lyra Del Rosio3, Andrew Hayes3, Samra Turajlic4, Farah Islam5, David Lawrence6, Mariam Jamal-Hanjani6, Martin D. Forster6, Edward Samuel1. 1Achilles Therapeutics, Stevenage, United Kingdom; 2University College London, London, United Kingdom; 3The Royal Marsden NHS Foundation Trust, London, United Kingdom; 4The Francis Crick Institute, London, United Kingdom; 5University College London Cancer Institute, London, United Kingdom; 6University College London Hospitals NHS Foundation Trust, London, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0H. Fraser:  ; Achilles Therapeutics. R. Pike:  ; Achilles Therapeutics. S. Thirkell:  ; Achilles Therapeutics. A. Arshad:  ; Achilles Therapeutics. S. Jide-Banwo:  ; Achilles Therapeutics. H. Bartley:  ; Achilles Therapeutics. E. Rologi:  ; Achilles Therapeutics. M. Pruchniak:  ; Achilles Therapeutics. S. Patel:  ; Achilles Therapeutics. J. Mootien:  ; Achilles Therapeutics. J. Robertson:  ; Achilles Therapeutics. A. Craig:  ; Achilles Therapeutics. M. Salm:  ; Achilles Therapeutics. K. Newton:  ; Achilles Therapeutics. L. Goodsell:  ; Achilles Therapeutics. F. Chan:  ; Achilles Therapeutics. G. Wilson:  ; Achilles Therapeutics. S. Frenk:  ; Achilles Therapeutics. I. Ali:  ; Achilles Therapeutics. K. Peggs:  ; Achilles Therapeutics. M.W. Lowdell:  ; Achilles Therapeutics.\\xa0L. Del Rosio: None.\\xa0A. Hayes: None.\\xa0S. Turajlic: None.\\xa0F. Islam: None.\\xa0D. Lawrence: None.\\xa0M. Jamal-Hanjani: None.\\xa0M.D. Forster: None. E. Samuel:  ; Achilles Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-12': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10876',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:05 PM - 12:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-13': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10960',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:10 PM - 12:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Theodore Roth. UCSF, San Francisco, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-14': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10877',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:25 PM - 12:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-15': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10798',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT055\\n                        \\n                         - Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:30 PM - 12:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Caron A. Jacobson1, Jason R. Westin2, David B. Miklos3, Alex F. Herrera4, Jennifer Lee5, Judy Seng5, John M. Rossi5, Jennifer Sun5, Jinghui Dong5, Zachary J. Roberts5, Remus Vezan5, Mauro P. Avanzi5, Frederick L. Locke6. 1Dana-Farber Cancer Institute, Boston, MA; 2University of Texas MD Anderson Cancer Center, Houston, TX; 3Stanford University School of Medicine, Stanford, CA; 4City of Hope National Medical Center, Duarte, CA; 5Kite, a Gilead Company, Santa Monica, CA; 6Moffitt Cancer Center, Tampa, FL ',\n",
       "  'Disclosures': \"\\xa0\\xa0C.A. Jacobson:  ; honoraria from Kite, a Gilead Company, Novartis, Pfizer, Celgene, Humanigen, Precision Biosciences, and Nkarta. ; consultancy or advisory role for Kite, a Gilead Company, Novartis, Celgene, Pfizer, Humanigen, Precision Biosciences, and Nkarta. ; speakers' bureau participation for Axis and Clinical Care Options. ; research funding from Pfizer. ; other; travel support from Kite, a Gilead Company, Celgene, Novartis, Pfizer, Humanigen, and Precision Biosciences.\\xa0J.R. Westin:  ; consultancy or advisory role for Kite, a Gilead Company, Novartis, Bristol-Myers Squibb, Genentech, Morphosys, Curis, and Janssen. ; research funding from Kite, a Gilead Company, Novartis, Bristol-Myers Squibb, Janssen, Genentech, Unum, and Curis, 47.\\xa0D.B. Miklos:  ; consultancy or advisory role for Kite, a Gilead Company, Novartis, Juno-Celgene-BMS, Adaptive Biotechnologies, Pharmacyclics, and Janssen. ; research funding from Kite, a Gilead Company, Novartis, Juno-Celgene-BMS, Adaptive Biotechnologies, and Pharmacyclics. ; other; patents, royalties, or other intellectual property from Pharmacyclics. ; other; travel support from Kite, a Gilead Company, Novartis, Juno-Celgene-BMS, Adaptive Biotechnologies, Pharmacyclics, and Janssen.\\xa0A.F. Herrera:  ; consultancy or advisory role for Bristol-Myers Squibb, Merck, Genentech, Gilead Sciences, and Adaptive Biotechnologies. ; research funding from Bristol-Myers Squibb, Merck, Genentech, Seattle Genetics, Immune Design, AstraZeneca, and Gilead Sciences. J. Lee:  ; employment with Kite, a Gilead Company. ; stock or other ownership in Gilead Sciences. J. Seng:  ; employment with Kite, a Gilead Company. J.M. Rossi:  ; employment with Kite, a Gilead Company. ; stock or other ownership in Gilead Sciences. J. Sun:  ; employment with Kite, a Gilead Company. J. Dong:  ; employment with Kite, a Gilead Company, and prior employment with GliaCure, Inc.. ; consultancy or advisory role for GliaCure, Inc.. ; other; patents, royalties, or other intellectual property from Patent US8598141 (Dec 03, 2013). Z.J. Roberts:  ; employment with Kite, a Gilead Company. ; stock or other ownership in Gilead Sciences. R. Vezan:  ; employment with Kite, a Gilead Company. ; stock or other ownership in Gilead Sciences, AbbVie, and Merck. M.P. Avanzi:  ; employment with Kite, a Gilead Company. ; stock or other ownership in Gilead Sciences. ; other; patents, royalties, or other intellectual property from MSKCC. ; other; travel support from Kite, a Gilead Company. F.L. Locke:  ; stock or other ownership in Cellular Biomedicine Group. ; consultancy or advisory role for Novartis, Celgene/BMS, Cellular Biomedicine Group, GammaDelta Therapeutics, Calibr, Wugen, and, Allogene. ; research funding from Kite, a Gilead Company. ; patents, royalties, or other intellectual property from; double mutant surviving vaccine, mathematical modeling of T cell therapy, methods of enhancing CAR T cell therapies, CAR T cells with enhanced metabolic fitnessmes, and PGC-1 alpha.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-16': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10878',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:40 PM - 12:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '854-17': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10763',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT056\\n                        \\n                         - Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:45 PM - 12:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ben Creelan1, Chao Wang1, Jamie Teer1, Eric Toloza1, John Mullinax1, Jiqiang Yao1, John Koomen1, Sungjune Kim1, Alberto Chiappori1, James Saller1, Leighann Montoya1, Ana Marie Landin1, Tawee Tanvetyanon1, Bin Fang1, Zachary Thompson1, Xiaoping Yu1, Andreas Saltos1, Dung-Tsa Chen1, Jose Conejo-Garcia1, Eric Haura1, Scott Antonia2. 1H. Lee Moffitt Cancer Center, Tampa, FL; 2Duke Cancer Institute, Durham, NC ',\n",
       "  'Disclosures': '\\xa0\\xa0B. Creelan:  ; Iovance Biotherapeutics Inc. ; Advisory Board Participation; E.R. Squibb LLC. ; F. Hoffmann-La Roche AG. ; AstraZeneca plc. ; Advisory Board Participation; KSQ Therapeutics Inc. ; Clinigen Group plc. ; Advisory Board Participation; GlaxoSmithKline plc. ; Advisory Board Participation; Gilead Sciences inc. ; ARIAD Pharmaceuticals, Inc. ; NeoGenomics Laboratories. ; Adaptive Biotechnologies Corp..\\xa0C. Wang: None.\\xa0J. Teer: None. E. Toloza:  ; Covidien LP. ; Davol Inc.. ; Neomend, Inc.. ; Pinnacle Biologics, Inc. J. Mullinax:  ; Advisory Participation; KCI USA, Inc. ; Advisory Participation; Davol Inc..\\xa0J. Yao: None.\\xa0J. Koomen: None. S. Kim:  ; Bristol-Myers. ; AstraZeneca LLC. ; Huya Biosciences. A. Chiappori:  ; Takeda Pharmaceuticals U.S.A., Inc.. ; Genentech USA, Inc.. ; Merck Sharp & Dohme Corporation. ; Celgene Corporation. ; AbbVie, Inc.. ; PFIZER INC.. ; Boehringer Ingelheim Pharmaceuticals, Inc.. ; Millennium Pharmaceuticals, Inc.. ; Novartis Pharmaceuticals Corporation. ; AstraZeneca Pharmaceuticals LP. ; ARIAD Pharmaceuticals, Inc.. ; E.R. Squibb & Sons, L.L.C..\\xa0J. Saller: None.\\xa0L. Montoya: None. A. Landin:  ; Iovance Biotherapeutics Inc.\\xa0T. Tanvetyanon: None.\\xa0B. Fang: None.\\xa0Z. Thompson: None.\\xa0X. Yu: None. A. Saltos:  ; Travel Conference; Daiichi Sankyo Inc..\\xa0D. Chen: None. J. Conejo-Garcia:  ; Compass Therapeutics. ; Anixa Bioscience. ; Leidos. E. Haura:  ; Advisory Board Participation; F. Hoffmann-La Roche AG. ; Advisory Board Participation; Janssen Research & Development LLC. ; Advisory Board Participation; Ventana Medical Systems. S. Antonia:  ; Advisory Board Participation; CBMG. ; AstraZeneca plc. ; F Hoffman Le Roche AG. ; Amgen Inc.. ; Regeneron Inc. ; Eli-Lilly and Co. ; E.R. Squibb & Sons, L.L.C.. ; Novartis Pharmaceuticals Corporation.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-18': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10879',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT056\\n                        \\n                         - Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:45 PM - 12:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ben Creelan1, Chao Wang1, Jamie Teer1, Eric Toloza1, John Mullinax1, Jiqiang Yao1, John Koomen1, Sungjune Kim1, Alberto Chiappori1, James Saller1, Leighann Montoya1, Ana Marie Landin1, Tawee Tanvetyanon1, Bin Fang1, Zachary Thompson1, Xiaoping Yu1, Andreas Saltos1, Dung-Tsa Chen1, Jose Conejo-Garcia1, Eric Haura1, Scott Antonia2. 1H. Lee Moffitt Cancer Center, Tampa, FL; 2Duke Cancer Institute, Durham, NC ',\n",
       "  'Disclosures': '\\xa0\\xa0B. Creelan:  ; Iovance Biotherapeutics Inc. ; Advisory Board Participation; E.R. Squibb LLC. ; F. Hoffmann-La Roche AG. ; AstraZeneca plc. ; Advisory Board Participation; KSQ Therapeutics Inc. ; Clinigen Group plc. ; Advisory Board Participation; GlaxoSmithKline plc. ; Advisory Board Participation; Gilead Sciences inc. ; ARIAD Pharmaceuticals, Inc. ; NeoGenomics Laboratories. ; Adaptive Biotechnologies Corp..\\xa0C. Wang: None.\\xa0J. Teer: None. E. Toloza:  ; Covidien LP. ; Davol Inc.. ; Neomend, Inc.. ; Pinnacle Biologics, Inc. J. Mullinax:  ; Advisory Participation; KCI USA, Inc. ; Advisory Participation; Davol Inc..\\xa0J. Yao: None.\\xa0J. Koomen: None. S. Kim:  ; Bristol-Myers. ; AstraZeneca LLC. ; Huya Biosciences. A. Chiappori:  ; Takeda Pharmaceuticals U.S.A., Inc.. ; Genentech USA, Inc.. ; Merck Sharp & Dohme Corporation. ; Celgene Corporation. ; AbbVie, Inc.. ; PFIZER INC.. ; Boehringer Ingelheim Pharmaceuticals, Inc.. ; Millennium Pharmaceuticals, Inc.. ; Novartis Pharmaceuticals Corporation. ; AstraZeneca Pharmaceuticals LP. ; ARIAD Pharmaceuticals, Inc.. ; E.R. Squibb & Sons, L.L.C..\\xa0J. Saller: None.\\xa0L. Montoya: None. A. Landin:  ; Iovance Biotherapeutics Inc.\\xa0T. Tanvetyanon: None.\\xa0B. Fang: None.\\xa0Z. Thompson: None.\\xa0X. Yu: None. A. Saltos:  ; Travel Conference; Daiichi Sankyo Inc..\\xa0D. Chen: None. J. Conejo-Garcia:  ; Compass Therapeutics. ; Anixa Bioscience. ; Leidos. E. Haura:  ; Advisory Board Participation; F. Hoffmann-La Roche AG. ; Advisory Board Participation; Janssen Research & Development LLC. ; Advisory Board Participation; Ventana Medical Systems. S. Antonia:  ; Advisory Board Participation; CBMG. ; AstraZeneca plc. ; F Hoffman Le Roche AG. ; Amgen Inc.. ; Regeneron Inc. ; Eli-Lilly and Co. ; E.R. Squibb & Sons, L.L.C.. ; Novartis Pharmaceuticals Corporation.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-19': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10766',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:00 PM - 1:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Gal Markel. Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat-Gan, Israel',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '854-20': {'Session Title': ' VCTPL05. Adoptive Cell Transfer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Clinical Research Excluding Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10880',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 1:20 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:15 PM - 1:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-1': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10772',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:55 PM - 1:56 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Dawn Hershman. Columbia University Irving Comp. Cancer Center, New York, NY',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-2': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10886',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:55 PM - 2:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-3': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10773',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT071\\n                        \\n                         - Talazoparib (TALA) in germline BRCA1/2 (gBRCA1/2)-mutated human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): Final overall survival (OS) results from randomized Phase 3 EMBRACA trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:00 PM - 2:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jennifer K. Litton1, Sara A. Hurvitz2, Lida A. Mina3, Hope S. Rugo4, Kyung-Hun Lee5, Anthony Gonalves6, Sami Diab7, Natasha Woodward8, Annabel Goodwin9, Rinat Yerushalmi10, Henri Roch11, Young-Hyuck Im12, Wolfgang Eiermann13, Ruben G. W. Quek14, Tiziana Usari15, Silvana Lanzalone15, Akos Czibere16, Joanne L. Blum17, Miguel Martin18, Johannes Ettl19. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; 3Banner M.D. Anderson Cancer Center, Gilbert, AZ; 4University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 5Seoul National University Hospital, Seoul, Korea, Republic of; 6Institut PaoliCalmettes, Marseille, France; 7Rocky Mountain Cancer Centers, Littleton, CO; 8Mater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Queensland, Australia; 9Medical Oncology Department, Concord Repatriation General Hospital, Concord, New South Wales, Australia; 10Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; 11Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France; 12Samsung Medical Center, Seoul, Korea, Republic of; 13Interdisziplinres Onkologisches Zentrum Mnchen, Munich, Germany; 14Pfizer Inc., San Francisco, CA; 15Pfizer Oncology, Milan, Italy; 16Pfizer Inc., Cambridge, MA; 17Texas OncologyBaylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; 18Instituto de Investigacin Sanitaria Gregorio Maran, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; 19Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universitt Mnchen, Munich, Germany ',\n",
       "  'Disclosures': \"\\xa0\\xa0J.K. Litton:  ; Reports grant or research support; Novartis. ; Reports grant or research support, membership on advisory committees or review panels, or board membership (uncompensated); Pfizer. ; Reports grant or research support; Genentech. ; Reports grant or research support; GSK. ; Reports grant or research support; EMD-Serono. ; Reports grant or research support, membership on advisory committees or review panels, or board membership (uncompensated); AstraZeneca. ; Reports grant or research support; MedImmune. ; Reports fees for speakers bureaus; Med Learning Group. ; Reports fees for speakers bureaus; Physician's Education Resource. ; Reports fees for speakers bureaus; Prime Oncology. ; Reports fees for speakers bureaus; Medscape. ; Reports fees for speakers bureaus; Medpage. ; Reports fees for speakers bureaus; Clinical Care Options. ; Reports honoraria; UpToDate. ; membership on advisory committees or review panels, or board membership (uncompensated); Ayala Pharmaceuticals. ; membership on review panels; NCCN. ; membership on review panels; ASCO. ; membership on review panels; NIH PDQ. ; Employment; University of Texas MD Anderson Cancer Center. S.A. Hurvitz:  ; Contracted research support and editorial assistance; Ambrx. ; Contracted research support and editorial assistance; Amgen. ; Contracted research support and editorial assistance; Bayer. ; Contracted research support and editorial assistance; Daiichi-Sankyo. ; Contracted research support and editorial assistance; Genentech/Roche. ; Contracted research support and editorial assistance; GSK. ; Contracted research support and editorial assistance; Immunomedics. ; Contracted research support and editorial assistance; Lilly. ; Contracted research support and editorial assistance; MacroGenics. ; Contracted research support and editorial assistance; Novartis. ; Contracted research support and editorial assistance; Pfizer. ; Contracted research support and editorial assistance; OBI Pharma. ; Contracted research support and editorial assistance; Pieris. ; Contracted research support and editorial assistance; PUMA. ; Contracted research support and editorial assistance; Radius. ; Contracted research support and editorial assistance; Sanofi. ; Contracted research support and editorial assistance; Seattle Genetics. ; Contracted research support and editorial assistance; Dignitana.\\xa0L.A. Mina: None. H.S. Rugo:  ; Reports research support to the University of California San Francisco; Eisai. ; Reports research support to the University of California San Francisco; Roche/Genentech. ; Reports research support to the University of California San Francisco; Eli Lilly. ; Reports research support to the University of California San Francisco; MacroGenics. ; Reports research support to the University of California San Francisco; Merck. ; Reports research support to the University of California San Francisco; OBI Pharma. ; Reports research support to the University of California San Francisco; Odonate. ; Reports research support to the University of California San Francisco; Immunomedics. ; Reports research support to the University of California San Francisco; Daiichi-Sankyo. ; Reports research support to the University of California San Francisco, travel support; Novartis. ; Reports research support to the University of California San Francisco, travel support; Pfizer. ; Travel support; Mylan. K. Lee:  ; Reports honoraria, participated in advisory boards; Roche. ; Reports honoraria, participated in advisory boards; AstraZeneca. ; Participated in advisory boards; Bayer. ; Participated in advisory boards; Ono Pharmaceutical. ; Participated in advisory boards; Samsung Bioepis. ; Participated in advisory boards; Eisai. A. Gonalves:  ; Reports travel/accommodation/meeting registration fees; Pfizer. ; Reports travel/accommodation/meeting registration fees; AstraZeneca. ; Reports travel/accommodation/meeting registration fees; Roche. ; Reports travel/accommodation/meeting registration fees; Novartis. S. Diab:  ; Speaker and advisor; Pfizer. ; Speaker and advisor; Novartis. ; Speaker and advisor; Puma. ; Speaker and advisor; Eli Lilly. ; Speaker and advisor; Clovis. ; Speaker and advisor; Genentech. ; Speaker and advisor; AstraZeneca. ; Speaker and advisor; Genomic Heath. ; Speaker and advisor; Agendia. N. Woodward:  ; Stock and ownership; CSL Behring. ; Reports research funding (institution); Medivation. ; Reports honoraria from advisory board; Novartis. ; Reports honoraria from advisory board; Pfizer. ; Consultancy fees, honoraria from advisory board and travel and accommodation fees; Roche. A. Goodwin:  ; Reports honoraria; AstraZeneca. ; Participation in advisory board; Pfizer. R. Yerushalmi:  ; Reports consulting fees, has been a speaker and reports a grant; Roche. ; Reports consulting fees, has been a speaker; Pfizer. ; Reports consulting fees, has been a speaker; Novartis. ; Reports consulting fees; Eli Lilly. ; Has been a speaker; Teva. ; Has been a speaker; Medison. ; Has been a speaker; MSD. ; Has been a speaker; AstraZeneca.\\xa0H. Roch: None.\\xa0Y. Im: None.\\xa0W. Eiermann: None. R.G.W. Quek:  ; Employment and ownership interest; Pfizer. ; Ownership interest; Amgen. T. Usari:  ; Employment and ownership interest; Pfizer. S. Lanzalone:  ; Employment and ownership interest; Pfizer. A. Czibere:  ; Employment and ownership interest; Pfizer. J.L. Blum:  ; Reports consulting fees; Pfizer. ; Reports consulting fees; Medivation. ; Reports consulting fees; Amgen. ; Reports consulting fees; Novartis. ; Reports consulting fees; Genomic Health. ; Reports consulting fees; Daiichi-Sankyo. ; Reports consulting fees; Myriad Genetics. M. Martin:  ; Reports grants, consulting fees; Roche. ; Reports grants, consulting fees; Novartis. ; Reports consulting fees; AstraZeneca. ; Reports consulting fees; GSK. ; Reports consulting fees; Eli Lilly. ; Reports consulting fees; Amgen. ; Reports consulting fees; Taiho. ; Reports consulting fees; Pharmamar. ; Reports consulting fees; Puma. ; Reports consulting fees; Pfizer. J. Ettl:  ; Reports contracted research; Seattle Genetics. ; Reports contracted research; Odonate. ; Reports consulting fees, contracted research; Roche. ; Reports contracted research and travel support; AstraZeneca. ; Reports consulting fees, contracted research, travel support; Pfizer. ; Reports consulting fees, contracted research, travel support; Novartis. ; Reports consulting fees, contracted research, travel support; Lilly. ; Reports consulting fees, travel support; Tesaro. ; Reports travel support; Celgene.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-4': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10887',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:10 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-5': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10774',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT072\\n                        \\n                         - Exploration of impact of tumor BRCA zygosity and genomic loss-of-heterozygosity (gLOH) on efficacy in Phase 3 EMBRACA study of talazoparib in patients (pts) with HER2-negative (HER2) advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA1/2) mutation\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:15 PM - 2:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jennifer K. Litton1, A. Douglas Laird2, Hope S. Rugo3, Johannes Ettl4, Sara A. Hurvitz5, Miguel Martin6, Henri Roch7, Young-Hyuck Im8, Annabel Goodwin9, Joanne L. Blum10, Wolfgang Eiermann11, Ying Chen12, Silvana Lanzalone13, Jijumon Chelliserry12, Akos Czibere14, Lee A. Albacker15, Garrett M. Frampton15, Lida A. Mina16. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2Pfizer Inc., San Francisco, CA; 3University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 4Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universitt Mnchen, Munich, Germany; 5University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; 6Instituto de Investigacin Sanitaria Gregorio Maran, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain; 7Institut Universitaire du Cancer de Toulouse, Toulouse, France; 8Samsung Medical Center, Seoul, Korea, Republic of; 9Concord Clinical School, University of Sydney, Sydney, NSW, Australia; 10Texas OncologyBaylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, TX; 11Interdisziplinres Onkologisches Zentrum Mnchen, Munich, Germany; 12Pfizer Inc., San Diego, CA; 13Pfizer Inc., Milan, Italy; 14Pfizer Inc., Cambridge, MA; 15Foundation Medicine Inc., Cambridge, MA; 16Banner MD Anderson Cancer Center, Gilbert, AZ ',\n",
       "  'Disclosures': \"\\xa0\\xa0J.K. Litton:  ; Reports grant or research support; Novartis. ; Reports grant or research support, Membership on advisory committees or review panels, or board membership (all uncompensated); Pfizer. ; Reports grant or research support; Genentech. ; Reports grant or research support; GSK. ; Reports grant or research support; EMD-Serono. ; Reports grant or research support, Membership on advisory committees or review panels, or board membership (all uncompensated); AstraZeneca. ; Reports grant or research support; MedImmune. ; Fees for speakers bureaus; Med Learning Group. ; Fees for speakers bureaus; Physician's Education Resource. ; Fees for speakers bureaus; Prime Oncology. ; Fees for speakers bureaus; Medscape. ; Fees for speakers bureaus; Medpage. ; Fees for speakers bureaus; Clinical Care Options. ; Honoraria; UpToDate. ; Membership on advisory committees or review panels, or board membership (all uncompensated); Ayala Pharmaceuticals. ; Membership on review panels; NCCN. ; Membership on review panels; ASCO. ; Membership on review panels; NIH PDQ. ; Employment; University of Texas MD Anderson Cancer Center. A.D. Laird:  ; Employee and owns stock; Pfizer. H.S. Rugo:  ; Reports research support to the University of California San Francisco; Eisai. ; Reports research support to the University of California San Francisco; Roche/Genentech. ; Reports research support to the University of California San Francisco; Eli Lilly. ; Reports research support to the University of California San Francisco; MacroGenics. ; Reports research support to the University of California San Francisco; Merck. ; Reports research support to the University of California San Francisco, Travel support; Novartis. ; Reports research support to the University of California San Francisco; OBI Pharma. ; Reports research support to the University of California San Francisco; Odonate. ; Reports research support to the University of California San Francisco; Immunomedics. ; Reports research support to the University of California San Francisco; Daiichi-Sankyo. ; Reports research support to the University of California San Francisco, Travel support; Pfizer. ; Travel support; Mylan. J. Ettl:  ; Received consulting fees, contracted research, travel support; Pfizer. ; Received consulting fees, contracted research, travel support; Novartis. ; Received consulting fees, contracted research, travel suppport; Lilly. ; Received consulting fees, contracted research; Roche. ; Received consulting fees, travel support; Tesaro. ; Contracted research; Seattle Genetics. ; Contracted research, travel support; AstraZeneca. ; Contracted research; Odonate. ; Travel support; Celgene. S.A. Hurvitz:  ; Contracted research support and editorial assistance; Ambrx. ; Contracted research support and editorial assistance; Amgen. ; Contracted research support and editorial assistance; Bayer. ; Contracted research support and editorial assistance; Daiichi-Sankyo. ; Contracted research support and editorial assistance; Genentech/Roche. ; Contracted research support and editorial assistance; GSK. ; Contracted research support and editorial assistance; Immunomedics. ; Contracted research support and editorial assistance; Lilly. ; Contracted research support and editorial assistance; MacroGenics. ; Contracted research support and editorial assistance; Novartis. ; Contracted research support and editorial assistance; Pfizer. ; Contracted research support and editorial assistance; OBI Pharma. ; Contracted research support and editorial assistance; Pieris. ; Contracted research support and editorial assistance; PUMA. ; Contracted research support and editorial assistance; Radius. ; Contracted research support and editorial assistance; Sanofi. ; Contracted research support and editorial assistance; Seattle Genetics. ; Contracted research support and editorial assistance; Dignitana. M. Martin:  ; Reports grants, consulting fees; Roche. ; Reports grants, consulting fees; Novartis. ; Reports consulting fees; AstraZeneca. ; Reports consulting fees; GSK. ; Reports consulting fees; Eli Lilly. ; Reports consulting fees; Amgen. ; Reports consulting fees; Taiho. ; Reports consulting fees; Pharmamar. ; Reports consulting fees; Puma. ; Reports consulting fees; Pfizer.\\xa0H. Roch: None.\\xa0Y. Im: None. A. Goodwin:  ; Reports honoraria; AstraZeneca. ; Participation in advisory boards; Pfizer. J.L. Blum:  ; Reports consulting fees; Pfizer. ; Reports consulting fees; Medivation. ; Reports consulting fees; Amgen. ; Reports consulting fees; Novartis. ; Reports consulting fees; Genomic Health. ; Reports consulting fees; Daiichi-Sankyo. ; Reports consulting fees; Myriad Genetics.\\xa0W. Eiermann: None. Y. Chen:  ; Contractor; Pfizer. S. Lanzalone:  ; Employee and owns stock; Pfizer. J. Chelliserry:  ; Employee and owns stock; Pfizer. A. Czibere:  ; Employee and owns stock; Pfizer. L.A. Albacker:  ; Employee; Foundation Medicine Inc.. ; Shareholder; of Roche Holding AG. G.M. Frampton:  ; Employee; Foundation Medicine Inc.. ; Shareholder; Roche Holding AG.\\xa0L.A. Mina: None.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-6': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10888',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:25 PM - 2:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-7': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10778',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:30 PM - 2:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Susan M. Domchek. Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-8': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10889',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:45 PM - 2:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-9': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10775',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT073\\n                        \\n                         - IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:50 PM - 3:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Steven J. O'Day1, Virginia F. Borges2, Bartosz Chmielowski3, Ruta D. Rao4, Maysa Abu-Khalaf5, Alison Stopeck6, Joyce A. O'Shaughnessy7, Michael Chisamore8, Vassiliki Karantza8, Joanna Cox9, Paulette Mattson9, Michele A. Gargano10, Bruno Osterwalder11, Mark Uhlik9, Nandita Bose9, Jeremy Graff12. 1John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA; 2University of Colorado Denver, Aurora, CO; 3Ronald Reagan UCLA Medical Center, Santa Monica, CA; 4Rush University Medical Center, Chicago, IL; 5Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, PA; 6Stony Brook Cancer Center, Stony Brook, NY; 7Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX; 8Merck & Co., Inc., Kenilworth, NJ; 9Biothera Pharmaceuticals, Inc., Roseville, MN; 10Biothera Pharmaceuticals, Inc., Eagan, MN; 11B.O. Consulting GmbH, Riehen, Switzerland; 12Biothera Pharmaceuticals, Inc., Rosesville, MN \",\n",
       "  'Disclosures': \"\\xa0\\xa0S.J. O'Day:  ; Biothera Pharmaceuticals. ; Merck.\\xa0V.F. Borges: None. B. Chmielowski:  ; Bristol-Meyers Squibb. ; Merck. ; Genentech/ Roche. ; Iovance Biotherapeutics. ; HUYA Bioscience International. ; Biothera Pharmaceuticals. ; Janssen. ; Novartis. ; Lilly/ ImClone. ; GlaxoSmithKline. ; Incyte. ; AstraZeneca. ; Bristol-Myers Squibb. ; Macrogenics. ; Array BioPharma. ; EMDSerono. ; Daiichi Sankyo. ; Karyopharm Therapeutics. ; Rgenix. ; Immunocore. R.D. Rao:  ; Puma. ; Eisai. ; Genentech. M. Abu-Khalaf:  ; Biothera Pharmaceuticals. ; Pfizer. ; Puma. ; Agedia. ; Immunomedics. ; Novartis. A. Stopeck:  ; Biothera Pharmaceuticals. ; Amgen. ; Sandoz. ; Macrogenics. ; Novartis. ; Genomic Health. J.A. O'Shaughnessy:  ; Biothera Pharmaceuticals. M. Chisamore:  ; Merck. V. Karantza:  ; Merck. J. Cox:  ; Biothera. P. Mattson:  ; Biothera. M.A. Gargano:  ; Biothera Pharmaceuticals. B. Osterwalder:  ; Biothera. M. Uhlik:  ; Biothera. N. Bose:  ; Biothera. J. Graff:  ; Biothera.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-10': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10890',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:00 PM - 3:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-11': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10776',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT074\\n                        \\n                         - Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:05 PM - 3:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Malin Dahlgren1, Anthony M. George1, Christian Brueffer1, Sergii Gladchuk1, Yilun Chen1, Johan Vallon-Christersson1, Cecilia Hegardt1, Jari Hkkinen1, Lisa Rydn2, Martin Malmberg2, Christer Larsson1, Sofia K. Gruvberger-Saal1, Anna Ehinger2, Niklas Loman2, ke Borg1, Lao H. Saal1. 1Lund University, Lund, Sweden; 2Skne University Hospital, Lund, Sweden ',\n",
       "  'Disclosures': '\\xa0M. Dahlgren: None. A.M. George:  ; SAGA Diagnostics AB. C. Brueffer:  ; SAGA Diagnostics AB. S. Gladchuk:  ; SAGA Diagnostics AB. Y. Chen:  ; SAGA Diagnostics AB.\\xa0J. Vallon-Christersson: None.\\xa0C. Hegardt: None.\\xa0J. Hkkinen: None.\\xa0L. Rydn: None.\\xa0M. Malmberg: None.\\xa0C. Larsson: None.\\xa0S.K. Gruvberger-Saal: None.\\xa0A. Ehinger: None.\\xa0N. Loman: None.\\xa0. Borg: None. L.H. Saal:  ; Novartis. ; Boehringer-Ingelheim. ; SAGA Diagnostics AB.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-12': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10891',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:15 PM - 3:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-13': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10779',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:20 PM - 3:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ben Ho Park. Vanderbilt-Ingram Cancer Center, Nashville, TN',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-14': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10892',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:35 PM - 3:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-15': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10777',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT075\\n                        \\n                         - Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:40 PM - 3:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Irene Caffa1, Vanessa Spagnolo2, Pamela Becherini1, Francesca Valdemarin1, Claudio Vernieri3, Min Wei4, Sebastian Brandhorst4, Chiara Zucal5, Else Driehuis6, Lorenzo Ferrando1, Luca Mastracci7, Michele Cilli7, Francesco Piacente1, Anna Laura Cremonini1, Mario Passalacqua8, Valerio Vellone7, Gabriele Zoppoli1, Michele Cea1, Giulia Salvadori2, Salvatore Cortellino3, Hans Clevers6, Filippo De Braud2, Alessandro Provenzani9, Valter D. Longo4, Alessio Nencioni1. 1Department of Internal Medicine, University of Genoa, Genova, Italy; 2Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy, Milano, Italy; 3IFOM, FIRC Institute of Molecular Oncology, Milan, Italy;, Milan, Italy; 4Longevity Institute and Davis School of Gerontology, University of Southern California, Los Angeles, CA, US., Los Angeles, CA; 5Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, 3584 CT Utrecht, The Netherlands, Utrecht, Netherlands; 6Center For Integrative Biology (CIBIO), University of Trento, via Sommarive 9, Trento, Italy;, Trento, Italy; 7IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genoa, Italy;, Genova, Italy; 8Department of Experimental Medicine and CEBR, University of Genoa, Viale Benedetto XV 1, 16132 Genoa, Italy, Genova, Italy; 9Center For Integrative Biology (CIBIO), University of Trento, via Sommarive 9, Trento, Italy, Trento, Italy ',\n",
       "  'Disclosures': '\\xa0I. Caffa: None.\\xa0V. Spagnolo: None.\\xa0P. Becherini: None.\\xa0F. Valdemarin: None.\\xa0C. Vernieri: None.\\xa0M. Wei: None.\\xa0S. Brandhorst: None.\\xa0C. Zucal: None.\\xa0E. Driehuis: None.\\xa0L. Ferrando: None.\\xa0L. Mastracci: None.\\xa0M. Cilli: None.\\xa0F. Piacente: None.\\xa0A. Cremonini: None.\\xa0M. Passalacqua: None.\\xa0V. Vellone: None.\\xa0G. Zoppoli: None.\\xa0M. Cea: None.\\xa0G. Salvadori: None.\\xa0S. Cortellino: None.\\xa0H. Clevers: None.\\xa0F. De Braud: None.\\xa0A. Provenzani: None.\\xa0V. Longo: None.\\xa0A. Nencioni: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-16': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10893',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:50 PM - 3:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '856-17': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10802',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:55 PM - 4:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Lewis C. Cantley. Weill Cornell Medicine, New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '856-18': {'Session Title': ' VCTPL07. Breast Cancer Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Research Excluding Trials,Prevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10894',\n",
       "  'Date': ' April 27, 2020, 1:55 PM - 4:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:10 PM - 4:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '35-1': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/97',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Cochair\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:45 AM - 12:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Philip Jones. UT MD Anderson Cancer Center, Houston, TX',\n",
       "  'Disclosures': '\\xa0P. Jones: None.',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '35-2': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/234',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Cochair\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:45 AM - 12:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Sara J. Buhrlage. Dana-Farber Cancer Institute, Boston, MA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '35-3': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/2167',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT02-01\\n                        \\n                         - RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:50 AM - 11:10 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Melissa M. Vasbinder, Joseph M. Gozgit, Ryan P. Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Z. Lu, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina P. Nayak, Ellen Bamberg, Jan-Rung Mo, W David Church, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack. Ribon Therapeutics, Inc, Cambridge, MA, Ribon Therapeutics, Inc, Cambridge, MA, Harvard Medical School, Boston, MA',\n",
       "  'Disclosures': '\\xa0M. M. Vasbinder,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). J. M. Gozgit,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). R. P. Abo,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). K. Kunii,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). K. G. Kuplast-Barr,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). B. Gui,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). A. Z. Lu,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). K. K. Swinger,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). T. J. Wigle,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). D. J. Blackwell,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). C. R. Majer,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). Y. Ren,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). M. Niepel,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). Z. A. Varsamis,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). S. P. Nayak,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). E. Bamberg,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). J. Mo,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). W. D. Church,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). J. Song,  RIBON THERAPEUTICS, INC Consultant/Independent Contractor. L. Utley,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). P. E. Rao,  RIBON THERAPEUTICS, INC Consultant/Independent Contractor. T. J. Mitchison,  RIBON THERAPEUTICS, INC Advisor/Board Member, Consultant/Independent Contractor, Stock Shareholder (self managed). Harvard Medical School Full-time/Part-time Employee. K. W. Kuntz,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). V. M. Richon,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed). H. Keilhack,  RIBON THERAPEUTICS, INC Full-time/Part-time Employee, Stock Shareholder (self managed).',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '35-4': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/6845',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT02-03\\n                        \\n                         - TAK-788: An EGFR inhibitor, currently in Phase II clinical trials, targeting lung cancers with Exon20 insertion mutations\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:15 AM - 11:35 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Francois Gonzalvez. Takeda Pharmaceuticals International Co., Cambridge, MA',\n",
       "  'Disclosures': '\\xa0F. Gonzalvez,  Takeda Full-time/Part-time Employee.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '35-5': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/2228',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT02-04\\n                        \\n                         - AMG 509: A novel, humanized, half-Life extended, bispecific STEAP1  CD3 T cell recruiting XmAb 2+1 antibody\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:40 AM - 12:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Olivier Nolan-Stevaux. Amgen Inc, South San Francisco, CA',\n",
       "  'Disclosures': '\\xa0O. Nolan-Stevaux,  Amgen, Inc Full-time/Part-time Employee, Stock Shareholder (self managed). Xencor, Inc Other, AMG 509 is being developed in partnership with Xencor Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '35-6': {'Session Title': ' VSY.DDT02. New Drugs on the Horizon: Part 2',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/2250',\n",
       "  'Date': ' April 28, 2020, 10:45 AM - 12:35 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT02-05\\n                        \\n                         - GDC-9545: Discovery of an oral estrogen receptor antagonist, degrader, and immobilizer for the treatment of ER+ breast cancer patients\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:05 PM - 12:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Xiaojing Wang, Xiaojing Wang. Genentech, Inc., South San Francisco, CA, Genentech, Inc., South San Francisco, CA',\n",
       "  'Disclosures': '\\xa0X. Wang,  Genentech Inc Full-time/Part-time Employee.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-1': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10703',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT261\\n                        \\n                         - METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Paolo Luraghi1, Luca Lazzari1, Maria Vittoria Dieci2, Serena Bellani1, Chiara Soffientini1, Rosario Rizzuto2, Antonio Rosato2, Vincenzo Costanzo1, Giorgio Scita1, Giannino Del Sal3, Massimiliano Pagani4, Marco Foiani1, Claudio Tripodo5, Silvio Bicciato6, Giovanni Blandino7, Alberto Zambelli8, Valter Torri9, Matteo Fassan2, PierFranco Conte2, Silvia Marsoni1, Stefano Piccolo2. 1IFOM - the FIRC Institute of Molecular Oncology, Milano, Italy; 2Universit degli Studi di Padova, Padova, Italy; 3CIB - Consorzio Interuniversitario per le Biotecnologie, trieste, Italy; 4Universit degli studi di Milano, Milano, Italy; 5University of Palermo School of Medicine, Palermo, Italy; 6Universit degli Studi di Modena e Reggio Emilia, Modena, Italy; 7Istituto Nazionale Tumori Regina Elena (IRE) I.R.C.C.S., Roma, Italy; 8ASST Papa Giovanni XXIII di Bergamo, Bergamo, Italy; 9Istituto di Ricerche Farmacologiche \"Mario Negri\" I.R.C.C.S., Milano, Italy ',\n",
       "  'Disclosures': '\\xa0P. Luraghi: None.\\xa0L. Lazzari: None.\\xa0M. Dieci: None.\\xa0S. Bellani: None.\\xa0C. Soffientini: None.\\xa0R. Rizzuto: None.\\xa0A. Rosato: None.\\xa0V. Costanzo: None.\\xa0G. Scita: None.\\xa0G. Del Sal: None.\\xa0M. Pagani: None.\\xa0M. Foiani: None.\\xa0C. Tripodo: None.\\xa0S. Bicciato: None.\\xa0G. Blandino: None.\\xa0A. Zambelli: None.\\xa0V. Torri: None.\\xa0M. Fassan: None.\\xa0P. Conte: None.\\xa0S. Marsoni: None.\\xa0S. Piccolo: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-2': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10704',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT262\\n                        \\n                         - Multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in HR-positive, HER2-positive metastatic breast cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Krystal Pauline Cascetta, Poulikos Poulikakos, Charles Shapiro, Julie Fasano, Aarti Bhardwaj, Hanna Irie, Anupama Goel, Paula Klein, Meng Ru, Amy Tiersten. Icahn School of Medicine at Mount Sinai, New York, NY ',\n",
       "  'Disclosures': '\\xa0K.P. Cascetta: None.\\xa0P. Poulikakos: None.\\xa0C. Shapiro: None.\\xa0J. Fasano: None.\\xa0A. Bhardwaj: None.\\xa0H. Irie: None.\\xa0A. Goel: None.\\xa0P. Klein: None.\\xa0M. Ru: None. A. Tiersten:  ; AstraZeneca. ; Cowen. ; Tersera. ; F. Hoffmann-La Roche Ltd.. ; Novartis. ; Eisai Inc.. ; Immunomedics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-3': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10705',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT263\\n                        \\n                         - Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Elena Elez1, Filippo Pietrantonio2, Andrea Sartore-Bianchi3, Clara Montagut4, Andres Cervantes5, Stefania Sciallero6, Maria Giulia Zampino7, Stefania Mosconi8, Valter Torri9, Noelia Tarazona5, Luca Lazzari10, Paolo Luraghi10, Susana Muoz11, Matteo Fassan12, Enzo Medico13, Livio Trusolino13, Maria Rescigno14, Salvatore Siena3, Alberto Sobrero15, Roberto Labianca8, Josep Tabernero1, Alberto Bardelli13, Sara Lonardi16, Silvia Marsoni10. 1Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; 2IRCCS National Cancer Institute (INT), University of Milano, Milano, Italy; 3Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, University of Milano, Milano, Italy; 4University Hospital del Mar - IMIM, CIBERONC, Barcelona, Spain; 5Biomedical Research institute INCLIVA, University of Valencia, Valencia, Spain; 6IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7European Institute of Oncology IRCCS, Milano, Italy; 8Cancer Center, ASST Papa Giovanni XXIII, Bergamo, Italy; 9Mario Negri Institute for Pharmacological Research - IRCCS, Milano, Italy; 10IFOM - the FIRC Institute of Molecular Oncology, Milano, Italy; 11Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; 12University of Padova, Padova, Italy; 13Candiolo Cancer Institute, University of Torino, Torino, Italy; 14Humanitas Clinical and Research Center  IRCCS, Humanitas University, Rozzano, Italy; 15IRCCS Ospedale Policlinico San MArtino, Genova, Italy; 16Veneto Institute of Oncology (IOV)  IRCCS, Padova, Italy \",\n",
       "  'Disclosures': '\\xa0E. Elez: None. F. Pietrantonio:  ; Roche, Merck Serono, Eli Lilly, Sanofi, Bayer, Servier. ; BMS. A. Sartore-Bianchi:  ; Amgen, Bayer, Sanofi, Servier. C. Montagut:  ; Biocartis.\\xa0A. Cervantes: None.\\xa0S. Sciallero: None.\\xa0M. Zampino: None.\\xa0S. Mosconi: None.\\xa0V. Torri: None.\\xa0N. Tarazona: None.\\xa0L. Lazzari: None.\\xa0P. Luraghi: None.\\xa0S. Muoz: None.\\xa0M. Fassan: None.\\xa0E. Medico: None. L. Trusolino:  ; Eli Lilly, AstraZeneca, Merck KGaA. ; Symphogen, Servier, Merus, Pfizer, Menarini.\\xa0M. Rescigno: None. S. Siena:  ; Guardant Health, Myriad Genetics.\\xa0A. Sobrero: None.\\xa0R. Labianca: None. J. Tabernero:  ; Scientific Consultancy; Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc. Genmab A/S, Halozyme, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD. ; Scientific Consultancy; Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen. ; Scientific Consultancy; Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. A. Bardelli:  ; Guardant Helath, Biocartis.\\xa0S. Lonardi: None.\\xa0S. Marsoni: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-4': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10706',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT264\\n                        \\n                         - Clinical phase II study of SCO-101 - an inhibitor of SRPK1 and ABCG2 - restoring sensitivity to FOLFIRI in metastatic FOLFIRI resistant colorectal cancer patients\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Peter Michael Vestlev1, Nicklas L. Roest1, Jakob HV Schou2, Jan Stenvang1, Nils Brnner1. 1Scandion Onclology, Copenhagen, Denmark; 2Herlev Hospital, Copenhagen, Denmark ',\n",
       "  'Disclosures': '\\xa0\\xa0P. Vestlev:  ; Scandion Oncology A/S. N.L. Roest:  ; Scandion Oncology. J.H. Schou:  ; PI; Scandion Oncology A/S. J. Stenvang:  ; Scandion Oncology A/S. N. Brnner:  ; Scandion Oncology A/S.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-5': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10707',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT265\\n                        \\n                         - A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hani B. Babiker1, Heinz-Josef Lenz2, Aaron J. Scott1, Shah Rahimian3, Michael J. Overman4. 1University of Arizona Cancer Center, Tucson, AZ; 2University of Southern California Comprehensive Cancer Center, Newport Beach, CA; 3Idera Pharmaceuticals, Exton, PA; 4MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0H.B. Babiker:  ; Bayer. ; BMS. ; Endocyte. ; Guardant360. ; SIRTeX. ; Tracon.\\xa0H. Lenz: None.\\xa0A.J. Scott: None. S. Rahimian:  ; Idera Pharmaceuticals.\\xa0M.J. Overman: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-6': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10709',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT266\\n                        \\n                         - Safety and efficacy of nimotuzumab in combination with chemotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Tao Hou, Min Lu, Xiayan Zhao, Yan He, Chunhong Hu, Ping Liu. the Second Xiangya Hospital, Central South University, Changsha, China ',\n",
       "  'Disclosures': '\\xa0T. Hou: None.\\xa0M. Lu: None.\\xa0X. Zhao: None.\\xa0Y. He: None.\\xa0C. Hu: None.\\xa0P. Liu: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-7': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10710',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT267\\n                        \\n                         - A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV non-small cell lung cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': \"Fabrice Barlesi1, Sandrine Hiret2, Christian Rolfo3, Italia Grenga4, Andre Kenig5, Yulia Vugmeyster4, Leora Horn6. 1Aix-Marseille University, CRCM, APHM, Marseille, France, Gustave Roussy Institute, Villejuif Cedex, France; 2Institut Cancerologie de l'Ouest, Saint Herblain, France; 3University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD; 4EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; a business of Merck KGaA, Darmstadt, Germany; 5Merck KGaA, Darmstadt, Germany; 6Vanderbilt University Medical Center, Nashville, TN \",\n",
       "  'Disclosures': '\\xa0\\xa0F. Barlesi:  ; Personal financial interests,\\tInstitutional financial interests, non financial interests: Principal Investigator for sponsored trials (or ISR); AstraZeneca,  Bristol-Myers Squibb, Merck, Pierre Fabre, F. HoffmannLa Roche Ltd.. ; Personal financial interests,\\tInstitutional financial interests; Bayer, Boehringer-Ingelheim, Eli Lilly Oncology, Novartis, MSD, Pfizer, Takeda. ; Institutional financial interests; Abbvie, ACEA, Amgen, Eisai, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Medimmune, Sanofi-Aventis. S. Hiret:  ; AstraZeneca. ; Bristol-Myers Squibb. ; Roche. C. Rolfo:  ; Non-financial Grants/Research support from: Guardant Health, Biomark; Lung Cancer Research Foundation, American Cancer Society. ; AstraZeneca, MSD. ; Editor in Chief of CROH; Elsevier. ; Non-financial advisor for Oncompass; Inivata, ARCHER, EMD Serono, Mylan. ; Educational committee member; IASLC. ; Vice president; International Society of Liquid Biopsy. ; Educational chair; Oncology Latin American Association. ; Faculty; ASCO International Scientific Committee. ; Member; European School of Oncology. I. Grenga:  ; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; a business of Merck KGaA, Darmstadt, Germany. A. Kenig:  ; Merck KGaA Darmstadt, Germany. Y. Vugmeyster:  ; Patent applications; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; a business of Merck KGaA, Darmstadt, Germany. L. Horn:  ; AstraZeneca, Incyte, EMD Serono, Merck, Genentech, Xcovery. ; Xcovery, BMS, BI. ; Travel; Xcovery, Roche.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-8': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10711',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT268\\n                        \\n                         - CURATE.AI-optimized modulation for multiple myeloma: An N-of-1 randomized trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Agata Blasiak1, Theodore Wonpeum Kee1, Masturah Bte Mohd Abdul Rashid2, Edward Kai-Hua Chow1, Sanjay De Mel3, Wee Joo Chng3, Dean Ho1. 1National University of Singapore, Singapore, Singapore; 2KYAN Therapeutics, Inc., Singapore, Singapore; 3National University Health System, Singapore, Singapore ',\n",
       "  'Disclosures': '\\xa0A. Blasiak: None.\\xa0T.W. Kee: None. M.B.A. Rashid:  ; KYAN. E.K. Chow:  ; KYAN.\\xa0S. De Mel: None. W. Chng:  ; KYAN. D. Ho:  ; KYAN.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-9': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10712',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT269\\n                        \\n                         - A phase 2 study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Timothy A. Yap1, Mallika Dhawan2, Andrew E. Hendifar3, Michele Maio4, Taofeek K. Owonikoko5, Miguel Quintela-Fandino6, Ronnie Shapira-Frommer7, Sanatan Saraf8, Ping Qiu8, Fan Jin8, Alexander Gozman8, Douglas A. Levine9. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; 3Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA; 4Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy; 5Winship Cancer Institute, Emory University, Atlanta, GA; 6Centro Nacional de Investigaciones Oncolgicas, Madrid, Spain; 7Chaim Sheba Medical Center, Tel HaShomer, Israel; 8Merck & Co., Inc., Kenilworth, NJ; 9Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY ',\n",
       "  'Disclosures': '\\xa0\\xa0T.A. Yap:  ; Merck. ; AstraZeneca.\\xa0M. Dhawan: None. A.E. Hendifar:  ; Merck. ; Ipsen. M. Maio:  ; Roche. ; MSD. ; Bristol-Myers Squibb. ; AstraZeneca. ; Astex. ; GlaxoSmithKline. ; Incyte. ; Pierre Fabre. ; Merck Serono. ; Eli Lilly. ; Sciclone. ; Epigen Therapeutics. T.K. Owonikoko:  ; Merck. M. Quintela-Fandino:  ; Bayer. ; AstraZeneca. ; MEI Pharma. ; Boehringer Ingelheim. ; Novartis. ; Roche. R. Shapira-Frommer:  ; Merck. ; Clovis Oncology. S. Saraf:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. P. Qiu:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. F. Jin:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. A. Gozman:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. D.A. Levine:  ; Tesaro/GlaxoSmithKline. ; Merck. ; Tesaro. ; Clovis Oncology. ; Regeneron. ; Agenus. ; Takeda. ; Immunogen. ; VBL Therapeutics. ; Genentech. ; Celsion Corporation. ; Ambry Genetics. ; Splash Pharmaceuticals.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-10': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10713',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT270\\n                        \\n                         - A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study \\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Anna Maria Di Giacomo1, Luana Calabr1, Riccardo Danielli1, Monica Valente1, Elisabetta Gambale1, Sandra Coral1, Giovanni Amato1, Harold Keer2, Diana Giannarelli3, Mohammad Azab2, Andrea Anichini4, Alessia Covre1, Michele Maio1. 1Center for Immuno-Oncology - University Hospital of Siena, Siena, Italy; 2ASTEX Pharmaceuticals Inc., Pleasanton, CA; 3Regina Elena National Cancer Institute, Rome, Italy; 4Human Tumur Immunobiology Unit- Dep of Research- Fondazione IRCCS  Istututo Nazionale dei Tumori, Milan, Italy ',\n",
       "  'Disclosures': '\\xa0\\xa0A.M. Di Giacomo:  ; Bristol-Myers Squibb. ; Incyte. ; MSD. ; GSK. L. Calabr:  ; Bristol-Myers Squibb. ; MDS. R. Danielli:  ; Merk-Serono.\\xa0M. Valente: None.\\xa0E. Gambale: None.\\xa0S. Coral: None.\\xa0G. Amato: None. H. Keer:  ; ASTEX Pharmaceuticals Inc..\\xa0D. Giannarelli: None. M. Azab:  ; ASTEX Pharmaceuticals Inc.\\xa0A. Anichini:  ; Travel/Accomodations; Bristol-Myers Squibb.\\xa0A. Covre: None. M. Maio:  ; Bristol-Myers Squibb. ; MSD. ; GSK. ; Astra Zeneca. ; Eli Lilly. ; Roche.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '846-11': {'Session Title': ' VPO.CT07.02. Phase II Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10812',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT271\\n                        \\n                         - PRECISION (Profiling early breast cancer for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Mira A. Patel1, Deborah A. Dillon2, Giulia Digiovanni2, Yu-Hui Chen2, Paul Catalano2, Carmen Perez3, David Wazer4, Jean Wright5, Rachel Jimenez6, Eric Winer2, Julia Wong2, Jennifer Bellon2, Lior Z. Braunstein1. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Dana Farber Cancer Institute, Boston, MA; 3NYU Langone, New York, NY; 4Tufts Medical Center, Boston, MA; 5Johns Hopkins University, Baltimore, MD; 6Massachusetts General Hospital, Boston, MA ',\n",
       "  'Disclosures': '\\xa0M.A. Patel: None.\\xa0D.A. Dillon: None.\\xa0G. Digiovanni: None.\\xa0Y. Chen: None.\\xa0P. Catalano: None.\\xa0C. Perez: None.\\xa0D. Wazer: None.\\xa0J. Wright: None.\\xa0R. Jimenez: None.\\xa0E. Winer: None.\\xa0J. Wong: None.\\xa0J. Bellon: None.\\xa0L.Z. Braunstein: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-1': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10975',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Gregory J. Riely. Memorial Sloan Kettering Cancer Center, New York, NY',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-2': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10977',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:00 PM - 4:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Gregory J. Riely. Memorial Sloan Kettering Cancer Center, New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-3': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11053',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Invited Speaker\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:05 PM - 4:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Gregory J. Riely. Memorial Sloan Kettering Cancer Center, New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-4': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11054',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:15 PM - 4:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-5': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10574',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1092\\n                        \\n                         - A systematic analysis of BRAF mutations and their sensitivity to different BRAF inhibitors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:20 PM - 4:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Zohar Barbash, Dikla Haham, Liat Hafzadi, Ron Zipor, Shaul Barth, Arie Aizenman, Lior Zimmerman, Gabi Tarcic. Novellusdx, Jerusalem, Israel ',\n",
       "  'Disclosures': '\\xa0\\xa0Z. Barbash:  ; NovellusDx. D. Haham:  ; NovellusDx. L. Hafzadi:  ; NovellusDx. R. Zipor:  ; NovellusDx. S. Barth:  ; NovellusDx. A. Aizenman:  ; NovellusDx. L. Zimmerman:  ; NovellusDx. G. Tarcic:  ; NovellusDx.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-6': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10987',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:30 PM - 4:35 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-7': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10575',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1093\\n                        \\n                         - Calibration Tool for Genomic Aggregates (CTGA): A deep learning framework for calibrating somatic mutation profiling data from conventional gene panel data\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:35 PM - 4:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jordan Anaya1, Craig Cummings2, Jocelyn Lee3, Alexander Baras1. 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, MD; 2Genentech, Inc., CA; 3AACR, Philadelphia, PA ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Anaya:  ; Genentech, Inc.\\xa0C. Cummings:  ; Genentech, Inc.\\xa0J. Lee:  ; Genentech, Inc.\\xa0A. Baras:  ; Genentech, Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-8': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10990',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:45 PM - 4:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-9': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10576',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1094\\n                        \\n                         - Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 5:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Giorgia Foggetti1, Chuan Li2, Hongchen Cai2, Wen-Yang Lin2, Deborah Ayeni1, Katherine Hastings1, Laura Andrejka2, Dylan Maghini2, Robert Homer1, Dmitri A. Petrov2, Monte M. Winslow2, Katerina Politi1. 1Yale School of Medicine, New Haven, CT; 2Stanford University School of Medicine, Stanford, CA ',\n",
       "  'Disclosures': '\\xa0G. Foggetti: None.\\xa0C. Li: None.\\xa0H. Cai: None.\\xa0W. Lin: None.\\xa0D. Ayeni: None.\\xa0K. Hastings: None.\\xa0L. Andrejka: None.\\xa0D. Maghini: None.\\xa0R. Homer: None. D.A. Petrov:  ; co-founder and equity holder; D2G Oncology, Inc.\\xa0M.M. Winslow:  ; co-founder and equity holder; D2G Oncology, Inc.\\xa0K. Politi:  ; AstraZeneca. ; Takeda. ; NCCN. ; Novartis. ; Merck. ; Tocagen. ; Maverick Therapeutics. ; Dynamo Therapeutics. ; Kolltan. ; Roche. ; Symphogen. ; Co-inventor on Patent; Molecular MD.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-10': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10993',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:00 PM - 5:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-11': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10577',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1095\\n                        \\n                         - Comprehensive pan-cancer analyses of RAS genomic diversity\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:05 PM - 5:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Robert Scharpf1, Gregory Riely2, Mark Awad3, Michele Lenoue-Newton4, Biagio Ricciuti3, Julia Rudolph2, Leon Raskin5, Andrew Park5, Jocelyn Lee6, Christine Lovly4, Valsamo Anagnostou1. 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3Dana-Farber Cancer Institute, Boston, MA; 4Vanderbilt-Ingram Cancer Center, Nashville, TN; 5Amgen, Inc., Thousand Oaks, CA; 6AACR, Philadelphia, PA ',\n",
       "  'Disclosures': '\\xa0\\xa0R. Scharpf:  ; Amgen, Inc.\\xa0G. Riely:  ; Amgen, Inc.\\xa0M. Awad:  ; Amgen, Inc.\\xa0M. Lenoue-Newton:  ; Amgen, Inc.\\xa0B. Ricciuti:  ; Amgen, Inc.\\xa0J. Rudolph:  ; Amgen, Inc.\\xa0L. Raskin:  ; Amgen, Inc.\\xa0A. Park:  ; Amgen, Inc.\\xa0J. Lee:  ; Amgen, Inc.\\xa0C. Lovly:  ; Amgen, Inc.\\xa0V. Anagnostou:  ; Amgen, Inc..',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-12': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10997',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:15 PM - 5:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-13': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10578',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1096\\n                        \\n                         - Harmonization standards from the Variant Interpretation for Cancer Consortium\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:20 PM - 5:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alex H. Wagner1, Reece K. Hart2, Larry Babb3, Robert R. Freimuth4, Adam Coffman1, Yonghao Liang1, Beth Pitel4, Angshumoy Roy5, Matthew Brush6, Jennifer Lee7, Anna Lu7, Thomas Coard7, Shruti Rao8, Deborah Ritter5, Brian Walsh6, Susan Mockus9, Peter Horak10, Ian King11, Dmitriy Sonkin7, Subha Madhavan8, Gordana Raca12, Debyani Chakravarty13, Malachi Griffith1, Obi L. Griffith1. 1Washington University School of Medicine, Saint Louis, MO; 2Reece Hart Consulting, CA; 3Broad Institute, Boston, MA; 4Mayo Clinic, Rochester, MN; 5Baylor College of Medicine, Houston, TX; 6Oregon Health and Science University, Portland, OR; 7National Cancer Institute, Bethesda, MD; 8Georgetown University, Washington, DC; 9The Jackson Laboratory for Genomic Medicine, Farmington, CT; 10National Center for Tumor Diseases, Heidelberg, Germany; 11University of Toronto, Toronto, ON, Canada; 12University of Southern California, Los Angeles, CA; 13Memorial Sloan Kettering Cancer Center, New York, NY ',\n",
       "  'Disclosures': '\\xa0A.H. Wagner: None.\\xa0R.K. Hart: None.\\xa0L. Babb: None.\\xa0R.R. Freimuth: None.\\xa0A. Coffman: None.\\xa0Y. Liang: None.\\xa0B. Pitel: None.\\xa0A. Roy: None.\\xa0M. Brush: None.\\xa0J. Lee: None.\\xa0A. Lu: None.\\xa0T. Coard: None.\\xa0S. Rao: None.\\xa0D. Ritter: None.\\xa0B. Walsh: None.\\xa0S. Mockus: None.\\xa0P. Horak: None.\\xa0I. King: None.\\xa0D. Sonkin: None.\\xa0S. Madhavan: None.\\xa0G. Raca: None.\\xa0D. Chakravarty: None.\\xa0M. Griffith: None.\\xa0O.L. Griffith: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-14': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10999',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:30 PM - 5:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-15': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10579',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1097\\n                        \\n                         - FGFR2 in-frame indels: A novel targetable alteration in intrahepatic cholangiocarcinoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:35 PM - 5:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Yvonne Y. Li1, James M. Cleary1, Srivatsan Raghavan1, Liam F. Spurr1, Qibiao Wu2, Lei Shi2, Lauren K. Brais1, Maureen Loftus1, Lipika Goyal2, Anuj K. Patel1, Atul B. Shinagare1, Thomas E. Clancy3, Geoffrey Shapiro1, Ethan Cerami1, William R. Sellers4, William C. Hahn1, Matthew Meyerson1, Nabeel Bardeesy2, Andrew D. Cherniack4, Brian M. Wolpin1. 1Dana-Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital, Boston, MA; 3Brigham and Women's Hospital, Boston, MA; 4Broad Institute of MIT and Harvard, Cambridge, MA \",\n",
       "  'Disclosures': '\\xa0Y.Y. Li: None. J.M. Cleary:  ; Travel; Bristol-Myers Squibb. ; Travel; Agios. ; Travel; Roche. ; Merck. ; Tesaro.\\xa0S. Raghavan: None.\\xa0L.F. Spurr: None.\\xa0Q. Wu: None.\\xa0L. Shi: None.\\xa0L.K. Brais: None.\\xa0M. Loftus: None. L. Goyal:  ; Consulting or Advisory Role; Debiopharm Group. ; Travel, Accommodations, Expenses; Taiho Pharmaceutical. A.K. Patel:  ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Eisai. A.B. Shinagare:  ; Consulting or Advisory Role; Arog.\\xa0T.E. Clancy: None. G. Shapiro:  ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; G1 Therapeutics. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Lilly. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Pfizer. ; Consulting or Advisory Role\\n; Roche. ; Consulting or Advisory Role\\n; Merck Serono. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Sierra Oncology. ; Consulting or Advisory Role\\n; Cybrexa Therapeutics. ; Consulting or Advisory Role\\n; Ipsen. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Bayer. ; Consulting or Advisory Role\\n; Fusion Pharmaceuticals. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Bicycle Therapeutics. ; Consulting or Advisory Role\\n; Almac Diagnostics. ; Consulting or Advisory Role\\n; Astex Pharmaceuticals. ; Consulting or Advisory Role\\n; Daiichi Sankyo. ; Patent holder; Dosage regimen for sapacitabine and seliciclib. ; Provisional Patent holder; Compositions and methods for predicting response and resistance to CDK4/6 inhibition. E. Cerami:  ; Blueprint Medicines. ; Travel, Accommodations, Expenses\\n; Merck. W.R. Sellers:  ; Consulting or Advisory Role\\nLeadership\\nTravel, Accommodations, Expenses\\n; Peloton Therapeutics. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; IDEAYA Biosciences. ; Consulting or Advisory Role\\n; Ipsen. ; Consulting or Advisory Role\\n; Array BioPharma. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; SERVIER. ; Consulting or Advisory Role\\nTravel, Accommodations, Expenses\\n; Astex Pharmaceuticacls. ; Consulting or Advisory Role\\n; Dynamo Therapeutics. ; Consulting or Advisory Role\\n; Syndax. ; Consulting or Advisory Role\\n; Vida Ventures. ; Consulting or Advisory Role\\n; Epidarex Capital. ; Leadership; Novartis. ; Leadership\\nTravel, Accommodations, Expenses\\n; Bluebird Bio. ; Leadership; Civetta Therapeutics. ; Deerfield Management. ; Patent holder; EGFR mutations for lung cancer diagnosis. W.C. Hahn:  ; Thermo-Fisher. ; KSQ Therapeutics. ; iTeos. ; Frontier Medicines. ; MPM. ; Solasta Ventures. ; Paraxel. ; Deerfield. ; Mark Foundation. M. Meyerson:  ; Consulting or Advisory Role\\n; OrigiMed. ; Bayer. ; Patent holder; EGFR mutations for lung cancer diagnosis.\\xa0N. Bardeesy: None. A.D. Cherniack:  ; Merck. ; Bayer. ; LabCorp. B.M. Wolpin:  ; Consulting or Advisory Role\\n; Genentech. ; Consulting or Advisory Role\\n; G1 Therapeutics. ; Consulting or Advisory Role\\n; BioLineRx. ; Consulting or Advisory Role\\n; GRAIL. ; Consulting or Advisory Role\\n; Celgene. ; Lilly.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '839-16': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11003',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:45 PM - 5:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '839-17': {'Session Title': ' VMS.MD01.01. Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nBioinformatics and Systems Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11007',\n",
       "  'Date': ' April 27, 2020, 4:00 PM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:50 PM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Gregory J. Riely. Memorial Sloan Kettering Cancer Center, New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-1': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10659',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT231\\n                        \\n                         - Clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adilia Hormigo, John Mandeli, Saadi Ghatan, Constantinos Hadjipanayis, Raymond Yong, Seunghee Kim-Schulze, Sacha Gnjatic. Icahn School of Medicine at Mount Sinai, New York, NY ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Hormigo:  ; Serono. ; Novocure.\\xa0J. Mandeli: None. S. Ghatan:  ; Neuropace. ; Monteris. C. Hadjipanayis:  ; He receives royalties from NXDC; NX Development Corporation (NXDC). ; Synaptive Medical Inc.\\xa0R. Yong: None.\\xa0S. Kim-Schulze: None. S. Gnjatic:  ; Immune Design. ; Janssen R&D. ; Agenus. ; Genentech. ; Pfizer. ; Regeneron. ; Takeda. ; Third Rock Ventures/Neon Therapeutics. ; B4CC. ; Merck. ; Dr. Gnjatic is a co-inventor on an issued patent for multiplex immunohistochemistry to characterize tumors and treatment responses. The technology is filed through Icahn School of Medicine at Mount Sinai (ISMMS) and non-exclusively licensed to Caprion. Mount Sinai has received payments associated with licensing this technology and both Mount Sinai and Dr. Gnjatic are entitled to future payments.; Patent.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-2': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10660',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT232\\n                        \\n                         - Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jennifer M. Specht1, David Maloney2, Robert Pierce2, Monica Dherin2, Susan Ra2, Quan V. Wu2, Cynthia Bamdad3. 1University of Washington, Seattle, WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Minerva Biotechnologies, Waltham, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0J.M. Specht:  ; Naktar Therapeutics. ; Genomic Health. ; Daiichi Sankyo. ; University of Washington. ; Genentech. ; Myriad Pharmaceuticals. ; Pfizer. ; Minerva Biotechnologies. ; Cascadian Therapeutics. ; Novartis. ; Merck. D. Maloney:  ; Kite Pharma. ; Celgene. ; patents; Juno Therapeutics. ; BioLine RX. ; Gilead. ; Novartis. ; Pharmacyclics. ; A2 Biotherapeutics. R. Pierce:  ; SRA; Minerva.\\xa0M. Dherin: None.\\xa0S. Ra: None.\\xa0Q.V. Wu: None. C. Bamdad:  ; IND Holder; Minerva.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-3': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10661',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT232\\n                        \\n                         - Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jennifer M. Specht1, David Maloney2, Robert Pierce2, Monica Dherin2, Susan Ra2, Quan V. Wu2, Cynthia Bamdad3. 1University of Washington, Seattle, WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Minerva Biotechnologies, Waltham, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0J.M. Specht:  ; Naktar Therapeutics. ; Genomic Health. ; Daiichi Sankyo. ; University of Washington. ; Genentech. ; Myriad Pharmaceuticals. ; Pfizer. ; Minerva Biotechnologies. ; Cascadian Therapeutics. ; Novartis. ; Merck. D. Maloney:  ; Kite Pharma. ; Celgene. ; patents; Juno Therapeutics. ; BioLine RX. ; Gilead. ; Novartis. ; Pharmacyclics. ; A2 Biotherapeutics. R. Pierce:  ; SRA; Minerva.\\xa0M. Dherin: None.\\xa0S. Ra: None.\\xa0Q.V. Wu: None. C. Bamdad:  ; IND Holder; Minerva.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-4': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10662',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT234\\n                        \\n                         - Phase I study of epacadostat added to preoperative chemoradiation in patients with locally advanced rectal cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Haeseong Park1, Ebunoluwa Otegbeye1, Hyun Kim1, Matthew Mutch1, Katrina Pedersen1, Manik Amin1, Benjamin Tan1, Nikolaos Trikalinos1, Kian-Huat Lim1, Olivia Aranha1, Rama Suresh1, Shahed Badiyan1, Matthew Silviera1, Lauren Henke1, Paul Wise1, Steven Hunt1, Jonathan Mitchem2, Esther Lu1, Andrea Wang-Gillam1, Matthew Ciorba1. 1Washington University in St. Louis, Saint Louis, MO; 2University of Missouri, Columbia, MO ',\n",
       "  'Disclosures': '\\xa0\\xa0H. Park:  ; Ambrx. ; Array Biopharma. ; Bayer. ; BeiGene. ; Bristol-Myers Squibb. ; Daiichi Pharmaceutical. ; Eli Lilly. ; EMD Serono. ; Genentech. ; GlaxoSmithKline. ; Immunomedics. ; Incyte. ; MacroGenics. ; Medimmune. ; Merck. ; Novartis. ; Oncologie. ; Pfizer. ; Puma Biotechnology. ; Regeneron Pharmceuticals.\\xa0E. Otegbeye: None.\\xa0H. Kim: None.\\xa0M. Mutch: None.\\xa0K. Pedersen: None.\\xa0M. Amin: None.\\xa0B. Tan: None.\\xa0N. Trikalinos: None.\\xa0K. Lim: None.\\xa0O. Aranha: None.\\xa0R. Suresh: None.\\xa0S. Badiyan: None.\\xa0M. Silviera: None.\\xa0L. Henke: None.\\xa0P. Wise: None.\\xa0S. Hunt: None.\\xa0J. Mitchem: None.\\xa0E. Lu: None.\\xa0A. Wang-Gillam: None. M. Ciorba:  ; Incyte.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-5': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10663',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT235\\n                        \\n                         - A phase 1b/2 study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Afsaneh Barzi1, Heinz-Josef Lenz1, Errin Samulsz2, Maya Ridinger2, Mark Erlander2, Tanios S. Bekaii-Saab3, Daniel H. Ahn3. 1USC Norris Comprehensive Cancer Center, Los Angeles, CA; 2Trovagene, Inc., San Diego, CA; 3Mayo Clinic Cancer Center, Phoenix, AZ ',\n",
       "  'Disclosures': '\\xa0A. Barzi: None. H. Lenz:  ; BMS. ; Merck KG. ; Bayer. E. Samulsz:  ; Trovagene. M. Ridinger:  ; Trovagene. M. Erlander:  ; Trovagene. T.S. Bekaii-Saab:  ; Boston Biomedical. ; Bayer. ; Amgen. ; Merck. ; Genentech. ; Ipsen. ; Array Biopharma. ; Incyte. ; IDMC/DSMB; Astra Zeneca. ; Imugene. ; Immuneering. ; Sun Biopharma. ; IDMC/DSMB; Lilly. ; Clovis. ; Seattle Genetics. ; Abgenomics. ; IDMC/DSMB; PanCan. ; IDMC/DSMB; 1Globe. ; IDMC/DSMB; Exelixis. D.H. Ahn:  ; Eisai. ; Exelixis. ; Genentech.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-6': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10664',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT236\\n                        \\n                         - A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Eduardo Vilar-Sanchez1, Carol Burke2, Marcia R. Cruz Correa3, Evelien Dekker4, William M. Grady5, Philippe Grandval6, Bryson W. Katona7, Xavier Llor8, Douglas L. Riegert-Johnson9, Jean-Christophe Saurin10, Peter Stanich11, Daniel A. Sussman12, David Weinberg13, Edward F. Attiyeh14, Devanand Joseph14, Kelly Raybold14, Gary V. Borzillo14, Thomas J. Prior14, Michael Smith14, Hong Xie14, Kurtis E. Bachman14, Jeffrey R. Infante14, Niloy Jewel Samadder15. 1MD Anderson Cancer Center, Houston, TX; 2Cleveland Clinic, Cleveland, OH; 3University of Puerto Rico School of Medicine, San Juan, PR; 4Amsterdam University Medical Centers, Amsterdam, Netherlands; 5Fred Hutchinson Cancer Research Center and University of Washington, School of Medicine, Seattle, WA; 6Assistance Publique Hpitaux de Marseille, Marseille, France; 7University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; 8Department of Medicine and Cancer Center, Yale University, New Haven, CT; 9Mayo Clinic, Jacksonville, FL; 10Hpital Edouard Herriot, Lyon, France; 11Ohio State University Wexner Medical Center, Columbus, OH; 12University of Miami Miller School of Medicine, Miami, FL; 13Fox Chase Cancer Center, Philadelphia, PA; 14Janssen Research & Development, LLC, Spring House, PA; 15Mayo Clinic, Phoenix, AZ ',\n",
       "  'Disclosures': '\\xa0E. Vilar-Sanchez: None.\\xa0C. Burke: None.\\xa0M.R. Cruz Correa: None. E. Dekker:  ; FujiFilm. ; Olympus. ; Tillots. ; GI Supply. ; CPP-FAP. ; Roche. ; eNose. W.M. Grady:  ; Guardant Health. ; Freenome. ; SEngine.\\xa0P. Grandval: None.\\xa0B.W. Katona: None. X. Llor:  ; Exact Sciences.\\xa0D.L. Riegert-Johnson: None.\\xa0J. Saurin: None.\\xa0P. Stanich: None.\\xa0D.A. Sussman: None.\\xa0D. Weinberg: None. E.F. Attiyeh:  ; Johnson & Johnson. D. Joseph:  ; Johnson & Johnson. K. Raybold:  ; Johnson & Johnson. G.V. Borzillo:  ; Johnson & Johnson. T.J. Prior:  ; Johnson & Johnson. M. Smith:  ; Johnson & Johnson. H. Xie:  ; Johnson & Johnson. K.E. Bachman:  ; Johnson & Johnson. J.R. Infante:  ; Johnson & Johnson.\\xa0N. Samadder: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-7': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10665',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT237\\n                        \\n                         - A phase I study to assess the safety, tolerability, and immunogenicity of personalized neoantigen/cancer testis antigen nanovaccine (PVAC) for high-risk resected gastric cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Qin Liu1, Hanqing Qian1, Jie Shao1, Qiuping Xu1, Huizi Sha1, Yang Yang1, Weifeng Wang2, Lixia Yu1, Baorui Liu1, Jia Wei1. 1The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China; 2OrigiMed, Shanghai, China ',\n",
       "  'Disclosures': '\\xa0Q. Liu: None.\\xa0H. Qian: None.\\xa0J. Shao: None.\\xa0Q. Xu: None.\\xa0H. Sha: None.\\xa0Y. Yang: None.\\xa0W. Wang: None.\\xa0L. Yu: None.\\xa0B. Liu: None.\\xa0J. Wei: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-8': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10666',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT238\\n                        \\n                         - An open-label, phase 1 study of IDO inhibitor KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Pratibha Desai1, Santosh Rao2, Yuta Ikawa3, Barbara Kapelan3, Sergey Efuni3, Robert Latek3, Takashi Sato4, Denis Healy3, Yousef Zakharia5. 1Comprehensive Hematology and Oncology, St. Petersburg, FL; 2Banner MD Anderson Cancer Center, Gilbert, AZ; 3Kyowa Kirin Pharmaceutical Development, Inc, Princeton, NJ; 4Kyowa Kirin Co., Ltd, Tokyo, Japan; 5University of Iowa Hospitals and Clinics, Iowa City, IA ',\n",
       "  'Disclosures': '\\xa0P. Desai: None.\\xa0S. Rao: None. Y. Ikawa:  ; Kyowa Kirin Pharmaceutical Development, Inc.\\xa0B. Kapelan:  ; Kyowa Kirin Pharmaceutical Development, Inc.\\xa0S. Efuni:  ; Kyowa Kirin Pharmaceutical Development, Inc.\\xa0R. Latek:  ; Kyowa Kirin Pharmaceutical Development, Inc.\\xa0T. Sato:  ; Kyowa Kirin Co., Ltd.\\xa0D. Healy:  ; Kyowa Kirin Pharmaceutical Development, Inc.\\xa0Y. Zakharia:  ; Amgen. ; Roche Diagnostics. ; Novartis. ; DSMC; Janssen. ; IST; Eisai. ; IST; Exelixis. ; Castle Bioscience. ; Array. ; Bayer. ; IST; Pfizer. ; Clovis. ; EMD Serono. ; IST; NewLink Genetics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-9': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10667',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT239\\n                        \\n                         - Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkins lymphomas\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hongying Zhang1, Nasrin Rastgoo1, Khalid Benbatoul1, Susan Sheng1, Matthew Thayer1, Stephen Howell2, William Rice1. 1Aptose Biosciences, San Diego, CA; 2University of California San Diego, Moores Cancer Center, San Diego, CA ',\n",
       "  'Disclosures': \"\\xa0\\xa0H. Zhang:  ; Aptose BioSciences Inc.\\xa0N. Rastgoo:  ; Aptose BioSciences Inc.\\xa0K. Benbatoul:  ; Aptose BioSciences Inc.\\xa0S. Sheng:  ; Aptose BioSciences Inc.\\xa0M. Thayer:  ; Aptose BioSciences Inc.\\xa0S. Howell:  ; Membership on an entity's Board of\\nDirectors or advisory committees; Aptose BioSciences Inc.\\xa0W. Rice:  ; Equity Ownership and Patents & Royalties; Aptose Biosciences Inc..\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-10': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10668',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT240\\n                        \\n                         - A phase I clinical trial to study the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ana Tari Ashizawa1, Locke Bryan2, William Wierda3. 1Bio-Path Holdings Inc, Bellaire, TX; 2Georgia Cancer Center, Augusta, GA; 3The University of Texas MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Tari Ashizawa:  ; Bio-Path Holdings, Inc..\\xa0L. Bryan: None.\\xa0W. Wierda: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-11': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10669',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT241\\n                        \\n                         - Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Joseph Markowitz, Andrew Brohl, Amod A. Sarnaik, Zeynep Eroglu, Deanryan B. De Aquino, Nikhil Khushalani, Ahmad Tarhini, Vernon K. Sondak, Shari Pilon-Thomas. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Markowitz:  ; Morphogenesis. ; Newlink Genetics. ; Jackson Laboratories. A. Brohl:  ; EMD Serano. ; Bayer. ; Deciphera. ; PierianDx.\\xa0A.A. Sarnaik: None. Z. Eroglu:  ; Regeneron. ; SunPharma. ; Array Biopharma. ; Novartis.\\xa0D.B. De Aquino: None. N. Khushalani:  ; BMS. ; Merck. ; Astrazeneca. ; Regeneron. ; HUYA. ; Bioscience. ; Genentech. ; Array. ; Immunocore. ; EMD Serano. ; Sanofi. ; Incyte. ; GSK. ; Novartis. ; Cellgene. ; Bellicum. ; Mazor Robotics. ; TranEnterix. ; Amarin.\\xa0A. Tarhini: None. V.K. Sondak:  ; Array Biopharma. ; Merck. ; Bristol-Myers Squibb. ; Regeneron. ; Pfizer. ; Replimune. ; Polynoma. S. Pilon-Thomas:  ; Iovance Biotherapeutics. ; Provectus. ; Intellia Therapeutics. ; Myst Therapeutics. ; Morphogenesis.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-12': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10670',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT241\\n                        \\n                         - Trial in progress: IFx-Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Joseph Markowitz, Andrew Brohl, Amod A. Sarnaik, Zeynep Eroglu, Deanryan B. De Aquino, Nikhil Khushalani, Ahmad Tarhini, Vernon K. Sondak, Shari Pilon-Thomas. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Markowitz:  ; Morphogenesis. ; Newlink Genetics. ; Jackson Laboratories. A. Brohl:  ; EMD Serano. ; Bayer. ; Deciphera. ; PierianDx.\\xa0A.A. Sarnaik: None. Z. Eroglu:  ; Regeneron. ; SunPharma. ; Array Biopharma. ; Novartis.\\xa0D.B. De Aquino: None. N. Khushalani:  ; BMS. ; Merck. ; Astrazeneca. ; Regeneron. ; HUYA. ; Bioscience. ; Genentech. ; Array. ; Immunocore. ; EMD Serano. ; Sanofi. ; Incyte. ; GSK. ; Novartis. ; Cellgene. ; Bellicum. ; Mazor Robotics. ; TranEnterix. ; Amarin.\\xa0A. Tarhini: None. V.K. Sondak:  ; Array Biopharma. ; Merck. ; Bristol-Myers Squibb. ; Regeneron. ; Pfizer. ; Replimune. ; Polynoma. S. Pilon-Thomas:  ; Iovance Biotherapeutics. ; Provectus. ; Intellia Therapeutics. ; Myst Therapeutics. ; Morphogenesis.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-13': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10671',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT242\\n                        \\n                         - SNDX-6352-0502: A phase 1, open-label, dose escalation trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of SNDX-6352 in combination with durvalumab in patients with unresectable, recurrent, locally-advanced, or metastatic solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Anthony W. Tolcher1, Drew Rasco2, Sunil Sharma3, Matthew Taylor4, Christine Quaranto5, David L. Tamang5, Robert Nordness5, Michael L. Meyers5, Serap Sankoh5, Peter Ordentlich5, Nilo Azad6. 1NEXT Oncology, San Antonio, TX; 2START Center for Cancer Care, San Antonio, TX; 3Honor Health, Scottsdale, AZ; 4Oregon Health and Science University, Portland, OR; 5Syndax Pharmaceuticals, Waltham, MA; 6Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD ',\n",
       "  'Disclosures': '\\xa0A.W. Tolcher: None.\\xa0D. Rasco: None.\\xa0S. Sharma: None.\\xa0M. Taylor: None. C. Quaranto:  ; Syndax Pharmaceuticals. D.L. Tamang:  ; Syndax Pharmaceuticals. R. Nordness:  ; Syndax Pharmaceuticals. M.L. Meyers:  ; Syndax Pharmaceuticals. S. Sankoh:  ; Syndax Pharmaceuticals. P. Ordentlich:  ; Syndax Pharmaceuticals.\\xa0N. Azad: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-14': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10672',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT244\\n                        \\n                         - A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Grace K. Dy1, Diwakar Davar2, Evanthia Galanis3, Danielle Townsley4, Djuro Karanovic4, Maria Schwaederle4, Beth Kelly4, Dmitriy Zamarin5, Mitesh Borad6, Kevin Harrington7. 1Roswell Park Comprehensive Cancer Center, Buffalo, NY; 2University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA; 3Mayo Clinic, Rochester, MN; 4AstraZeneca, Gaithersburg, MD; 5Memorial Sloan Kettering Cancer Center, New York, NY; 6Mayo Clinic, Scottsdale, AZ; 7Institute of Cancer Research, London, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0G.K. Dy:  ; AstraZeneca. D. Davar:  ; Merck. ; Bristol-Myers Squibb. ; Tesaro. ; Checkmate Pharmaceuticals. ; Amgen. E. Galanis:  ; Other support to institution; AstraZeneca. ; Tracon. ; Genentech. ; Bristol-Myers Squibb. ; Other support to institution; Karyopharm. D. Townsley:  ; AstraZeneca. D. Karanovic:  ; AstraZeneca. M. Schwaederle:  ; AstraZeneca. B. Kelly:  ; AstraZeneca. D. Zamarin:  ; AstraZeneca. ; Synlogic Therapeutics. ; Tesaro. ; Western Oncolytics. ; Agenus. ; Travel; Genentech. ; Calidi Biotherapeutics. ; Merck. M. Borad:  ; AstraZeneca. K. Harrington:  ; AstraZeneca. ; Bristol-Myers Squibb. ; Boehringer Ingelheim. ; MSD. ; Merck-Serono. ; Pfizer. ; Replimune. ; Vyriad. ; Oncolys.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-15': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10673',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT245\\n                        \\n                         - NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jing Yang, Gary Means, Almudena Tercero, Kristi Manjarrez, Jan Hillson, Stanford L. Peng. Alpine Immune Sciences, Inc, Seattle, WA ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Yang:  ; Alpine Immune Sciences, Inc. G. Means:  ; Alpine Immune Sciences, Inc.\\xa0A. Tercero:  ; Alpine Immune Sciences, Inc.\\xa0K. Manjarrez:  ; Alpine Immune Sciences, Inc.\\xa0J. Hillson:  ; Alpine Immune Sciences, Inc.\\xa0S.L. Peng:  ; Alpine Immune Sciences, Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-16': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10674',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT245\\n                        \\n                         - NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jing Yang, Gary Means, Almudena Tercero, Kristi Manjarrez, Jan Hillson, Stanford L. Peng. Alpine Immune Sciences, Inc, Seattle, WA ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Yang:  ; Alpine Immune Sciences, Inc. G. Means:  ; Alpine Immune Sciences, Inc.\\xa0A. Tercero:  ; Alpine Immune Sciences, Inc.\\xa0K. Manjarrez:  ; Alpine Immune Sciences, Inc.\\xa0J. Hillson:  ; Alpine Immune Sciences, Inc.\\xa0S.L. Peng:  ; Alpine Immune Sciences, Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-17': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10675',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT247\\n                        \\n                         - A phase 1/2 study of GB1275, a first-in-class CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36) \\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Andrea Wang-Gillam1, Drew W. Rasco2, Wungki Park3, Eileen O'Reilly3, Wells Messersmith4, David G. DeNardo1, Vineet Gupta5, Lei Zhou6, Anna Galkin6, Debbie Slee6, Laura L. Carter6, David Nickle6, Rebecca Tran6, Jack Li6, Beatrice Ferguson6, Marya F. Chaney7, Luisa Salter-Cid6, Jakob Dupont6, Johanna C. Bendell8. 1Washington University School of Medicine, St. Louis, MO; 2The START Center for Cancer Care., San Antonio, TX; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4University of Colorado School of Medicine, Denver, CO; 5Rush University Medical Center, Chicago, IL; 6Gossamer Bio, Inc., San Diego, CA; 7Merck & Co, Inc., Kenilworth, NJ; 8Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN \",\n",
       "  'Disclosures': \"\\xa0\\xa0A. Wang-Gillam:  ; Merck & Co., Inc.. ; Gossamer Bio, Inc.\\xa0D.W. Rasco:  ; Gossasmer Bio, Inc.\\xa0W. Park:  ; Gossamer Bio, Inc.. ; Merck & Co., Inc.. ; Astellas Pharma Inc.. ; Ipsen Pharma. E. O'Reilly:  ; Gossamer Bio, Inc.. ; Celgene. ; Merck & Co, Inc.\\xa0W. Messersmith:  ; Gossamer Bio., Inc.\\xa0D.G. DeNardo:  ; Gossamer Bio, Inc.\\xa0V. Gupta:  ; Gossamer Bio, Inc.. ; Adhaere Pharmaceuticals, Inc.\\xa0L. Zhou:  ; Gossamer Bio, Inc.\\xa0A. Galkin:  ; Gossamer Bio, Inc.\\xa0D. Slee:  ; Gossamer Bio, Inc.\\xa0L.L. Carter:  ; Gossamer Bio, Inc.\\xa0D. Nickle:  ; Gossamer Bio, Inc.\\xa0R. Tran:  ; Gossamer Bio, Inc.\\xa0J. Li:  ; Gossamer Bio, Inc.\\xa0B. Ferguson:  ; Gossamer Bio, Inc.\\xa0M.F. Chaney:  ; Merck & Co., Inc.\\xa0L. Salter-Cid:  ; Gossamer Bio, Inc.\\xa0J. Dupont:  ; Gossamer Bio, Inc.\\xa0J.C. Bendell:  ; Gossamer Bio, Inc.. ; Merck & Co, Inc.. ; Celgene. ; Eli Lilly & Co.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-18': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10676',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT248\\n                        \\n                         - AZD7648: A Phase I/IIa first-in-human trial of a novel, potent and selective DNA-PK inhibitor in patients with advanced malignancies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Timothy A. Yap1, Yingxue Chen2, Lisa H. Butler3, Si-houy Lao-Sirieix3, Elaine Cadogan3, Lenka Oplustil O'Connor3, Karthick Vishwanathan2, Younghwa Kim3, Dnal Landers3, Emma Dean3. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2AstraZeneca, Boston, MA; 3AstraZeneca, Cambridge, United Kingdom \",\n",
       "  'Disclosures': \"\\xa0\\xa0T. Yap:  ; AstraZeneca. ; Bayer, Clovis, Constellation, Cyteir , Eli Lilly, EMD Serono, Forbius/Formation Biologics, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Novartis, Pfizer, Ribon. ; Almac, Aduro, Atrin, Axiom, Bayer, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Kyn Therapeutics, Merck, Pfizer, Roche, Seattle Genetics, and Zai La. ; Pfizer and Tesaro. ; Medical Director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors.; Institute for Applied Cancer Science. Y. Chen:  ; AstraZeneca. L. Butler:  ; AstraZeneca. S. Lao-Sirieix:  ; AstraZeneca. E. Cadogan:  ; AstraZeneca. L. Oplustil O'Connor:  ; AstraZeneca. K. Vishwanathan:  ; AstraZeneca. Y. Kim:  ; AstraZeneca. D. Landers:  ; AstraZeneca. E. Dean:  ; AstraZeneca.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-19': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10677',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT249\\n                        \\n                         - A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ecaterina E. Ileana Dumbrava1, Maria Suarez-Almazor1, Jeane Painter1, Tanner M. Johanns2, Michael L. Dougan3, Laura Cappelli4, Yinghong Wang1, Clifton Bingham4, Sarthak Gupta5, Blake M. Warner6, Osama Rahma7, Jarushka Naidoo4, Patrick A. Ott7, David A. Hafler8, Harriet Kluger8, Arezou Khosroshahi9, Rafeh Naqash10, Lorinda Chung11, Tamiko R. Katsumoto11, Shivaani Kummar11, Hussein Tawbi1, Elad Sharon10. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2Washington University, St. LouIs, MO; 3Massachusetts General Hospital/Dana-Farber Cancer Institute, Boston, MA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD; 6National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD; 7Dana Farber Cancer Institute, Boston, MA; 8Yale School of Medicine, New Haven, CT; 9Emory University School of Medicine, Atlanta, GA; 10National Cancer Institute, Bethesda, MD; 11Stanford University School of Medicine, Stanford, CA ',\n",
       "  'Disclosures': '\\xa0E.E. Ileana Dumbrava: None.\\xa0M. Suarez-Almazor: None.\\xa0J. Painter: None. T.M. Johanns:  ; Novocure, Geneos. M.L. Dougan:  ; Tillotts Pharma, Genentech, Partner Therapeutic. ; Novartis. ; Neoleukin Therapeutics. L. Cappelli:  ; Bristol-Myers Squibb. Y. Wang:  ; Tillotts Pharma. C. Bingham:  ; Bristol-Myers Squibb.\\xa0S. Gupta: None.\\xa0B.M. Warner: None. O. Rahma:  ; Speaker for CME activity sponsored by BMS; Bristol-Myers Squibb. J. Naidoo:  ; Astrazeneca. ; Merck. ; Bristol-Myers Squibb. ; Roche/Genentech. P.A. Ott:  ; Merck. ; Bristol-Myers Squibb. ; Neon Therapeutics. ; Celldex. ; ArmoBiosciences. ; Astrazeneca/Medimmune. ; Novartis. ; Pfizer. ; CytomX. ; Genentech. ; Array. D.A. Hafler:  ; Bristol-Myers Squibb. ; Sanofi. ; Genentech. H. Kluger:  ; Bristol-Myers Squibb. ; Apexigen. ; Merck. ; Corvus. ; Nektar. ; Biodesix. ; Roche-Genentech. ; Pfizer. ; Iovance. ; Immunocore. ; Celldex. ; Array Biopharma. ; Elevate Bio.\\xa0A. Khosroshahi: None.\\xa0R. Naqash: None.\\xa0L. Chung: None. T.R. Katsumoto:  ; Bristol-Myers Squibb. ; Roche/Genentech.\\xa0S. Kummar: None. H. Tawbi:  ; Bristol-Myers Squibb. ; Novartis. ; Merck. ; Genentech. ; Array. ; GlaxoSmithKline. ; Celgene.\\xa0E. Sharon: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '845-20': {'Session Title': ' VPO.CT07.01. Phase I Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10678',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT250\\n                        \\n                         - A Phase 1a/1b, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': 'Mihaela Cristea1, Bartosz Chmielowski2, Roel Funke3, Todd Stallings-Schmitt3, Mitch Denker3, Mark Frohlich3, Alex Franzusoff3, Mehrdad Abedi4, Samuel Ejadi5. 1City of Hope Comprehensive Cancer Center, Duarte, CA; 2Jonsson Comprehensive Cancer Center, Los Angeles, CA; 3PACT Pharma, South San Francisco, CA; 4University of Davis Comprehensive Cancer Center, Sacramento, CA; 5UC Irvine Medical Center, Orange, CA ',\n",
       "  'Disclosures': '\\xa0M. Cristea: None.\\xa0B. Chmielowski: None. R. Funke:  ; PACT Pharma. T. Stallings-Schmitt:  ; PACT Pharma. M. Denker:  ; PACT Pharma. M. Frohlich:  ; PACT Pharma. A. Franzusoff:  ; PACT Pharma.\\xa0M. Abedi: None.\\xa0S. Ejadi: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-1': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10721',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT281\\n                        \\n                         - Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jorge Ferrer1, David Carr2, Irene Wapnir3, Kelly Hunt4, Peter Blumencranz5, Nayana Dekhne6, Daleela Dodge7, Donna Lynn Dyess8, Shelley Hwang9, Stephanie Valente10, Lynne Clark11, Beth-Ann Lesnikoski12, Anees Chagpar13, Paticia Clark14, Marie Catherine Lee15, Brian Schlossberg1, Sean Madden1, Livia Gjylameti1, Manna Chang1, Kate Smith1, Barbara Smith16. 1Lumicell, Inc, Newton, MA; 2Novant Health, Winston-Salem, NC; 3Stanford Cancer Institute, Stanford, CA; 4The University of Texas M.D. Anderson Cancer Center, Houston, TX; 5The Comprehensive Breast Care Center of Tampa Bay (BayCare), Clearwater, FL; 6Beaumont Health System, Royal Oak, MI; 7Penn State Milton S. Hershey Medical Center, Hershey, PA; 8Mitchell Cancer Institute-University of South Alabama, Mobile, AL; 9Duke University Medical Center, Durham, NC; 10Cleveland Clinic Foundation, Cleveland, OH; 11CHI Franciscan Research Center, Tacoma, WA; 12Baptist MD Anderson Cancer Center, Jacksonville, FL; 13Yale University-Smilow Cancer Center, New Haven, CT; 14HonorHealth Research Institute, Scottsdale, AZ; 15Moffitt Cancer Center, Tampa, FL; 16Massachusetts General Hospital, Boston, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0J. Ferrer:  ; Lumicell, Inc.\\xa0D. Carr: None.\\xa0I. Wapnir: None.\\xa0K. Hunt: None.\\xa0P. Blumencranz: None.\\xa0N. Dekhne: None.\\xa0D. Dodge: None.\\xa0D. Dyess: None.\\xa0S. Hwang: None.\\xa0S. Valente: None.\\xa0L. Clark: None.\\xa0B. Lesnikoski: None.\\xa0A. Chagpar: None.\\xa0P. Clark: None.\\xa0M. Lee: None. B. Schlossberg:  ; Lumicell, Inc.\\xa0S. Madden:  ; Lumicell, Inc.\\xa0L. Gjylameti:  ; Lumicell, Inc.\\xa0M. Chang:  ; Lumicell, Inc.\\xa0K. Smith:  ; Lumicell, Inc..\\xa0B. Smith: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-2': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10722',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT282\\n                        \\n                         - KEYNOTE-975: A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab vs placebo in participants with esophageal carcinoma receiving concurrent definitive chemoradiotherapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Manish A. Shah1, Jaafar Bennouna2, Toshihiko Doi3, Lin Shen4, Ken Kato5, Antoine Adenis6, Harvey Mamon7, Markus Moehler8, Xiaolong Fu9, Byoung Chul Cho10, Pooja Bhagia11, Chie-Schin Shih11, Anjali Desai11, Peter Enzinger12. 1Weill Cornell Medical College, New York, NY; 2Institut de Cancerologie de LOuest, Nantes, France; 3National Cancer Center Hospital East, Kashiwa, Japan; 4Peking University Cancer Hospital, Beijing, China; 5National Cancer Center Hospital, Tokyo, Japan; 6Institut du Cancer de Montpellier, Montpellier, France; 7Brigham and Womens Hospital, Boston, MA; 8Johannes-Gutenberg University, Mainz, Germany; 9Shanghai Chest Hospital, Shanghai, China; 10Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of; 11Merck & Co., Inc., Kenilworth, NJ; 12Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0M.A. Shah:  ; Macrogenics. ; Lilly. ; NIH. ; SU2C. J. Bennouna:  ; Symposium; personal fees; MSD. ; Symposium; personal fees; Roche. ; Symposium; personal fees; BMS. ; Symposium; personal fees; Servier. ; Symposium; personal fees; AstraZeneca. ; Symposium; personal fees; Bayer. T. Doi:  ; Personal fees; Lilly. ; Personal fees; Kyowa Hakko Kirin. ; Personal fees; MSD. ; Personal fees; Daiichi Sankyo. ; Personal fees; Amgen. ; Personal fees; Sumitomo Dainippon. ; Personal fees; Taiho. ; Personal fees; Novartis. ; Merck Serono, Janssen, Pfizer, Quintiles, Eisai. ; Personal fees; Boehringer Ingelheim. ; Personal fees; Takeda. ; Personal fees; Chugai Pharma. ; Personal fees; Bristol-Myers Squibb. ; Personal fees; AbbVie. ; Personal fees; Rakuten Medical. ; Personal fees; Bayer. ; Personal fees; Ono Pharmaceutical. ; Personal fees; Astellas Pharma. ; Personal fees; Oncolys BioPharma.\\xa0L. Shen: None. K. Kato:  ; ONO. ; MSD. ; Beigene. ; Merck Bio. ; Eli Lilly. ; Taiho. ; Nihon Kayaku. ; TORAY. ; BMS. ; Shionogi. ; Oncolys Biopharma. A. Adenis:  ; Travel, accommodations, expenses; MSD. ; Travel, accommodations, expenses; BMS. ; Servier. ; Travel, accommodations, expenses; Bayer.\\xa0H. Mamon: None. M. Moehler:  ; MSD.\\xa0X. Fu: None. B. Cho:  ; Novartis. ; AstraZeneca. ; Boehringer-Ingelheim. ; Roche. ; BMS. ; Ono. ; Yuhan. ; Pfizer. ; Eli Lilly. ; Janssen. ; Takeda. ; MSD. ; TheraCanVac Inc. ; Gencurix Inc. ; Bridgebio Therapeutics. ; Bayer. ; MOGAM Institute. ; Dong-A ST. ; Licensing/Royalties; Champions Oncology. ; Dizal Pharma. P. Bhagia:  ; Merck & Co., Inc.\\xa0C. Shih:  ; Merck & Co., Inc.. ; Travel, accommodations, or\\nother expenses; Exelixis. A. Desai:  ; Merck & Co., Inc.\\xa0P. Enzinger:  ; Astellas. ; AstraZeneca. ; Beigene. ; Celgene. ; Daiichi-Sankyo. ; FivePrime. ; Lilly. ; Loxo. ; Merck. ; Taiho. ; Zymeworks.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-3': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10723',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT282\\n                        \\n                         - KEYNOTE-975: A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab vs placebo in participants with esophageal carcinoma receiving concurrent definitive chemoradiotherapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Manish A. Shah1, Jaafar Bennouna2, Toshihiko Doi3, Lin Shen4, Ken Kato5, Antoine Adenis6, Harvey Mamon7, Markus Moehler8, Xiaolong Fu9, Byoung Chul Cho10, Pooja Bhagia11, Chie-Schin Shih11, Anjali Desai11, Peter Enzinger12. 1Weill Cornell Medical College, New York, NY; 2Institut de Cancerologie de LOuest, Nantes, France; 3National Cancer Center Hospital East, Kashiwa, Japan; 4Peking University Cancer Hospital, Beijing, China; 5National Cancer Center Hospital, Tokyo, Japan; 6Institut du Cancer de Montpellier, Montpellier, France; 7Brigham and Womens Hospital, Boston, MA; 8Johannes-Gutenberg University, Mainz, Germany; 9Shanghai Chest Hospital, Shanghai, China; 10Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of; 11Merck & Co., Inc., Kenilworth, NJ; 12Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0M.A. Shah:  ; Macrogenics. ; Lilly. ; NIH. ; SU2C. J. Bennouna:  ; Symposium; personal fees; MSD. ; Symposium; personal fees; Roche. ; Symposium; personal fees; BMS. ; Symposium; personal fees; Servier. ; Symposium; personal fees; AstraZeneca. ; Symposium; personal fees; Bayer. T. Doi:  ; Personal fees; Lilly. ; Personal fees; Kyowa Hakko Kirin. ; Personal fees; MSD. ; Personal fees; Daiichi Sankyo. ; Personal fees; Amgen. ; Personal fees; Sumitomo Dainippon. ; Personal fees; Taiho. ; Personal fees; Novartis. ; Merck Serono, Janssen, Pfizer, Quintiles, Eisai. ; Personal fees; Boehringer Ingelheim. ; Personal fees; Takeda. ; Personal fees; Chugai Pharma. ; Personal fees; Bristol-Myers Squibb. ; Personal fees; AbbVie. ; Personal fees; Rakuten Medical. ; Personal fees; Bayer. ; Personal fees; Ono Pharmaceutical. ; Personal fees; Astellas Pharma. ; Personal fees; Oncolys BioPharma.\\xa0L. Shen: None. K. Kato:  ; ONO. ; MSD. ; Beigene. ; Merck Bio. ; Eli Lilly. ; Taiho. ; Nihon Kayaku. ; TORAY. ; BMS. ; Shionogi. ; Oncolys Biopharma. A. Adenis:  ; Travel, accommodations, expenses; MSD. ; Travel, accommodations, expenses; BMS. ; Servier. ; Travel, accommodations, expenses; Bayer.\\xa0H. Mamon: None. M. Moehler:  ; MSD.\\xa0X. Fu: None. B. Cho:  ; Novartis. ; AstraZeneca. ; Boehringer-Ingelheim. ; Roche. ; BMS. ; Ono. ; Yuhan. ; Pfizer. ; Eli Lilly. ; Janssen. ; Takeda. ; MSD. ; TheraCanVac Inc. ; Gencurix Inc. ; Bridgebio Therapeutics. ; Bayer. ; MOGAM Institute. ; Dong-A ST. ; Licensing/Royalties; Champions Oncology. ; Dizal Pharma. P. Bhagia:  ; Merck & Co., Inc.\\xa0C. Shih:  ; Merck & Co., Inc.. ; Travel, accommodations, or\\nother expenses; Exelixis. A. Desai:  ; Merck & Co., Inc.\\xa0P. Enzinger:  ; Astellas. ; AstraZeneca. ; Beigene. ; Celgene. ; Daiichi-Sankyo. ; FivePrime. ; Lilly. ; Loxo. ; Merck. ; Taiho. ; Zymeworks.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-4': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10724',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT284\\n                        \\n                         - Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Andrew Zhu1, Masatoshi Kudo2, Arndt Vogel3, Thomas Yau4, Jian Zhou5, Eunhee Kim6, Usha Malhotra6, Abby B. Siegel6, Ann-Lii Cheng7. 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 2Kindai University School of Medicine, Osaka, Japan; 3Medizinische Hochschule, Hannover, Germany; 4University of Hong Kong, Queen Mary Hospital,, Hong Kong, Hong Kong; 5Zhongshan Hospital, Fudan University, Shanghai, China; 6Merck & Co., Inc., Kenilworth, NJ; 7National Taiwan University Hospital Cancer Center, Taipei, Taiwan ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Zhu:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; travel; Eli Lilly. ; BMS. ; Novartis. ; Bayer. ; Eisai. ; Sanofi. ; Exelixis. M. Kudo:  ; MSD. ; Eisai. ; Bayer. ; Ono. ; BMS. ; Eli Lilly. ; EA Pharma. ; Gilead. ; Takeda. ; Otsuka. ; Taiho. A. Vogel:  ; MSD. ; Novartis. ; Delcath Systems. ; Lilly. ; Roche. ; Amgen. ; Bayer. ; Baxalta. ; Sanofi. ; BMS. T. Yau:  ; MSD. ; BMS. J. Zhou:  ; MSD. E. Kim:  ; Merck & Co., Inc.\\xa0U. Malhotra:  ; Merck & Co., Inc.\\xa0A.B. Siegel:  ; Merck & Co., Inc.\\xa0A. Cheng:  ; MSD. ; Bayer. ; travel; Eisai. ; Merck Serono. ; travel; Novartis. ; travel; Ono. ; Exelixis. ; Nucleix Ltd. ; travel; Roche/Genentech. ; travel; IQVIA. ; BMS. ; travel; Bayer Yakuhin, Ltd. ; Amgen Taiwan. ; Bayer Schering Pharma.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-5': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10725',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT284\\n                        \\n                         - Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Andrew Zhu1, Masatoshi Kudo2, Arndt Vogel3, Thomas Yau4, Jian Zhou5, Eunhee Kim6, Usha Malhotra6, Abby B. Siegel6, Ann-Lii Cheng7. 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; 2Kindai University School of Medicine, Osaka, Japan; 3Medizinische Hochschule, Hannover, Germany; 4University of Hong Kong, Queen Mary Hospital,, Hong Kong, Hong Kong; 5Zhongshan Hospital, Fudan University, Shanghai, China; 6Merck & Co., Inc., Kenilworth, NJ; 7National Taiwan University Hospital Cancer Center, Taipei, Taiwan ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Zhu:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; travel; Eli Lilly. ; BMS. ; Novartis. ; Bayer. ; Eisai. ; Sanofi. ; Exelixis. M. Kudo:  ; MSD. ; Eisai. ; Bayer. ; Ono. ; BMS. ; Eli Lilly. ; EA Pharma. ; Gilead. ; Takeda. ; Otsuka. ; Taiho. A. Vogel:  ; MSD. ; Novartis. ; Delcath Systems. ; Lilly. ; Roche. ; Amgen. ; Bayer. ; Baxalta. ; Sanofi. ; BMS. T. Yau:  ; MSD. ; BMS. J. Zhou:  ; MSD. E. Kim:  ; Merck & Co., Inc.\\xa0U. Malhotra:  ; Merck & Co., Inc.\\xa0A.B. Siegel:  ; Merck & Co., Inc.\\xa0A. Cheng:  ; MSD. ; Bayer. ; travel; Eisai. ; Merck Serono. ; travel; Novartis. ; travel; Ono. ; Exelixis. ; Nucleix Ltd. ; travel; Roche/Genentech. ; travel; IQVIA. ; BMS. ; travel; Bayer Yakuhin, Ltd. ; Amgen Taiwan. ; Bayer Schering Pharma.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-6': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10726',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT286\\n                        \\n                         - CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Luis Paz-Ares1, Edward B. Garon2, Tony Mok3, Andrea Ardizzoni4, Fabrice Barlesi5, Byoung Chul Cho6, Gilberto de Castro7, Pedro De Marchi8, Enriqueta Felip9, Yasushi Goto10, Alastair Greystoke11, Shun Lu12, Darren Wan-Teck Lim13, Martin Reck14, Benjamin J. Solomon15, David R. Spigel16, Daniel SW Tan13, Michael Thomas17, James Chih-Hsin Yang18, Jay M. Lee19, Pilar Garrido20, Edward Kim21, Bruce E. Johnson22. 1University Hospital 12 de Octubre, Madrid, Spain; 2David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, CA; 3Chinese University of Hong Kong, Shatin, Hong Kong; 4S. Orsola-Malpighi University Polyclinic, Bologna, Italy; 5Aix-Marseille University, Marseille, France; 6Yonsei University College of Medicine, Seoul, Korea, Republic of; 7Instituto do Cncer do Estado de So Paulo, So Paulo, Brazil; 8Hospital de Cncer de Barretos, So Paulo, Brazil; 9Vall dHebron Institute of Oncology, Barcelona, Spain; 10National Cancer Center Hospital, Department of Thoracic Oncology, Tokyo, Japan; 11Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom; 12Shanghai Chest Hospital, Jiaotong University, Shanghai, China; 13National Cancer Centre Singapore, Singapore, Singapore; 14LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany; 15Peter MacCallum Cancer Centre, Melbourne, Australia; 16Sarah Cannon Research Institute, Nashville, TN; 17Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universittsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Heidelberg, Germany; 18Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; 19University of California, Los Angeles, Los Angeles, CA; 20Hospital Universitario Ramon y Cajal, Madrid, Spain; 21Levine Cancer Institute, Charlotte, NC; 22Dana-Farber Cancer Institute, Boston, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0L. Paz-Ares:  ; Genmica. ; Lilly. ; MSD. ; Roche. ; PharmaMar. ; Merck. ; AstraZeneca. ; Novartis. ; Boehringer Ingelheim. ; Celgene. ; Servier. ; Sysmex. ; Amgen. ; Incyte. ; Pfizer. ; Ipsen, Adacap, Sanofi, Bayer, Blueprint. ; Bristol-Myers Squibb. ; Altum Sequencing. E.B. Garon:  ; Dracen. ; EMD Serono. ; AstraZeneca. ; Genentech. ; BMS. ; Merck. ; Eli Lilly. ; Novartis. ; Iovance. ; Neon. ; Dynavax. ; Mirati. T. Mok:  ; Officer/Board of Directors; Remunerated: AstraZeneca PLC and Hutchison Chi-Med. ; The Chinese University of Hong Kong (Full time). ; Leadership role (Non-remunerated); American Society of Clinical Oncology (ASCO), Asian Thoracic Oncology Research Group (ATORG), Chinese Lung Cancer Research Foundation Limited (CLCRF), Chinese Society of Clinical Oncology (CSCO). ; Leadership role (Non-remunerated); Hong Kong Cancer Fund (HKCF), Hong Kong Cancer Therapy Society (HKCTS), St. Stephens College & Prep. School. ; Leadership role (Non-remunerated); International Association for the Study of Lung Cancer (IASLC)  term ended on 30/4/19. ; AbbVie, ACEA Pharma, Amgen, Bayer, BI, Blueprint Medicines Corporation, Celgene, CStone Pharmaceuticals. ; Daiichi Sankyo, Eli Lilly, Fishawack Facilitate, Hengrui Therapeutics, Ignyta, Incyte Corporation, IQVIA, Janssen. ; OncoGenex Pharmaceuticals, Roche/Genentech, Sanofi-Aventis R&D, Vertex Pharmaceuticals, Yuhan Corporation. ; Sanomics, Clearbridge Biomedics (now Biolidics). ; Clovis Oncology, Roche, XCovery. ; Alpha Biopharma, Amoy Diagnostics, InMed Medical Communication, Medscape/WebMD, MoreHealth, PeerVoice, PrIME Oncology. ; BMS, AstraZeneca (before 1/1/19), Merck Serono, MSD, Novartis, Pfizer, SFJ Pharmaceuticals, Takeda Pharmaceuticals HK. ; Loxo Oncology, OrigiMed. ; Cirina, geneDecode. ; G1 Therapeutics. ; Hutchison Chi-Med, Virtus Medical Group. A. Ardizzoni:  ; BMS. ; MSD. ; Roche. ; AstraZeneca. ; Eli Lilly. ; Celgene. ; Ipsen. F. Barlesi:  ; AstraZeneca. ; Bayer. ; Bristol-Myers Squibb. ; Boehringer Ingelheim. ; Eli Lilly Oncology. ; F. HoffmannLa Roche. ; Novartis. ; Merck. ; MSD. ; Pierre Fabre. ; Pfizer. ; Takeda. ; AbbVie. ; ACEA. ; Amgen. ; Eisai. ; Genentech. ; Ipsen, Ignyta, Innate Pharma. ; Loxo, MedImmune, Sanofi-Aventis. B. Cho:  ; Novartis. ; Bayer. ; AstraZeneca. ; MOGAM Institute. ; Dong-A ST. ; Licensing/Royalties; Champions Oncology. ; Janssen. ; Yuhan. ; Ono. ; Dizal Pharma. ; MSD. ; Boehringer Ingelheim. ; Roche. ; BMS. ; Pfizer. ; Eli Lilly. ; Takeda. ; TheraCanVac. ; Gencurix. ; BridgeBio Therapeutics. G. de Castro:  ; Travel/Accommodation/Expenses; Lilly. ; Travel/Accommodation/Expenses; AstraZeneca. ; Travel/Accommodation/Expenses; Bayer. ; Travel/Accommodation/Expenses; Bristol-Myers Squibb. ; Travel/Accommodation/Expenses; Boehringer Ingelheim. ; Travel/Accommodation/Expenses; Merck Serono. ; Travel/Accommodation/Expenses; MSD. ; Travel/Accommodation/Expenses; Novartis. ; Travel/Accommodation/Expenses; Pfizer. ; Travel/Accommodation/Expenses; Roche. ; Yuhan. ; Travel/Accommodation/Expenses; Pierre Fabre. ; GSK. ; Beigene. P. De Marchi:  ; Pfizer. ; Travel/Accommodation/Expenses; BMS. ; Travel/Accommodation/Expenses; MSD. ; Travel/Accommodation/Expenses; Roche. ; Travel/Accommodation/Expenses; AstraZeneca. ; Bayer. ; BeiGene. E. Felip:  ; Pfizer. ; Roche. ; Boehringer Ingelheim. ; AstraZeneca. ; Bristol-Myers Squibb. ; Guardant Health. ; Novartis. ; Takeda. ; AbbVie. ; Blueprint Medicines. ; Lilly. ; Merck kGaA. ; Merck Sharp & Dohme. ; Janssen. ; Samsung. ; Medscape. ; PrIME Oncology, TouchTime. ; Fundacin Merck Salud. ; Grant for Oncology Innovation (GOI). ; Grfols (Independent Member). Y. Goto:  ; Eli Lilly. ; Chugai. ; Taiho Pharmaceutical. ; Boehringer Ingelheim. ; Pfizer. ; Novartis. ; AstraZeneca. ; GlaxoSmithKline. ; MSD. ; Guardant Health. ; Daiichi Sankyo. ; Kyorin. ; Illumina. ; Ono Pharmaceutical. ; Bristol-Myers Squibb. ; Shionogi Pharma. ; AbbVie. A. Greystoke:  ; AstraZeneca. ; Travel/Accommodation/Expenses; Boehringer Ingelheim. ; Travel/Accommodation/Expenses; Bristol-Myers Squibb. ; Travel/Accommodation/Expenses; MSD. ; Travel/Accommodation/Expenses; Novartis. ; Pfizer. ; Travel/Accommodation/Expenses; Takeda. ; Travel/Accommodation/Expenses; Roche. S. Lu:  ; Boehringer Ingelheim. ; Hutchison MediPharma. ; Simcere. ; Roche. ; AstraZeneca. ; Pfizer. D. Lim:  ; Boehringer Ingelheim. ; MSD. ; Pfizer. ; Novartis. ; Janssen. ; Bristol-Myers Squibb. ; Biolidics. ; Mesh Bio. M. Reck:  ; Travel/Accommodation/Expenses; AbbVie. ; Travel/Accommodation/Expenses; Amgen. ; Travel/Accommodation/Expenses; Boehringer Ingelheim. ; Travel/Accommodation/Expenses; BMS. ; Travel/Accommodation/Expenses; Celgene. ; Travel/Accommodation/Expenses; Merck. ; Travel/Accommodation/Expenses; MSD. ; Travel/Accommodation/Expenses; Novartis. ; Travel/Accommodation/Expenses; Pfizer. ; Travel/Accommodation/Expenses; Roche. ; Travel/Accommodation/Expenses; Lilly. B.J. Solomon:  ; Novartis. ; AstraZeneca. ; Roche-Genentech. ; Bristol-Myers Squibb. ; Merck. ; Loxo Oncology. ; Gritstone Oncology. ; Pfizer. ; Licensing/Royalties; UpToDate. D.R. Spigel:  ; Travel, Accommodations, Expenses; AstraZeneca, Boehringer Ingelheim, Celgene, Lilly, Bristol-Myers Squibb. ; Moderna Therapeutics, TRM Oncology, Precision Oncology, Evelo Therapeutics, Illumina, PharmaMar. ; Travel, Accommodations, Expenses; Genentech, Genzyme, Intuitive Surgical. ; Celldex, Clovis Oncology, Daiichi Sankyo, Acerta Pharma, Oncogenex, Astellas Pharma. ; GRAIL, Transgene, Aeglea Biotherapeutics, Tesaro, Ipsen, ARMO BioSciences, Millennium. ; Travel, Accommodations, Expenses; EMD Serono. ; Travel, Accommodations, Expenses; Merck, Pfizer. ; Travel, Accommodations, Expenses; Purdue Pharma, Spectrum Pharmaceuticals, Sysmex. ; Genentech/Roche, Novartis. ; University of Texas Southwestern Medical Center - Simmons Cancer Center. ; AbbVie, GlaxoSmithKline. ; G1 Therapeutics, Neon Therapeutics. ; Takeda, Foundation Medicine, Nektar, Amgen. ; Leadership; Centennial Medical Center. D. Tan:  ; Travel/Accommodation/Expenses; Merck. ; Travel/Accommodation/Expenses; Pfizer. ; Travel/Accommodation/Expenses; Novartis. ; Travel/Accommodation/Expenses; Boehringer Ingelheim. ; Travel/Accommodation/Expenses; Roche. ; Travel/Accommodation/Expenses; Takeda. ; Bayer. ; Celgene. ; AstraZeneca. ; Eli Lilly. ; Loxo. ; GlaxoSmithKline. M. Thomas:  ; Travelling support; BMS. ; Travelling support; MSD. ; Travelling support; AstraZeneca. ; Travelling support; Novartis. ; Travelling support; Roche. ; Travelling support; Takeda. ; Travelling support; Lilly. ; Travelling support; Chugai. ; Travelling support; Celgene. ; Travelling support; Boehringer. ; Travelling support; Pfizer. J. Yang:  ; Boehringer Ingelheim. ; Eli Lilly. ; Roche/Genentech/Chugai. ; MSD. ; Novartis. ; BMS. ; Ono pharmaceutical. ; AstraZeneca. ; Takeda Oncology. ; Bayer. ; Merck Serono. ; Pfizer. ; Celgene. ; Yuhan Pharmaceuticals. ; Daiichi Sankyo. ; Blueprint Medicines. ; Hansoh Pharmaceutical. ; G1 Therapeutics. J.M. Lee:  ; AstraZeneca. ; Bristol-Myers Squibb. ; Genentech. ; Novartis. ; Merck. P. Garrido:  ; Roche. ; AstraZeneca. ; Bristol (BMS). ; Guardant Health. ; MSD. ; Pfizer. ; Janssen. ; Boehringer Ingelheim. ; Novartis. ; Gilead. ; Rovi. ; AbbVie. ; Lilly. ; Takeda. ; Sysmex. ; Blueprint Medicines. ; Bayer. E. Kim:  ; Travel/Accommodation/Expenses; Roche. ; Travel/Accommodation/Expenses; Boehringer Ingelheim. ; Travel/Accommodation/Expenses; Pfizer. ; Travel/Accommodation/Expenses; AstraZeneca. ; Travel/Accommodation/Expenses; Merck. ; Travel/Accommodation/Expenses; Takeda. B.E. Johnson:  ; Novartis.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-7': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10727',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT287\\n                        \\n                         - CANOPY-A: A phase III, multicenter, randomized trial evaluating canakinumab versus placebo as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Edward B. Garon1, Andrea Ardizzoni2, Fabrice Barlesi3, Byoung Chul Cho4, Pedro De Marchi5, Yasushi Goto6, Dariusz Kowalski7, Shun Lu8, Luis Paz-Ares9, David R. Spigel10, Alexander Spira11, Michael Thomas12, Mimi Leung13, Jason Baum14, Zewen Zhu15, Bijoyesh Mookerjee13, James Chih-Hsin Yang16. 1David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, CA; 2S. Orsola-Malpighi University Polyclinic, Bologna, Italy; 3Aix-Marseille University, Marseille, France; 4Yonsei University College of Medicine, Seoul, Korea, Republic of; 5Hospital de Cncer de Barretos, So Paulo, Brazil; 6National Cancer Center Hospital, Department of Thoracic Oncology, Tokyo, Japan; 7Oncology Centre - Institute M. Sklodowska- Curie, Warsaw, Poland; 8Shanghai Chest Hospital, Jiaotong University, Shanghai, China; 9University Hospital 12 de Octubre, Madrid, Spain; 10Sarah Cannon Research Institute, Nashville, TN; 11Virginia Cancer Specialists, Fairfax, VA; 12Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universittsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; 13Department of Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ; 14Department of Oncology, Novartis Institutes for BioMedical Research, Cambridge, MA; 15Department of Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ; 16Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan ',\n",
       "  'Disclosures': '\\xa0\\xa0E.B. Garon:  ; Dracen. ; EMD Serono. ; AstraZeneca. ; Genentech. ; BMS. ; Merck. ; Eli Lilly. ; Novartis. ; Iovance. ; Neon. ; Dynavax. ; Mirati. A. Ardizzoni:  ; BMS. ; MSD. ; Roche. ; AstraZeneca. ; Eli Lilly. ; Celgene. ; Ipsen. F. Barlesi:  ; AstraZeneca. ; Bayer. ; Bristol-Myers Squibb. ; Boehringer Ingelheim. ; Eli Lilly Oncology. ; F. HoffmannLa Roche. ; Novartis. ; Merck. ; MSD. ; Pierre Fabre. ; Pfizer. ; Takeda. ; AbbVie. ; ACEA. ; Amgen. ; Eisai. ; Genentech. ; Ipsen. ; Ignyta. ; Innate Pharma, Loxo, Medimmune, Sanofi-Aventis. B. Cho:  ; Novartis. ; Bayer. ; AstraZeneca. ; MOGAM Institute. ; Dong-A ST. ; Licensing/Royalties; Champions Oncology. ; Janssen. ; Yuhan. ; Ono. ; Dizal Pharma. ; MSD. ; Boehringer Ingelheim. ; Roche. ; BMS. ; Pfizer. ; Eli Lilly. ; Takeda. ; TheraCanVac. ; Gencurix. ; Bridgebio Therapeutics. P. De Marchi:  ; Pfizer. ; Travel/Accommodation/Expenses; BMS. ; Travel/Accommodation/Expenses; MSD. ; Travel/Accommodation/Expenses; Roche. ; Travel/Accommodation/Expenses; AstraZeneca. ; Bayer. ; BeiGene. Y. Goto:  ; Eli Lilly. ; Chugai. ; Taiho Pharmaceutical. ; Boehringer Ingelheim. ; Pfizer. ; Novartis. ; AstraZeneca. ; GlaxoSmithKline. ; MSD. ; Guardant Health. ; Daiichi Sankyo. ; Kyorin. ; Illumina. ; Ono Pharmaceutical. ; Bristol-Myers Squibb. ; Shionogi Pharma. ; AbbVie.\\xa0D. Kowalski: None. S. Lu:  ; Boehringer Ingelheim. ; Hutchison MediPharma. ; Simcere. ; Roche. ; AstraZeneca. ; Pfizer. L. Paz-Ares:  ; Genmica. ; Lilly. ; MSD. ; Roche. ; PharmaMar. ; Merck. ; AstraZeneca. ; Novartis. ; Boehringer Ingelheim. ; Celgene. ; Servier. ; Sysmex. ; Amgen. ; Incyte. ; Pfizer. ; Ipsen. ; Adacap. ; Sanofi, Blueprint, Bayer. ; Bristol-Myers Squibb. ; Altum Sequencing. D.R. Spigel:  ; Leadership; Centennial Medical Center. ; Travel, Accomodation, Expenses; AstraZeneca, Boehringer Ingelheim, Celgene, Lilly. ; Travel, Accomodation, Expenses; EMD Serono. ; Travel, Accomodation, Expenses; Bristol-Myers Squibb, Merck, Pfizer. ; Travel, Accomodation, Expenses; Genentech, Genzyme, Intuitive Surgical. ; Travel, Accomodation, Expenses; Purdue Pharma, Spectrum Pharmaceuticals, Sysmex. ; Genentech/Roche, Novartis, AbbVie. ; University of Texas Southwestern Medical Center - Simmons Cancer Center. ; G1 Therapeutics, Neon Therapeutics. ; Takeda, Foundation Medicine, Nektar. ; Celldex, Clovis Oncology, Daiichi Sankyo. ; Acerta Pharma, Oncogenex, Astellas Pharma. ; GRAIL, Transgene, Aeglea Biotherapeutics. ; Tesaro, Ipsen, ARMO BioSciences. ; GlaxoSmithKline, Amgen. ; Moderna Therapeutics, TRM Oncology, Precision Oncology. ; Evelo Therapeutics, Illumina, PharmaMar. ; Millennium. A. Spira:  ; Eli Lilly. ; Merck, Takeda. ; AstraZeneca/MedImmune. ; Incyte, Amgen, Novartis. ; Array BioPharma. ; LAM Therapeutics, Roche, AstraZeneca. ; Boehringer Ingelheim, Astellas Pharma, MedImmune. ; Newlink Genetics, AbbVie, Ignyta. ; Trovagene, Takeda, MacroGenics. ; Astex Pharmaceuticals, Bristol-Myers Squibb. ; Loxo, Arch Therapeutics, Gritstone. ; Plexxikon, Daiichi Sankyo. ; CytomX Therapeutics. M. Thomas:  ; Travelling support; BMS. ; Travelling support; MSD. ; Travelling support; AstraZeneca. ; Travelling support; Novartis. ; Travelling support; Roche. ; Travelling support; Takeda. ; Travelling support; Lilly. ; Travelling support; Chugai. ; Travelling support; Celgene. ; Travelling support; Boehringer. ; Travelling support; Pfizer. M. Leung:  ; Novartis. J. Baum:  ; Employment (Spouse [Lauren Baum]  Abbott Laboratories); Novartis. Z. Zhu:  ; Novartis. B. Mookerjee:  ; Novartis. ; GlaxoSmithKline. ; Incyte. ; AstraZeneca. J. Yang:  ; Boehringer Ingelheim. ; Eli Lilly. ; Roche/Genentech/Chugai. ; MSD. ; Novartis. ; BMS. ; Ono Pharmaceutical. ; AstraZeneca. ; Takeda Oncology. ; Bayer. ; Merck Serono. ; Pfizer. ; Celgene. ; Yuhan Pharmaceuticals. ; Daiichi Sankyo. ; Blueprint Medicines. ; Hansoh Pharmaceutical. ; G1 Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-8': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10728',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT288\\n                        \\n                         - Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with inoperable stage I/IIA non-small-cell lung cancer (NSCLC): KEYNOTE-867\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Salma K. Jabbour1, Baerin Houghton2, Andrew G. Robinson3, Xavier Quantin4, Thomas Wehler5, Dariusz Kowalski6, Myung-Ju Ahn7, Mustafa Erman8, Giuseppe Giaccone9, Hossein Borghaei10, Jessica McLean11, Jin Zhang12, Fabricio Souza11, Roy Decker13. 1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ; 2Mid North Coast Cancer Institute, Port Macquarie Base Hospital, Port Macquarie, NSW, Australia; 3Department of Oncology, Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada; 4Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France; 5Department of Hematology, Oncology and Pulmonology, Evangelisches Krankenhaus Hamm gGmbH, Hamm, Germany; 6Department of Lung Cancer and Thoracic Oncology, Maria Skodowska-Curie Institute of Oncology, Warsaw, Poland; 7Department of Hematology & Oncology, Samsung Medical Center, Seoul, Korea, Republic of; 8Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey; 9Weill-Cornell Medical Center, New York, NY; 10Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA; 11Oncology Clinical Research, Merck & Co., Inc., Kenilworth, NJ; 12Biostatistics, Merck & Co., Inc., Kenilworth, NJ; 13Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Jabbour:  ; Merck. ; Nestle. B. Houghton:  ; Merck. ; AstraZeneca. A. Robinson:  ; Bristol-Myers Squibb. ; Merck. ; Roche. ; AstraZeneca. X. Quantin:  ; MSD. ; Roche. ; AstraZeneca. ; BMS. ; Takeda.\\xa0T. Wehler: None.\\xa0D. Kowalski: None. M. Ahn:  ; BMS. ; ONO. ; MSD. ; AstraZeneca. ; Takeda. ; Lilly. ; Alpha Pharm. M. Erman:  ; BMS. ; Roche. ; MDS. ; Nobel. ; Takeda. ; Boehringer Ingelheim. ; AstraZeneca.\\xa0G. Giaccone: None. H. Borghaei:  ; Millennium. ; Merck. ; Bristol-Myers Squibb. ; Lilly. ; Celgene. ; Pfizer, EMD-Serono, AstraZeneca, Genmab, Genentech, Novartis, Regeneron, BioNTech, Cantargia AB, Amgen, Abbvie, Axiom, PharmaMar, Takeda, Boehringer Ingelheim. ; University of Pennsylvania CAR T Program. ; Incyte. ; Takeda. ; Sonnetbio BioTherapeutics. ; Rgenix. J. McLean:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. J. Zhang:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. F. Souza:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. R. Decker:  ; Merck & Co. ; Genentech. ; Astra Zeneca. ; Regeneron. ; Noxopharm. ; Cybrexa Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-9': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10729',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT289\\n                        \\n                         - Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Natasha B. Leighl1, Rina Hui2, Delvys Rodrguez-Abreu3, Makoto Nishio4, Matthew D. Hellmann5, Chooi Lee6, Xuan Deng7, Debra Kush7, Hossein Borghaei8, Justin Gainor9. 1Princess Margaret Cancer Centre, Toronto, ON, Canada; 2Westmead Hospital and the University of Sydney, Sydney, Australia; 3Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; 4Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 5Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; 6Eisai Ltd., Hatfield, Hertfordshire, United Kingdom; 7Merck & Co., Inc., Kenilworth, NJ; 8Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA; 9Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0N. Leighl:  ; Roche. ; MSD. ; Array. ; Guardant Health. ; Bristol-Myers Squibb. R. Hui:  ; MSD. ; Novartis. ; Roche. ; AstraZeneca. ; BMS. ; Eli Lilly. D. Rodrguez-Abreu:  ; BMS. ; MSD. ; AstraZeneca. ; Boehringer Ingelheim. ; Eli Lilly. ; Roche. ; Novartis. ; Pfizer. M. Nishio:  ; Boehringer Ingelheim. ; Ono Pharmaceutical. ; Bristol-Myers Squibb. ; Pfizer. ; Chugai Pharmaceutical. ; Eli Lilly. ; Taiho Pharmaceutical. ; AstraZeneca. ; MSD. ; Novartis. M. Hellmann:  ; Non-financial support; Bristol-Myers Squibb. ; Non-financial support; Merck. ; Non-financial support; AstraZenecaMedImmune. ; GenentechRoche. ; Nektar. ; Syndax. ; Mirati. ; Shattuck Labs. ; Blueprint Medicines. ; Immunai. ; Non-financial support; Eli Lilly. ; has a patent filed related to the use of tumour mutation burden to predict response to immunotherapy (PCTUS2015062208), licensed to Personal Genome Diagnostics Inc; MSK. C. Lee:  ; Eisai Ltd., Hatfield, Hertfordshire, UK. X. Deng:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. D. Kush:  ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. H. Borghaei:  ; Millennium. ; Merck. ; Celgene. ; Bristol-Myers Squibb. ; Eli Lilly. ; Genentech, Pfizer, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, Abbvie, Axiom, PharmaMar, Takeda, Huya Bioscience, GLG, Daiichi Sankyo. ; University of Pennsylvania CAR T Program. ; Takeda. J. Gainor:  ; Bristol-Myers Squibb, Genentech/Roche, Ariad/Takeda, Blueprint, Novartis, Merck. ; Loxo, Oncorus, Regeneron, Gilead, Pfizer, Incyte, Agios, Amgen, Array, Clovis Oncology. ; Tesaro, Moderna, Jounce, Array Biopharma, Adaptimmune, Alexo Therapeutics (currently ALX Oncology). ; Immediate family member is an employee; Ironwood Pharmaceuticals.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-10': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10730',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT290\\n                        \\n                         - Ibrutinib-rituximab versus placebo-rituximab for first-line treatment of follicular lymphoma: PERSPECTIVE, a randomized phase 3 study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nathan Fowler1, Ian W. Flinn2, Simon Rule3, Robert Chen4, Long Kwei5, Alvina D. Chu5, Leo Gordon6. 1University of Texas MD Anderson Cancer Center, Houston, TX; 2Sarah Cannon Research Institute, Nashville, TN; 3University of Plymouth Peninsula Medical School, Plymouth, United Kingdom; 4City of Hope National Medical Center, Duarte, CA; 5Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; 6Robert H. Lurie Comprehensive Cancer Care Center, Chicago, IL ',\n",
       "  'Disclosures': '\\xa0\\xa0N. Fowler:  ; AbbVie. ; Celgene. ; Janssen. ; Roche. ; TG Therapeutics. I.W. Flinn:  ; AbbVie. ; TG Therapeutics. ; Verastem. ; Seattle Genetics. ; Pharmacyclics LLC, an AbbVie Company. ; AstraZeneca, Celgene, Janssen, Roche, AG Pharma. ; Acerta, Agios, ArQule, BeiGene, Calithera, Constellation. ; Curis, Forma, Forty Seven, Genentech, Gilead, Incyte. ; Infinity, Juno, Karyopharm, KITE, Merck, Morphosys. ; Novartis, Pfizer, Portola, Takeda, Teva, Trillium, Unum. S. Rule:  ; Janssen. ; Pharmacyclics LLC, an AbbVie Company.\\xa0R. Chen: None. L. Kwei:  ; AbbVie. ; Pharmacyclics LLC, an AbbVie Company. A.D. Chu:  ; AbbVie. ; Pharmacyclics LLC, an AbbVie Company. L. Gordon:  ; BMS-Celgene-Juno. ; Gilead-Kite. ; Bayer. ; Janssen. ; Patent; Gold Nanoparticles in Cancer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '847-11': {'Session Title': ' VPO.CT07.03. Phase III Trials in Progress',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Poster Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10731',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT291\\n                        \\n                         - The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice\\n',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Lincoln Nadauld1, Charles H. McDonnell III2, Minetta C. Liu3, Eric Klein4, Tomasz M. Beer5, Deborah Schrag6, Andrew G. Hudnut7, Richard Whittington8, Bruce Taylor8, Joanna Tierney8, Jafi Lipson9, Margarita Lopatin9, Karen C. Chung9, Eric Fung9, Anne-Renee Hartman9, Geoffrey R. Oxnard6, Catherine Marinac6. 1Intermountain Healthcare, St. George, UT; 2Sutter Health, Sacramento, CA; 3Mayo Clinic, Rochester, MN; 4Cleveland Clinic, Cleveland, OH; 5Oregon Health & Science University Knight Cancer Institute, Portland, OR; 6Dana-Farber Cancer Institute, Boston, MA; 7Sutter Health, Sacremento, CA; 8Intermountain Healthcare, Salt Lake City, UT; 9GRAIL, Menlo Park, CA ',\n",
       "  'Disclosures': '\\xa0L. Nadauld: None.\\xa0C.H. McDonnell III: None. M.C. Liu:  ; The Mayo Clinic was compensated for MCLs advisory board activities for GRAIL, Inc.; GRAIL. E. Klein:  ; GRAIL. ; Cellanyx.\\xa0T.M. Beer: None.\\xa0D. Schrag: None.\\xa0A.G. Hudnut: None.\\xa0R. Whittington: None.\\xa0B. Taylor: None.\\xa0J. Tierney: None. J. Lipson:  ; GRAIL. M. Lopatin:  ; GRAIL. K.C. Chung:  ; GRAIL. E. Fung:  ; GRAIL. A. Hartman:  ; Former employee of GRAIL at time of development; GRAIL. G.R. Oxnard:  ; Inivata. ; Guardant Health. ; Sysmex Corporation. ; Bio-Rad Laboratories. ; DropWorks. ; AstraZeneca. ; GRAIL.\\xa0C. Marinac: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-1': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10520',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 11:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Zoran Rankovic. St. Jude Children's Research Hospital, Memphis, TN\",\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-2': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10521',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 11:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Christopher G. Nasveschuk. C4 Therapeutics, Watertown, MA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-3': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10996',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 11:50 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-4': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10522',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1036\\n                        \\n                         - Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:50 AM - 12:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Changwei Wang1, Rohan Kalyan Rej1, Jianfeng Lu1, Mi Wang1, Kaitlin P. Harvey1, Chao-Yie Yang1, Ester Fernandez-Salas1, Jeanne Stuckey1, Elyse Petrunak1, Caroline Foster1, Yunlong Zhou2, Rubin Zhou2, Guozhi Tang2, Jianyong Chen2, Shaomeng Wang1. 1Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, Life Sciences Institute, University of Michigan, Ann Arbor, MI; 2Ascentage Pharma Group, Taizhou, Jiangsu, China ',\n",
       "  'Disclosures': '\\xa0C. Wang: None.\\xa0R.K. Rej: None.\\xa0J. Lu: None.\\xa0M. Wang: None.\\xa0K.P. Harvey: None.\\xa0C. Yang: None.\\xa0E. Fernandez-Salas: None.\\xa0J. Stuckey: None.\\xa0E. Petrunak: None.\\xa0C. Foster: None. Y. Zhou:  ; Ascentage Pharma Group. R. Zhou:  ; Ascentage Pharma Group. G. Tang:  ; Ascentage Pharma Group. J. Chen:  ; Ascentage Pharma Group. S. Wang:  ; The authors declare the following competing financial interest(s): The University of Michigan has filed a patent application on these EED inhibitors and their analogues, which has been licensed by Ascentage. S. Wang is a co-inventor on the patent, a paid consultant of Ascentage and owns stock in Ascentage.  The University of Michigan also owns stock in Ascentage.; Ascentage Pharma Group.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-5': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10998',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:00 PM - 12:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-6': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10523',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1037\\n                        \\n                         - Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:05 PM - 12:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Xiaohui Du, Brian Blank, Brenda Chan, Xi Chen, Yuping Chen, Frank Duong, Lori Friedman, Tom Huang, Melissa R. Junttila, Wayne Kong, Todd Metzger, Jared Moore, Daqing Sun, Jessica Sun, Dena Sutimantanapi, Natalie Yuen, Tatiana Zavorotinskaya. ORIC Pharmaceuticals, South San Francisco, CA ',\n",
       "  'Disclosures': '\\xa0\\xa0X. Du:  ; ORIC Pharmaceuticals. B. Blank:  ; ORIC Pharmaceuticals. B. Chan:  ; ORIC Pharmaceuticals. X. Chen:  ; ORIC Pharmaceuticals. Y. Chen:  ; ORIC Pharmaceuticals. F. Duong:  ; ORIC Pharmaceuticals. L. Friedman:  ; ORIC Pharmaceuticals. T. Huang:  ; ORIC Pharmaceuticals. M.R. Junttila:  ; ORIC Pharmaceuticals. W. Kong:  ; ORIC Pharmaceuticals. T. Metzger:  ; ORIC Pharmaceuticals. J. Moore:  ; ORIC Pharmaceuticals. D. Sun:  ; ORIC Pharmaceuticals. J. Sun:  ; ORIC Pharmaceuticals. D. Sutimantanapi:  ; ORIC Pharmaceuticals. N. Yuen:  ; ORIC Pharmaceuticals. T. Zavorotinskaya:  ; ORIC Pharmaceuticals.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-7': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11005',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:15 PM - 12:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-8': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10524',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1038\\n                        \\n                         - A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:20 PM - 12:30 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': 'Laurie Schenkel, Jennifer Molina, Kerren Swinger, Ryan Abo, Danielle Blackwell, Anne Cheung, William Church, Kristy Kuplast-Barr, Alvin Lu, Elena Minissale, Mario Niepel, Melissa Vasbinder, Tim Wigle, Victoria Richon, Heike Keilhack, Kevin Kuntz. Ribon Therapeutics, Cambridge, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0L. Schenkel:  ; Ribon Therapeutics. J. Molina:  ; Ribon Therapeutics. K. Swinger:  ; Ribon Therapeutics. R. Abo:  ; Ribon Therapeutics. D. Blackwell:  ; Ribon Therapeutics. A. Cheung:  ; Revitope. W. Church:  ; Ribon Therapeutics. K. Kuplast-Barr:  ; Ribon Therapeutics. A. Lu:  ; Ribon Therapeutics. E. Minissale:  ; Ribon Therapeutics. M. Niepel:  ; Ribon Therapeutics. M. Vasbinder:  ; Ribon Therapeutics. T. Wigle:  ; Ribon Therapeutics. V. Richon:  ; Ribon Therapeutics. H. Keilhack:  ; Ribon Therapeutics. K. Kuntz:  ; Ribon Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-9': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11004',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1038\\n                        \\n                         - A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:20 PM - 12:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Laurie Schenkel, Jennifer Molina, Kerren Swinger, Ryan Abo, Danielle Blackwell, Anne Cheung, William Church, Kristy Kuplast-Barr, Alvin Lu, Elena Minissale, Mario Niepel, Melissa Vasbinder, Tim Wigle, Victoria Richon, Heike Keilhack, Kevin Kuntz. Ribon Therapeutics, Cambridge, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0L. Schenkel:  ; Ribon Therapeutics. J. Molina:  ; Ribon Therapeutics. K. Swinger:  ; Ribon Therapeutics. R. Abo:  ; Ribon Therapeutics. D. Blackwell:  ; Ribon Therapeutics. A. Cheung:  ; Revitope. W. Church:  ; Ribon Therapeutics. K. Kuplast-Barr:  ; Ribon Therapeutics. A. Lu:  ; Ribon Therapeutics. E. Minissale:  ; Ribon Therapeutics. M. Niepel:  ; Ribon Therapeutics. M. Vasbinder:  ; Ribon Therapeutics. T. Wigle:  ; Ribon Therapeutics. V. Richon:  ; Ribon Therapeutics. H. Keilhack:  ; Ribon Therapeutics. K. Kuntz:  ; Ribon Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-10': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10525',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1039\\n                        \\n                         - Fragment-based drug discovery to identify small molecule allosteric inhibitors of SHP2\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:35 PM - 12:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Philip J. Day1, Valerio Berdini1, Juan Castro1, Gianni Chessari1, Thomas G. Davies1, James E. H. Day1, Satoshi Fukaya2, Chris Hamlett1, Keisha Hearn1, Steve Hiscock1, Rhian Holvey1, Satoru Ito2, Yasuo Kodama2, Kenichi Matsuo2, Yoko Nakatsuru2, Nick Palmer1, Amanda Price1, Tadashi Shimamura2, Jeffrey D. St. Denis1, Nicola G. Wallis1, Glyn Williams1, Christopher N. Johnson1. 1Astex Pharmaceuticals, Inc., Cambridge, United Kingdom; 2Taiho Pharmaceutical Co., Ltd, Tsukuba, Japan ',\n",
       "  'Disclosures': '\\xa0P.J. Day: None.\\xa0V. Berdini: None.\\xa0J. Castro: None.\\xa0G. Chessari: None.\\xa0T.G. Davies: None.\\xa0J.E.H. Day: None.\\xa0S. Fukaya: None.\\xa0C. Hamlett: None.\\xa0K. Hearn: None.\\xa0S. Hiscock: None.\\xa0R. Holvey: None.\\xa0S. Ito: None.\\xa0Y. Kodama: None.\\xa0K. Matsuo: None.\\xa0Y. Nakatsuru: None.\\xa0N. Palmer: None.\\xa0A. Price: None.\\xa0T. Shimamura: None.\\xa0J.D. St. Denis: None.\\xa0N.G. Wallis: None.\\xa0G. Williams: None.\\xa0C.N. Johnson: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-11': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11008',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:45 PM - 12:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-12': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10526',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1040\\n                        \\n                         - Development of potential PROTAC degraders of JAK2: Design, synthesis, and SAR studies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:50 PM - 1:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Baoli Li, Sang Yun, Ryan Davis, Pradeep Reddy Nareddy, Narmin Amin, Gary W. Reuther, Ernst Schnbrunn, Harshani R. Lawrence, Nicholas J. Lawrence. Moffitt Cancer Center, Tampa, FL ',\n",
       "  'Disclosures': '\\xa0B. Li: None.\\xa0S. Yun: None.\\xa0R. Davis: None.\\xa0P.R. Nareddy: None.\\xa0N. Amin: None.\\xa0G.W. Reuther: None.\\xa0E. Schnbrunn: None.\\xa0H.R. Lawrence: None.\\xa0N.J. Lawrence: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-13': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11009',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:00 PM - 1:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-14': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10528',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1042\\n                        \\n                         - Preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:05 PM - 1:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Eric T. Gangl, Roshini Markandu, Pradeep Sharma, Andy Sykes, Petar Pop-Damkov, Pablo Morentin Gutierrez, James S. Scott, Dermot F. McGinnity, Adrian J. Fretland, Teresa Klinowska. AstraZeneca, Waltham, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0E.T. Gangl:  ; AstraZeneca. R. Markandu:  ; AstraZeneca. P. Sharma:  ; AstraZeneca. A. Sykes:  ; AstraZeneca. P. Pop-Damkov:  ; AstraZeneca. P. Morentin Gutierrez:  ; AstraZeneca. J.S. Scott:  ; AstraZeneca. D.F. McGinnity:  ; AstraZeneca. A.J. Fretland:  ; AstraZeneca. T. Klinowska:  ; AstraZenca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '833-15': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11010',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:15 PM - 1:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '833-16': {'Session Title': ' VMS.CH01.01. Advances in Cancer Drug Design and Discovery',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nCancer Chemistry\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11028',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:20 PM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Christopher G. Nasveschuk. MA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '855-1': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10767',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:00 PM - 4:01 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'E.G. Elisabeth De Vries. University Medical Center Groningen, Groningen, Netherlands',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '855-2': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10881',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:00 PM - 4:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '855-3': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10768',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT061\\n                        \\n                         - Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:05 PM - 4:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"James M. Cleary1, Victoria Wang1, Rebecca Heist2, Scott Kopetz3, Edith P. Mitchell4, James Zwiebel5, Helen X. Chen6, Shuli Li1, Robert Gray1, Lisa McShane7, Larry Rubinstein8, David Patton5, Funda Meric-Bernstam9, Melissa Dillmon10, Mickey Williams5, Stanley Hamilton11, Barbara Conley5, Peter O'Dwyer12, Lyndsay Harris5, Carlos Arteaga13, Alice Chen5, Keith Flaherty2. 1Dana-Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital, Boston, MA; 3MD Anderson Cancer Institute, Houston, TX; 4Thomas Jefferson University, Philadelphia, PA; 5National Cancer Institute, Bethesda, MD; 6National Cancer Institute, Betheseda, MD; 7National Cancer Institute, Bethesda, MA; 8National Cancer Institute, Boston, MA; 9MD Anderson Cancer Center, Houston, TX; 10Harbin Clinic, Rome, GA; 11MD Anderson Cancer Instittute, Houston, TX; 12University of Pennsylvania, Philadelpha, PA; 13UT Southwestern, Dallas, TX \",\n",
       "  'Disclosures': \"\\xa0\\xa0J.M. Cleary:  ; Tesaro. ; Merck. ; Travel; BMS.\\xa0V. Wang: None. R. Heist:  ; Boehringer Ingelheim. ; Novartis. ; Apollomics. ; Tarveda. ; Research funding to institution; Novartis. ; Research funding to institution; Abbvie. ; Research funding to institution; Daichii Sankyo. ; Research funding to instituion; Agios. ; Research funding to institution; Corvus. ; Research funding to institution; Genentech. ; Research funding to institution; Mirati. ; Research funding to institution; Exelixis.\\xa0S. Kopetz: None.\\xa0E.P. Mitchell: None.\\xa0J. Zwiebel: None.\\xa0H.X. Chen: None.\\xa0S. Li: None.\\xa0R. Gray: None.\\xa0L. McShane: None.\\xa0L. Rubinstein: None.\\xa0D. Patton: None.\\xa0F. Meric-Bernstam: None.\\xa0M. Dillmon: None.\\xa0M. Williams: None.\\xa0S. Hamilton: None.\\xa0B. Conley: None.\\xa0P. O'Dwyer: None.\\xa0L. Harris: None.\\xa0C. Arteaga: None.\\xa0A. Chen: None.\\xa0K. Flaherty: None.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '855-4': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10882',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:15 PM - 4:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '855-5': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10962',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:20 PM - 4:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"David S. Hong1, Afshin Dowlati2, Howard Burris3, Edward Chu4, Marcia S. Brose5, Anna F. Farago6, Cornelis M. van Tilburg7, Shivaani Kummar8, Leo Mascarenhas9, John A. Reeves10, Marion Rudolph11, Patricia Maeda10, Barrett H. Childs10, Theodore W. Laetsch12, Alexander Drilon13. 1The University of Texas MD Anderson Cancer Center, Houston, TX; 2University Hospitals Ahuja Medical Center, Beachwood, OH; 3Sarah Cannon Research Institute, Nashville, TN; 4Division of Hematology-Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA; 5Abramson Cancer Center of the University of Pennsylvania School of Medicine, Philadelphia, PA; 6Massachusetts General Hospital Cancer Center, Boston, MA; 7Hopp Childrens Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; 8Stanford Cancer Institute, Stanford University, Palo Alto, CA; 9Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA; 10Bayer HealthCare Pharmaceuticals, Whippany, NJ; 11Bayer AG, Pharmaceuticals, Berlin, Germany; 12University of Texas Southwestern Medical Center/Childrens Health, Dallas, TX; 13Memorial Sloan Kettering Cancer Center, New York, NY \",\n",
       "  'Disclosures': '\\xa0\\xa0D.S. Hong:  ; Novartis. ; Merck. ; Loxo Oncology. ; AstraZeneca. ; Personal fees; Roche. ; Personal fees; Pfizer. ; Takeda. ; Bristol-Myers Squibb. ; Personal fees; Boehringer Ingleheim. ; GSK. A. Dowlati:  ; Takeda. ; Abbvie. ; Seattle Genetics. ; AstraZeneca. ; Bristol Myers Squibb. ; Loxo. ; Bayer. ; Incuron. ; Takeda. ; Regeneron. ; Tesaro. ; Amgen. ; Seattle genetics. ; Symphogen. ; Abbvie. ; Ipsen. H. Burris:  ; Leadership; HCA healthcare/Sarah Canon. ; AZ. ; FORMA therapeutics. ; Celgene. ; Incyte. ; Roche. ; Genentech. ; BMS. ; MedImmune. ; Macrogenics. ; Novartis. ; Boehringer Ingelheim. ; Lilly. ; Seattle Genetics. ; Merck. ; Agios. ; Jounce Therapeutics. ; Moderna therapeutics. ; cytom X. ; GSK. E. Chu:  ; Proteus Digital Health. M.S. Brose:  ; Bayer. ; Loxo Oncology. ; Genentech. ; Eisai. ; Blueprint Medicines. ; Lilly. ; Novartis. ; AstraZeneca. ; Clinical Care Options. ; OncLive. ; PeerView. ; Medscape. A.F. Farago:  ; Bayer. ; Loxo Oncology. ; Genentech. ; Roche. ; Bristol-Myers Squibb. ; AstraZeneca. ; AbbVie. ; PharmaMar. ; Merck. ; Ignyta. ; Amgen. ; Lilly. ; Boehringer Ingelheim. ; Pfizer. ; H3 Biomedicine. ; Clinical Care Options. ; Medscape. ; Onclive. ; Research to Practice. ; PeerView. C.M. van Tilburg:  ; Advisory fees; Bayer. ; Advisory fees; Novartis. S. Kummar:  ; Travel support; Bayer. L. Mascarenhas:  ; Clinical trial support; Bayer. ; Clinical trial support; Lilly. ; Clinical trial support; AstraZeneca. ; Clinical trial support; Salarius. J.A. Reeves:  ; Bayer. M. Rudolph:  ; Bayer. P. Maeda:  ; Bayer. B.H. Childs:  ; Bayer. T.W. Laetsch:  ; Novartis. ; Bayer. ; Loxo. ; Lilly. ; Pfizer. ; Abbvie. ; Amgen. ; Atara. ; Biotherapeutics. ; BMS. ; Jubilant Pharmaceuticals. ; Epizyme. ; GSK. ; Janssen. ; Novella Clinical. ; Servier. A. Drilon:  ; Ignyta/Genentech/Roche. ; Loxo Oncology/Bayer/Lilly. ; Takeda/Ariad/Millenium. ; TP Therapeutics. ; AstraZeneca. ; Pfizer. ; Blueprint Medicines. ; Helsinn. ; Beigene. ; BergenBio. ; Hengrui Therapeutics. ; Exelixis. ; Tyra Biosciences. ; Verastem. ; MORE Health. ; GlaxoSmithKline, Teva, Taiho, PharmaMar. ; Foundation Medicine. ; Food and beverage; Merck and Puma Biotechnology. ; CME honoraria; Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, and Research to Practice. ; Royalties; Wolters Kluwer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '855-6': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10883',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:30 PM - 4:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '855-7': {'Session Title': ' VCTPL06. Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10885',\n",
       "  'Date': ' April 28, 2020, 4:00 PM - 4:55 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 4:50 PM - 4:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-1': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10555',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'J. Silvio Gutkind. UCSD Moores Cancer Center, La Jolla, CA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-2': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10556',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adrienne D. Cox. University of North Carolina at Chapel Hill, Chapel Hill, NC',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-3': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10983',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adrienne D. Cox. University of North Carolina at Chapel Hill, Chapel Hill, NC',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-4': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10557',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 11:55 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'J. Silvio Gutkind. UCSD Moores Cancer Center, La Jolla, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-5': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10986',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 11:55 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'J. Silvio Gutkind. UCSD Moores Cancer Center, La Jolla, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-6': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10558',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1086\\n                        \\n                         - Downstream kinase signaling is dictated by specific KRAS mutations\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:10 PM - 12:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Konstantin Budagyan1, Jonathan Chernoff2. 1Drexel University College of Medicine, Philadelphia, PA; 2Fox Chase Cancer Center, Philadelphia, PA ',\n",
       "  'Disclosures': '\\xa0K. Budagyan: None.\\xa0J. Chernoff: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-7': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10988',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:20 PM - 12:25 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-8': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10559',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1087\\n                        \\n                         - NF1 regulates the RAS-related GTPases, RRAS and RRAS2, independent of RAS activity\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:25 PM - 12:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jillian M. Silva, Lizzeth Canche, Frank McCormick. University of California, San Francisco, San Francisco, CA ',\n",
       "  'Disclosures': '\\xa0J.M. Silva: None.\\xa0L. Canche: None.\\xa0F. McCormick: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-9': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10991',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1087\\n                        \\n                         - NF1 regulates the RAS-related GTPases, RRAS and RRAS2, independent of RAS activity\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:25 PM - 12:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jillian M. Silva, Lizzeth Canche, Frank McCormick. University of California, San Francisco, San Francisco, CA ',\n",
       "  'Disclosures': '\\xa0J.M. Silva: None.\\xa0L. Canche: None.\\xa0F. McCormick: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-10': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10560',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:35 PM - 12:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-11': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10989',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1088\\n                        \\n                         - Elucidating the regulation of delayed-early gene targets of sustained MAPK signaling\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:40 PM - 12:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Kali J. Dale1, Martin McMahon2. 1University of Utah, Salt Lake City, UT; 2Huntsman Cancer Institute, Salt Lake City, UT ',\n",
       "  'Disclosures': '\\xa0K.J. Dale: None.\\xa0M. McMahon: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-12': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10562',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:50 PM - 12:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-13': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10992',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1090\\n                        \\n                         - Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:55 PM - 1:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Radha Mukherjee1, Kiran Gireesan Vanaja2, Jacob A. Boyer1, Juan Qiu1, Xiaoping Chen1, Elisa de Stanchina1, Sarat Chandarlapaty1, Andre Levchenko2, Neal Rosen1. 1Memorial Sloan Kettering Cancer Center, New York, NY; 2Yale University, West Haven, CT ',\n",
       "  'Disclosures': '\\xa0R. Mukherjee: None.\\xa0K. Gireesan Vanaja: None.\\xa0J.A. Boyer: None.\\xa0J. Qiu: None.\\xa0X. Chen: None.\\xa0E. de Stanchina: None. S. Chandarlapaty:  ; Eli Lilly. ; Novartis. ; Sermonix. ; Revolution Medicine. ; Context. ; Mristol Myers Squibb. ; Paige AI. ; Daichi-Sankyo. ; Sanofi.\\xa0A. Levchenko: None. N. Rosen:  ; Beigene. ; Fortress Biotech. ; Kura Oncology. ; MapKure. ; Ribon Therapeutics. ; Zai Lab. ; AstraZeneca. ; Boehringer Ingelheim. ; Chugai Pharmaceuticals. ; Revolution Medicines.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-14': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10563',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1091\\n                        \\n                         - BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:10 PM - 1:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Daniel Gerlach1, Michael Gmachl1, Juergen Ramharter1, Jessica Teh2, Szu-Chin Fu2, Francesca Trapani1, Dirk Kessler1, Klaus Rumpel1, Dana-Adriana Botesteanu1, Peter Ettmayer1, Heribert Arnhof1, Thomas Gerstberger1, Christiane Kofink1, Tobias Wunberg1, Christopher P. Vellano2, Timothy P. Heffernan2, Joseph R. Marszalek2, Mark Pearson1, Darryl B. McConnell1, Norbert Kraut1, Marco H. Hofmann1. 1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria; 2The University of Texas MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0D. Gerlach:  ; Boehringer Ingelheim RCV GmbH & Co KG. M. Gmachl:  ; Inventor on patents for BI-3406 and BI 1701963; Boehringer Ingelheim RCV GmbH & Co KG. J. Ramharter:  ; Inventor on patents for BI-3406 and BI 1701963; Boehringer Ingelheim RCV GmbH & Co KG. J. Teh:  ; The University of Texas MD Anderson Cancer Center. ; Boehringer Ingelheim RCV GmbH & Co KG. S. Fu:  ; The University of Texas MD Anderson Cancer Center. ; Boehringer Ingelheim RCV GmbH & Co KG. F. Trapani:  ; Boehringer Ingelheim RCV GmbH & Co KG. D. Kessler:  ; Boehringer Ingelheim RCV GmbH & Co KG. K. Rumpel:  ; Boehringer Ingelheim RCV GmbH & Co KG. D. Botesteanu:  ; Boehringer Ingelheim RCV GmbH & Co KG. P. Ettmayer:  ; Boehringer Ingelheim RCV GmbH & Co KG. H. Arnhof:  ; Boehringer Ingelheim RCV GmbH & Co KG. T. Gerstberger:  ; Boehringer Ingelheim RCV GmbH & Co KG. C. Kofink:  ; Boehringer Ingelheim RCV GmbH & Co KG. T. Wunberg:  ; Boehringer Ingelheim RCV GmbH & Co KG. C.P. Vellano:  ; The University of Texas MD Anderson Cancer Center. ; Boehringer Ingelheim RCV GmbH & Co KG. T.P. Heffernan:  ; The University of Texas MD Anderson Cancer Center. ; Boehringer Ingelheim RCV GmbH & Co KG. J.R. Marszalek:  ; The University of Texas MD Anderson Cancer Center. ; Boehringer Ingelheim RCV GmbH & Co KG. M. Pearson:  ; Boehringer Ingelheim RCV GmbH & Co KG. D.B. McConnell:  ; Boehringer Ingelheim RCV GmbH & Co KG. N. Kraut:  ; Boehringer Ingelheim RCV GmbH & Co KG. M.H. Hofmann:  ; Inventor on patents with BI-3406 and BI 1701963; Boehringer Ingelheim RCV GmbH & Co KG.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '837-15': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10994',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:05 PM - 1:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '837-16': {'Session Title': ' VMS.MCB01.01. Emerging Signaling Vulnerabilities in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10985',\n",
       "  'Date': ' April 27, 2020, 11:45 AM - 1:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:25 PM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adrienne D. Cox. University of North Carolina at Chapel Hill, Chapel Hill, NC',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '840-1': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10580',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Christine Spencer. Parker Institute for Cancer Immunotherapy, San Francisco, CA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '840-2': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10581',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adriana Albini. MultiMedica Foundation onlus, Italy, Milano, Italy',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '840-3': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11034',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 4:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Christine Spencer. Parker Institute for Cancer Immunotherapy, San Francisco, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '840-4': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10583',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5730\\n                        \\n                         - A new polyphenol prebiotic isolated from Myrciaria dubia improves gut microbiota composition and increases anti-PD-1 efficacy in murine cancer models\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:55 PM - 5:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Meriem Messaoudene1, Florent Cauchois1, Reilly Piedgeon2, Khoudia Diop1, Corentin Richard1, Thibault Varin3, Jocelyn Trottier4, Olivier Barbier4, Genevive Pilon3, Simon Turcotte5, Andr Marette3, Bastien Castagner2, Bertrand Routy6. 1University of Montral Research Center (CRCHUM), Montreal, QC, Canada; 2Faculty of Medicine, McGill University, Montreal, QC, Canada; 3Faculty of Medicine, Cardiology Axis of the Quebec Heart and Lung Institute and Institute of Nutrition and Functional Foods, Laval University, Quebec, QC, Canada; 4Laboratory of Molecular Pharmacology, Endocrinology-Nephrology Axis, CHU-Qubec Research Centre, Quebec, QC, Canada; 5University of Montral Research Center (CRCHUM), Hepatopancreatobiliary and Liver Transplantation Division, Centre hospitalier de l'Universit de Montral, Montreal, QC, Canada; 6University of Montral Research Center (CRCHUM), Hematology-Oncology Division University of Montreal Healthcare Centre (CHUM), Montreal, QC, Canada \",\n",
       "  'Disclosures': '\\xa0M. Messaoudene: None.\\xa0F. Cauchois: None.\\xa0R. Piedgeon: None.\\xa0K. Diop: None.\\xa0C. Richard: None.\\xa0T. Varin: None.\\xa0J. Trottier: None.\\xa0O. Barbier: None.\\xa0G. Pilon: None.\\xa0S. Turcotte: None.\\xa0A. Marette: None.\\xa0B. Castagner: None.\\xa0B. Routy: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '840-5': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11036',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:05 PM - 5:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '840-6': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10586',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5733\\n                        \\n                         - Versican proteolytic fragments (matrikines) synergize with STING agonists to elicit robust anti-tumor CD8+ T cell responses\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:10 PM - 5:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Athanasios Papadas1, Evan Flietner2, Zachary Morrow2, Joshua Wiesner2, Alexander Cicala2, Adam Pagenkopf2, Chelsea Hope2, Philip Emmerich2, Dustin Deming2, Jing Zhang2, Peiman Hematti2, Natalie Callander2, Alexander Rakhmilevich2, Mario Otto2, Christian Capitini2, Fotis Asimakopoulos1. 1UCSD, La Jolla, CA; 2UW-Madison, Madison, WI ',\n",
       "  'Disclosures': '\\xa0A. Papadas: None.\\xa0E. Flietner: None.\\xa0Z. Morrow: None.\\xa0J. Wiesner: None.\\xa0A. Cicala: None.\\xa0A. Pagenkopf: None.\\xa0C. Hope: None.\\xa0P. Emmerich: None.\\xa0D. Deming: None.\\xa0J. Zhang: None.\\xa0P. Hematti: None.\\xa0N. Callander: None.\\xa0A. Rakhmilevich: None.\\xa0M. Otto: None.\\xa0C. Capitini: None.\\xa0F. Asimakopoulos: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '840-7': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11037',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:20 PM - 5:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '840-8': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10587',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5734\\n                        \\n                         - Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:25 PM - 5:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Marcel Batten1, Erin Shanahan2, Rebecca Simpson2, Mark Read2, Ines P. Silva1, Alexandra Angelatos2, Jian Tan2, Chandra Adhikari1, Alexander M. Menzies3, Robyn P. M. Saw3, Laurence Macia2, Maria Gonzalez3, Kerwin Shannon3, Rebecca Velickovic1, Irene L. M. Reijers4, Christian U. Blank4, James S. Wilmott1, Andrew J. Holmes2, Richard A. Scolyer1, Georgina V. Long1. 1Melanoma Insitute Australia, Camperdown, Australia; 2University of Sydney, Camperdown, Australia; 3Melanoma Insitute Australia, Sydney, Australia; 4Netherlands Cancer Institute, Amsterdam, Netherlands ',\n",
       "  'Disclosures': '\\xa0M. Batten: None.\\xa0E. Shanahan: None.\\xa0R. Simpson: None.\\xa0M. Read: None.\\xa0I.P. Silva: None.\\xa0A. Angelatos: None.\\xa0J. Tan: None.\\xa0C. Adhikari: None. A.M. Menzies:  ; BMS. ; MSD. ; Novartis. ; Roche. ; Pierre-Fabre.\\xa0R.P.M. Saw: None.\\xa0L. Macia: None.\\xa0M. Gonzalez: None.\\xa0K. Shannon: None.\\xa0R. Velickovic: None.\\xa0I.L.M. Reijers: None. C.U. Blank:  ; BMS. ; MSD. ; Roche. ; Novartis. ; GSK. ; AZ. ; Pfizer. ; Lilly. ; GenMab. ; Pierre Fabre. ; Nanostring. ; Uniti Cars. ; Neon Therapeutics. ; Forty Seven.\\xa0J.S. Wilmott: None.\\xa0A.J. Holmes: None. R.A. Scolyer:  ; Merck Sharp & Dohme. ; GlaxoSmithKline Australia. ; Bristol-Myers Squibb. ; Dermpedia. ; Novartis Pharmaceuticals Australia Pty Ltd. ; Myriad. ; NeraCare. ; Amgen. G.V. Long:  ; Aduro. ; Amgen. ; Array. ; BMS. ; MSD. ; Novartis. ; Roche. ; Pierre-Fabre. ; Sandoz.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '840-9': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11039',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:35 PM - 5:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '840-10': {'Session Title': ' VMS.TB06.02. Therapeutic Modification of the Tumor Microenvironment or Microbiome',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nTumor Biology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11033',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 5:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:40 PM - 5:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adriana Albini. MultiMedica Foundation onlus, Italy, Milano, Italy',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-1': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10547',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:15 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Naoko Takebe. National Cancer Institute, Bethesda, MD',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-2': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10548',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:15 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Roger S. Lo. University of California (UCLA), Los Angeles, CA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-3': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10963',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:15 PM - 2:20 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': 'Naoko Takebe. National Cancer Institute, Bethesda, MD',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-4': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10549',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1057\\n                        \\n                         - Targeting MTHFD2 using first-in-class inhibitors kills haematological and solid cancer through thymineless-induced replication stress\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:20 PM - 2:30 PM',\n",
       "  'Presentation Location': '\\n\\n',\n",
       "  'Presenter/Authors': 'Thomas Helleday. University of Sheffield, Sheffield, United Kingdom ',\n",
       "  'Disclosures': '\\xa0T. Helleday: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-5': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10965',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:30 PM - 2:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-6': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10550',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1058\\n                        \\n                         - Targeting chromatin remodeling-associated genetic vulnerabilities in cancer: PBRM1 defects are synthetic lethal with PARP and ATR inhibitors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:35 PM - 2:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Roman Merial Chabanon1, Daphn Morel1, Lo Colmet-Daage1, Thomas Eychenne1, Nicolas Dorvault1, Ilirjana Bajrami2, Marlne Garrido1, Suzanna Hopkins3, Cornelia Meisenberg3, Andrew Lamb4, Theo Roumeliotis3, Samuel Jouny3, Clmence Astier1, Asha Konde3, Genevive Almouzni5, Jyoti Choudhary3, Jean-Charles Soria6, Jessica Downs3, Christopher J. Lord3, Sophie Postel-Vinay7. 1Gustave Roussy, Villejuif, France; 2The Francis Crick Institute, London, United Kingdom; 3Institute of Cancer Research, London, United Kingdom; 4Sage Bionetworks, Seattle, WA; 5Institut Curie, Paris, France; 6Universit Paris-Sud/Universit Paris-Saclay, Le Kremlin-Bictre, France; 7Gustave Roussy Cancer Campus and U981 INSERM, ATIP-Avenir group, Villejuif, France ',\n",
       "  'Disclosures': '\\xa0R.M. Chabanon: None.\\xa0D. Morel: None.\\xa0L. Colmet-Daage: None.\\xa0T. Eychenne: None.\\xa0N. Dorvault: None.\\xa0I. Bajrami: None.\\xa0M. Garrido: None. S. Hopkins:  ; Fishawack Group of Companies.\\xa0C. Meisenberg: None.\\xa0A. Lamb: None.\\xa0T. Roumeliotis: None.\\xa0S. Jouny: None.\\xa0C. Astier: None.\\xa0A. Konde: None.\\xa0G. Almouzni: None.\\xa0J. Choudhary: None. J. Soria:  ; Medimmune/AstraZeneca. ; Astex. ; Gritstone. ; Clovis. ; GSK. ; GamaMabs. ; Lilly. ; MSD. ; Mission Therapeutics. ; Merus. ; Pfizer. ; PharmaMar. ; Pierre Fabre. ; Roche/Genentech. ; Sanofi. ; Servier. ; Symphogen. ; Takeda.\\xa0J. Downs: None. C.J. Lord:  ; AstraZeneca. ; Merck KGaA. ; Artios. ; Tango. ; Sun Pharma. ; GLG. ; Vertex. ; Ono Pharma. ; Third Rock Ventures. S. Postel-Vinay:  ; Merck KGaA. ; Principal investigator of clinical trials for Gustave Roussy.; Boehringer Ingelheim. ; Principal investigator of clinical trials for Gustave Roussy.; Roche. ; Principal investigator of clinical trials for Gustave Roussy.\\nBenefited from reimbursement for attending symposia.; AstraZeneca. ; Principal investigator of clinical trials for Gustave Roussy.; Clovis. ; Principal investigator of clinical trials for Gustave Roussy.; Bristol-Myers Squibb. ; Principal investigator of clinical trials for Gustave Roussy.; Agios. ; Principal investigator of clinical trials for Gustave Roussy.; GSK.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-7': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10966',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:45 PM - 2:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-8': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10551',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1059\\n                        \\n                         - Targeting IDH1/2 mutant cancers with unique combinations of DNA repair inhibitors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:50 PM - 3:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Amrita D. Sule, Ranjini Sundaram, Ranjit Bindra. Yale University, New Haven, CT ',\n",
       "  'Disclosures': '\\xa0\\xa0A.D. Sule:  ; AACR-AstraZeneca START grantee.\\xa0R. Sundaram: None.\\xa0R. Bindra: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-9': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10967',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:00 PM - 3:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-10': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10552',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1060\\n                        \\n                         - Genetic and pharmacologic inhibition of Skp2, an E3 ubiquitin ligase and RB1-target, has antitumor activity in RB1-deficient human and mouse small cell lung cancer (SCLC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:05 PM - 3:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Hongling Zhao1, Vineeth Sukrithan1, Niloy Iqbal1, Cari Nicholas1, Yingjiao Xue1, Joseph Locker2, Juntao Zou1, Liang Zhu1, Edward L. Schwartz1. 1Albert Einstein College of Medicine, Bronx, NY; 2University of Pittsburgh Medical Center, Pittsburgh, PA ',\n",
       "  'Disclosures': '\\xa0H. Zhao: None.\\xa0V. Sukrithan: None.\\xa0N. Iqbal: None.\\xa0C. Nicholas: None.\\xa0Y. Xue: None.\\xa0J. Locker: None.\\xa0J. Zou: None.\\xa0L. Zhu: None.\\xa0E.L. Schwartz: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-11': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10968',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:15 PM - 3:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-12': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10553',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1061\\n                        \\n                         - Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:20 PM - 3:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Michel Demeule1, Jean-Christophe Currie1, Cyndia Charfi2, Alain Larocque1, Alain Zgheib2, Sophie Kozelko1, Richard Bliveau2, Christian Marsolais1, Borhane Annabi2. 1Theratechnologies, Montreal, QC, Canada; 2Universit du Qubec  Montral, Montreal, QC, Canada ',\n",
       "  'Disclosures': '\\xa0\\xa0M. Demeule:  ; Theratechnologies. J. Currie:  ; Theratechnologies. C. Charfi:  ; Theratechnologies. A. Larocque:  ; Theratechnologies. A. Zgheib:  ; Theratechnologies. S. Kozelko:  ; Theratechnologies. R. Bliveau:  ; Theratechnologies. C. Marsolais:  ; Theratechnologies. B. Annabi:  ; Theratechnologies.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '836-13': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10970',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:30 PM - 3:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '836-14': {'Session Title': ' VMS.ET04.01. Novel Targets and Therapies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10961',\n",
       "  'Date': ' April 28, 2020, 2:15 PM - 3:45 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 3:35 PM - 3:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Roger S. Lo. University of California (UCLA), Los Angeles, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-1': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10796',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:40 AM - 11:41 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Katerina A. Politi. Yale Cancer Center, New Haven, CT',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-2': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10852',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:40 AM - 11:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-3': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10741',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT031\\n                        \\n                         - COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:45 AM - 11:55 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ryan Sullivan1, Drew Rasco2, Emerson Lim3, Manish Sharma4, Dale Shepard5, Amita Patnaik2, Erika Hamilton6, Gini Fleming7, Kyri Papadopoulos2, Adam ElNaggar8, Adeboye Henry Adewoye9, Bartosz Chmielowski10, Ecaterina Dumbrava11, Dan Vaena8. 1Massachusetts General Hospital, Harvard Medical School., Boston, MA; 2South Texas Accelerated Research Therapeutics, San Antonio, TX; 3Columbia University-Herbert Irving Comprehensive Cancer Center, New York City, NY; 4START Midwest, Grand Rapids, MI; 5Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 6Tennessee Oncology, PLLC and Sarah Cannon Research Institute, Nashville, TN; 7University of Chicago School of Medicine., Chicago, IL; 8University of Tennessee West Cancer Center, Memphis, TN; 9Compugen USA, Inc., South San Francisco, CA; 10David Geffen School of Medicine at UCLA, Los Angeles, CA; 11The University of Texas MD Anderson Cancer Center, Houston, TX ',\n",
       "  'Disclosures': '\\xa0\\xa0R. Sullivan:  ; Compugen USA Inc.\\xa0D. Rasco:  ; Compugen USA Inc. E. Lim:  ; Compugen USA Inc.\\xa0M. Sharma:  ; Compugen USA Inc.\\xa0D. Shepard:  ; Comupgen USA Inc.\\xa0A. Patnaik:  ; Compugen USA Inc. E. Hamilton:  ; Compugen USA Inc. G. Fleming:  ; Compugen USA Inc.\\xa0K. Papadopoulos:  ; Compugen USA Inc. A. ElNaggar:  ; Compugen USA Inc. A.H. Adewoye:  ; Compugen USA inc.\\xa0B. Chmielowski:  ; Compugen USA Inc. E. Dumbrava:  ; Compugen USA Inc.\\xa0D. Vaena:  ; Compugen USA Inc.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-4': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10853',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 11:55 AM - 12:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-5': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10742',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT032\\n                        \\n                         - A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:00 PM - 12:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Antonio Jimeno1, Shilpa Gupta2, Ryan Sullivan3, Khanh T. Do4, Wallace L. Akerley5, Ding Wang6, Deanna Teoh7, Kurt Schalper8, Sima J. Zacharek9, Jing Sun9, Andressa S. Laino9, Joshua Frederick9, Honghong Zhou9, William Randolph9, Stephanie Pascarella9, Lisa Johansen9, Pamela S. Cohen9, ROBERT S. MEEHAN, Sr.9, Todd M. Bauer10. 1University of Colorado Cancer Center, Aurora, CO; 2Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, OH; 3Massachusetts General Hospital, Boston, MA; 4Dana Farber Cancer Institute, Boston, MA; 5University of Utah Huntsman Cancer Institute, Salt Lake City, UT; 6Henry Ford Hospital, Detroit, MI; 7University of Minnesota Medical Center, Minneapolis, MN; 8Yale School of Medicine, New Haven, CT; 9MODERNA Tx INC., CAMBRIDGE, MA; 10Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN ',\n",
       "  'Disclosures': '\\xa0\\xa0A. Jimeno:  ; Patents,Royalties, Other IP; Suvica. ; AstraZeneca. ; Bayer. ; Celldex. ; Pfizer. ; Merck. ; Medimmune. ; Roche. ; Acerta Pharma. ; Kinex. ; Karyopharm Therapeutics. ; OncoMed. ; Iovance Biotherapetutics. ; Genocea Biosciences. ; Moderna Therapeutics. ; HolyStone. S. Gupta:  ; Genetech. ; Merck. ; Janssen Oncology. ; Nektar. ; AstraZeneca. ; Astellas Medivation. ; Pfizer. ; Moderna Therapeutics. ; Incyte. R. Sullivan:  ; Amgen. ; Merck. ; Replimmune. ; Novartis. ; Syndax. ; Boehringer Ingelheim. K.T. Do:  ; QED Therapeutics. W.L. Akerley:  ; AstraZeneca. ; Bristol-Myers Squibb. ; Incyte. ; Loxo. D. Wang:  ; Travel, Accommodations, Expenses; Merck. ; Moderna. D. Teoh:  ; Acelity. ; Tesaro. K. Schalper:  ; Tessaro. ; Takeda. ; Surface Oncology. ; Navigate BioPharma. ; Moderna Therapeutics. ; Merck. ; Pierre Fabre. ; Merck. ; Bristol-Myers Squibb. ; Lilly. ; AstraZeneca. ; Fluidigm. ; Torque. ; Agenus. ; Abbvie. ; EMD Serono. ; Celgene. ; Clinica Alemana Santiago. ; Shattuck Labs. ; Dyanamo Therapeutics. S.J. Zacharek:  ; Moderna Therapeutics. J. Sun:  ; Moderna Therapeutics. A.S. Laino:  ; Moderna Therapeutics. J. Frederick:  ; Moderna Therapeutics. H. Zhou:  ; Moderna Therapeutics. ; Merck. W. Randolph:  ; Moderna Therapeutics. S. Pascarella:  ; Moderna Therapeutics. L. Johansen:  ; Moderna Therapeutics. P.S. Cohen:  ; Moderna Therapeutics. R.S. Meehan:  ; Moderna Tx Inc.\\xa0T.M. Bauer:  ; Tennesse Oncology. ; Ignyta. ; Guardant Health. ; Loxo. ; Pfizer. ; Moderna Therapeutics. ; Exelixis. ; Blueprint Medicines. ; Bayer. ; Travel, Accommodations, Expenses; Astellas Pharma. ; Travel, Accommodations, Expenses; AstraZeneca. ; Travel, Accommodations, Expenses; Celgene. ; Travel, Accommodations, Expenses; Clovis Oncology. ; Travel, Accommodations, Expenses; EMD Serono. ; Travel, Accommodations, Expenses; Genetech. ; Travel, Accommodations, Expenses; Merck. ; Travel, Accommodations, Expenses; Lilly. ; Travel, Accommodations, Expenses; Novartis. ; Travel, Accommodations, Expenses; Sysmex. ; Travel, Accommodations, Expenses; Leap Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-6': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10854',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:10 PM - 12:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-7': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10746',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:15 PM - 12:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ignacio Melero. University of Navarra, Pamplona, Spain',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-8': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10855',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:30 PM - 12:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-9': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10743',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT033\\n                        \\n                         - Efficacy and safety results of pembrolizumab combined with GX-188E, a therapeutic DNA vaccine administration in patients with HPV 16- and/or 18- positive advanced cervical cancer: Phase II interim analysis results\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:35 PM - 12:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Sooyoung Hur1, Jong Sup Park2, Yong-Man Kim3, Myong Cheol Lim4, Jae Hong No5, Byoung-Gie Kim6, Jae-Kwan Lee7, Chi Heum Cho8, Yoon-Jeong Choi2, You Suk Suh2, Jung Won Woo2, Young Chul Sung2. 1The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of; 2Genexine, Inc., Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of; 3Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of; 4National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of; 5Seoul National University Bundang Hospital, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea, Republic of; 6Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of; 7Korea University Guro Hospital, Guro-gu, Seoul, Korea, Republic of; 8Keimyung University Dongsan Medical Center, Dalseo-gu, Daegu, Korea, Republic of \",\n",
       "  'Disclosures': '\\xa0\\xa0S. Hur:  ; Genexine. J. Park:  ; Genexine. Y. Kim:  ; Genexine. M. Lim:  ; Genexine. J. No:  ; Genexine. B. Kim:  ; Genexine. J. Lee:  ; Genexine. C. Cho:  ; Genexine. Y. Choi:  ; Genexine. Y. Suh:  ; Genexine. J. Woo:  ; Genexine. Y. Sung:  ; CEO; Genexine.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-10': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10856',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:45 PM - 12:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-11': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10747',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 12:50 PM - 1:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Nina Bhardwaj. Icahn School of Medicine at Mount Sinai, New York, NY',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-12': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10857',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:05 PM - 1:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-13': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10744',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT034\\n                        \\n                         - Phase I study of WNT974 + spartalizumab in patients (pts) with advanced solid tumors\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:10 PM - 1:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Filip Janku1, Filip de Vos2, Maria de Miguel3, Patrick Forde4, Antoni Ribas5, Misako Nagasaka6, Guillem Argiles7, Ana Maria Arance8, Aitano Calvo9, Marios Giannakis10, Maritza Melendez11, Jiachang Gong12, Sebastian Szpakowski13, Rebecca Kan13, Susan E. Moody13, Maja De Jonge14. 1The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2UMC Utrecht Cancer Center, Utrecht, Netherlands; 3START Madrid, CIOCC, Madrid, Spain; 4Johns Hopkins University, Baltimore, MD; 5University of California, Los Angeles, CA; 6Karmanos Cancer Institute, Wayne State University, Detroit, MI; 7Vall dHebron University Hospital and Universitat Autnoma de Barcelona, Barcelona, Spain; 8Hospital Clinic de Barcelona, Barcelona, Spain; 9Hospital Gregorio Maranon, Madrid, Spain; 10Dana-Farber Cancer Institute, Boston, MA; 11Novartis Pharma AG, Basel, Switzerland; 12Novartis Insts. for BioMedical Research, East Hanover, NJ; 13Novartis Insts. for BioMedical Research, Cambridge, MA; 14Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands ',\n",
       "  'Disclosures': '\\xa0\\xa0F. Janku:  ; Novartis. ; Genetech. ; BioMed Valley Discoveries. ; Plexxikon. ; Deciphera. ; Piqur. ; Symphogen. ; Bayer. ; FujiFilm Corporation and Upsher-Smith Laboratories. ; Astex. ; Asana. ; Astellas. ; Agios. ; Proximagen. ; Bristol-Myers Squibb. ; IFM Therapeutics. ; Synlogic; Guardant Health. ; Ideaya; PureTech Health. ; Travogene. ; Immunomet; Jazz Pharmaceuticals; Sotio. F. de Vos:  ; AbbVie. ; Novartis. ; Travel costs; Roche.\\xa0M. de Miguel: None. P. Forde:  ; AstraZeneca. ; BMS. ; Kyowa. ; Novartis. ; Corvus. ; Janssen. A. Ribas:  ; Amgen. ; Chugai. ; Merck. ; Novartis. ; Sanofi. ; Arcus. ; Bioncotech. ; Compugen. ; CytomX. ; ImaginAb. ; Isoplexis. ; Merus. ; Rgenix. ; Lutris. ; PACT Pharma. ; Tango Therapeutics. M. Nagasaka:  ; AstraZeneca. ; Tempus. ; Caris. G. Argiles:  ; Roche. ; Merck Serono. ; Amgen. ; Sanofi. ; BMS. A. Arance:  ; Personal fees; BMS. ; Personal fees; Pierre-Fabre. ; Personal fees; Roche. ; Personal fees; Novartis. ; Personal fees; Amgen. ; Personal fees; MSD. ; Personal fees; Merck. ; Personal fees; Sanofi.\\xa0A. Calvo: None. M. Giannakis:  ; Bristol-Myers Squibb. ; Merck. M. Melendez:  ; Novartis. J. Gong:  ; Novartis. S. Szpakowski:  ; Novartis. R. Kan:  ; Novartis. S.E. Moody:  ; Novartis.\\xa0M. De Jonge: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-14': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10858',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:20 PM - 1:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-15': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10745',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT035\\n                        \\n                         - TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:25 PM - 1:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jayakumar Vadakekolathu1, Catherine Lai2, Stephen Reeder1, Sarah E. Church3, Tressa Hood3, John Muth4, Heidi Altmann5, Marilena Ciciarello6, Antonio Curti6, Peter J. M. Valk7, Bob Lwenberg7, Martin Bornhuser5, John F. DiPersio8, Jan K. Davidson-Moncada4, Sergio Rutella1. 1John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom; 2MedStar Georgetown University Hospitals Lombardi Comprehensive Cancer Center, Washington, DC; 3NanoString Technologies Inc., Seattle, WA; 4MacroGenics Inc., Rockville, MD; 5University Hospital Carl Gustav Carus, Technische Universitt Dresden, Dresden, Germany; 6Institute of Hematology \"L. and A. Sergnoli\", Department of Hematology and Oncology, University Hospital S. Orsola-Malpighi, Bologna, Italy; 7Department of Hematology, Erasmus Medical Centre, Rotterdam, Netherlands; 8Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, St Louis, MO ',\n",
       "  'Disclosures': '\\xa0J. Vadakekolathu: None.\\xa0C. Lai: None.\\xa0S. Reeder: None. S.E. Church:  ; NanoString Technologies Inc.\\xa0T. Hood:  ; NanoString Technologies Inc.\\xa0J. Muth:  ; MacroGenics Inc..\\xa0H. Altmann: None.\\xa0M. Ciciarello: None.\\xa0A. Curti: None.\\xa0P.J.M. Valk: None.\\xa0B. Lwenberg: None.\\xa0M. Bornhuser: None.\\xa0J.F. DiPersio: None. J.K. Davidson-Moncada:  ; MacroGenics Inc.\\xa0S. Rutella:  ; MacroGenics Inc.. ; NanoString Technologis, Inc.. ; Kura Oncology.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '852-16': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10859',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:35 PM - 1:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '852-17': {'Session Title': ' VCTPL03. Immunotherapy Clinical Trials 1',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials,Immunology\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10860',\n",
       "  'Date': ' April 27, 2020, 11:40 AM - 2:00 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:55 PM - 2:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '34-1': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/95',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Cochair\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Andrew J. Phillips. C4 Therapeutics, Watertown, MA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '34-2': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8514',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Cochair\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Michael Brands. Bayer Pharma AG, Berlin, Germany',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '34-3': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11063',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:50 PM - 4:54 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Andrew J. Phillips. C4 Therapeutics, Watertown, MA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '34-4': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/6808',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT01-01\\n                        \\n                         - A first-in-class Menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemias\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:54 PM - 5:14 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jerry McGeehan. Syndax Pharmaceuticals, Inc., Waltham, MA',\n",
       "  'Disclosures': '\\xa0J. McGeehan,  Syndax Pharmaceuticals, Inc. Full-time/Part-time Employee.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '34-5': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/6809',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT01-02\\n                        \\n                         - BAY 2416964: The first Aryl Hydrocarbon Receptor (AhR) inhibitor to enter phase I clinical development as a novel cancer immunotherapy\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:17 PM - 5:37 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Ilona Gutcher, Christina Kober, Julian Rwe, Ulrike Roehn, Lars Roese, Florian Prinz, Detlef Stoeckigt, Benjamin Bader, Matyas Gorjanacz, Rafael Carretero, Norbert Schmees, Horst Irlbacher, Helge Roider, Katharina Sahm, Hilmar Weinmann, Ingo V. Hartung, Bertolt Kreft, Rienk Offringa, Michael Platten. Bayer AG, Berlin, Germany, Bayer AG, Germany, DKFZ, Heidelberg, Germany',\n",
       "  'Disclosures': '\\xa0I. Gutcher,  Bayer AG Full-time/Part-time Employee, Stock Shareholder (self managed).C. Kober,  None..J. Rwe,  None.\\xa0U. Roehn,  Bayer AG Full-time/Part-time Employee. L. Roese,  Bayer AG Full-time/Part-time Employee. F. Prinz,  Bayer AG Full-time/Part-time Employee. D. Stoeckigt,  Bayer AG Full-time/Part-time Employee. B. Bader,  Bayer AG Full-time/Part-time Employee, Stock Shareholder (self managed). M. Gorjanacz,  Bayer AG Full-time/Part-time Employee, Stock Shareholder (self managed). R. Carretero,  Bayer AG Full-time/Part-time Employee. N. Schmees,  Bayer AG Full-time/Part-time Employee, Stock Shareholder (self managed). H. Irlbacher,  Bayer AG Full-time/Part-time Employee, Stock Shareholder (self managed). H. Roider,  Bayer AG Full-time/Part-time Employee.K. Sahm,  None.\\xa0H. Weinmann,  Bayer AG Stock Shareholder (self managed). I. V. Hartung,  Bayer AG Stock Shareholder (self managed). B. Kreft,  Bayer AG Full-time/Part-time Employee. R. Offringa,  Bayer AG Grants/Research Support Recipient. M. Platten,  Bayer AG Grants/Research Support Recipient, Consultant/Independent Contractor.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '34-6': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8516',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT01-03\\n                        \\n                         - IPN60090: A potent and selective inhibitor of glutaminase being developed for KEAP1/NFE2L2 mutant NSCLC and ASNS-low HGSOC patients\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 5:40 PM - 6:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jeffrey J. Kovacs. UT MD Anderson Cancer Center, Houston, TX',\n",
       "  'Disclosures': '\\xa0J. J. Kovacs,  Ipsen Grants/Research Support Recipient, Other, IPN60090 was licensed from MD Anderson Cancer Center by Ipsen as part of a global licensing and joint development agreement.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '34-7': {'Session Title': ' VSY.DDT01. New Drugs on the Horizon: Part 1',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11064',\n",
       "  'Date': ' April 27, 2020, 4:50 PM - 6:05 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 6:04 PM - 6:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Michael Brands. Bayer Pharma AG, Berlin, Germany',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-1': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10781',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:00 PM - 2:01 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Suresh S. Ramalingam. Emory University, Winship Cancer Institute, Atlanta, GA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-2': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10895',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:00 PM - 2:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-3': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10782',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT081\\n                        \\n                         - Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:05 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Xiuning Le1, Jonathan Goldman2, Jeffrey Clarke3, Nishan Techekmedyian4, Zofia Piotrowska5, David Chu6, Gajanan Bhat6, Francois Lebel6, Mark Socinski7. 1MD Anderson Cancer Center, Houston, TX; 2University of California, Los Angeles, Los Angeles, CA; 3Duke University, Durham, NC; 4Pacific Shores Medical Group, Long Beach, CA; 5Massachusetts General Hospital, Boston, MA; 6Spectrum Pharmaceuticals, Irvine, CA; 7Advent Health, Orlando, FL ',\n",
       "  'Disclosures': '\\xa0\\xa0X. Le:  ; Spectrum Pharmaceuticals. ; EMD Serono. ; Astra Zeneca. ; Eli Lilly. ; Boehringer Ingleheim. J. Goldman:  ; Spectrum Pharmaceuticals. J. Clarke:  ; Spectrum Pharmaceuticals. ; Bristol-Myers Squibb. ; Eli Lilly. ; Genentech. ; Adaptimmune. ; Medpacto. ; Bayer. ; Abbvie. ; Moderna. ; Glaxo SmithKline. ; Array. ; Guardant. ; Astra Zeneca. ; NGM Biopharmaceiticals. ; Merck. N. Techekmedyian:  ; Spectrum Pharmaceuticals. Z. Piotrowska:  ; Spectrum Pharmaceuticals. ; Astra Zeneca. ; Takeda Oncology. ; Novartis. ; Immunogen. ; Abbvie. ; Guardant Health. ; Genentech. ; Eli Lilly. ; Incyte. ; Medtronic. ; Tesaro. D. Chu:  ; Spectrum Pharmaceuticals. G. Bhat:  ; Spectrum Pharmaceuticals. F. Lebel:  ; Spectrum Pharmaceuticals. M. Socinski:  ; Spectrum Pharmaceuticals. ; Genentech. ; Novartis. ; Astra Zeneca. ; Guardant. ; Bristol-Myers Squibb. ; Merck. ; Bayer.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-4': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10896',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:15 PM - 2:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-5': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10783',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT082\\n                        \\n                         - Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:20 PM - 2:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Edward B. Garon1, Rebecca S. Heist2, Takashi Seto3, Ji-Youn Han4, Noemi Reguart5, Harry J. M. Groen6, Daniel SW Tan7, Toyoaki Hida8, Maja J. A. de Jonge9, Sergey V. Orlov10, Egbert F. Smit11, Pierre-Jean Souquet12, Johan Vansteenkiste13, Sylvie Le Mouhaer14, Anna Robeva15, Maeve Waldron-Lynch16, Monica Giovannini15, Juergen Wolf17. 1University of California, Los Angeles, CA; 2Massachusetts General Hospital, Boston, MA; 3National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; 4National Cancer Center, Gyeonggi-do, Korea, Republic of; 5University Hospital Clinic of Barcelona, Barcelona, Spain; 6University of Groningen and University Medical Center Groningen, Groningen, Netherlands; 7National Cancer Centre Singapore, Singapore, Singapore; 8Aichi Cancer Center, Nagoya, Japan; 9Erasmus MC Cancer Institute, Rotterdam, Netherlands; 10St Petersburg Pavlov State Medical University, St Petersburg, Russian Federation; 11Netherlands Cancer Institute, Amsterdam, Netherlands; 12University Hospital of Lyon-Sud, Lyon, France; 13Gasthuisberg University Hospital, Leuven, Belgium; 14Novartis Pharma S.A.S, Rueil-Malmaison, France; 15Novartis Pharmaceuticals Corporation, East Hanover, NJ; 16Novartis Pharma AG, Basel, Switzerland; 17Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany ',\n",
       "  'Disclosures': '\\xa0\\xa0E.B. Garon:  ; AstraZeneca. ; BMS. ; Genentech. ; Eli Lilly. ; Novartis. ; Merck. ; Neon. ; Dynavax. ; Iovance. ; Mirati. ; Dracen. ; EMD Serono. R.S. Heist:  ; Boehringer Ingelheim. ; Novartis. ; Apollomics. ; Tarveda. ; Daichii Sankyo. ; Agios. ; Celgene. ; Corvus. ; Genentech Roche. ; Exelixis. ; Mirati. ; Incyte. ; AbbVie. ; Millenium. T. Seto:  ; Astellas Pharma. ; AstraZeneca. ; Bristol-Myers Squibb. ; Chugai Pharma. ; Lilly. ; MSD. ; Nippon Boehringer Ingelheim. ; Kissei Pharmaceutical, Lilly Japan, Loxo, Merck Serono. ; Novartis. ; Ono Pharmaceutical. ; Pfizer. ; Taiho Pharmaceutical. ; Takeda. ; Thermo Fisher Scientific. ; Bayer Yakuhin. ; Daiichi Sankyo. J. Han:  ; Roche. ; AstraZeneca. ; BMS. ; MSD. ; Takeda. ; Eli Lilly. ; Novartis. ; Pfizer. ; Ono. N. Reguart:  ; AstraZeneca. ; Roche. ; MSD. ; Takeda. ; Pfizer. ; Novartis. H.J.M. Groen:  ; AbbVie. ; AstraZeneca. ; Bristol-Myers Squibb. ; Eli Lilly. ; MSD Oncology. ; Novartis. ; Pfizer. ; Roche/Genentech. ; Roche. D. Tan:  ; Travel/Accommodation/Expenses; Merck. ; Travel/Accommodation/Expenses; Pfizer. ; Travel/Accommodation/Expenses; Novartis. ; Travel/Accommodation/Expenses; Boehringer Ingelheim. ; Travel/Accommodation/Expenses; Roche. ; Travel/Accommodation/Expenses; Takeda. ; Bayer. ; Celgene. ; AstraZeneca. ; Eli Lilly. ; Loxo. ; GlaxoSmithKline. T. Hida:  ; Ono Pharmaceuticals. ; Novartis. ; Chugai Pharmaceuticals. ; Eli Lilly. ; Taiho Pharmaceuticals. ; AstraZeneca. ; Nippon Boehringer Ingelheim. ; Pfizer. ; MSD. ; Kissei. ; Clovis Oncology. ; Bristol-Myers Squibb. ; Eisai. ; Takeda. ; Dainippon Sumitomo. ; AbbVie. ; Merck Serono. ; Kyowa Hakko Kirin. ; Daiichi Sankyo, Servier, Ingyta, Janssen, Astellas.\\xa0M.J.A. de Jonge: None.\\xa0S.V. Orlov: None.\\xa0E.F. Smit: None. P. Souquet:  ; AstraZeneca. ; Travel, Accommodations, Expenses; Bristol-Myers Squibb. ; Eli Lilly. ; Novartis. ; Pfizer. ; Travel, Accommodations, Expenses; Roche. ; Takeda. ; AbbVie. ; Boehringer Ingelheim. ; Lilly/ImClone. ; Roche/Genentech. ; Astellas Pharma. ; Chugai Pharma. ; Sandoz. J. Vansteenkiste:  ; AstraZeneca. ; Bristol-Myers Squibb. ; MSD Oncology. ; Boehringer Ingelheim. ; Merck Serono. ; Novartis. ; Roche. ; MSD. S. Le Mouhaer:  ; Novartis. A. Robeva:  ; Novartis. M. Waldron-Lynch:  ; Novartis. M. Giovannini:  ; Leadership - Novartis; Novartis. J. Wolf:  ; AbbVie. ; AstraZeneca. ; Boehringer Ingelheim. ; Bristol-Myers Squibb. ; MSD. ; Novartis. ; Roche. ; Lecture Fees; Blueprint Medicines. ; Chugai Pharma. ; Ignyta. ; Janssen/Johnson & Johnson. ; Lilly. ; Loxo/Lilly. ; MSD Oncology. ; Pfizer. ; Lecture Fees; Amgen, Takeda.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-6': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10897',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:30 PM - 2:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-7': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10789',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:35 PM - 2:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Taofeek Kunle Owonikoko. Emory University, Atlanta, GA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-8': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10898',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:50 PM - 2:55 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-9': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10784',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT083\\n                        \\n                         - Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:55 PM - 3:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jie Wang1, Yun Fan2, Jun Zhao3, Qiming Wang4, Dingzhi Huang5, Xingya Li6, Jianhua Chen7, Yong Fang8, Zhijie Wang1, Caicun Zhou9, Yanping Hu10, Haihua Yang11, Yi Hu12, Jianying Zhou13, Xiaoyan Lin14, Lifeng Wang15, Yanjun Xu16, Hanying Li16. 1National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Zhejiang Cancer Hospital, Hangzhou, China; 3Beijing Cancer Hospital, Beijing, China; 4Henan\\u2002Cancer\\u2002Hospital, Zhengzhou, China; 5Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; 6The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 7Hunan Cancer Hospital, Changsha, China; 8Sir Run Run Shaw Hospital  ZheJiang University School Of Medicine, Hangzhou, China; 9Shanghai Pulmonary Hospital, Tongji University, Shanghai, China; 10Hubei\\xa0Cancer\\xa0Hospital, Wuhan, China; 11Taizhou Hospital of Zhejiang Province, Taizhou, China; 12Chinese PLA General Hospital, Beijing, China; 13The First Affiliated Hospital of Zhejiang University, Hangzhou, China; 14Fujian Medical University Union Hospital, Fuzhou, China; 15Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, China; 16Jiangsu Hengrui Medicine Co. Ltd, Shanghai, China ',\n",
       "  'Disclosures': '\\xa0J. Wang: None.\\xa0Y. Fan: None.\\xa0J. Zhao: None.\\xa0Q. Wang: None.\\xa0D. Huang: None.\\xa0X. Li: None.\\xa0J. Chen: None.\\xa0Y. Fang: None.\\xa0Z. Wang: None.\\xa0C. Zhou: None.\\xa0Y. Hu: None.\\xa0H. Yang: None.\\xa0Y. Hu: None.\\xa0J. Zhou: None.\\xa0X. Lin: None. L. Wang:  ; Hengrui. Y. Xu:  ; Hengrui. H. Li:  ; Hengrui.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-10': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10899',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:05 PM - 3:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-11': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10785',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT084\\n                        \\n                         - Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:10 PM - 3:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Byoung Chul Cho1, Gilberto Lopes2, Dariusz M. Kowalski3, Kazuo Kasahara4, Yi-Long Wu5, Gilberto Castro, Jr.6, Hande Z. Turna7, Razvan Cristescu8, Deepti Aurora-Garg8, Andrey Loboda8, Jared Lunceford8, Julie Kobie8, Mark Ayers8, M. Catherine Pietanza8, Bilal Piperdi8, Tony S. K. Mok9. 1Yonsei University Cancer Center, Seoul, Korea, Republic of; 2Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL; 3Maria Sklodowska-Curie National Research Institute of Oncology, Department of Lung Cancer and Chest Tumours, Warsaw, Poland; 4Kanazawa University Hospital, Kanazawa, Japan; 5Guangdong Lung Cancer Institute, Guangdong, China; 6Instituto do Cncer do Estado de Sao Paulo, Sao Paulo, Brazil; 7Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey; 8Merck & Co., Inc., Kenilworth, NJ; 9State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, Hong Kong ',\n",
       "  'Disclosures': '\\xa0\\xa0B. Cho:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; Novartis. ; Bayer. ; AstraZeneca. ; MOGAM Institute. ; Dong-A ST. ; royalty; Champions Oncology. ; Janssen. ; Yuhan. ; Ono. ; Dizal Pharma. ; Boehringer-Ingelheim. ; Roche. ; BMS. ; Pfizer. ; Eli LIlly. ; Takeda. ; TheraCanVac Inc. ; Gencurix Inc. ; Bridgebio therapeutics. G. Lopes:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; EMD Serono. ; AstraZeneca. D.M. Kowalski:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; Pfizer. ; Roche-Genentech. ; Boehringer Ingelheim. ; Astra Zeneca. ; BMS. ; MERCK. K. Kasahara:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; Boehringer-Ingelheim. ; Pfizer. ; Chugai Pharmaceutical. ; Eli Lilly. ; Taiho. ; AstraZeneca. Y. Wu:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; Boehringer-Ingelheim. ; Roche. ; AstraZeneca. ; Eli Lilly. ; Pierre Fabre. ; Pfizer. ; Sanofi. G. Castro:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; Astra Zeneca. ; Bristol-Myers Squibb. ; Roche. ; Merck Serono. H.Z. Turna:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). R. Cristescu:  ; Merck & Co., Inc.\\xa0D. Aurora-Garg:  ; Merck & Co., Inc.\\xa0A. Loboda:  ; Merck & Co., Inc.\\xa0J. Lunceford:  ; Merck & Co., Inc.\\xa0J. Kobie:  ; Merck & Co., Inc.\\xa0M. Ayers:  ; Merck & Co., Inc.\\xa0M. Pietanza:  ; Merck & Co., Inc.\\xa0B. Piperdi:  ; Merck & Co., Inc.\\xa0T.S.K. Mok:  ; Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. (to institution). ; Astra Zeneca. ; Boehringer Ingelheim. ; BMS. ; Clovis Oncology. ; Eisai. ; Novartis. ; Pfizer. ; Roche. ; SFJ Pharmaceuticals. ; Taiho. ; Xcovery. ; Roche/Genentech. ; Hutchinson MedPharma. ; Janssen. ; Takeda. ; Fishawack Facilitate Ltd. ; Eli Lilly. ; Merck Serono, Celgene, Vertex, geneDecode, OncoGenex, Ignyta, Cirina. ; Sanomic Ltd.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-12': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10900',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:20 PM - 3:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-13': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10786',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT085\\n                        \\n                         - Safety of pemetrexed (Pem) plus platinum (Plat) in combination with pembrolizumab (Pembro) for metastatic nonsquamous NSCLC: A post hoc analysis of KEYNOTE-189\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:25 PM - 3:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Edward B. Garon1, Fangfang Sun2, Catherine E. Muehlenbein3, Jong S. Kim3, Shirish M. Gadgeel4. 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Eli Lilly and Company, Branchburg, NJ; 3Eli Lilly and Company, Indianapolis, IN; 4Rogel Cancer Center, University of Michigan, Ann Arbor, MI ',\n",
       "  'Disclosures': '\\xa0\\xa0E.B. Garon:  ; Dracen. ; Novartis. ; EMD Serono. ; AstraZeneca. ; BMS. ; Eli Lilly. ; Genentech. ; Merck. ; Iovance. ; Mirati. ; Dynavax. ; Neon. F. Sun:  ; Eli Lilly and Company. C.E. Muehlenbein:  ; Eli Lilly and Company. J.S. Kim:  ; Eli Lilly and Company. S.M. Gadgeel:  ; Novocure. ; Boehringer-Ingelheim. ; Astra-Zeneca. ; Takeda. ; Roche/Genentech. ; Xcovery.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-14': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10901',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:35 PM - 3:40 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-15': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10902',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:55 PM - 4:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-16': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10787',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT086\\n                        \\n                         - Pneumonitis incidence in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy in clinical trials and real-world data\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:00 PM - 4:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Qi Liu1, Chenan Zhang2, Yutao Gong1, Hao Zhu1, Elaine Chang1, Cheryl Cho-Phan2, Jonathan Hirsch2, Michael A. Thompson3, Gideon Blumenthal1, Shiew Mei Huang1, Thomas D. Brown2. 1United States Food and Drug Administration, Silver Spring, MD; 2Syapse, San Francisco, CA; 3Advocate Aurora Health, Milwaukee, WI ',\n",
       "  'Disclosures': '\\xa0Q. Liu: None. C. Zhang:  ; Syapse.\\xa0Y. Gong: None.\\xa0H. Zhu: None.\\xa0E. Chang: None. C. Cho-Phan:  ; Syapse. ; Spouse is employee, stockholder; Roche. J. Hirsch:  ; Syapse. ; Travel funding; Genentech. ; Travel funding; NCCN. M.A. Thompson:  ; Travel funding; Syapse. ; Strata Oncology Advisory Board. ; Co-Chair Medical Hematology ITP Committee; VIA Oncology. ; Adaptive. ; Peer Review for Plasma Cell Dyscrasias (receives royalty); UpToDate. ; Glaxo Smith Kline (GSK). ; Insight - Multiple Myeloma Registry; Takeda. ; Co-Chair Medical Oncology Myeloma Committee, Co-Chair Medical Oncology Indolent Lymphoma Committee; VIA Oncology. ; Connect MDS/AML Registry  Scientific Steering Comm Member; Celgene. ; Doximity. ; AbbVie. ; BMS (trial closed to accrual). ; CRAB CTC (trial closed to accrual). ; Denovo. ; Hoosier Research Network (trial closed to accrual). ; Lilly. ; LynxBio. ; Strata Oncology. ; Takeda. ; TG Therapeutics.\\xa0G. Blumenthal: None.\\xa0S. Huang: None. T.D. Brown:  ; Chief Medical Officer, Syapse. ; Novartis. ; GenomiCare Biotechnology.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-17': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10903',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:10 PM - 4:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-18': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10788',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        CT087\\n                        \\n                         - A geospatial approach to explore the socioecological context of tobacco and vape shop locations\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:15 PM - 4:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Kimlin T. Ashing1, Brian Tiep1, Jonjon Macalintal1, Sophia Yeung1, Timothy O'Connor1, Bin Xie2, Udochukwu Obodo1, Ming-Hsiang Tsou3, Gaole Song1, Faith Abuan1, Christyl Dawson4. 1City of Hope, Duarte, CA; 2Claremont Graduate University, Claremont, CA; 3San Diego State University, San Diego, CA; 4Florida International University, Miami, FL \",\n",
       "  'Disclosures': \"\\xa0\\xa0K.T. Ashing:  ; City of Hope Medical Center. B. Tiep:  ; City of Hope Medical Center. ; patent holder and consultant for oxygen devices; CHAD Therapeutics Division of Drive Medical. J. Macalintal:  ; City of Hope Medical Center. S. Yeung:  ; City of Hope Medical Center. T. O'Connor:  ; City of Hope Medical Center. B. Xie:  ; Claremont Graduate University. U. Obodo:  ; City of Hope Medical Center. M. Tsou:  ; San Diego State University.\\xa0G. Song: None.\\xa0F. Abuan: None.\\xa0C. Dawson: None.\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-19': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10904',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:25 PM - 4:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '857-20': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10791',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussant\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:30 PM - 4:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jarushka Naidoo. Sidney Kimmel Cancer Center, Baltimore, MD',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '857-21': {'Session Title': ' VCTPL08. Lung Cancer Targeted Therapy',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nImmunology,Science Policy\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10910',\n",
       "  'Date': ' April 27, 2020, 2:00 PM - 4:50 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 4:45 PM - 4:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-1': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10538',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:30 PM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'John S. Lazo. University of Virginia, Charlottesville, VA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-2': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10539',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:30 PM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Peter C. Lucas. University of Pittsburgh School of Medicine, Pittsburgh, PA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-3': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11055',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:30 AM - 1:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-4': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10540',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3398\\n                        \\n                         - PTPN22 is a systemic target for augmenting antitumor immunity\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:35 PM - 1:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Won Jin Ho1, Jianping Lin2, Ludmila Danilova1, Zaw Phyo1, Soren Charmsaz1, Aditya Mohan1, Todd Armstrong1, Ben H. Park3, Elana J. Fertig1, Zhong-Yin Zhang2, Elizabeth M. Jaffee1. 1Johns Hopkins Sidney Kimmel Comp. Cancer Center, Baltimore, MD; 2Purdue University, Baltimore, MD; 3Vanderbilt University Medical Center, Baltimore, MD ',\n",
       "  'Disclosures': '\\xa0\\xa0W. Ho:  ; potential royalties; Rodeo Therapeutics.\\xa0J. Lin: None.\\xa0L. Danilova: None.\\xa0Z. Phyo: None.\\xa0S. Charmsaz: None.\\xa0A. Mohan: None.\\xa0T. Armstrong: None. B.H. Park:  ; prior ownership interest, member of scientific advisory board; Loxo Oncology. ; prior consultant; Foundation Medicine. ; prior consultant; Lilly. ; prior consultant; Casdin Capital. ; prior consultant; Roche. ; Celcuity. ; Jackson Laboratories. ; under separate licensing agreements with Johns Hopkins University, entitled to a share of royalties; Horizon Discovery. E.J. Fertig:  ; Champions Oncology.\\xa0Z. Zhang: None. E.M. Jaffee:  ; Bristol-Myers Squibb. ; potential royalties; Aduro Biotech. ; Genocea Biosciences.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-5': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11056',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:45 PM - 1:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-6': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10541',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3399\\n                        \\n                         - Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 1:50 PM - 2:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Peggy A. Thompson, Nathan P. Young, Adina Gerson-Gurwitz, Boreth Eam, Vikas Goel, Craig R. Stumpf, Joan Chen, Gregory S. Parker, Sarah Fish, Maria Barrera, Eric Sung, Jocelyn Staunton, Gary G. Chiang, Kevin R. Webster. eFFECTOR Therapeutics, San Diego, CA ',\n",
       "  'Disclosures': '\\xa0\\xa0P.A. Thompson:  ; eFFECTOR Therapeutics. N.P. Young:  ; eFFECTOR Therapeutics. A. Gerson-Gurwitz:  ; eFFECTOR Therapeutics. B. Eam:  ; eFFECTOR Therapeutics. V. Goel:  ; eFFECTOR Therapeutics. C.R. Stumpf:  ; eFFECTOR Therapeutics. J. Chen:  ; eFFECTOR Therapeutics. G.S. Parker:  ; eFFECTOR Therapeutics. S. Fish:  ; eFFECTOR Therapeutics. M. Barrera:  ; eFFECTOR Therapeutics. E. Sung:  ; eFFECTOR Therapeutics. J. Staunton:  ; eFFECTOR Therapeutics. G.G. Chiang:  ; eFFECTOR Therapeutics. K.R. Webster:  ; eFFECTOR Therapeutics.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-7': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11057',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:00 PM - 2:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-8': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10542',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3400\\n                        \\n                         - Adenosine receptor antagonists exhibit potent and selective off-target killing of FOXA1-high cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:05 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Steven M. Corsello1, Ryan D. Spangler2, Ranad Humeidi2, Caitlin N. Harrington2, Rohith T. Nagari2, Ritu Singh2, Vickie Wang2, Mustafa Kocak2, Jordan Rossen2, Amael Madec2, Nancy Dumont2, Todd R. Golub2. 1Dana-Farber Cancer Institute, Boston, MA; 2Broad Institute of MIT and Harvard, Cambridge, MA ',\n",
       "  'Disclosures': '\\xa0S.M. Corsello: None.\\xa0R.D. Spangler: None.\\xa0R. Humeidi: None.\\xa0C.N. Harrington: None.\\xa0R.T. Nagari: None.\\xa0R. Singh: None.\\xa0V. Wang: None.\\xa0M. Kocak: None.\\xa0J. Rossen: None.\\xa0A. Madec: None.\\xa0N. Dumont: None.\\xa0T.R. Golub: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-9': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11058',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:15 PM - 2:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-10': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10543',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3401\\n                        \\n                         - Targeting lysosomal homeostasis in ovarian cancer through drug repurposing\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:20 PM - 2:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Stefano Marastoni1, Aleksandra Pesic1, Sree Narayanan Nair1, Zhu Juan Li2, Ali Madani1, Benjamin Haibe-Kains1, Bradly G. Wouters1, Anthony Joshua3. 1University Health Network, Toronto, ON, Canada; 2Janssen Inc, Toronto, ON, Canada; 3The Kinghorn Cancer Centre, Sydney, Australia ',\n",
       "  'Disclosures': '\\xa0S. Marastoni: None.\\xa0A. Pesic: None.\\xa0S. Nair: None. Z. Li:  ; Janssen Inc. A. Madani:  ; PhD fellow; Cyclica. B. Haibe-Kains:  ; Altis Labs (Canada). ; Caris Life Sciences (USA).\\xa0B. Wouters: None.\\xa0A. Joshua: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-11': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11059',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:30 PM - 2:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-12': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10544',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3402\\n                        \\n                         - BCAT1 as a druggable target in immuno-oncology\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:35 PM - 2:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Adonia E. Papathanassiu1, Francesca Lodi2, Hagar Elkafrawy3, Michelangelo Certo4, Hong Vu1, Jeong Hun Ko5, Jacques Behmoaras5, Claudio Mauro4, Diether Lambrechts2. 1Ergon Pharmaceuticals, Washington, DC; 2VIB Cancer Centre-KULeuven, Leuven, Belgium; 3Alexandria University, Alexandria, Egypt; 4University of Birmingham, Birmingham, United Kingdom; 5Imperial College London, London, United Kingdom ',\n",
       "  'Disclosures': '\\xa0\\xa0A.E. Papathanassiu:  ; Ergon Pharmaceuticals LLC.\\xa0F. Lodi: None.\\xa0H. Elkafrawy: None.\\xa0M. Certo: None.\\xa0H. Vu: None.\\xa0J.H. Ko: None.\\xa0J. Behmoaras: None.\\xa0C. Mauro: None.\\xa0D. Lambrechts: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-13': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11060',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:45 PM - 2:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-14': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10545',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3403\\n                        \\n                         - Drugging the undruggable: Lessons learned from protein phosphatase 2A\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 2:50 PM - 3:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Derek Taylor1, Goutham Narla2. 1Case Western Reserve University, Cleveland, OH; 2University of Michigan, Ann Arbor, MI ',\n",
       "  'Disclosures': '\\xa0\\xa0D. Taylor:  ; RAPPTA Therapeutics. G. Narla:  ; RAPPTA Therapeutics. ; HERA.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-15': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11061',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 24, 2020, 3:00 PM - 3:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-16': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10546',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        3404\\n                        \\n                         - Inhibition of BCL10-MALT1 interaction to treat diffuse large B-cell lymphoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:05 PM - 3:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Heejae Kang1, Dong Hu1, Marcelo Murai2, Ahmed Mady3, Bill Chen1, Zaneta Nikolovska-Coleska3, Linda M. McAllister-Lucas4, Peter C. Lucas1. 1University of Pittsburgh School of Medicine, Pittsburgh, PA; 2Merck, Kenilworth, NJ; 3University of Michigan School of Medicine, Ann Arbor, MI; 4UPMC Children's Hospital, Pittsburgh, PA \",\n",
       "  'Disclosures': '\\xa0H. Kang: None.\\xa0D. Hu: None. M. Murai:  ; Merck. A. Mady:  ; Ribon Therapeutics. B. Chen:  ; Generian Pharmaceutical. ; Koutif Therapeutics.\\xa0Z. Nikolovska-Coleska: None.\\xa0L.M. McAllister-Lucas: None. P.C. Lucas:  ; Amgen.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '835-17': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11062',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:15 PM - 3:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '835-18': {'Session Title': ' VMS.ET01.01. Drugging Undrugged Cancer Targets',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11066',\n",
       "  'Date': ' April 27, 2020, 1:30 PM - 3:30 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 3:20 PM - 3:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Peter C. Lucas. University of Pittsburgh School of Medicine, Pittsburgh, PA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-1': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10825',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:30 PM - 12:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Aurora Esquela Kerscher. Eastern Virginia Medical School, Norfolk, VA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-2': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11016',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:30 PM - 12:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Aurora Esquela Kerscher. Eastern Virginia Medical School, Norfolk, VA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-3': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10829',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5716\\n                        \\n                         - miR-21 inhibition regulates mutant KRAS effector pathways and intercepts development of pancreatic ductal adenocarcinoma\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:35 PM - 12:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Jacquelyn W. Zimmerman1, Richard A. Burkhart1, Nina J. Chu2, Elana J. Fertig1, Elizabeth M. Jaffee1. 1Johns Hopkins Sidney Kimmel Comp. Cancer Center, Baltimore, MD; 2AstraZeneca, Gaithersburg, MD ',\n",
       "  'Disclosures': '\\xa0J.W. Zimmerman: None.\\xa0R.A. Burkhart: None. N.J. Chu:  ; AstraZeneca. E.J. Fertig:  ; Champions Oncology. E.M. Jaffee:  ; vaccine licensing; Aduro Biotech. ; Lustgarten Foundation. ; Genocea. ; Adaptive Biotech. ; DragonFly. ; CSTONE. ; Achilles. ; Parker Institute. ; National Cancer Advisory Board. ; Amgen. ; Bristol Myer Squibb. ; Hertix. ; Corvus.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-4': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10835',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:45 PM - 12:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-5': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10830',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5717\\n                        \\n                         - LncRNA RP11-291B21.2 is associated with Durvalumab response in NSCLC and BLCA cancers\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:50 PM - 1:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Song Wu1, Sarah Hsu2, Qu Zhang1, Lydia Greenlees1, Mike Xiao1, Ashok Gupta1. 1Astrazeneca, Gaithersburg, MD; 2MGH, MA ',\n",
       "  'Disclosures': '\\xa0\\xa0S. Wu:  ; I own AstraZeneca stock share.; Astrazeneca.\\xa0S. Hsu: None. Q. Zhang:  ; Qu Zhang owns AstraZeneca stock share.; Astrazeneca. L. Greenlees:  ; Lydia Greenlees owns AstraZeneca stock share.; Astrazeneca. M. Xiao:  ; Mike Xiao owns AstraZeneca stock share.; Astrazeneca. A. Gupta:  ; Ashok Gupta owns AstraZeneca stock share.; Astrazeneca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-6': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11012',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:00 PM - 1:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-7': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10831',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5718\\n                        \\n                         - miRNA-629: A circulating exosomal biomarker of NK cell function\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:05 PM - 1:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Yelena Lazdun, Lydia M. Greenlees, Fernanda Pilataxi, Radhika Rayanki, Katie Streicher. Astrazeneca, Gaithersburg, MD ',\n",
       "  'Disclosures': '\\xa0\\xa0Y. Lazdun:  ; Astrazeneca. L.M. Greenlees:  ; Astrazeneca. F. Pilataxi:  ; Astrazeneca. R. Rayanki:  ; Astrazeneca. K. Streicher:  ; Astrazeneca.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-8': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11013',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:15 PM - 1:20 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-9': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10832',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5719\\n                        \\n                         - Tumor-suppressive stromal activity of pro-fibrogenic microRNA-21 in initiation and progression of K-Ras-driven mouse models of pancreatic cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:20 PM - 1:30 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Josh Schipper1, Brooke Jackson2, Ian Beddows1, Elizabeth Kenyon2, Katie Powell2, Neil Robertson2, Galen Hostetter1, Matti Kiupel2, Anna Moore2, Jose Conejo-Garcia3, Lorenzo sempere2. 1Van Andel Research Institute, Grand Rapids, MI; 2Michigan State University, East Lansing, MI; 3H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL ',\n",
       "  'Disclosures': '\\xa0J. Schipper: None.\\xa0B. Jackson: None.\\xa0I. Beddows: None.\\xa0E. Kenyon: None.\\xa0K. Powell: None.\\xa0N. Robertson: None.\\xa0G. Hostetter: None.\\xa0M. Kiupel: None.\\xa0A. Moore: None.\\xa0J. Conejo-Garcia: None.\\xa0L. sempere: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-10': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11014',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:30 PM - 1:35 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-11': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10833',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5720\\n                        \\n                         - MicroRNA deregulation of the serine synthesis pathway controls intrinsic and non-cell autonomous mechanism of resistance to Regorafenib in metastatic colorectal cancer (mCRC)\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:35 PM - 1:45 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Somaieh Hedayat1, Andrea Lampis1, George Vlachogiannis1, khurum Khan2, Silvia Marchetti1, Matteo Fassan3, Michele Ghidini4, Ruwaida Begum5, Marta Schirripa6, Rodolfo Passalacqua7, David Cunningham5, Fotios Loupakis6, Nicola Valeri1. 1Institute of Cancer Research, Sutton, United Kingdom; 2The Royal Marsden NHS Trust, London, United Kingdom; 3Surgical Pathology and Cytopathology Unit, University of Padua,, Italy; 4Azienda Ospedaliera di Cremona, Sutton, Italy; 5The Royal Marsden NHS Trust, Sutton, United Kingdom; 6Istituto Oncologico Veneto  IRCCS, Padua, Sutton, Italy; 7Azienda Ospedaliera di Cremona, Cremona, Sutton, Italy ',\n",
       "  'Disclosures': '\\xa0S. Hedayat: None.\\xa0A. Lampis: None.\\xa0G. Vlachogiannis: None.\\xa0K. Khan: None.\\xa0S. Marchetti: None.\\xa0M. Fassan: None.\\xa0M. Ghidini: None.\\xa0R. Begum: None.\\xa0M. Schirripa: None.\\xa0R. Passalacqua: None.\\xa0D. Cunningham: None.\\xa0F. Loupakis: None.\\xa0N. Valeri: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-12': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11018',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:45 PM - 1:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-13': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10834',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        5721\\n                        \\n                         - The super-enhancer driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 1:50 PM - 2:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Sujanna Mondal1, Matthew Wong1, Andrew Tee1, Nicholas Ho1, David S. Ziegler1, Glenn M. Marshall1, Pei Y. Liu1, Marcel Dinger2, Tao Liu1. 1Children's Cancer Institute, Sydney, UNSW, Australia; 2School of Biotechnology and Biomolecular Sciences, UNSW Science, Sydney, UNSW, Australia \",\n",
       "  'Disclosures': '\\xa0S. Mondal: None.\\xa0M. Wong: None.\\xa0A. Tee: None.\\xa0N. Ho: None.\\xa0D. Ziegler: None.\\xa0G. Marshall: None.\\xa0P. Liu: None.\\xa0M. Dinger: None.\\xa0T. Liu: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '860-14': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11019',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:00 PM - 2:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '860-15': {'Session Title': ' VMS.MCB10.01. Non-coding RNAs in Cancer',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nMolecular and Cellular Biology/Genetics\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11017',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 2:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 2:05 PM - 2:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Aurora Esquela Kerscher. Eastern Virginia Medical School, Norfolk, VA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-1': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10814',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Eva Szabo. National Cancer Institute, Bethesda, MD',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-2': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10815',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Frank G. Ondrey. University of Minnesota, Minneapolis, MN',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-3': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10959',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:30 AM - 10:35 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Eva Szabo. National Cancer Institute, Bethesda, MD',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-4': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10817',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1098\\n                        \\n                         - Mediators of early immune response in bronchial premalignant lesions\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:35 AM - 10:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Carter Merenstein1, Julia Breda1, Sarah Mazzilli1, Eric Burks1, Christopher Stevenson2, Mary Reid3, Avrum Spira1, Marc Lenburg1, Jennifer Beane1. 1Boston University, Boston, MA; 2Janssen Research and Development, High Wycombe, United Kingdom; 3Roswell Park Cancer Center, Buffalo, NY ',\n",
       "  'Disclosures': '\\xa0C. Merenstein: None.\\xa0J. Breda: None. S. Mazzilli:  ; Janssen Research & Development.\\xa0E. Burks: None. C. Stevenson:  ; Janssen Pharmaceutical.\\xa0M. Reid: None. A. Spira:  ; Johnson and Johnson Pharmaceutical. M. Lenburg:  ; Johnson and Johnson Pharmaceutical. J. Beane:  ; Janssen Research & Development.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-5': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10816',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:45 AM - 10:50 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-6': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10818',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1099\\n                        \\n                         - Combination of bazedoxifene and lapatinib profoundly inhibits estrogen receptor positive (ER+) and Negative (ER-) mammary tumorigenesis\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:50 AM - 11:00 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Altaf Mohammed1, Shizuko Sei1, Robert Shoemakers1, Clinton J. Grubbs2. 1National Cancer Institute, Rockville, MD; 2University of Alabama Comp. Cancer Center, Birmingham, AL ',\n",
       "  'Disclosures': '\\xa0A. Mohammed: None.\\xa0S. Sei: None.\\xa0R. Shoemakers: None.\\xa0C.J. Grubbs: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-7': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10824',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:00 AM - 11:05 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-8': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10820',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1101\\n                        \\n                         - A BARD1 autoimmune antibodies test for early detection of ovarian cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:05 AM - 11:15 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Maxim Pilyugin1, Magda Ratajska2, Marie Cohen1, Irmgard Irminger-Finger3. 1University of Geneva, Geneva, Switzerland; 2University of Gdansk, Gdansk, Poland; 3BARD1 Life Sciences Limited, Geneva, Switzerland ',\n",
       "  'Disclosures': '\\xa0\\xa0M. Pilyugin:  ; BARD1 LIfe Sciences Limited.\\xa0M. Ratajska: None.\\xa0M. Cohen: None. I. Irminger-Finger:  ; BARD1 LIfe Sciences Limited.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-9': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11026',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:15 AM - 11:20 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-10': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10821',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1102\\n                        \\n                         - Model optimization and chemoprevention of IPMN driven PDAC in KPSD4 mouse model\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:20 AM - 11:30 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Gaurav Kumar1, Venkateshwar Madka1, Anil Singh1, Nandini Kumar1, Nicole Stratton1, Stanley Lightfoot1, Altaf Mohammed2, Mark S. Miller2, Chinthalapally V. Rao1. 1Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK; 2National Cancer Institute, Rockville, MD ',\n",
       "  'Disclosures': '\\xa0G. Kumar: None.\\xa0V. Madka: None.\\xa0A. Singh: None.\\xa0N. Kumar: None.\\xa0N. Stratton: None.\\xa0S. Lightfoot: None.\\xa0A. Mohammed: None.\\xa0M.S. Miller: None.\\xa0C.V. Rao: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-11': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11027',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:30 AM - 11:35 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-12': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10822',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1103\\n                        \\n                         - Aspirin reduces the incidence of metastasis in a preclinical study of Braf mutant colorectal cancer\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:35 AM - 11:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Alexandra Kane, Cheng Liu, Lochlan Fennell, Diane McKeone, Jennifer Borowsky, Barbara Leggett, Vicki Whitehall. QIMR Berghofer Medical Research Institute, Brisbane, Australia ',\n",
       "  'Disclosures': '\\xa0A. Kane: None.\\xa0C. Liu: None.\\xa0L. Fennell: None.\\xa0D. McKeone: None.\\xa0J. Borowsky: None.\\xa0B. Leggett: None.\\xa0V. Whitehall: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-13': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11029',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:45 AM - 11:50 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-14': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10823',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        1104\\n                        \\n                         - Folate intake and colorectal cancer risk during 36 years of follow-up in US women: A prospective cohort study\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 11:50 AM - 12:00 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Fenglei Wang, Kana Wu, Yanping Li, Stephanie Smith-Warner, Edward Giovannucci, Walter Willett. Harvard T.H. Chan School of Public Health, Boston, MA ',\n",
       "  'Disclosures': '\\xa0F. Wang: None.\\xa0K. Wu: None.\\xa0Y. Li: None.\\xa0S. Smith-Warner: None.\\xa0E. Giovannucci: None.\\xa0W. Willett: None.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '861-15': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11030',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:00 PM - 12:05 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '861-16': {'Session Title': ' VMS.PR01.01 . Translational Prevention Studies',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTrack(s)\\nPrevention Research\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/11031',\n",
       "  'Date': ' April 28, 2020, 10:30 AM - 12:15 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Closing Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:05 PM - 12:15 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Frank G. Ondrey. University of Minnesota, Minneapolis, MN',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '865-1': {'Session Title': ' VOS.01. Opening Session',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Opening Session\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10954',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 9:30 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Opening Video\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:00 AM - 9:05 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '865-2': {'Session Title': ' VOS.01. Opening Session',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Opening Session\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10955',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 9:30 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - AACR President: Opening Remarks\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:05 AM - 9:15 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': \"Elaine R. Mardis. Nationwide Children's Hospital, Columbus, OH\",\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '865-3': {'Session Title': ' VOS.01. Opening Session',\n",
       "  'Description': '',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Opening Session\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10956',\n",
       "  'Date': ' April 27, 2020, 9:00 AM - 9:30 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - AACR Annual Meeting Program Chair: Review of Program for AACR Virtual Annual Meeting I\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 27, 2020, 9:15 AM - 9:30 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Antoni Ribas. UCLA Medical Center, Los Angeles, CA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '862-1': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10924',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 9:00 AM - 9:01 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Antoni Ribas. UCLA Medical Center, Los Angeles, CA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '862-2': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10926',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Introduction\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 9:00 AM - 9:01 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '862-3': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10932',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - The experience of treating patients with cancer during the COVID-19 pandemic in China\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 9:00 AM - 9:15 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Li Zhang. Tongji Medical College, Wuhan, China',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '862-4': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10927',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Data on 100 patients with lung malignancies and COVID-19 infection\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 9:15 AM - 9:30 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Marina C. Garassino. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '862-5': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10935',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 9:30 AM - 9:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Fabrice Barlesi. Gustave Roussy, Villejuif, France',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '862-6': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10937',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Adapting Oncologic practice to COVID19 outbreak: from outpatient triage to risk assessment for specific treatment in Madrid, Spain\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 9:45 AM - 10:00 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Carlos Gomez-Martin. Octubre University Hospital, Madrid, Spain',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '862-7': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10938',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Experience in using oncology drugs in patients with COVID-19 infections\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:00 AM - 10:15 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Paolo A. Ascierto. Istituto Nazionale Tumori, Naples, Italy',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '862-8': {'Session Title': ' VCTPL09. COVID-19 and Cancer',\n",
       "  'Description': '\\nDescription\\nAccess to AACR Virtual Annual Meeting I sessions are free with registration. Register now at https://cloud.aacr-outbound.com/virtual-am20\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Plenary Session\\nTrack(s)\\nClinical Trials\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/10936',\n",
       "  'Date': ' April 28, 2020, 9:00 AM - 10:45 AM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Discussion\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 10:30 AM - 10:45 AM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': '',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '36-1': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/99',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Cochair\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:30 PM - 1:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Andrew J. Phillips. C4 Therapeutics, Watertown, MA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '36-2': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8520',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        \\n                        \\n                         - Chairperson\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:30 PM - 1:25 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Xiaojing Wang. Genentech, Inc., South San Francisco, CA',\n",
       "  'Abstract': 'There is no abstract associated with this presentation.'},\n",
       " '36-3': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8521',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT03-01\\n                        \\n                         - ABBV-184: A novel survivin specific T cell receptor/CD3 bispecific therapeutic that targets both solid tumor and hematological malignancies\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:35 PM - 12:50 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Edward B. Reilly. AbbVie Inc., North Chicago, IL, IL',\n",
       "  'Disclosures': '\\xa0E. B. Reilly,  AbbVie Inc Full-time/Part-time Employee.',\n",
       "  'Abstract': 'Abstract embargoed at this time.'},\n",
       " '36-4': {'Session Title': ' VSY.DDT03. New Drugs on the Horizon: Part 3',\n",
       "  'Description': '\\nDescription\\nThe Chemistry in Cancer Research (CICR)-sponsored New Drugs on the Horizon Symposia offer the opportunity for Annual Meeting attendees to see the first disclosures of innovative agents, both small molecules and biologics, that have recently entered phase I clinical trials for the treatment of cancer. All presentations will reveal the chemical structure of the agent under investigation, key highlights of the drug discovery program, and ongoing clinical development plans.\\n \\n\\n',\n",
       "  'Objectives': '\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s)\\nExperimental and Molecular Therapeutics,Drug Development\\n\\n\\n',\n",
       "  'PresentationUrl': 'https://www.abstractsonline.com/pp8/#!/9045/presentation/8522',\n",
       "  'Date': ' April 28, 2020, 12:30 PM - 1:25 PM',\n",
       "  'Presentation Title': '\\n                        \\n\\n                        \\n                        DDT03-02\\n                        \\n                         - The discovery of TNO155: A first in class SHP2 inhibitor\\n                        \\n\\n\\n                    ',\n",
       "  'Presentation Time': ' April 28, 2020, 12:55 PM - 1:10 PM',\n",
       "  'Presentation Location': '\\n Virtual Meeting\\n                        ',\n",
       "  'Presenter/Authors': 'Matthew J. LaMarche. Novartis, Cambridge, MA',\n",
       "  'Abstract': 'Abstract embargoed at this time.'}}"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "PresentationDetails"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'107-9'"
      ]
     },
     "execution_count": 199,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t = list(SessionDetails.keys())\n",
    "t[1973]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame.from_dict(PresentationDetails,orient = 'index')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Session Title</th>\n",
       "      <th>Description</th>\n",
       "      <th>Objectives</th>\n",
       "      <th>PresentationUrl</th>\n",
       "      <th>Date</th>\n",
       "      <th>Presentation Title</th>\n",
       "      <th>Presentation Time</th>\n",
       "      <th>Presentation Location</th>\n",
       "      <th>Presenter/Authors</th>\n",
       "      <th>Abstract</th>\n",
       "      <th>Disclosures</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>838-1</th>\n",
       "      <td>VMS.MCB09.01. Evaluating Cancer Genomics from...</td>\n",
       "      <td></td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Samra Turajlic. The Francis Crick Institute, L...</td>\n",
       "      <td>There is no abstract associated with this pres...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838-2</th>\n",
       "      <td>VMS.MCB09.01. Evaluating Cancer Genomics from...</td>\n",
       "      <td></td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Elana Judith Fertig. Johns Hopkins Sidney Kimm...</td>\n",
       "      <td>There is no abstract associated with this pres...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838-3</th>\n",
       "      <td>VMS.MCB09.01. Evaluating Cancer Genomics from...</td>\n",
       "      <td></td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 3:55 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Samra Turajlic. The Francis Crick Institute, L...</td>\n",
       "      <td>Abstract embargoed at this time.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838-4</th>\n",
       "      <td>VMS.MCB09.01. Evaluating Cancer Genomics from...</td>\n",
       "      <td></td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 3:55 PM - 4:05 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Tapsi Kumar1, Quy Nguyen2, Kevin Nee2, Shansha...</td>\n",
       "      <td>Abstract embargoed at this time.</td>\n",
       "      <td>T. Kumar: None.Q. Nguyen: None.K. Nee: None...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>838-5</th>\n",
       "      <td>VMS.MCB09.01. Evaluating Cancer Genomics from...</td>\n",
       "      <td></td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 3:50 PM - 5:35 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 4:05 PM - 4:10 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td></td>\n",
       "      <td>There is no abstract associated with this pres...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>862-8</th>\n",
       "      <td>VCTPL09. COVID-19 and Cancer</td>\n",
       "      <td>\\nDescription\\nAccess to AACR Virtual Annual M...</td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Plenary Session\\nT...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 9:00 AM - 10:45 AM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 10:30 AM - 10:45 AM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td></td>\n",
       "      <td>There is no abstract associated with this pres...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36-1</th>\n",
       "      <td>VSY.DDT03. New Drugs on the Horizon: Part 3</td>\n",
       "      <td>\\nDescription\\nThe Chemistry in Cancer Researc...</td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 12:30 PM - 1:25 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 12:30 PM - 1:25 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Andrew J. Phillips. C4 Therapeutics, Watertown...</td>\n",
       "      <td>There is no abstract associated with this pres...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36-2</th>\n",
       "      <td>VSY.DDT03. New Drugs on the Horizon: Part 3</td>\n",
       "      <td>\\nDescription\\nThe Chemistry in Cancer Researc...</td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 12:30 PM - 1:25 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 12:30 PM - 1:25 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Xiaojing Wang. Genentech, Inc., South San Fran...</td>\n",
       "      <td>There is no abstract associated with this pres...</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36-3</th>\n",
       "      <td>VSY.DDT03. New Drugs on the Horizon: Part 3</td>\n",
       "      <td>\\nDescription\\nThe Chemistry in Cancer Researc...</td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 12:30 PM - 1:25 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 12:35 PM - 12:50 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Edward B. Reilly. AbbVie Inc., North Chicago, ...</td>\n",
       "      <td>Abstract embargoed at this time.</td>\n",
       "      <td>E. B. Reilly,  AbbVie Inc Full-time/Part-time...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36-4</th>\n",
       "      <td>VSY.DDT03. New Drugs on the Horizon: Part 3</td>\n",
       "      <td>\\nDescription\\nThe Chemistry in Cancer Researc...</td>\n",
       "      <td>\\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...</td>\n",
       "      <td>https://www.abstractsonline.com/pp8/#!/9045/pr...</td>\n",
       "      <td>April 28, 2020, 12:30 PM - 1:25 PM</td>\n",
       "      <td>\\n                        \\n\\n                ...</td>\n",
       "      <td>April 28, 2020, 12:55 PM - 1:10 PM</td>\n",
       "      <td>\\n Virtual Meeting\\n</td>\n",
       "      <td>Matthew J. LaMarche. Novartis, Cambridge, MA</td>\n",
       "      <td>Abstract embargoed at this time.</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>440 rows  11 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           Session Title  \\\n",
       "838-1   VMS.MCB09.01. Evaluating Cancer Genomics from...   \n",
       "838-2   VMS.MCB09.01. Evaluating Cancer Genomics from...   \n",
       "838-3   VMS.MCB09.01. Evaluating Cancer Genomics from...   \n",
       "838-4   VMS.MCB09.01. Evaluating Cancer Genomics from...   \n",
       "838-5   VMS.MCB09.01. Evaluating Cancer Genomics from...   \n",
       "...                                                  ...   \n",
       "862-8                       VCTPL09. COVID-19 and Cancer   \n",
       "36-1         VSY.DDT03. New Drugs on the Horizon: Part 3   \n",
       "36-2         VSY.DDT03. New Drugs on the Horizon: Part 3   \n",
       "36-3         VSY.DDT03. New Drugs on the Horizon: Part 3   \n",
       "36-4         VSY.DDT03. New Drugs on the Horizon: Part 3   \n",
       "\n",
       "                                             Description  \\\n",
       "838-1                                                      \n",
       "838-2                                                      \n",
       "838-3                                                      \n",
       "838-4                                                      \n",
       "838-5                                                      \n",
       "...                                                  ...   \n",
       "862-8  \\nDescription\\nAccess to AACR Virtual Annual M...   \n",
       "36-1   \\nDescription\\nThe Chemistry in Cancer Researc...   \n",
       "36-2   \\nDescription\\nThe Chemistry in Cancer Researc...   \n",
       "36-3   \\nDescription\\nThe Chemistry in Cancer Researc...   \n",
       "36-4   \\nDescription\\nThe Chemistry in Cancer Researc...   \n",
       "\n",
       "                                              Objectives  \\\n",
       "838-1  \\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...   \n",
       "838-2  \\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...   \n",
       "838-3  \\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...   \n",
       "838-4  \\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...   \n",
       "838-5  \\n\\n\\nSession Type\\nVirtual Minisymposium\\nTra...   \n",
       "...                                                  ...   \n",
       "862-8  \\n\\n\\nSession Type\\nVirtual Plenary Session\\nT...   \n",
       "36-1   \\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...   \n",
       "36-2   \\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...   \n",
       "36-3   \\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...   \n",
       "36-4   \\n\\n\\nSession Type\\nVirtual Symposium\\nTrack(s...   \n",
       "\n",
       "                                         PresentationUrl  \\\n",
       "838-1  https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "838-2  https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "838-3  https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "838-4  https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "838-5  https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "...                                                  ...   \n",
       "862-8  https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "36-1   https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "36-2   https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "36-3   https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "36-4   https://www.abstractsonline.com/pp8/#!/9045/pr...   \n",
       "\n",
       "                                      Date  \\\n",
       "838-1    April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "838-2    April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "838-3    April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "838-4    April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "838-5    April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "...                                    ...   \n",
       "862-8   April 28, 2020, 9:00 AM - 10:45 AM   \n",
       "36-1    April 28, 2020, 12:30 PM - 1:25 PM   \n",
       "36-2    April 28, 2020, 12:30 PM - 1:25 PM   \n",
       "36-3    April 28, 2020, 12:30 PM - 1:25 PM   \n",
       "36-4    April 28, 2020, 12:30 PM - 1:25 PM   \n",
       "\n",
       "                                      Presentation Title  \\\n",
       "838-1  \\n                        \\n\\n                ...   \n",
       "838-2  \\n                        \\n\\n                ...   \n",
       "838-3  \\n                        \\n\\n                ...   \n",
       "838-4  \\n                        \\n\\n                ...   \n",
       "838-5  \\n                        \\n\\n                ...   \n",
       "...                                                  ...   \n",
       "862-8  \\n                        \\n\\n                ...   \n",
       "36-1   \\n                        \\n\\n                ...   \n",
       "36-2   \\n                        \\n\\n                ...   \n",
       "36-3   \\n                        \\n\\n                ...   \n",
       "36-4   \\n                        \\n\\n                ...   \n",
       "\n",
       "                          Presentation Time  \\\n",
       "838-1     April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "838-2     April 28, 2020, 3:50 PM - 5:35 PM   \n",
       "838-3     April 28, 2020, 3:50 PM - 3:55 PM   \n",
       "838-4     April 28, 2020, 3:55 PM - 4:05 PM   \n",
       "838-5     April 28, 2020, 4:05 PM - 4:10 PM   \n",
       "...                                     ...   \n",
       "862-8   April 28, 2020, 10:30 AM - 10:45 AM   \n",
       "36-1     April 28, 2020, 12:30 PM - 1:25 PM   \n",
       "36-2     April 28, 2020, 12:30 PM - 1:25 PM   \n",
       "36-3    April 28, 2020, 12:35 PM - 12:50 PM   \n",
       "36-4     April 28, 2020, 12:55 PM - 1:10 PM   \n",
       "\n",
       "                              Presentation Location  \\\n",
       "838-1  \\n Virtual Meeting\\n                           \n",
       "838-2  \\n Virtual Meeting\\n                           \n",
       "838-3  \\n Virtual Meeting\\n                           \n",
       "838-4  \\n Virtual Meeting\\n                           \n",
       "838-5  \\n Virtual Meeting\\n                           \n",
       "...                                             ...   \n",
       "862-8  \\n Virtual Meeting\\n                           \n",
       "36-1   \\n Virtual Meeting\\n                           \n",
       "36-2   \\n Virtual Meeting\\n                           \n",
       "36-3   \\n Virtual Meeting\\n                           \n",
       "36-4   \\n Virtual Meeting\\n                           \n",
       "\n",
       "                                       Presenter/Authors  \\\n",
       "838-1  Samra Turajlic. The Francis Crick Institute, L...   \n",
       "838-2  Elana Judith Fertig. Johns Hopkins Sidney Kimm...   \n",
       "838-3  Samra Turajlic. The Francis Crick Institute, L...   \n",
       "838-4  Tapsi Kumar1, Quy Nguyen2, Kevin Nee2, Shansha...   \n",
       "838-5                                                      \n",
       "...                                                  ...   \n",
       "862-8                                                      \n",
       "36-1   Andrew J. Phillips. C4 Therapeutics, Watertown...   \n",
       "36-2   Xiaojing Wang. Genentech, Inc., South San Fran...   \n",
       "36-3   Edward B. Reilly. AbbVie Inc., North Chicago, ...   \n",
       "36-4        Matthew J. LaMarche. Novartis, Cambridge, MA   \n",
       "\n",
       "                                                Abstract  \\\n",
       "838-1  There is no abstract associated with this pres...   \n",
       "838-2  There is no abstract associated with this pres...   \n",
       "838-3                   Abstract embargoed at this time.   \n",
       "838-4                   Abstract embargoed at this time.   \n",
       "838-5  There is no abstract associated with this pres...   \n",
       "...                                                  ...   \n",
       "862-8  There is no abstract associated with this pres...   \n",
       "36-1   There is no abstract associated with this pres...   \n",
       "36-2   There is no abstract associated with this pres...   \n",
       "36-3                    Abstract embargoed at this time.   \n",
       "36-4                    Abstract embargoed at this time.   \n",
       "\n",
       "                                             Disclosures  \n",
       "838-1                                                NaN  \n",
       "838-2                                                NaN  \n",
       "838-3                                                NaN  \n",
       "838-4  T. Kumar: None.Q. Nguyen: None.K. Nee: None...  \n",
       "838-5                                                NaN  \n",
       "...                                                  ...  \n",
       "862-8                                                NaN  \n",
       "36-1                                                 NaN  \n",
       "36-2                                                 NaN  \n",
       "36-3   E. B. Reilly,  AbbVie Inc Full-time/Part-time...  \n",
       "36-4                                                 NaN  \n",
       "\n",
       "[440 rows x 11 columns]"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Description'] = df['Description'].str.replace('\\n','')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Objectives'] = df['Objectives'].str.replace('\\n','')\n",
    "df['Presentation Title'] = df['Presentation Title'].str.replace('\\n','').str.strip()\n",
    "df['Presentation Location'] = df['Presentation Location'].str.replace('\\n','')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Presentation Start Time'] = df['Presentation Time'].str.split(',',expand = True)[2].str.split(' - ',expand = True)[0]\n",
    "df['Presentation End Time'] =  df['Presentation Time'].str.split(',',expand = True)[2].str.split(' - ',expand = True)[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "df['Presentation Date'] = df['Presentation Time'].str.split(',',expand = True)[0]+', '+df['Presentation Time'].str.split(',',expand = True)[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_excel('AACR2020.xls')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
